<html lang="en" class="pb-page js" data-request-id="94d65ade13caf211-SJC"><head data-pb-dropzone="head"><style type="text/css" nonce="94d65ade13caf211-SJC">@font-face {font-family: "Source Sans Pro";src: url(https://consent.trustarc.com/get?name=SourceSansPro-Regular.ttf) format("truetype"),url(https://consent.trustarc.com/get?name=SourceSansPro-Regular.woff) format("woff"),url(https://consent.trustarc.com/get?name=SourceSansPro-Regular.otf) format("opentype"),url(https://consent.trustarc.com/get?name=SourceSansPro-Regular.eot) format("embedded-opentype");}.truste_cursor_pointer {cursor: pointer;}.truste_border_none {border: none;}.truste_accessible_link {font-family: "Source Sans Pro", sans-serif;color: #1D4ED8;font-size: 14px;font-weight: 600;text-decoration: underline;}.truste_accessible_link:hover {color: #1D4ED8;text-decoration: none !important;}.truste_accessible_link:focus-visible {outline: none;border-radius: 4px;box-shadow: 0 0 0 1px #FFFFFF, 0 0 0 4px #3699F1;}</style><script src="https://ssl-cdn.janraincapture.com/widget_data/flow.js:7h8bznq6j7bvyvzqcrwvyp8dfb:en-US:20240514181256512029:standard" type="text/javascript"></script><script src="https://cssjs.nejm.org/akamai/capture:login" type="text/javascript"></script><script src="https://ssl-widget-cdn.rpxnow.com/translations/login/en-US" type="text/javascript"></script><script type="text/javascript" id="janrainAuthWidget" src="https://cssjs.nejm.org/akamai/mms-prod.js"></script><script type="text/javascript" src="https://www.nejm.org/RSJNdn0f_Sgj5J2D_2suuWQ4O-uYnS844BfIAd5Zx2fJFHX4ZtuuFQtPjynku5VfsUmgjnfRdZrJJpftTn37Ww=="></script>
            

<meta charset="UTF-8">






    
        
            
        
    
        
            
        
    
        
            
        
    
        
            
        
    
        
    
        
    
        
            
                
                
<title>Cytokine Storm | New England Journal of Medicine</title>





                
            
        
    







    
        
            
        
    
        
            
        
    
        
            
                
                



                
            
        
    
        
            
        
    
        
    
        
    
        
            
        
    











    








    

    
    

    
    
    
    
        
            
                <link rel="stylesheet" type="text/css" href="/wro/1125813~article-metrics.css">
            
            
            
        
    

    
    
        
            <link rel="icon" href="/products/mms-nextgen/mms/releasedAssets/images/favicon/fav_nejm_1-994b0160d1eb33dc79517ef0295aab1b.ico" type="image/x-icon">
        
        
            <link rel="icon" href="/products/mms-nextgen/mms/releasedAssets/images/favicon/fav_16-4aa032aa775940f725817b7ff42f0e2c.png" type="image/png" sizes="16x16">
        
        
            <link rel="icon" href="/products/mms-nextgen/mms/releasedAssets/images/favicon/fav_32-0a94fa44823476ffa0bb15bdb320fb34.png" type="image/png" sizes="32x32">
        
        
            <link rel="apple-touch-icon" href="/products/mms-nextgen/mms/releasedAssets/images/favicon/fav_152-d6c3522864a8e483996b7e9c132c901a.png" sizes="152x152">
        
        
            <link rel="apple-touch-icon" href="/products/mms-nextgen/mms/releasedAssets/images/favicon/fav_180-f2538afc53a365d4cd3f10ab73c56aad.png" sizes="180x180">
        
        
            <link rel="apple-touch-icon" href="/products/mms-nextgen/mms/releasedAssets/images/favicon/fav_167-8e888012bbdd31a00c3e54bc5b8ca5b6.png" sizes="167x167">
        
    

    
    
            <link rel="stylesheet" href="/products/mms-nextgen/mms/releasedAssets/css/build-5b89b331018866a4a965.css" media="all">
        <link rel="stylesheet" href="/products/mms-nextgen/mms/releasedAssets/css/print-5b89b331018866a4a965.css" media="print">
           <link rel="stylesheet" href="/products/mms-nextgen/mms/releasedAssets/css/build-article-5b89b331018866a4a965.css" media="all" id="article-style-sheet">
    
        <script nonce="94d65ade13caf211-SJC">
        try {
            document.documentElement.classList.add('js');
        } catch (e) {
        }
    </script>
     
    

















    
        
            
                
                
                
                    
                    <!-- TrustArc Scripts -->
<script async="async" src="https://consent.trustarc.com/notice?domain=nejm.com&amp;c=teconsent&amp;js=nj&amp;noticeType=bb&amp;gtm=1&amp;text=true&amp;pcookie" crossorigin="" id="truste_0.6678974106075611"></script>
<script src="https://consent.trustarc.com/autoblockasset/core.min.js?domain=nejm.com"></script>
<script src="https://consent.trustarc.com/autoblockoptout?domain=nejm.com"></script>
<!-- /TrustArc Scripts -->
<!-- BlueConic Scripts -->
<script src="https://bc.nejm.org/script.js"></script>
    <!-- /BlueConic Scripts -->
<!-- Printing Meta Tags -->
    <meta name="topics" content="Hematology/Oncology General|Infectious Disease General|Coronavirus|Critical Care|Pulmonary/Critical Care General|Shock|Allergy/Immunology General">
<meta name="articleCategory" content="Review">
<meta name="articleType" content="Review Article">
<meta name="Specialties" content="Allergy/Immunology|Hematology/Oncology|Pulmonary/Critical Care|Emergency Medicine|Infectious Disease"><script type="text/javascript">var mmsData = {"access":{"isFreeCountry":"n"},"ad":{"category":"article"},"imageChallenge":{"id":null},"article":{"doi":"10.1056/NEJMra2026131","title":"Cytokine Storm","category":"Review","type":"Review Article","topics":"Hematology/Oncology General|Infectious Disease General|Coronavirus|Critical Care|Pulmonary/Critical Care General|Shock|Allergy/Immunology General","specialties":"Allergy/Immunology|Hematology/Oncology|Pulmonary/Critical Care|Emergency Medicine|Infectious Disease","seriesTitle":"","viewType":"Full","age":"2Years-1990","issueDate":"2020-12-03T00:00Z","isFree":"y","broadTopics":"","perspectiveTopics":"","granularTopics":"","methodologicalArea":"","isOnlineFirst":"n","isCurrentIssue":"n","metaTags":"\u003cmeta name\u003d\"topics\" content\u003d\"Hematology/Oncology General|Infectious Disease General|Coronavirus|Critical Care|Pulmonary/Critical Care General|Shock|Allergy/Immunology General\"/\u003e\n\u003cmeta name\u003d\"articleCategory\" content\u003d\"Review\"/\u003e\n\u003cmeta name\u003d\"articleType\" content\u003d\"Review Article\"/\u003e\n\u003cmeta name\u003d\"Specialties\" content\u003d\"Allergy/Immunology|Hematology/Oncology|Pulmonary/Critical Care|Emergency Medicine|Infectious Disease\"/\u003e"},"page":{"activity":"showFullText","url":"www.nejm.org/doi/full/10.1056/NEJMra2026131","viewType":"desktop","journal":"NEJM"},"user":{"ucid":null,"audienceSegment":null,"specialtyGroupCode":null,"meterCountRemaining":null,"totalMeterCount":null},"object":[]};</script>
    <script type="text/javascript">var mmsDataAdd = {"user":{"customerType":"null","accessInstitutionID":"null"}};</script>
    <!-- Prehiding snippet for Adobe Target with asynchronous Launch deployment -->
    <!-- placeholder id=null, description=Adobe-Target-Prehiding-Snippet --><!--
  Adobe Target - Prehiding Snippet
  v2.0.0
-->
<script nonce="94d65ade13caf211-SJC">
function tgtNoFlicker(e,n,t,o,i,c,l,r){function d(){return n.getElementsByTagName("head")[0]}function a(e,t){if(e){var o=n.getElementById(t);o&&e.removeChild(o)}}function f(e,o){!function(e,t,o){if(e){var i=n.createElement("style");i.id=t,i.innerHTML=o,e.appendChild(i)}}(d(),t,e),setTimeout(function(){a(d(),t)},o)}var m;n.location.href.indexOf(c)>-1?f(l,r):f(o,i),n.location.href.indexOf("mboxDisable")>-1?(a(d(),t),console.log("[TARGET] - Disabled, removing prehiding style")):(m=function(e){e&&(a(d(),t),console.log("[TARGET] - Blocked, removing prehiding style"))},fetch("//cdn.tt.omtrdc.net/cdn/target-vec.js",{method:"HEAD",mode:"no-cors"}).then(e=>m(!1)).catch(e=>m(!0)))}

tgtNoFlicker(window, document, 'at-body-style', 'div[data-location-name="Anonymous Module"], div[data-location-name="Anonymous Banner"], main > div.page-body > div > div > div > div.col-md-2-3.o-col.o-col--primary > div[class*="u-hide"], main > div.page-body > div > div > div > div.col-md-1-3.o-col.o-col--secondary > aside, header > h1#mainContent, a.m-article__link[href*="/10.1056/NEJMoa2116747"] > span.m-article__blurb > p, li.g-nejm-group__user-tool-secondary {opacity: 0 !important}', 3000);

tgtNoFlicker(window, document, 'at-mbox-style', '.N-ad-global-top-right, #N-ad-myNEJM-contextual-top, .N-ad-recentArticles, #N-ad-article-rightRail-1, #N-ad-siteWide-rightRail-1, #N-ad-imageChallenge-rightRail-2 {opacity: 0 !important}', 3000);
</script><!-- /Prehiding snippet for Adobe Target with asynchronous Launch deployment -->
    <!-- Launch Header Embed Code -->
    <script src="//assets.adobedtm.com/launch-ENcd6450fae3ae4870becbe6a2b01ab2e1.min.js" async="" type="ta-blocked" data-ta-blocked="1"></script>
    <!-- /Launch Header Embed Code -->

                    
                
            
        
    
        
            
                
                
                
                    
                    <link rel="schema.DC" href="http://purl.org/DC/elements/1.0/"><meta name="citation_journal_title" content="New England Journal of Medicine"><meta name="dc.Title" content="Cytokine Storm"><meta name="dc.Creator" content="David C. Fajgenbaum"><meta name="dc.Creator" content="Carl H. June"><meta name="dc.Description" content="Cytokine storm, a life-threatening disorder involving cytokine elevations and immune-cell hyperactivation, has various causes and is characterized by constitutional symptoms, systemic inflammation,..."><meta name="Description" content="Cytokine storm, a life-threatening disorder involving cytokine elevations and immune-cell hyperactivation, has various causes and is characterized by constitutional symptoms, systemic inflammation,..."><meta name="dc.Publisher" content="Massachusetts Medical Society"><meta name="dc.Contributor" content="Dan L. Longo"><meta name="dc.Date" scheme="WTN8601" content="2020-12-03"><meta name="dc.Type" content="review-article"><meta name="dc.Format" content="text/HTML"><meta name="dc.Identifier" scheme="doi" content="10.1056/NEJMra2026131"><meta name="dc.Identifier" scheme="publisher-id" content="NJ202012033832313"><meta name="dc.Language" content="EN"><meta name="dc.Relation" content="YXQYra2026131"><meta name="dc.Coverage" content="world"><meta name="dc.Rights" content="Copyright © 2020 Massachusetts Medical Society. All rights reserved.">




<link rel="meta" type="application/atom+xml" href="https://doi.org/10.1056%2FNEJMra2026131">
<link rel="meta" type="application/rdf+json" href="https://doi.org/10.1056%2FNEJMra2026131">
<link rel="meta" type="application/unixref+xml" href="https://doi.org/10.1056%2FNEJMra2026131">


                    
                
            
        
    
        
            
                
                
                
                
                
            
        
    
        
            
                
                
                
                    
                    





<meta name="robots" content="noarchive">





    





    
    
        
        <meta name="twitter:title" content="Cytokine Storm | NEJM">
        <meta property="og:title" content="Cytokine Storm | NEJM">
    


    <meta property="og:type" content="article">


    
    
        <meta property="og:url" content="https://www.nejm.org/doi/full/10.1056/NEJMra2026131">
    
    


    
    
        <meta property="og:image" content="https://www.nejm.org/cms/asset/909f0648-4b51-4338-9760-cefa7aab4ca6/nejmra2026131_f1.jpg">
        <meta name="twitter:image" content="https://www.nejm.org/cms/asset/909f0648-4b51-4338-9760-cefa7aab4ca6/nejmra2026131_f1.jpg">
    



    <meta property="og:site_name" content="The New England Journal of Medicine">


    
    
        
        <meta property="og:description" content="Cytokine storm, a life-threatening disorder involving cytokine elevations and immune-cell
hyperactivation, has various causes and is characterized by constitutional symptoms,
systemic inflammation,...">
        <meta name="twitter:description" content="Cytokine storm, a life-threatening disorder involving cytokine elevations and immune-cell
hyperactivation, has various causes and is characterized by constitutional symptoms,
systemic inflammation,...">
    


    
    
        <meta property="og:image:width" content="2640">
    


    
    
        <meta property="og:image:height" content="2206">
    


    <meta name="twitter:card" content="summary">


    <meta name="twitter:site" content="@NEJM">


<meta name="viewport" content="width=device-width,initial-scale=1"><meta name="citation_fulltext_world_readable" content="">
    <meta name="publication_doi" content="10.1056/NEJMra2026131">


    















                    
                
            
        
    
        
    
        
    
        
            
                
                
                
                
                
            
        
    




<meta name="format-detection" content="telephone=no">

<meta http-equiv="X-UA-Compatible" content="IE=edge">
    




    
        
        
        <link rel="canonical" href="https://www.nejm.org/doi/full/10.1056/NEJMra2026131">
    
    







<meta name="pbContext" content=";requestedJournal:journal:nejm;page:string:Article/Chapter View;ctype:string:Journal Content;issue:issue:doi\:10.1056/nejm_2020.383.issue-23;article:article:doi\:10.1056/NEJMra2026131;wgroup:string:MMS NextGen Website Group;pageGroup:string:Publication Pages;subPage:string:Full Text;website:website:mms-site;journal:journal:nejms">
        <link rel="stylesheet" type="text/css" href="https://cssjs.nejm.org/custreg-933-8e181dff8b36ea01dc4c.css"><link rel="stylesheet" type="text/css" href="https://cssjs.nejm.org/custreg-34-6ea546d794fb7a1cea52.css"><link rel="stylesheet" type="text/css" href="https://cssjs.nejm.org/custreg-743-ddd329e1530654ec0846.css"><link rel="stylesheet" type="text/css" href="https://cssjs.nejm.org/custreg-305-9eee37798fdfe5196307.css"><link rel="stylesheet" type="text/css" href="https://cssjs.nejm.org/custreg-388-bb098c62445f518c0b46.css"><link rel="stylesheet" type="text/css" href="https://cssjs.nejm.org/custreg-556-8e58ca05fb5497e541ef.css"><script charset="utf-8" src="https://www.nejm.org/products/mms-nextgen/mms/releasedAssets/js/0-dfd243c732a07d3608f6.js"></script><script charset="utf-8" src="https://www.nejm.org/products/mms-nextgen/mms/releasedAssets/js/7-10d355ba95f7ec1fddf2.js"></script><script charset="utf-8" src="https://www.nejm.org/products/mms-nextgen/mms/releasedAssets/js/11-04bf2a0da30146b4a5d0.js"></script><script id="altmetric-embed-js" src="https://d1bxh8uas1mnw7.cloudfront.net/assets/altmetric_badges-288192a491f0ad9cc434f05ea175659426f5ab0cfd6befb3f3592f96bb90b0d1.js"></script><link id="altmetric-embed-css" rel="stylesheet" type="text/css" href="https://d1bxh8uas1mnw7.cloudfront.net/assets/embed-59614f5c46b49b21eeef3bb28c4fb38d1e7069e8d014752fcb66e84942556802.css"><link rel="stylesheet" href="https://quilt-cdn.janrain.com/HEAD/providers.css" type="text/css"><script src="https://static.addtoany.com/menu/modules/core.pt5ow5lr.js" type="module"></script><link rel="preconnect" href="https://use.typekit.net"><meta http-equiv="P3P" content="CP=&quot;NOI DSP ADM OUR IND OTC&quot;"><style type="text/css">.a2a_hide{display:none}.a2a_logo_color{background-color:#0166ff}.a2a_menu,.a2a_menu *{-moz-box-sizing:content-box;-webkit-box-sizing:content-box;box-sizing:content-box;float:none;margin:0;padding:0;position:static;height:auto;width:auto}.a2a_menu{border-radius:6px;display:none;direction:ltr;background:#FFF;font:16px sans-serif-light,HelveticaNeue-Light,"Helvetica Neue Light","Helvetica Neue",Arial,Helvetica,"Liberation Sans",sans-serif;color:#000;line-height:12px;border:1px solid #CCC;vertical-align:baseline;overflow:hidden}.a2a_mini{min-width:200px;position:absolute;width:300px;z-index:9999997}.a2a_overlay{display:none;background:#616c7deb;backdrop-filter:blur(4px);-webkit-backdrop-filter:blur(4px);position:fixed;top:0;right:0;left:0;bottom:0;z-index:9999998;-webkit-tap-highlight-color:transparent;transition:opacity .14s,backdrop-filter .14s}.a2a_full{background:#FFF;border:1px solid #FFF;box-shadow:#2a2a2a1a 0 0 20px 10px;height:auto;height:calc(320px);top:15%;left:50%;margin-left:-320px;position:fixed;text-align:center;width:640px;z-index:9999999;transition:transform .14s,opacity .14s}.a2a_full_footer,.a2a_full_header,.a2a_full_services{border:0;margin:0;padding:12px;box-sizing:border-box}.a2a_full_header{padding-bottom:8px}.a2a_full_services{height:280px;overflow-y:scroll;padding:0 12px;-webkit-overflow-scrolling:touch}.a2a_full_services .a2a_i{display:inline-block;float:none;width:181px;width:calc(33.334% - 18px)}div.a2a_full_footer{font-size:12px;text-align:center;padding:8px 14px}div.a2a_full_footer a,div.a2a_full_footer a:visited{display:inline;font-size:12px;line-height:14px;padding:8px 14px}div.a2a_full_footer a:focus,div.a2a_full_footer a:hover{background:0 0;border:0;color:#0166FF}div.a2a_full_footer a span.a2a_s_a2a,div.a2a_full_footer a span.a2a_w_a2a{background-size:14px;border-radius:3px;display:inline-block;height:14px;line-height:14px;margin:0 3px 0 0;vertical-align:top;width:14px}.a2a_modal{height:0;left:50%;margin-left:-320px;position:fixed;text-align:center;top:15%;width:640px;z-index:9999999;transition:transform .14s,opacity .14s;-webkit-tap-highlight-color:transparent}.a2a_modal_body{background:0 0;border:0;font:24px sans-serif-light,HelveticaNeue-Light,"Helvetica Neue Light","Helvetica Neue",Arial,Helvetica,"Liberation Sans",sans-serif;position:relative;height:auto;width:auto}.a2a_thanks{color:#fff;height:auto;margin-top:20px;width:auto}.a2a_thanks>div:first-child{margin:0 0 40px 0}.a2a_thanks div *{height:inherit}#a2a_copy_link{background:#FFF;border:1px solid #FFF;cursor:pointer;margin-top:15%}label.a2a_s_link#a2a_copy_link_icon,label.a2a_w_link#a2a_copy_link_icon{background-size:48px;border-radius:0;display:inline-block;height:48px;left:0;line-height:48px;margin:0 3px 0 0;position:absolute;vertical-align:top;width:48px}#a2a_modal input#a2a_copy_link_text{background-color:transparent;border:0;color:#2A2A2A;cursor:pointer;font:inherit;height:48px;left:62px;max-width:initial;min-height:auto;padding:0;position:relative;width:564px;width:calc(100% - 76px)}#a2a_copy_link_copied{background-color:#0166ff;color:#fff;display:none;font:inherit;font-size:16px;margin-top:1px;padding:3px 8px}@media (forced-colors:active){.a2a_color_buttons a,.a2a_svg{forced-color-adjust:none}}@media (prefers-color-scheme:dark){.a2a_menu a,.a2a_menu a.a2a_i,.a2a_menu a.a2a_i:visited,.a2a_menu a.a2a_more,i.a2a_i{border-color:#2a2a2a!important;color:#fff!important}.a2a_menu a.a2a_i:active,.a2a_menu a.a2a_i:focus,.a2a_menu a.a2a_i:hover,.a2a_menu a.a2a_more:active,.a2a_menu a.a2a_more:focus,.a2a_menu a.a2a_more:hover,.a2a_menu_find_container{border-color:#444!important;background-color:#444!important}.a2a_menu:not(.a2a_thanks){background-color:#2a2a2a;border-color:#2a2a2a}.a2a_menu_find{color:#fff!important}.a2a_menu label.a2a_s_find svg{background-color:transparent!important}.a2a_menu label.a2a_s_find svg path{fill:#fff!important}.a2a_full{box-shadow:#00000066 0 0 20px 10px}.a2a_overlay{background-color:#373737eb}}@media print{.a2a_floating_style,.a2a_menu,.a2a_overlay{visibility:hidden}}@keyframes a2aFadeIn{from{opacity:0}to{opacity:1}}.a2a_starting{opacity:0}.a2a_starting.a2a_full,.a2a_starting.a2a_modal{transform:scale(.8)}@media (max-width:639px){.a2a_full{border-radius:0;top:15%;left:0;margin-left:auto;width:100%}.a2a_modal{left:0;margin-left:10px;width:calc(100% - 20px)}}@media (min-width:318px) and (max-width:437px){.a2a_full .a2a_full_services .a2a_i{width:calc(50% - 18px)}}@media (max-width:317px){.a2a_full .a2a_full_services .a2a_i{width:calc(100% - 18px)}}@media (max-height:436px){.a2a_full{bottom:40px;height:auto;top:40px}}@media (max-height:550px){.a2a_modal{top:30px}}@media (max-height:360px){.a2a_modal{top:20px}.a2a_thanks>div:first-child{margin-bottom:20px}}.a2a_menu a{color:#0166FF;text-decoration:none;font:16px sans-serif-light,HelveticaNeue-Light,"Helvetica Neue Light","Helvetica Neue",Arial,Helvetica,"Liberation Sans",sans-serif;line-height:14px;height:auto;width:auto;outline:0}.a2a_menu a.a2a_i:visited,.a2a_menu a.a2a_more{color:#0166FF}.a2a_menu a.a2a_i:active,.a2a_menu a.a2a_i:focus,.a2a_menu a.a2a_i:hover,.a2a_menu a.a2a_more:active,.a2a_menu a.a2a_more:focus,.a2a_menu a.a2a_more:hover{color:#2A2A2A;border-color:#EEE;border-style:solid;background-color:#EEE;text-decoration:none}.a2a_menu label.a2a_s_find{background-size:24px;height:24px;left:8px;pointer-events:auto;position:absolute;top:7px;width:24px}.a2a_menu label.a2a_s_find svg{background-color:#FFF}.a2a_menu label.a2a_s_find svg path{fill:#CCC}#a2a_menu_container{display:inline-block}.a2a_menu_find_container{border:1px solid #CCC;border-radius:6px;padding:2px 24px 2px 0;position:relative;text-align:left}.a2a_cols_container .a2a_col1{overflow-x:hidden;overflow-y:auto;-webkit-overflow-scrolling:touch}#a2a_modal input,#a2a_modal input[type=text],.a2a_menu input,.a2a_menu input[type=text]{display:block;background-image:none;box-shadow:none;line-height:100%;margin:0;outline:0;overflow:hidden;padding:0;-moz-box-shadow:none;-webkit-box-shadow:none;-webkit-appearance:none}#a2afeed_find_container input,#a2afeed_find_container input[type=text],#a2apage_find_container input,#a2apage_find_container input[type=text]{background-color:transparent;border:0;box-sizing:content-box;color:#2A2A2A;float:none;font:inherit;font-size:16px;height:28px;line-height:20px;left:38px;outline:0;margin:0;max-width:initial;min-height:initial;padding:2px 0;position:relative;width:99%}.a2a_clear{clear:both}.a2a_svg{background-repeat:no-repeat;display:block;overflow:hidden;height:32px;line-height:32px;padding:0;pointer-events:none;width:32px}.a2a_svg svg{background-repeat:no-repeat;background-position:50% 50%;border:none;display:block;left:0;margin:0 auto;overflow:hidden;padding:0;position:relative;top:0;width:auto;height:auto}a.a2a_i,i.a2a_i{display:block;float:left;border:1px solid #FFF;line-height:24px;padding:6px 8px;text-align:left;white-space:nowrap;overflow:hidden;text-overflow:ellipsis;width:132px}a.a2a_i span,a.a2a_more span{display:inline-block;overflow:hidden;vertical-align:top}a.a2a_i .a2a_svg{margin:0 6px 0 0}a.a2a_i .a2a_svg,a.a2a_more .a2a_svg{background-size:24px;height:24px;line-height:24px;width:24px}a.a2a_sss:hover{border-left:1px solid #CCC}a.a2a_more{border-bottom:1px solid #FFF;border-left:0;border-right:0;line-height:24px;margin:6px 0 0;padding:6px;-webkit-touch-callout:none}a.a2a_more span{height:24px;margin:0 6px 0 0}.a2a_kit .a2a_svg{background-repeat:repeat}.a2a_default_style a:empty,.a2a_flex_style a:empty,.a2a_floating_style a:empty,.a2a_overlay_style a:empty{display:none}.a2a_color_buttons a,.a2a_floating_style a{text-decoration:none}.a2a_default_style:not(.a2a_flex_style) a{float:left;line-height:16px;padding:0 2px}.a2a_default_style a:hover .a2a_svg,.a2a_floating_style a:hover .a2a_svg,.a2a_overlay_style a:hover .a2a_svg svg{opacity:.7}.a2a_overlay_style.a2a_default_style a:hover .a2a_svg{opacity:1}.a2a_default_style .a2a_count,.a2a_default_style .a2a_svg,.a2a_floating_style .a2a_svg,.a2a_menu .a2a_svg,.a2a_vertical_style .a2a_count,.a2a_vertical_style .a2a_svg{border-radius:4px}.a2a_default_style .a2a_counter img,.a2a_default_style .a2a_dd,.a2a_default_style .a2a_svg{float:left}.a2a_default_style .a2a_img_text{margin-right:4px}.a2a_default_style .a2a_divider{border-left:1px solid #000;display:inline;float:left;height:16px;line-height:16px;margin:0 5px}.a2a_kit a{cursor:pointer;transition:none}.a2a_floating_style{background-color:#fff;border-radius:6px;position:fixed;z-index:9999995}.a2a_overlay_style{z-index:2147483647}.a2a_floating_style,.a2a_overlay_style{animation:a2aFadeIn .2s ease-in;padding:4px}.a2a_vertical_style:not(.a2a_flex_style) a{clear:left;display:block;overflow:hidden;padding:4px}.a2a_floating_style.a2a_default_style{bottom:0}.a2a_floating_style.a2a_default_style a,.a2a_overlay_style.a2a_default_style a{padding:4px}.a2a_count{background-color:#fff;border:1px solid #ccc;box-sizing:border-box;color:#2a2a2a;display:block;float:left;font:12px Arial,Helvetica,sans-serif;height:16px;margin-left:4px;position:relative;text-align:center;width:50px}.a2a_count:after,.a2a_count:before{border:solid transparent;border-width:4px 4px 4px 0;content:"";height:0;left:0;line-height:0;margin:-4px 0 0 -4px;position:absolute;top:50%;width:0}.a2a_count:before{border-right-color:#ccc}.a2a_count:after{border-right-color:#fff;margin-left:-3px}.a2a_count span{animation:a2aFadeIn .14s ease-in}.a2a_vertical_style .a2a_counter img{display:block}.a2a_vertical_style .a2a_count{float:none;margin-left:0;margin-top:6px}.a2a_vertical_style .a2a_count:after,.a2a_vertical_style .a2a_count:before{border:solid transparent;border-width:0 4px 4px 4px;content:"";height:0;left:50%;line-height:0;margin:-4px 0 0 -4px;position:absolute;top:0;width:0}.a2a_vertical_style .a2a_count:before{border-bottom-color:#ccc}.a2a_vertical_style .a2a_count:after{border-bottom-color:#fff;margin-top:-3px}.a2a_color_buttons .a2a_count,.a2a_color_buttons .a2a_count:after,.a2a_color_buttons .a2a_count:before,.a2a_color_buttons.a2a_vertical_style .a2a_count:after,.a2a_color_buttons.a2a_vertical_style .a2a_count:before{background-color:transparent;border:none;color:#fff;float:none;width:auto}.a2a_color_buttons.a2a_vertical_style .a2a_count{margin-top:0}.a2a_flex_style{display:flex;align-items:flex-start;gap:0}.a2a_default_style.a2a_flex_style{left:0;right:0;width:100%}.a2a_vertical_style.a2a_flex_style{flex-direction:column;top:0;bottom:0}.a2a_flex_style a{display:flex;justify-content:center;flex:1;padding:4px}.a2a_flex_style.a2a_vertical_style a{flex-direction:column}.a2a_floating_style.a2a_color_buttons,.a2a_floating_style.a2a_flex_style{border-radius:0;padding:0}.a2a_floating_style.a2a_default_style.a2a_flex_style{bottom:0}.a2a_kit.a2a_flex_style .a2a_counter img,.a2a_kit.a2a_flex_style .a2a_dd,.a2a_kit.a2a_flex_style .a2a_svg{float:none}.a2a_nowrap{white-space:nowrap}.a2a_note{margin:0 auto;padding:9px;font-size:12px;text-align:center}.a2a_note .a2a_note_note{margin:0;color:#2A2A2A}.a2a_wide a{display:block;margin-top:3px;border-top:1px solid #EEE;text-align:center}.a2a_label{position:absolute!important;clip-path:polygon(0px 0px,0px 0px,0px 0px);-webkit-clip-path:polygon(0px 0px,0px 0px,0px 0px);overflow:hidden;height:1px;width:1px}.a2a_kit,.a2a_menu,.a2a_modal,.a2a_overlay{-ms-touch-action:manipulation;touch-action:manipulation;outline:0}.a2a_dd{-webkit-user-drag:none}.a2a_dd img{border:0}.a2a_button_facebook_like iframe{max-width:none}</style></head>
    

    



    
        
        
        
            <body class="pb-ui website-mms-site loaded">
            






    
    
        





    
    
        
        
    
    
    







<input type="hidden" id="isRoMode" name="isRoMode" value="false">

        <div id="pb-page-content" data-ng-non-bindable="">
                
            <div data-pb-dropzone="main" data-pb-dropzone-name="Main">
                
                    
                        



        
        <header data-sticky="false" class="ng-header js_stickyAd"><a href="#mainContent" class="ng-skipToMainContent">Skip to main content</a><div class="ng-header_topAd"><div class="ng-header_topAd-content d-flex justify-content-center align-items-center">



        
        <div id="DTM_Position_Topbanner" class="ad">
 <!--emptycomment-->
</div>
</div></div><div class="ng-header_journal-navbar"><div class="ng-header_journal-navbar-content"><div class="container-fluid"><div class="row"><div class="ng-header_journal-navbar_left col-lg-8 col-sm-12 pr-lg-0 d-flex align-items-center"><div data-location="nejm_group_product_nav" class="ng-header_journalNavMenu">



        
        <nav data-location="nejm_group_product_nav" role="navigation" class="ng-journalNavMenu">
<ul class="ng-journalNavMenu_list">
<li class="ng-journalNavMenu_list-item"><a href="/" class="ng-journalNavMenu_mainLink active" aria-current="page" aria-label="The New England Journal of Medicine selected item"><span class="ng-journalNavMenu_mainLink-text d-lg-block d-none">The New England Journal of Medicine</span><span class="ng-journalNavMenu_mainLink-text d-lg-none d-block">NEJM</span></a></li>
<li class="ng-journalNavMenu_list-item"><a href="https://evidence.nejm.org/" class="ng-journalNavMenu_mainLink"><span class="ng-journalNavMenu_mainLink-text"><span class="ng-journalNavMenu_mainLink-text-firstWord">NEJM</span> Evidence</span></a></li>
<li class="ng-journalNavMenu_list-item"><a href="https://ai.nejm.org/" class="ng-journalNavMenu_mainLink"><span class="ng-journalNavMenu_mainLink-text"><span class="ng-journalNavMenu_mainLink-text-firstWord">NEJM</span> AI</span></a></li>
<li class="ng-journalNavMenu_list-item"><a href="https://catalyst.nejm.org/" class="ng-journalNavMenu_mainLink"><span class="ng-journalNavMenu_mainLink-text"><span class="ng-journalNavMenu_mainLink-text-firstWord">NEJM</span> Catalyst</span></a></li>
<li class="ng-journalNavMenu_list-item"><a href="https://www.jwatch.org/" class="ng-journalNavMenu_mainLink"><span class="ng-journalNavMenu_mainLink-text"><span class="ng-journalNavMenu_mainLink-text-firstWord">NEJM</span> Journal Watch</span></a></li>
</ul>
</nav>

</div></div><div class="ng-header_journal-navbar_right col-lg-4 pl-lg-0 d-none d-xl-flex align-items-center justify-content-end"><div class="ng-header_loginBar d-xl-flex align-items-lg-center">



        
        <div data-location="authstring_nav" class="ng-header_loginBar-menu"><span class="ng-simple-menu_mainLink-icon signIn newIcon-2"><span class="icon-component"><svg aria-hidden="true"><use xlink:href="/specs/products/mms-nextgen/mms/releasedAssets/icons/icons.spritemap.svg#user2"></use></svg></span></span><span class="ng-header_loginBar-signIn"><a href="/sign-in?uri=/doi/full/10.1056/NEJMra2026131" class="ng-header_loginBar-signIn-link">Sign In</a></span><span class="ng-header_loginBar-separator">|</span><span class="ng-header_loginBar-createAcc"><a href="/action/storeProxy?action=register&amp;promo=ONFLNRC1" class="ng-header_loginBar-createAcc-link ro-mode_disabled">Create Account</a></span></div><div data-location="authstring_nav" class="ng-header_loginBar-subscribe pl-xl-16"><a href="/action/storeProxy?action=subscribe&amp;promo=ONF4NRS1" class="ng-header_loginBar-subscribe-btn ng-btn_primary ro-mode_disabled">Subscribe</a></div>
</div></div></div></div></div></div><div class="ng-header_instBanner d-none d-lg-block"></div><div class="ng-header_logoBar"><div class="container-fluid"><div class="row"><div data-location="logo" class="ng-header_logoBar_left col-lg-4 col-6 d-flex align-items-center justify-content-start"><a href="/" title="The New England Journal of Medicine homepage" class="ng-header_logo-link"><img src="/specs/products/mms-nextgen/mms/releasedAssets/images/other-images/nejm-logo-166667e91992a5212bc723b03e45d39f.svg" alt="The New England Journal of Medicine homepage" width="366" height="58" class="ng-header_logo-image"></a></div><div class="ng-header_logoBar_right ng-header_navBar col-lg-8 col-sm-12 p-lg-0 align-items-center justify-content-end"><div class="ng-header_navBar-content"><div class="container-fluid"><div class="row"><div class="ng-header_instBanner-md col-12 d-block d-lg-none"></div><div class="ng-header_loginBar-md col-12 d-block d-xl-none">



        
        <div data-location="authstring_nav" class="ng-header_loginBar-menu"><span class="ng-simple-menu_mainLink-icon signIn newIcon-2"><span class="icon-component"><svg aria-hidden="true"><use xlink:href="/specs/products/mms-nextgen/mms/releasedAssets/icons/icons.spritemap.svg#user2"></use></svg></span></span><span class="ng-header_loginBar-signIn"><a href="/sign-in?uri=/doi/full/10.1056/NEJMra2026131" class="ng-header_loginBar-signIn-link">Sign In</a></span><span class="ng-header_loginBar-separator">|</span><span class="ng-header_loginBar-createAcc"><a href="/action/storeProxy?action=register&amp;promo=ONFLNRC1" class="ng-header_loginBar-createAcc-link ro-mode_disabled">Create Account</a></span></div><div data-location="authstring_nav" class="ng-header_loginBar-subscribe pl-xl-16"><a href="/action/storeProxy?action=subscribe&amp;promo=ONF4NRS1" class="ng-header_loginBar-subscribe-btn ng-btn_primary ro-mode_disabled">Subscribe</a></div>
</div><div class="ng-header_navBar_left col-lg-8 col-sm-12 d-flex align-items-center"><div class="ng-header_stickyLogo mr-32"><a href="/" title="The New England Journal of Medicine homepage" class="ng-header_stickyLogo-link"><img src="/specs/products/mms-nextgen/mms/releasedAssets/images/other-images/nejm-small-logo-070df7a3f4d8cfa2e71c3c45bb4b172f.svg" alt="The New England Journal of Medicine homepage" class="ng-header_stickyLogo-image"></a></div><div class="ng-header_mainMenu">









    
    
        <div data-widget-def="menuWidget" data-widget-id="97fb3983-db63-4b0b-97dd-d9bb7929fce1" data-location="main_nav">
        



        
        <nav class="ng-menu"><ul class="ng-menu_list ng-simple-menu"><li class="ng-menu_list-item ng-simple-menu_item hasChildren"><a href="/toc/nejm/current" class="ng-simple-menu_mainLink"><span class="ng-simple-menu_mainLink-text">current issue</span><span class="ng-simple-menu_mainLink-arrowIcon"><span class="icon-component "><svg aria-hidden="true" style=""><use xlink:href="/specs/products/mms-nextgen/mms/releasedAssets/icons/icons-3acb348e68a3edd0c676698e8d598c68.spritemap.svg#arrows-down"></use></svg></span></span></a><div class="ng-simple-menu_dropblock"><div class="ng-simple-menu_dropblock-cont"><div class="ng-simple-menu_list"><ul class="ng-simple-menu_list-items"><li class="ng-simple-menu_list-item"><a href="/toc/nejm/current" class="ng-simple-menu_list-link">VIEW CURRENT ISSUE</a></li><li class="ng-simple-menu_list-item"><a href="/toc/nejm/recently-published" class="ng-simple-menu_list-link">BROWSE RECENTLY PUBLISHED</a></li><li class="ng-simple-menu_list-item"><a href="/loi/nejm" class="ng-simple-menu_list-link">BROWSE ALL ISSUES</a></li></ul></div></div></div></li><li class="ng-menu_list-item ng-simple-menu_item hasChildren"><a href="/medical-specialties" class="ng-simple-menu_mainLink"><span class="ng-simple-menu_mainLink-text">SPECIALTIES</span><span class="ng-simple-menu_mainLink-arrowIcon"><span class="icon-component "><svg aria-hidden="true" style=""><use xlink:href="/specs/products/mms-nextgen/mms/releasedAssets/icons/icons-3acb348e68a3edd0c676698e8d598c68.spritemap.svg#arrows-down"></use></svg></span></span></a><div class="ng-simple-menu_dropblock"><div class="ng-simple-menu_dropblock-cont"><div class="ng-simple-menu_list"><ul class="ng-simple-menu_list-items"><li class="ng-simple-menu_list-item"><a href="/browse/specialty/cardiology" class="ng-simple-menu_list-link">Cardiology</a></li><li class="ng-simple-menu_list-item"><a href="/browse/specialty/clinical-medicine" class="ng-simple-menu_list-link">Clinical Medicine</a></li><li class="ng-simple-menu_list-item"><a href="/browse/specialty/endocrinology" class="ng-simple-menu_list-link">Endocrinology</a></li><li class="ng-simple-menu_list-item"><a href="/browse/specialty/gastroenterology" class="ng-simple-menu_list-link">Gastroenterology</a></li><li class="ng-simple-menu_list-item"><a href="/browse/specialty/hematology-oncology" class="ng-simple-menu_list-link">Hematology/Oncology</a></li><li class="ng-simple-menu_list-item"><a href="/browse/specialty/infectious-disease" class="ng-simple-menu_list-link">Infectious Disease</a></li><li class="ng-simple-menu_list-item"><a href="/browse/specialty/nephrology" class="ng-simple-menu_list-link">Nephrology</a></li><li class="ng-simple-menu_list-item"><a href="/browse/specialty/neurology-neurosurgery" class="ng-simple-menu_list-link">Neurology/Neurosurgery</a></li><li class="ng-simple-menu_list-item"><a href="/browse/specialty/obstetrics-gynecology" class="ng-simple-menu_list-link">Obstetrics/Gynecology</a></li><li class="ng-simple-menu_list-item"><a href="/browse/specialty/pediatrics" class="ng-simple-menu_list-link">Pediatrics</a></li><li class="ng-simple-menu_list-item"><a href="/browse/specialty/pulmonary-critical-care" class="ng-simple-menu_list-link">Pulmonary/Critical Care</a></li><li class="ng-simple-menu_list-item"><a href="/browse/specialty/surgery" class="ng-simple-menu_list-link">Surgery</a></li><li class="ng-simple-menu_list-item"><a href="/medical-specialties" class="ng-simple-menu_list-link">View All Specialties</a></li></ul></div></div></div></li><li class="ng-menu_list-item ng-simple-menu_item hasChildren"><a href="/topics" class="ng-simple-menu_mainLink"><span class="ng-simple-menu_mainLink-text">TOPICS</span><span class="ng-simple-menu_mainLink-arrowIcon"><span class="icon-component "><svg aria-hidden="true" style=""><use xlink:href="/specs/products/mms-nextgen/mms/releasedAssets/icons/icons-3acb348e68a3edd0c676698e8d598c68.spritemap.svg#arrows-down"></use></svg></span></span></a><div class="ng-simple-menu_dropblock"><div class="ng-simple-menu_dropblock-cont"><div class="ng-simple-menu_list"><ul class="ng-simple-menu_list-items"><li class="ng-simple-menu_list-item"><a href="/ai-in-medicine" class="ng-simple-menu_list-link">AI in Medicine</a></li><li class="ng-simple-menu_list-item"><a href="/browse/specialty/climate-change" class="ng-simple-menu_list-link">Climate Change</a></li><li class="ng-simple-menu_list-item"><a href="/coronavirus" class="ng-simple-menu_list-link">Coronavirus</a></li><li class="ng-simple-menu_list-item"><a href="/equity" class="ng-simple-menu_list-link">Efforts toward Equity</a></li><li class="ng-simple-menu_list-item"><a href="/firearm-injury-prevention" class="ng-simple-menu_list-link">Firearm Injury Prevention</a></li><li class="ng-simple-menu_list-item"><a href="/nam" class="ng-simple-menu_list-link">From the National Academy of Medicine</a></li><li class="ng-simple-menu_list-item"><a href="/fundamentals-of-medical-ethics" class="ng-simple-menu_list-link">Fundamentals of Medical Ethics</a></li><li class="ng-simple-menu_list-item"><a href="/gray-matters" class="ng-simple-menu_list-link">Gray Matters</a></li><li class="ng-simple-menu_list-item"><a href="/browse/specialty/health-policy" class="ng-simple-menu_list-link">Health Policy</a></li><li class="ng-simple-menu_list-item"><a href="/medicine-and-society" class="ng-simple-menu_list-link">Medicine and Society</a></li><li class="ng-simple-menu_list-item"><a href="/nutrition-in-medicine" class="ng-simple-menu_list-link">Nutrition in Medicine</a></li><li class="ng-simple-menu_list-item"><a href="/outbreaks" class="ng-simple-menu_list-link">Outbreaks Center</a></li><li class="ng-simple-menu_list-item"><a href="/race-and-medicine" class="ng-simple-menu_list-link">Race and Medicine</a></li><li class="ng-simple-menu_list-item"><a href="/recognizing-historical-injustices" class="ng-simple-menu_list-link">Recognizing Historical Injustices and the Journal</a></li><li class="ng-simple-menu_list-item"><a href="/tobacco-use-reduction" class="ng-simple-menu_list-link">Tobacco Use Reduction</a></li><li class="ng-simple-menu_list-item"><a href="/topics" class="ng-simple-menu_list-link">View All Topics</a></li></ul></div></div></div></li><li class="ng-menu_list-item ng-simple-menu_item hasChildren"><a href="/multimedia" class="ng-simple-menu_mainLink"><span class="ng-simple-menu_mainLink-text">MULTIMEDIA</span><span class="ng-simple-menu_mainLink-arrowIcon"><span class="icon-component "><svg aria-hidden="true" style=""><use xlink:href="/specs/products/mms-nextgen/mms/releasedAssets/icons/icons-3acb348e68a3edd0c676698e8d598c68.spritemap.svg#arrows-down"></use></svg></span></span></a><div class="ng-simple-menu_dropblock"><div class="ng-simple-menu_dropblock-cont"><div class="ng-simple-menu_list"><ul class="ng-simple-menu_list-items"><li class="ng-simple-menu_list-item"><a href="/rss-feed" class="ng-simple-menu_list-link">Podcasts</a></li><li class="ng-simple-menu_list-item"><a href="/double-take" class="ng-simple-menu_list-link">Double Takes</a></li><li class="ng-simple-menu_list-item"><a href="https://illustrated-glossary.nejm.org/" class="ng-simple-menu_list-link">Illustrated Glossary</a></li><li class="ng-simple-menu_list-item"><a href="/image-challenge" class="ng-simple-menu_list-link">Image Challenge</a></li><li class="ng-simple-menu_list-item"><a href="/browse/nejm-media-type/images-in-clinical-medicine" class="ng-simple-menu_list-link">Images in Clinical Medicine</a></li><li class="ng-simple-menu_list-item"><a href="/browse/nejm-media-type/interactive-medical-case" class="ng-simple-menu_list-link">Interactive Medical Cases</a></li><li class="ng-simple-menu_list-item"><a href="/plain-language-research-summaries" class="ng-simple-menu_list-link">Plain Language/Research Summaries</a></li><li class="ng-simple-menu_list-item"><a href="/multimedia/quick-take-video" class="ng-simple-menu_list-link">Quick Takes</a></li><li class="ng-simple-menu_list-item"><a href="/browse/nejm-media-type/videos-in-clinical-medicine" class="ng-simple-menu_list-link">Videos in Clinical Medicine</a></li><li class="ng-simple-menu_list-item"><a href="/multimedia" class="ng-simple-menu_list-link">View All Multimedia</a></li></ul></div></div></div></li><li class="ng-menu_list-item ng-simple-menu_item hasChildren"><a href="/learning" class="ng-simple-menu_mainLink"><span class="ng-simple-menu_mainLink-text">LEARNING/CME</span><span class="ng-simple-menu_mainLink-arrowIcon"><span class="icon-component "><svg aria-hidden="true" style=""><use xlink:href="/specs/products/mms-nextgen/mms/releasedAssets/icons/icons-3acb348e68a3edd0c676698e8d598c68.spritemap.svg#arrows-down"></use></svg></span></span></a><div class="ng-simple-menu_dropblock"><div class="ng-simple-menu_dropblock-cont"><div class="ng-simple-menu_list"><ul class="ng-simple-menu_list-items"><li class="ng-simple-menu_list-item"><a href="/continuing-medical-education" class="ng-simple-menu_list-link">Weekly CME</a></li><li class="ng-simple-menu_list-item"><a href="/cme-ce/obesity" class="ng-simple-menu_list-link">Obesity CME/CE</a></li><li class="ng-simple-menu_list-item"><a href="/learning" class="ng-simple-menu_list-link">VIEW ALL LEARNING/CME</a></li></ul></div></div></div></li><li class="ng-menu_list-item ng-simple-menu_item"><a href="/author-center/home" class="ng-simple-menu_mainLink"><span class="ng-simple-menu_mainLink-text">AUTHOR CENTER</span></a></li></ul></nav>

        </div>
    

</div><button aria-label="Search" class="ng-header_searchBtn searchBtnNav d-block ml-24"><span class="icon-component "><svg aria-hidden="true" style=""><use xlink:href="/specs/products/mms-nextgen/mms/releasedAssets/icons/icons-3acb348e68a3edd0c676698e8d598c68.spritemap.svg#search"></use></svg></span></button></div><div class="ng-header_loginBar ng-header_loginBar-sticky col-4">



        
        <div data-location="authstring_nav" class="ng-header_loginBar-menu"><span class="ng-simple-menu_mainLink-icon signIn newIcon-2"><span class="icon-component"><svg aria-hidden="true"><use xlink:href="/specs/products/mms-nextgen/mms/releasedAssets/icons/icons.spritemap.svg#user2"></use></svg></span></span><span class="ng-header_loginBar-signIn"><a href="/sign-in?uri=/doi/full/10.1056/NEJMra2026131" class="ng-header_loginBar-signIn-link">Sign In</a></span><span class="ng-header_loginBar-separator">|</span><span class="ng-header_loginBar-createAcc"><a href="/action/storeProxy?action=register&amp;promo=ONFLNRC1" class="ng-header_loginBar-createAcc-link ro-mode_disabled">Create Account</a></span></div><div data-location="authstring_nav" class="ng-header_loginBar-subscribe pl-xl-16"><a href="/action/storeProxy?action=subscribe&amp;promo=ONF4NRS1" class="ng-header_loginBar-subscribe-btn ng-btn_primary ro-mode_disabled">Subscribe</a></div>
</div></div></div></div></div><div class="ng-header_logoBar_right-lg col-lg-8 col-6 d-flex align-items-center justify-content-end d-xl-none"><button aria-label="Search" class="ng-header_searchBtn d-flex justify-content-end"><span class="icon-component "><svg aria-hidden="true" style=""><use xlink:href="/specs/products/mms-nextgen/mms/releasedAssets/icons/icons-3acb348e68a3edd0c676698e8d598c68.spritemap.svg#search"></use></svg></span></button><div class="ng-header_openCloseBtns d-flex align-items-center justify-content-end"><button aria-label="Open" class="ng-header_openBtn"><span class="icon-component "><svg aria-hidden="true" style=""><use xlink:href="/specs/products/mms-nextgen/mms/releasedAssets/icons/icons-3acb348e68a3edd0c676698e8d598c68.spritemap.svg#burger"></use></svg></span></button><button aria-label="Close" class="ng-header_closeBtn"><span class="icon-component "><svg aria-hidden="true" style=""><use xlink:href="/specs/products/mms-nextgen/mms/releasedAssets/icons/icons-3acb348e68a3edd0c676698e8d598c68.spritemap.svg#close"></use></svg></span></button></div></div><div class="ng-header_quickSearch col-12"><div class="ng-header_quickSearch-content">



        
        <div class="ng-quick-search js-ng-quick-search"><form action="/search" method="get" class="ng-quick-search_form js-form"><div class="ng-quick-search_inputArea js-inputArea"><input type="search" name="q" placeholder="Enter keyword, author, title or citation" autocomplete="off" value="" required="required" class="ng-quick-search_allField ng-large-text-input js-allField js-allField-def-tmpl ui-autocomplete-input"><button type="submit" aria-label="Search Button" class="ng-quick-search_iconBtn d-xl-none d-block js-submitBtn"><span class="icon-component "><svg aria-hidden="true" style=""><use xlink:href="/specs/products/mms-nextgen/mms/releasedAssets/icons/icons-3acb348e68a3edd0c676698e8d598c68.spritemap.svg#search"></use></svg></span></button><ul id="ui-id-1" tabindex="0" class="ui-menu ui-widget ui-widget-content ui-autocomplete ui-front" style="display: none;"></ul></div><div class="ng-quick-search_btnsArea d-none d-xl-flex align-items-center justify-content-end"><a href="/search/advanced" class="ng-quick-search_advSearchLink ng-btn_link js-advancedSearchLink">Advanced Search</a><button type="submit" class="ng-quick-search_textBtn ng-btn_secondary ng-btn_iconRight js-submitBtn"><span class="ng-btn_text">SEARCH</span><span class="icon-component "><svg aria-hidden="true" style=""><use xlink:href="/specs/products/mms-nextgen/mms/releasedAssets/icons/icons-3acb348e68a3edd0c676698e8d598c68.spritemap.svg#arrows-right"></use></svg></span></button></div></form></div>
</div></div></div></div></div></header><div class="ng-header_overlay"></div><div class="ng-header_after">









    
    
        <div data-widget-def="literatumAd" data-widget-id="4931ddbd-d46e-4597-b4fd-92549e9847ca" id="ad-global-banner-FULLx64-1">
        



        
        



    

    

    
        
    



        </div>
    

</div>

                    
                        



        
        <div>









    
    
        <main data-widget-def="axelPublicationContent" data-widget-id="fcdb5261-d6a2-4a9c-81d5-3a3e2304e9c1" id="mainContent">
        



        
        <div class="article-tools__savePopup"><div class="ng-save"><input type="hidden" value="/action/getSavedTags" class="getKeywordsServiceUrl"><input type="hidden" value="/action/mmsSaveItemsService?itemType=article" class="saveServiceUrl"><input type="hidden" value="article" class="saveType"><input type="hidden" value="10.1056/NEJMra2026131" class="inputDoi"><input type="hidden" value="D.C. Fajgenbaum and C.H. June" class="inputAuthor"><input type="hidden" value="N Engl J Med 2020;383:2255-2273" class="inputCitation"><input type="hidden" value="12-02-2020" class="inputEPubDate"><input type="hidden" value="December 2020" class="inputCoverDate"><input type="hidden" value="Review Article" class="inputContentType"><input type="hidden" value="Cytokine Storm" class="inputArticleTitle"><input type="hidden" value="/browse/nejm-article-type/review-article" class="inputContentTypeUrl"><button type="button" id="saveArticleShowPopupBtn" aria-hidden="true" tabindex="-1" class="ng-save-btn ng-btn_secondary isLoggedOut">Save</button></div></div><div class="article-tools__articleAlertPopup"><div id="articleAlertModal" tabindex="-1" role="dialog" aria-labelledby="exampleModalCenterTitle" aria-hidden="true" class="ng-modal modal"><div role="document" class="ng-modal_dialog modal-dialog modal-dialog-centered"><div class="ng-modal_content modal-content"><div class="ng-modal_header modal-header"><h5 id="articleAlertModalTitle" class="ng-modal_title modal-title">Create an E-mail Alert for This Article</h5><button type="button" data-dismiss="modal" aria-label="Close" class="ng-modal_close close"><span aria-hidden="true"><span class="icon-component "><svg aria-hidden="true" style=""><use xlink:href="/specs/products/mms-nextgen/mms/releasedAssets/icons/icons-3acb348e68a3edd0c676698e8d598c68.spritemap.svg#close"></use></svg></span></span></button></div><div class="ng-modal_body modal-body"></div></div></div></div></div><div class="ng-do-media_popup"><div id="doPopup" tabindex="-1" role="dialog" aria-labelledby="exampleModalCenterTitle" aria-hidden="true" class="ng-modal modal"><div role="document" class="ng-modal_dialog modal-dialog modal-dialog-centered"><div class="ng-modal_content modal-content"><div class="ng-modal_header modal-header"><button type="button" data-dismiss="modal" aria-label="Close" class="ng-modal_close close"><span aria-hidden="true"><span class="icon-component "><svg aria-hidden="true" style=""><use xlink:href="/specs/products/mms-nextgen/mms/releasedAssets/icons/icons-3acb348e68a3edd0c676698e8d598c68.spritemap.svg#close"></use></svg></span></span></button></div><div class="ng-modal_body modal-body"></div></div></div></div></div><link id="build-style-article" rel="stylesheet" type="text/css" href="/products/mms-nextgen/mms/releasedAssets/css/build-article-5b89b331018866a4a965.css"><article xmlns="http://www.w3.org/1999/xhtml" data-design="pill" data-has="right-rail" data-type="review-article" vocab="http://schema.org/" typeof="ScholarlyArticle" lang="en" dir="ltr"><header data-extent="frontmatter" data-location="header_article"><div class="core-container"><div data-article-access="free" data-article-access-type="free" class="meta-panel"><div class="meta-panel__left-content"><div class="meta-panel__type"><a href="/browse/nejm-article-type/review-article">Review Article</a></div></div><div class="meta-panel__right-content"><div class="meta-panel__share">









    
    
        <div data-widget-def="UX3share" data-widget-id="eee5f139-16f2-48f8-97ea-1b114367da16" data-location="share_tools_article">
        



        
        <!-- Go to https://www.addtoany.com/buttons/customize/ to customize your tools --><script type="text/javascript" defer="defer" src="https://static.addtoany.com/menu/page.js" nonce="94d65ade13caf211-SJC"></script><div class="share"><div class="share__block share__inline-links"><div class="pb-dropzone" data-pb-dropzone="shareBlock" title="shareBlock"></div><span class="sr-only">Share on</span><ul class="d-flex list-unstyled a2a a2a_kit a2a_default_style mb-0 a2a_kit_size_32" style="line-height: 32px;"><li class="a2a_listitem_custom"><a role="link" title="Facebook" data-interactiontype="social" class="share__link a2a_button_facebook" target="_blank" rel="nofollow noopener" href="/#facebook"><span class="icon-component " style="height: 24px; width: 24px"><svg aria-hidden="true" style="height: 24px; width: 24px"><use xlink:href="/specs/products/mms-nextgen/mms/releasedAssets/icons/icons-3acb348e68a3edd0c676698e8d598c68.spritemap.svg#social-facebook"></use></svg></span></a></li><li class="a2a_listitem_custom"><a role="link" title="X (formerly Twitter)" data-interactiontype="social" class="share__link a2a_button_twitter" target="_blank" rel="nofollow noopener" href="/#twitter"><span class="icon-component " style="height: 24px; width: 24px"><svg aria-hidden="true" style="height: 24px; width: 24px"><use xlink:href="/specs/products/mms-nextgen/mms/releasedAssets/icons/icons-3acb348e68a3edd0c676698e8d598c68.spritemap.svg#social-twitter"></use></svg></span></a></li><li class="a2a_listitem_custom"><a role="link" title="Linked In" data-interactiontype="social" class="share__link a2a_button_linkedin" target="_blank" rel="nofollow noopener" href="/#linkedin"><span class="icon-component " style="height: 24px; width: 24px"><svg aria-hidden="true" style="height: 24px; width: 24px"><use xlink:href="/specs/products/mms-nextgen/mms/releasedAssets/icons/icons-3acb348e68a3edd0c676698e8d598c68.spritemap.svg#social-linkedin"></use></svg></span></a></li><li class="a2a_listitem_custom"><a role="link" title="Email" data-interactiontype="content_email_click" class="share__link a2a_button_email" target="_blank" rel="nofollow noopener" href="/#email"><span class="icon-component " style="height: 24px; width: 24px"><svg aria-hidden="true" style="height: 24px; width: 24px"><use xlink:href="/specs/products/mms-nextgen/mms/releasedAssets/icons/icons-3acb348e68a3edd0c676698e8d598c68.spritemap.svg#social-email"></use></svg></span></a></li><li class="a2a_listitem_custom"><a role="link" title="Bluesky" data-interactiontype="social" class="share__link a2a_button_bluesky" target="_blank" rel="nofollow noopener" href="/#bluesky"><span class="icon-component " style="height: 24px; width: 24px"><svg aria-hidden="true" style="height: 24px; width: 24px"><use xlink:href="/specs/products/mms-nextgen/mms/releasedAssets/icons/icons-3acb348e68a3edd0c676698e8d598c68.spritemap.svg#social-bluesky"></use></svg></span></a></li></ul></div></div>

        </div>
    

</div></div></div><h1 property="name">Cytokine Storm</h1><div class="core-relations my-3"></div><div class="contributors"><span class="authors"><span class="heading">Authors</span>: <span role="list"><span property="author" typeof="Person" role="listitem"><span property="givenName">David C.</span> <span property="familyName">Fajgenbaum</span>, <span property="honorificSuffix">M.D.</span> <a class="orcid-id" href="https://orcid.org/0000-0002-7367-8184" property="identifier" aria-label="ORCID identifier" target="_blank">https://orcid.org/0000-0002-7367-8184</a></span>, and <span property="author" typeof="Person" role="listitem"><span property="givenName">Carl H.</span> <span property="familyName">June</span>, <span property="honorificSuffix">M.D.</span> <a class="orcid-id" href="https://orcid.org/0000-0003-0241-3557" property="identifier" aria-label="ORCID identifier" target="_blank">https://orcid.org/0000-0003-0241-3557</a></span></span></span><a href="#tab-contributors" class="to-authors-affiliations" data-id="article-authors-viewall">Author Info &amp; Affiliations</a></div><div class="core-self-citation"><div class="core-date-published">Published <span property="datePublished">December 2, 2020</span></div><div property="isPartOf" typeof="Periodical"><span property="name">N Engl J Med</span> 2020<span property="isPartOf" typeof="PublicationVolume">;<span property="volumeNumber">383</span></span>:<span property="pageStart">2255</span>-<span property="pageEnd">2273</span></div><div class="doi">DOI: 10.1056/NEJMra2026131</div><div class="core-enumeration"><a href="/toc/nejm/383/23"><span property="isPartOf" typeof="PublicationVolume">VOL. <span property="volumeNumber">383</span></span> <span property="isPartOf" typeof="PublicationIssue">NO. <span property="issueNumber">23</span></span></a></div><div><a href="#tab-information">Copyright © 2020</a></div></div><div class="info-panel"><div class="info-panel__left-content"><div class="info-panel__metrics info-panel__item"></div></div><div data-location="tools_article" class="info-panel__right-content"><div class="info-panel__article_tools info-panel__item">



        
        <div data-permission="/servlet/linkout?type=rightslink&amp;url=publisherName%3Dmassmed%26author%3DDavid%2BC.%2BFajgenbaum%252C%2BCarl%2BH.%2BJune%26publication%3Dnejm%26orderBeanReset%3Dtrue%26volumeNum%3D383%26issueNum%3D23%26contentID%3D10.1056%252FNEJMra2026131%26title%3DCytokine%2BStorm%26publicationDate%3D12%252F03%252F2020" class="article-tools"><button id="articleToolsAlertBtn" data-url="/action/addCitationAlert?doi=10.1056%2FNEJMra2026131" data-toggle="" data-target="#articleAlertModal" aria-label="Sign in or create account to add an article alert" data-interactiontype="article_alert" class="article-tools__citation btn btn--slim isLoggedOut"><span title="" data-toggle="tooltip" class="d-inline-block" data-original-title="Sign in or create account to add an article alert"><span class="icon-component "><svg aria-hidden="true" style=""><use xlink:href="/specs/products/mms-nextgen/mms/releasedAssets/icons/icons-3acb348e68a3edd0c676698e8d598c68.spritemap.svg#alerts"></use></svg></span></span></button><button id="articleToolsSaveBtn" data-toggle="modal" data-target="#saveArticle" aria-label="Sign in or create account to save this article" data-interactiontype="article_tools_save_click" class="article-tools__favorite btn btn--slim isLoggedOut"><span title="" data-toggle="tooltip" class="d-inline-block" data-original-title="Sign in or create account to save this article"><span class="icon-component "><svg aria-hidden="true" style=""><use xlink:href="/specs/products/mms-nextgen/mms/releasedAssets/icons/icons-3acb348e68a3edd0c676698e8d598c68.spritemap.svg#bookmarkFilled"></use></svg></span></span></button><a href="/servlet/linkout?type=rightslink&amp;url=publisherName%3Dmassmed%26author%3DDavid%2BC.%2BFajgenbaum%252C%2BCarl%2BH.%2BJune%26publication%3Dnejm%26orderBeanReset%3Dtrue%26volumeNum%3D383%26issueNum%3D23%26contentID%3D10.1056%252FNEJMra2026131%26title%3DCytokine%2BStorm%26publicationDate%3D12%252F03%252F2020" target="_blank" title="" data-toggle="tooltip" aria-label="Permissions" data-interactiontype="article_tools_permissions_click" class="article-tools__permissions btn btn--slim" data-original-title="Permissions"><span class="icon-component "><svg aria-hidden="true" style=""><use xlink:href="/specs/products/mms-nextgen/mms/releasedAssets/icons/icons-3acb348e68a3edd0c676698e8d598c68.spritemap.svg#permissions"></use></svg></span></a><a href="/about-nejm/reprints" title="" data-toggle="tooltip" aria-label="Reprints" data-interactiontype="article_tools_reprints_click" class="article-tools__reprints btn btn--slim" data-original-title="Reprints"><span class="icon-component "><svg aria-hidden="true" style=""><use xlink:href="/specs/products/mms-nextgen/mms/releasedAssets/icons/icons-3acb348e68a3edd0c676698e8d598c68.spritemap.svg#reprints"></use></svg></span></a><a href="/cms/asset/0fbd95ac-bf0a-418e-9941-1771fa5caeb7/nejmra2026131.pptx" target="_blank" title="" data-toggle="tooltip" aria-label="Download Slides" data-interactiontype="article_tools_slide_set_download" data-multimedia-type="Article Slideset" data-multimedia-filename="nejmra2026131.pptx" class="article-tools__downloadSlides btn btn--slim" data-original-title="Download Slides"><span class="icon-component "><svg aria-hidden="true" style=""><use xlink:href="/specs/products/mms-nextgen/mms/releasedAssets/icons/icons-3acb348e68a3edd0c676698e8d598c68.spritemap.svg#download"></use></svg></span></a><div class="article-tools__permissionsPopup"><div id="permissionsModal" tabindex="-1" role="dialog" aria-labelledby="exampleModalCenterTitle" aria-hidden="true" class="ng-modal modal"><div role="document" class="ng-modal_dialog modal-dialog modal-dialog-centered"><div class="ng-modal_content modal-content"><div class="ng-modal_header modal-header"><h5 id="permissionsModalTitle" class="ng-modal_title modal-title">Permissions</h5><button type="button" data-dismiss="modal" aria-label="Close" class="ng-modal_close close"><span aria-hidden="true"><span class="icon-component "><svg aria-hidden="true" style=""><use xlink:href="/specs/products/mms-nextgen/mms/releasedAssets/icons/icons-3acb348e68a3edd0c676698e8d598c68.spritemap.svg#close"></use></svg></span></span></button></div><div class="ng-modal_body modal-body">For permission requests, please contact NEJM Reprints at <a href="mailto:reprints@nejm.org">reprints@nejm.org</a></div></div></div></div></div></div>
</div><div class="info-panel__citations info-panel__item"><a href="#tab-citations" class="btn btn--slim" aria-label="View Citations" data-toggle="tooltip" data-original-title="View Citations" data-interactiontype="article_tools_citation_download" data-multimedia-type="Citation"><i aria-hidden="true" class="icon-format_quote"></i></a></div><div class="info-panel__formats info-panel__item"><a href="https://www.nejm.org/doi/pdf/10.1056/NEJMra2026131" class="btn btn--pdf btn--slim" aria-label="View PDF" data-toggle="tooltip" data-original-title="View PDF" data-behavior="trackDownloadEvent" data-doi="10.1056/NEJMra2026131" data-interactiontype="article_tools_download_pdf" data-multimedia-type="Article PDF" data-multimedia-filename="nejmra2026131.pdf"><i aria-hidden="true" class="icon-PDF"></i></a></div></div></div></div></header><div data-core-nav="header" data-extent="frontmatter"><div class="core-nav-wrapper core-container" aria-label="Article navigation"><div class="core-sections-menu"><button data-id="article-toolbar-showhide" aria-controls="article_sections_menu" aria-expanded="false" aria-label="Toggle section navigation menu" style="margin-top: 0px;"><i class="icon-list" aria-hidden="true"></i><span>Contents</span></button><nav id="article_sections_menu" aria-label="Contents" data-core-nav="article" style="margin-top: 0px;"><ul><li><a href="#sec-1" aria-current="false">Clinical Features and Laboratory Abnormalities</a></li><li><a href="#sec-2" aria-current="false">Pathophysiological Features of Cytokine Storm</a></li><li><a href="#sec-3" aria-current="false">Iatrogenic Cytokine Storm</a></li><li><a href="#sec-4" aria-current="false">Pathogen-Induced Cytokine Storm</a></li><li><a href="#sec-5" aria-current="false">Monogenic or Autoimmune Cytokine Storm</a></li><li><a href="#sec-6" aria-current="false">Covid-19–Associated Cytokine Storm</a></li><li><a href="#sec-7" aria-current="false">Therapeutics</a></li><li><a href="#sec-8" aria-current="false">Summary</a></li><li class="bordered"><a href="#backnotes" aria-current="false">Notes</a></li><li><a href="#supplementary-materials" aria-current="false">Supplementary Material</a></li><li><a href="#bibliography" aria-current="false">References</a></li></ul></nav></div><nav id="article_collateral_menu"><ul data-core-nav="collateral" class="collateral-pill" style="margin-top: 0px;"><li><a href="#core-collateral-info" data-id="article-nav-menubar-info" title="" tabindex="0" data-toggle="tooltip" data-placement="left" data-offset="4px, 16px" data-original-title="Information &amp; Authors"><i aria-hidden="true" class="icon-info"></i><span class="sr-only">Information &amp; Authors</span></a></li><li><a href="#core-collateral-metrics" data-id="article-nav-menubar-metrics" title="" tabindex="0" data-toggle="tooltip" data-placement="left" data-offset="4px, 16px" data-original-title="Metrics &amp; Citations"><i aria-hidden="true" class="icon-timeline"></i><span class="sr-only">Metrics &amp; Citations</span></a></li><li><a href="#core-collateral-fulltext-options" data-id="article-nav-menubar-metrics" title="" tabindex="0" data-toggle="tooltip" data-placement="left" data-offset="4px, 16px" data-original-title="View Options"><i aria-hidden="true" class="icon-eye"></i><span class="sr-only">View Options</span></a></li><li><a href="#core-collateral-references" data-id="article-nav-menubar-references" title="" tabindex="0" data-toggle="tooltip" data-placement="left" data-offset="4px, 16px" data-original-title="References"><i aria-hidden="true" class="icon-references"></i><span class="sr-only">References</span></a></li><li><a href="#core-collateral-media" data-id="article-nav-menubar-media" title="" tabindex="0" data-toggle="tooltip" data-placement="left" data-offset="4px, 16px" data-original-title="Media"><i aria-hidden="true" class="icon-photo"></i><span class="sr-only">Media</span></a></li><li><a href="#core-collateral-tables" data-id="article-nav-menubar-tables" title="" tabindex="0" data-toggle="tooltip" data-placement="left" data-offset="4px, 16px" data-original-title="Tables"><i aria-hidden="true" class="icon-tables"></i><span class="sr-only">Tables</span></a></li><li><a href="#core-collateral-share" data-id="article-nav-menubar-share" title="" tabindex="0" data-toggle="tooltip" data-placement="left" data-offset="4px, 16px" data-original-title="Share"><i aria-hidden="true" class="icon-share"></i><span class="sr-only">Share</span></a></li></ul></nav></div></div><div data-core-wrapper="content"><section id="bodymatter" data-extent="bodymatter" property="articleBody" typeof="Text" data-location="articleTab_article"><div class="core-container"><div role="paragraph">The severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) pandemic has reminded us of the critical role of an effective host immune response and the devastating effect of immune dysregulation. This year marks 10 years since the first description of a cytokine storm that developed after chimeric antigen receptor (CAR) T-cell therapy<sup><a href="#core-r1" role="doc-biblioref" data-xml-rid="r1" id="body-ref-r1" href-manipulated="true" aria-label="Reference 1">1</a></sup> and 27 years since the term was first used in the literature to describe the engraftment syndrome of acute graft-versus-host disease after allogeneic hematopoietic stem-cell transplantation.<sup><a href="#core-r2" role="doc-biblioref" data-xml-rid="r2" id="body-ref-r2" href-manipulated="true" aria-label="Reference 2">2</a></sup> The term “cytokine release syndrome” was coined to describe a similar syndrome after infusion of muromonab-CD3 (OKT3).<sup><a href="#core-r3" role="doc-biblioref" data-xml-rid="r3" id="body-ref-r3" href-manipulated="true" aria-label="Reference 3">3</a></sup> Cytokine storm and cytokine release syndrome are life-threatening systemic inflammatory syndromes involving elevated levels of circulating cytokines and immune-cell hyperactivation that can be triggered by various therapies, pathogens, cancers, autoimmune conditions, and monogenic disorders.</div><div role="paragraph">From a historical perspective, cytokine storm was previously referred to as an influenza-like syndrome that occurred after systemic infections such as sepsis and after immunotherapies such as Coley’s toxins.<sup><a href="#core-r4" role="doc-biblioref" data-xml-rid="r4" id="body-ref-r4" href-manipulated="true" aria-label="Reference 4">4</a></sup> <i>Yersinia pestis</i> infection (i.e., the plague) has led to major pandemics (e.g., the Black Death) and triggers alveolar macrophages to produce excessive amounts of cytokines, resulting in cytokine storm.<sup><a href="#core-r5" role="doc-biblioref" data-xml-rid="r5" id="body-ref-r5" href-manipulated="true" aria-label="Reference 5">5</a></sup> An exaggerated immune response was suspected to contribute to the lethality of the 1918–1919 influenza pandemic. In fact, a reconstructed H1N1 virus isolated from the 1918 pandemic, as compared with common reference strains of the virus that causes influenza A, triggered marked pulmonary inflammation in mice.<sup><a href="#core-r6" role="doc-biblioref" data-xml-rid="r6" id="body-ref-r6" href-manipulated="true" aria-label="Reference 6">6</a></sup> Recognition that the immune response to the pathogen, but not the pathogen itself, can contribute to multiorgan dysfunction and that similar cytokine storm syndromes could occur with no obvious infection led to the investigation of immunomodulators and cytokine-directed therapies. One of the earliest targeted therapies for abrogation of a cytokine storm was the anti–interleukin-6 receptor monoclonal antibody tocilizumab, which was developed for the treatment of idiopathic multicentric Castleman’s disease in the 1990s. A host of other disorders have been described as causes of cytokine storm and targeted with immune-directed therapies, such as sepsis, primary and secondary hemophagocytic lymphohistiocytosis (HLH), autoinflammatory disorders, and coronavirus disease 2019 (Covid-19).</div><div role="paragraph">No single definition of cytokine storm or the cytokine release syndrome is widely accepted, and there is disagreement about how these disorders differ from an appropriate inflammatory response. The National Cancer Institute’s definition, based on the Common Terminology Criteria for Adverse Events (CTCAE), is too broad, since the criteria for an inflammatory syndrome can also apply to other physiological states, and the definition of the American Society for Transplantation and Cellular Therapy is based on criteria that focus too specifically on iatrogenic causes of cytokine storm alone.<sup><a href="#core-r7" role="doc-biblioref" data-xml-rid="r7" id="body-ref-r7-1" href-manipulated="true" aria-label="Reference 7">7</a></sup> Although cytokine storm is easy to identify in disorders with elevated cytokine levels in the absence of pathogens, the line between a normal and a dysregulated response to a severe infection is blurry, especially considering that certain cytokines may be both helpful in controlling an infection and harmful to the host. The interdependence of these inflammatory mediators further complicates the distinction between a normal and a dysregulated response.</div><div role="paragraph">It is important for the clinician to recognize cytokine storm because it has prognostic and therapeutic implications. In this review, we propose a unifying definition of cytokine storm; discuss the pathophysiological features, clinical presentation, and management of the syndrome; and provide an overview of iatrogenic, pathogen-induced, neoplasia-induced, and monogenic causes. Our goal is to provide physicians with a conceptual framework, a unifying definition, and essential staging, assessment, and therapeutic tools to manage cytokine storm.</div><section id="sec-1"><h2>Clinical Features and Laboratory Abnormalities</h2><div role="paragraph">Cytokine storm is an umbrella term encompassing several disorders of immune dysregulation characterized by constitutional symptoms, systemic inflammation, and multiorgan dysfunction that can lead to multiorgan failure if inadequately treated (<a href="#f1">Figure 1</a>). The onset and duration of cytokine storm vary, depending on the cause and treatments administered.<sup><a href="#core-r7" role="doc-biblioref" data-xml-rid="r7" id="body-ref-r7-2" href-manipulated="true" aria-label="Reference 7">7</a></sup> Although the initial drivers may differ, late-stage clinical manifestations of cytokine storm converge and often overlap. Nearly all patients with cytokine storm are febrile, and the fever may be high grade in severe cases.<sup><a href="#core-r8" role="doc-biblioref" data-xml-rid="r8" id="body-ref-r8-1" href-manipulated="true" aria-label="Reference 8">8</a></sup> In addition, patients may have fatigue, anorexia, headache, rash, diarrhea, arthralgia, myalgia, and neuropsychiatric findings. These symptoms may be due directly to cytokine-induced tissue damage or acute-phase physiological changes or may result from immune-cell–mediated responses. Cases can progress rapidly to disseminated intravascular coagulation with either vascular occlusion or catastrophic hemorrhages, dyspnea, hypoxemia, hypotension, hemostatic imbalance, vasodilatory shock, and death. Many patients have respiratory symptoms, including cough and tachypnea, that can progress to acute respiratory distress syndrome (ARDS), with hypoxemia that may require mechanical ventilation. The combination of hyperinflammation, coagulopathy, and low platelet counts places patients with cytokine storm at high risk for spontaneous hemorrhage.</div><div class="figure-wrap" data-presentation="diminished-in-flow"><header><div class="label">Figure 1</div><nav><a href="#f1" title="Open in viewer" class="open-in-viewer" data-index="0" data-interactiontype="multimedia_click" data-multimedia-type="Figure" data-multimedia-filename="nejmra2026131_f1.jpg"><i aria-hidden="true" class="icon-expand"></i></a></nav></header><figure id="f1" class="graphic"><a aria-label="Open figure in viewer" class="open-in-viewer" data-index="0" href="#f1" data-interactiontype="multimedia_click" data-multimedia-type="Figure" data-multimedia-filename="nejmra2026131_f1.jpg"><img src="/cms/10.1056/NEJMra2026131/asset/909f0648-4b51-4338-9760-cefa7aab4ca6/assets/images/large/nejmra2026131_f1.jpg" height="2206" width="2640" aria-labelledby="f1" loading="lazy"></a><figcaption><div class="caption">Clinical Presentation of Cytokine Storm.</div><div class="notes"><div role="doc-footnote">A wide range of clinical and laboratory abnormalities can be observed in cytokine storm. However, all cases involve elevated circulating cytokine levels, acute systemic inflammatory symptoms, and secondary organ dysfunction (often renal, hepatic, or pulmonary). ARDS denotes acute respiratory distress syndrome, CRP C-reactive protein, and VEGF vascular endothelial growth factor.</div></div></figcaption></figure></div><div role="paragraph">In severe cases of cytokine storm, renal failure, acute liver injury or cholestasis, and a stress-related or takotsubo-like cardiomyopathy can also develop.<sup><a href="#core-r9" role="doc-biblioref" data-xml-rid="r9" id="body-ref-r9" href-manipulated="true" aria-label="Reference 9">9</a></sup> The combination of renal dysfunction, endothelial-cell death, and acute-phase hypoalbuminemia can lead to capillary leak syndrome and anasarca — changes that are similar to those observed in patients with cancer who are treated with high-dose interleukin-2.<sup><a href="#core-r10" role="doc-biblioref" data-xml-rid="r10" id="body-ref-r10" href-manipulated="true" aria-label="Reference 10">10</a></sup> Neurologic toxicity associated with T-cell immunotherapy is referred to as immune effector cell–associated neurotoxicity syndrome or cytokine release syndrome–associated encephalopathy.<sup><a href="#core-r7" role="doc-biblioref" data-xml-rid="r7" id="body-ref-r7-3" href-manipulated="true" aria-label="Reference 7">7</a></sup> The neurologic toxic effects are often delayed, developing several days after the onset of the cytokine storm.</div><div role="paragraph">The laboratory findings in cytokine storm are variable and influenced by the underlying cause. Nonspecific markers of inflammation such as C-reactive protein (CRP) are universally elevated and correlate with severity.<sup><a href="#core-r11" role="doc-biblioref" data-xml-rid="r11" id="body-ref-r11" href-manipulated="true" aria-label="Reference 11">11</a></sup> Many patients have hypertriglyceridemia and various blood-count abnormalities, such as leukocytosis, leukopenia, anemia, thrombocytopenia, and elevated ferritin and <span data-style="small-caps">d</span>-dimer levels. Changes in circulating cell counts are most likely due to a complex interplay among cytokine-induced changes in production and mobilization of cells from the bone marrow, immune-mediated destruction, and chemokine-induced migration. Prominent elevations in serum inflammatory cytokine levels, such as interferon-γ (or CXCL9 and CXCL10, chemokines induced by interferon-γ), interleukin-6, interleukin-10, and soluble interleukin-2 receptor alpha, a marker of T-cell activation, are usually present. Highly elevated serum interleukin-6 levels are found in CAR T-cell therapy–induced cytokine storm and several other cytokine storm disorders.<sup><a href="#core-r8" role="doc-biblioref" data-xml-rid="r8" id="body-ref-r8-2" href-manipulated="true" aria-label="Reference 8">8</a></sup></div><div role="paragraph">The approach to evaluating a patient with cytokine storm should accomplish the following three main goals: identifying the underlying disorder (and ruling out disorders that may mimic cytokine storm), establishing severity, and determining the clinical trajectory. A complete workup for infection, as well as laboratory assessment of kidney and liver function, should be performed in all suspected cases of cytokine storm. Measurements of inflammatory acute-phase biomarkers, such as CRP and ferritin, and blood counts should be obtained, since they correlate with disease activity. Arterial blood-gas measurement should be performed if the respiratory evaluation warrants it. Cytokine profiles may be helpful in determining the trend from baseline values, although these findings are typically not available soon enough to include as part of the immediate workup or to guide treatment decisions.</div><div role="paragraph">Establishing the disorder underlying the cytokine storm can be challenging. Cytokine storm is not a diagnosis of exclusion, and it can encompass many disorders. For example, patients may have both sepsis and cytokine storm. However, it is important to distinguish between cytokine storm due to an iatrogenic cause such as CAR T-cell therapy and cytokine storm due to systemic infection, since immunosuppressive treatments could be detrimental if used in patients with septicemia. Unfortunately, it is difficult to distinguish cytokine storm due to sepsis from cytokine storm due to CAR T-cell therapy on the basis of clinical features alone. Levels of serum cytokines — most prominently, interferon-γ — are often more elevated in patients with cytokine storm due to CAR T-cell therapy than in patients with sepsis-induced cytokine storm, who often have higher levels of circulating interleukin-1β, procalcitonin, and markers of endothelial damage.<sup><a href="#core-r12" role="doc-biblioref" data-xml-rid="r12" id="body-ref-r12" href-manipulated="true" aria-label="Reference 12">12</a></sup> Thus, combinations of assays to rule out infection and measure serum cytokines can help to identify the cause of the cytokine storm. However, CAR T-cell therapy and other noninfectious causes can also occur with infections, and infections can develop during the course of therapy, so continued monitoring for infections is warranted. Disorders that should be ruled out in considering cytokine storm include anaphylaxis and physiological responses to microbial infections.</div><div role="paragraph">The grading systems used to predict and assess the severity of cytokine storm differ according to the cause. Serum biomarkers, including glycoprotein 130 (gp130), interferon-γ, and interleukin-1–receptor antagonist (IL1RA), can be used to predict the severity of cytokine storm induced by CAR T-cell therapy,<sup><a href="#core-r13" role="doc-biblioref" data-xml-rid="r13" id="body-ref-r13" href-manipulated="true" aria-label="Reference 13">13</a></sup> with a separate grading scale used to assess the current severity.<sup><a href="#core-r7" role="doc-biblioref" data-xml-rid="r7" id="body-ref-r7-4" href-manipulated="true" aria-label="Reference 7">7</a></sup> HScore and MS score are used for classifying HLH-associated cytokine storm, and HLH-2004 guides treatment. For the grading of cytokine storm due to other causes, the immune systems disorders section of CTCAE is used (<a href="https://ctep.cancer.gov/protocolDevelopment/electronic_applications/docs/CTCAE_v5_Quick_Reference_5x7.pdf" target="_blank">https://ctep.cancer.gov/protocolDevelopment/electronic_applications/docs/CTCAE_v5_Quick_Reference_5x7.pdf</a>).</div></section><section id="sec-2"><h2>Pathophysiological Features of Cytokine Storm</h2><div role="paragraph">Inflammation involves a set of biologic mechanisms that evolved in multicellular organisms to contain invasive pathogens and resolve injuries by activating innate and adaptive immune responses. The immune system is expected to recognize foreign invaders, respond proportionally to the pathogen burden, and then return to homeostasis. This response requires a balance between sufficient cytokine production to eliminate the pathogen and avoidance of a hyperinflammatory response in which an overabundance of cytokines causes clinically significant collateral damage. Cytokines play a key role in coordinating antimicrobial effector cells and providing regulatory signals that direct, amplify, and resolve the immune response. Cytokines have short half-lives, which normally prevents them from having effects outside lymphoid tissue and sites of inflammation. Although typically considered to be pathologic, sustained production of cytokines that leads to elevated circulating levels may be necessary to appropriately control some disseminated infections. At increased levels, cytokines can have systemic effects and cause collateral damage to vital organ systems.</div><div role="paragraph">Immune hyperactivation in cytokine storm can occur as a result of inappropriate triggering or danger sensing, with a response initiated in the absence of a pathogen (e.g., in genetic disorders involving inappropriate inflammasome activation or idiopathic multicentric Castleman’s disease); an inappropriate or ineffective amplitude of response, involving excessive effector immune-cell activation (e.g., in cytokine storm due to CAR T-cell therapy), an overwhelming pathogen burden (e.g., in sepsis), or uncontrolled infections and prolonged immune activation (e.g., in HLH associated with Epstein–Barr virus [EBV]); or failure to resolve the immune response and return to homeostasis (e.g., in primary HLH) (<a href="#f2">Figure 2</a>). In each of these states, there is a failure of negative feedback mechanisms that are meant to prevent hyperinflammation and the overproduction of inflammatory cytokines and soluble mediators. The excessive cytokine production leads to hyperinflammation and multiorgan failure. Regulatory cell types, decoy receptors for proinflammatory cytokines such as IL1RA, and antiinflammatory cytokines such as interleukin-10 are important for antagonizing inflammatory-cell populations and preventing immune hyperactivity.</div><div class="figure-wrap" data-presentation="diminished-in-flow"><header><div class="label">Figure 2</div><nav><a href="#f2" title="Open in viewer" class="open-in-viewer" data-index="0" data-interactiontype="multimedia_click" data-multimedia-type="Figure" data-multimedia-filename="nejmra2026131_f2.jpg"><i aria-hidden="true" class="icon-expand"></i></a></nav></header><figure id="f2" class="graphic"><a aria-label="Open figure in viewer" class="open-in-viewer" data-index="0" href="#f2" data-interactiontype="multimedia_click" data-multimedia-type="Figure" data-multimedia-filename="nejmra2026131_f2.jpg"><img src="/cms/10.1056/NEJMra2026131/asset/90086a76-be54-4325-874f-c36584350de8/assets/images/large/nejmra2026131_f2.jpg" height="3341" width="2640" aria-labelledby="f2" loading="lazy"></a><figcaption><div class="caption">Pathophysiological Features of Cytokine Storm.</div><div class="notes"><div role="doc-footnote">Cytokine storm can occur as a result of inappropriate recognition (e.g., in hypersensitivity) or ineffective recognition with immune evasion (e.g., in Epstein–Barr virus [EBV]–associated hemophagocytic lymphohistiocytosis [HLH]), an inappropriate response with an exaggerated effector response and cytokine production (e.g., in chimeric antigen receptor [CAR] T-cell therapy) or an ineffective response due to immune evasion (e.g., in sepsis), or failure to terminate homeostasis or return to homeostasis (e.g., in HLH). Examples of drugs that can inhibit signaling pathways are shown in boxes. Covid-19 denotes coronavirus disease 2019, CS cytokine storm, IL1RA interleukin-1–receptor antagonist, IP-10 interferon-inducible protein 10, JAK-STAT3 Janus kinase–signal transducer and activator of transcription 3, MAPK mitogen-activated protein kinase, MCP-1 monocyte chemotactic protein 1, MIP-1α macrophage inflammatory protein 1α, mTOR mammalian target of rapamycin, NF-κB nuclear factor κB, TNF tumor necrosis factor, and Tregs regulatory T cells.</div></div></figcaption></figure></div><div role="paragraph">Given the lack of a unifying definition for cytokine storm<sup><a href="#core-r14" role="doc-biblioref" data-xml-rid="r14" id="body-ref-r14-1" href-manipulated="true" aria-label="Reference 14">14</a></sup> and disagreement about the distinction between cytokine storm and a physiologic inflammatory response, we propose the following three criteria for identifying cytokine storm: elevated circulating cytokine levels, acute systemic inflammatory symptoms, and either secondary organ dysfunction (often renal, hepatic, or pulmonary) due to inflammation beyond that which could be attributed to a normal response to a pathogen (if a pathogen is present), or any cytokine-driven organ dysfunction (if no pathogen is present). Improvement in outcomes with cytokine neutralization or antiinflammatory agents further supports the pathologic role of excessive cytokines and the classification of a condition as a cytokine storm. However, lack of a treatment response does not necessarily rule out cytokine storm, because underlying conditions are likely to play a part, a different cytokine may be the disease driver, or the timing of treatment may have been poor.</div><div role="paragraph">In short, cytokine storm involves an immune response that causes collateral damage, which may be greater than the immediate benefit of the immune response. Thus, an exuberant inflammatory response to a large pathogen burden may be appropriate for controlling the infection if excessive secondary organ dysfunction does not occur, whereas similarly high levels of cytokines in cancer-associated HLH or idiopathic multicentric Castleman’s disease would be considered a pathologic state of cytokine storm because no pathogen requiring an immune response is involved and patients benefit from treatment with cytokine neutralization and other antiinflammatory agents. Circulating cytokine levels can be difficult to measure because cytokines have short half-lives, circulating levels may not accurately reflect local tissue levels, and measurements may not be easily obtained worldwide. We do not propose a specific threshold for elevations in cytokine levels above the normal range, and we do not recommend specific cytokine panels or list particular cytokines whose levels must be elevated, given the lack of available evidence. However, we believe that this is an important area for future research and could benefit from systematic assessment by a multidisciplinary consortium.</div><section id="sec-2-1"><h3>Cell Types Involved in Cytokine Storm</h3><div role="paragraph">The cells of the innate immune system are the first line of defense against pathogens. Neutrophils, monocytes, and macrophages recognize pathogens, produce cytokines, and engulf pathogens and cells by phagocytosis. There are many other innate immune cells, such as dendritic cells, gamma–delta T cells, and natural killer (NK) cells.<sup><a href="#core-r15" role="doc-biblioref" data-xml-rid="r15" id="body-ref-r15" href-manipulated="true" aria-label="Reference 15">15</a></sup> Innate immune cells use pattern-recognition receptors, which are not specific for any particular antigen, to recognize and respond to a wide variety of microbial invaders by producing cytokines that activate cells of the adaptive immune system.</div><div role="paragraph">Innate cells that are most often implicated in the pathogenesis of cytokine storm include neutrophils, macrophages, and NK cells. Neutrophils can produce neutrophil extracellular traps, a network of fibers that contribute to thrombi formation and amplify cytokine production during cytokine storm. Macrophages, which are tissue-resident cells that are often derived from circulating monocytes, do not divide; they have diverse functions, from the removal of senescent cells by engulfment, to tissue repair and immunoregulation, to antigen presentation. In many forms of cytokine storm, macrophages become activated and secrete excessive amounts of cytokines, ultimately causing severe tissue damage that can lead to organ failure. Hemophagocytic macrophages are often observed in bone marrow biopsy specimens from patients with cytokine storm. Interferon-γ can induce hemophagocytosis by macrophages, and this may contribute to the cytopenias commonly observed in patients with cytokine storm.<sup><a href="#core-r16" role="doc-biblioref" data-xml-rid="r16" id="body-ref-r16" href-manipulated="true" aria-label="Reference 16">16</a></sup> The cytolytic function of NK cells is diminished in some forms of cytokine storm, which can lead to prolonged antigenic stimulation and difficulty resolving inflammation.<sup><a href="#core-r17" role="doc-biblioref" data-xml-rid="r17" id="body-ref-r17" href-manipulated="true" aria-label="Reference 17">17</a></sup> Excess interleukin-6 may mediate the impairment in NK-cell function by lowering perforin and granzyme production.</div><div role="paragraph">The adaptive immune system is composed of B cells and T cells. T cells differentiate into a number of subsets with distinct effector-cell functions potentially involved in cytokine storm (<a href="#f3">Figure 3</a>). Type 1 helper T (Th1) cells and cytotoxic T lymphocytes (CTLs) are primarily responsible for the host defense against viral infections. Th1 cells regulate the recruitment of macrophages, whereas type 2 helper T (Th2) cells recruit eosinophils and basophils, type 9 helper T (Th9) cells recruit mast cells, and type 17 helper T (Th17) cells recruit neutrophils.<sup><a href="#core-r18" role="doc-biblioref" data-xml-rid="r18" id="body-ref-r18" href-manipulated="true" aria-label="Reference 18">18</a></sup> An exaggerated Th1-type inflammatory response often occurs during cytokine storm. Th1 cells produce large quantities of interferon-γ, induce delayed hypersensitivity reactions, activate macrophages, and are essential for defense against intracellular pathogens.<sup><a href="#core-r19" role="doc-biblioref" data-xml-rid="r19" id="body-ref-r19" href-manipulated="true" aria-label="Reference 19">19</a></sup> Iatrogenic causes of cytokine storm involving excessive T-cell activation, such as CAR T-cell and anti-CD28 antibody therapy, point to the ability of activated T cells to initiate cytokine storm. Impaired granule-mediated killing of infected cells or tumor cells by CTLs is a key aspect of some forms of cytokine storm.<sup><a href="#core-r20" role="doc-biblioref" data-xml-rid="r20" id="body-ref-r20" href-manipulated="true" aria-label="Reference 20">20</a></sup> Data from mouse models of HLH and patients with cytokine storm indicate that the inability of CTLs to kill efficiently leads to prolonged activation of T cells, triggering a cascade of inflammatory tissue damage.<sup><a href="#core-r21" role="doc-biblioref" data-xml-rid="r21 r22 r23" id="body-ref-r23-1" href-manipulated="true">21-23</a></sup> Th17 cells have a major role in host defense, particularly antifungal protection, and abnormal Th17-cell function can lead to autoimmunity.<sup><a href="#core-r24" role="doc-biblioref" data-xml-rid="r24" id="body-ref-r24" href-manipulated="true" aria-label="Reference 24">24</a></sup> An experimental model of macrophage activation syndrome (a form of secondary HLH) provides evidence that Th17 cells can be drivers of a cytokine storm that is independent of interferon-γ.<sup><a href="#core-r25" role="doc-biblioref" data-xml-rid="r25" id="body-ref-r25" href-manipulated="true" aria-label="Reference 25">25</a></sup></div><div class="figure-wrap" data-presentation="diminished-in-flow"><header><div class="label">Figure 3</div><nav><a href="#f3" title="Open in viewer" class="open-in-viewer" data-index="0" data-interactiontype="multimedia_click" data-multimedia-type="Figure" data-multimedia-filename="nejmra2026131_f3.jpg"><i aria-hidden="true" class="icon-expand"></i></a></nav></header><figure id="f3" class="graphic"><a aria-label="Open figure in viewer" class="open-in-viewer" data-index="0" href="#f3" data-interactiontype="multimedia_click" data-multimedia-type="Figure" data-multimedia-filename="nejmra2026131_f3.jpg"><img src="/cms/10.1056/NEJMra2026131/asset/7aaf6482-acae-4bdc-8a34-aeafb104077d/assets/images/large/nejmra2026131_f3.jpg" height="1605" width="2640" aria-labelledby="f3" loading="lazy"></a><figcaption><div class="caption">T-Cell Effector Subgroups Involved in Cytokine Storm.</div><div class="notes"><div role="doc-footnote">The master transcription factors (T-bet, GATA-3, PU.1, RORγT, and eomesodermin [eomes]), effector molecules, and cell targets are shown for the following T-cell subgroups: types 1, 2, 9, and 17 helper T (Th1, Th2, Th9, and Th17, respectively) cells and cytotoxic T lymphocytes.</div></div></figcaption></figure></div><div role="paragraph">B cells are not often associated with the pathogenesis of cytokine storm. However, the effectiveness of B-cell depletion in treating some cytokine storm disorders, such as human herpesvirus 8 (HHV-8)–associated multicentric Castleman’s disease, suggests that these cells are capable of initiating or propagating cytokine storm, particularly when virally infected.</div></section><section id="sec-2-2"><h3>Cytokines</h3><div role="paragraph">As noted above, the recognition of cytokine storm as an entity is relatively recent. The advent of molecular cloning technologies led to the discovery of the panoply of cytokines and chemokines involved in cytokine storm (<a href="#t1">Table 1</a>); the realization that diverse entities can cause cytokine storm (<a href="#t2">Table 2</a>) also contributed to its recognition. The administration of recombinant cytokines (e.g., interleukin-1, interleukin-6, interleukin-12, interleukin-18, tumor necrosis factor [TNF], and interferon-γ) in animal models and for cancer treatment in humans induces severe toxic effects or lethality consistent with the central role of cytokines as mediators of hyperinflammation in cytokine storm.<sup><a href="#core-r27" role="doc-biblioref" data-xml-rid="r27 r28 r29" id="body-ref-r29" href-manipulated="true">27-29</a></sup> Conversely, reduction in symptoms and improvement in organ function with neutralization of specific cytokines with monoclonal antibodies also reveal that excessive levels of certain cytokines play a critical role in a number of cytokine storm disorders.</div><div class="figure-wrap" data-presentation="diminished-in-flow"><header><div class="label">Table 1</div><nav><a href="#t1" title="Open in viewer" class="open-in-viewer" data-index="0" data-interactiontype="multimedia_click" data-multimedia-type="Table" data-multimedia-filename="nejmra2026131_t1.jpg"><i aria-hidden="true" class="icon-expand"></i></a></nav></header><figure id="t1" class="table"><div class="graphic-wrap" data-presentation="suppressed-in-viewer"><a aria-label="Open figure in viewer" class="open-in-viewer" data-index="0" href="#t1" data-interactiontype="multimedia_click" data-multimedia-type="Table" data-multimedia-filename="nejmra2026131_t1.jpg"><img src="/cms/10.1056/NEJMra2026131/asset/d37b4562-4a3c-4afe-afb6-e6a499ad5023/assets/images/large/nejmra2026131_t1.jpg" height="2618" width="1999" loading="lazy"></a></div><div class="table-wrap catalyst-standard" data-presentation="suppressed-in-flow"><table data-shading="custom"><thead><tr class="head1" data-type="row head1"><th class="txlx-borders" data-xml-align="left">Mediator</th><th class="txxx-borders">Main Cell Source</th><th class="txxr-borders">Type and Function</th></tr></thead><tbody><tr data-type="row"><td class="xxlx-borders hanging01 shading"><b>Cytokines and growth factors</b></td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxr-borders shading">&nbsp;</td></tr><tr data-type="row"><td class="xxlx-borders hanging01">Interleukin-1</td><td class="xxxx-borders hanging01">Macrophages, epithelial cells; pyroptotic cells</td><td class="xxxr-borders hanging01">Proinflammatory alarmin cytokine; pyrogenic function, macrophage and Th17 cell activation</td></tr><tr data-type="row"><td class="xxlx-borders hanging01 shading">Interleukin-2</td><td class="xxxx-borders shading">T cells</td><td class="xxxr-borders hanging01 shading">Effector T-cell and regulatory T-cell growth factor</td></tr><tr data-type="row"><td class="xxlx-borders hanging01">Interleukin-6</td><td class="xxxx-borders">Macrophages, T cells, endothelial cells</td><td class="xxxr-borders hanging01">Proinflammatory cytokine; pyrogenic function, increased antibody production, induction of acute-phase reactants</td></tr><tr data-type="row"><td class="xxlx-borders hanging01 shading">Interleukin-9</td><td class="xxxx-borders shading">Th9 cells</td><td class="xxxr-borders hanging01 shading">Protection from helminth infections, activation of mast cells, association with type I interferon in Covid-19<sup><a href="#core-r26" role="doc-biblioref" data-xml-rid="r26" id="body-ref-r26-1" href-manipulated="true" aria-label="Reference 26">26</a></sup></td></tr><tr data-type="row"><td class="xxlx-borders hanging01">Interleukin-10</td><td class="xxxx-borders">Regulatory T cells, Th9 cells</td><td class="xxxr-borders hanging01">Antiinflammatory cytokine; inhibition of Th1 cells and cytokine release</td></tr><tr data-type="row"><td class="xxlx-borders hanging01 shading">Interleukin-12</td><td class="xxxx-borders shading">Dendritic cells, macrophages</td><td class="xxxr-borders hanging01 shading">Activation of the Th1 pathway; induction of interferon-γ from Th1 cells, CTLs, and NK cells; acting in synergy with interleukin-18</td></tr><tr data-type="row"><td class="xxlx-borders hanging01">Interleukin-17</td><td class="xxxx-borders hanging01">Th17 cells, NK cells, group 3 innate lymphoid cells</td><td class="xxxr-borders hanging01">Promoting neutrophilic inflammation, protection from bacterial and fungal infections</td></tr><tr data-type="row"><td class="xxlx-borders hanging01 shading">Interleukin-18</td><td class="xxxx-borders hanging01 shading">Monocytes, macrophages, dendritic cells</td><td class="xxxr-borders hanging01 shading">Proinflammatory alarmin cytokine; activation of Th1 pathway, acting in synergy with interleukin-12</td></tr><tr data-type="row"><td class="xxlx-borders hanging01">Interleukin-33</td><td class="xxxx-borders hanging01">Macrophages, dendritic cells, mast cells, epithelial cells</td><td class="xxxr-borders hanging01">Proinflammatory alarmin cytokine; amplification of Th1 and Th2 cells, activation of NK cells, CTLs, and mast cells</td></tr><tr data-type="row"><td class="xxlx-borders hanging01 shading">Interferon-γ</td><td class="xxxx-borders hanging01 shading">Th1 cells, CTLs, group 1 innate lymphoid cells, and NK cells</td><td class="xxxr-borders hanging01 shading">Proinflammatory cytokine; activation of macrophages</td></tr><tr data-type="row"><td class="xxlx-borders hanging01">Tumor necrosis factor</td><td class="xxxx-borders">Macrophages, T cells, NK cells, mast cells</td><td class="xxxr-borders hanging01">Increasing vascular permeability; pyrogenic function</td></tr><tr data-type="row"><td class="xxlx-borders hanging01 shading">GM-CSF</td><td class="xxxx-borders shading">Th17 cells</td><td class="xxxr-borders shading">Proinflammatory cytokine</td></tr><tr data-type="row"><td class="xxlx-borders hanging01">VEGF</td><td class="xxxx-borders">Macrophages</td><td class="xxxr-borders">Angiogenesis</td></tr><tr data-type="row"><td class="xxlx-borders hanging01 shading"><b>Chemokines</b></td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxr-borders shading">&nbsp;</td></tr><tr data-type="row"><td class="xxlx-borders hanging01">Interleukin-8 (CXCL8)</td><td class="xxxx-borders">Macrophages, epithelial cells</td><td class="xxxr-borders">Recruitment of neutrophils</td></tr><tr data-type="row"><td class="xxlx-borders hanging01 shading">MIG (CXCL9)</td><td class="xxxx-borders hanging01 shading">Monocytes, endothelial cells, keratinocytes</td><td class="xxxr-borders hanging01 shading">Interferon-inducible chemokine; recruitment of Th1 cells, NK cells, plasmacytoid dendritic cells</td></tr><tr data-type="row"><td class="xxlx-borders hanging01">IP-10 (CXCL10)</td><td class="xxxx-borders hanging01">Monocytes, endothelial cells, keratinocytes</td><td class="xxxr-borders hanging01">Interferon-inducible chemokine; recruitment of macrophages, Th1 cells, NK cells</td></tr><tr data-type="row"><td class="xxlx-borders hanging01 shading">MCP-1 (CCL2)</td><td class="xxxx-borders hanging01 shading">Macrophages, dendritic cells, cardiac myocytes</td><td class="xxxr-borders hanging01 shading">Recruitment of Th2 cells, monocytes, dendritic cells, basophils</td></tr><tr data-type="row"><td class="xxlx-borders hanging01">MIP-1α (CCL3)</td><td class="xxxx-borders hanging01">Monocytes, neutrophils, dendritic cells, NK cells, mast cells</td><td class="xxxr-borders hanging01">Recruitment of macrophages, Th1 cells, NK cells, eosinophils, dendritic cells; pyrogenic function</td></tr><tr data-type="row"><td class="xxlx-borders hanging01 shading">MIP-1β (CCL4)</td><td class="xxxx-borders shading">Macrophages, neutrophils, endothelium</td><td class="xxxr-borders hanging01 shading">Recruitment of macrophages, Th1 cells, NK cells, dendritic cells</td></tr><tr data-type="row"><td class="xxlx-borders hanging01">BLC (CXCL13)</td><td class="xxxx-borders">B cells, follicular dendritic cells</td><td class="xxxr-borders hanging01">Recruitment of B cells, CD4 T cells, dendritic cells<a href="#t1fn2" role="doc-noteref">†</a></td></tr><tr data-type="row"><td class="xxlx-borders hanging01 shading"><b>Plasma proteins</b></td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxr-borders shading">&nbsp;</td></tr><tr data-type="row"><td class="xxlx-borders hanging01">CRP</td><td class="xxxx-borders">Hepatocytes</td><td class="xxxr-borders hanging01">Monomeric CRP increases interleukin-8 and MCP-1 secretion; interleukin-6 increases CRP expression</td></tr><tr data-type="row"><td class="xxlx-borders hanging01 shading">Complement</td><td class="xxxx-borders shading">Hepatocytes, other cells</td><td class="xxxr-borders hanging01 shading">Complement activation contributes to tissue damage in cytokine storm; complement inhibition can reduce immunopathologic effects of cytokine storm</td></tr><tr data-type="row"><td class="xblx-borders hanging01">Ferritin</td><td class="xbxx-borders">Ubiquitous</td><td class="xbxr-borders">Primary site of iron storage in cells</td></tr></tbody></table></div><figcaption><div class="caption">Soluble Mediators in Cytokine Storm.<a href="#t1fn1" role="doc-noteref">*</a></div><div class="notes"><div role="doc-footnote" data-has="label"><div class="label">*</div><div id="t1fn1" role="paragraph">BLC denotes B-lymphocyte chemoattractant; Covid-19 coronavirus disease 2019; CRP C-reactive protein; CTLs cytotoxic T lymphocytes; CXCL C-X-C motif chemokine ligand; GM-CSF granulocyte–macrophage colony-stimulating factor; IP-10 interferon-inducible protein 10; MCP-1 monocyte chemoattractant protein 1; MIG monokine induced by interferon-γ; MIP-1α and MIP-1β macrophage inflammatory protein 1α and 1β, respectively; NK natural killer; Th1, Th2, Th9, and Th17 cells types 1, 2, 9, and 17 helper T cells, respectively; and VEGF vascular endothelial growth factor.</div></div><div role="doc-footnote" data-has="label"><div class="label">†</div><div id="t1fn2" role="paragraph">In idiopathic multicentric Castleman’s disease, the levels of CXCL13 are the most elevated of all the cytokines or chemokines.</div></div></div></figcaption></figure></div><div class="figure-wrap" data-presentation="diminished-in-flow"><header><div class="label">Table 2</div><nav><a href="#t2" title="Open in viewer" class="open-in-viewer" data-index="0" data-interactiontype="multimedia_click" data-multimedia-type="Table" data-multimedia-filename="nejmra2026131_t2.jpg"><i aria-hidden="true" class="icon-expand"></i></a></nav></header><figure id="t2" class="table"><div class="graphic-wrap" data-presentation="suppressed-in-viewer"><a aria-label="Open figure in viewer" class="open-in-viewer" data-index="0" href="#t2" data-interactiontype="multimedia_click" data-multimedia-type="Table" data-multimedia-filename="nejmra2026131_t2.jpg"><img src="/cms/10.1056/NEJMra2026131/asset/ed1d87f1-fbe3-4da7-a16d-548275efabdc/assets/images/large/nejmra2026131_t2.jpg" height="1831" width="1999" loading="lazy"></a></div><div class="table-wrap catalyst-standard" data-presentation="suppressed-in-flow"><table data-shading="custom"><thead><tr class="head1" data-type="row head1"><th class="txlx-borders" data-xml-align="left">Type of Cytokine Storm and Trigger</th><th class="txxx-borders">Cause</th><th class="txxx-borders">Pathologic Cellular or Cytokine Driver</th><th class="txxr-borders">Common Therapeutic Approaches</th></tr></thead><tbody><tr data-type="row"><td class="xxlx-borders hanging01 shading"><b>Iatrogenic</b></td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxr-borders shading">&nbsp;</td></tr><tr data-type="row"><td class="xxlx-borders hanging01">CAR T-cell therapy</td><td class="xxxx-borders hanging01">Infusion of CAR T cells</td><td class="xxxx-borders hanging01">Macrophages, CAR T cells, interleukin-6, interleukin-1β</td><td class="xxxr-borders hanging01">Anti–interleukin-6 antibody, glucocorticoids</td></tr><tr data-type="row"><td class="xxlx-borders hanging01 shading">Blinatumomab</td><td class="xxxx-borders hanging01 shading">Infusion of CD19- and CD3-specific T-cell receptor–engaging antibody</td><td class="xxxx-borders hanging01 shading">Activated T cells, macrophages, interleukin-6</td><td class="xxxr-borders hanging01 shading">Anti–interleukin-6 antibody, glucocorticoids</td></tr><tr data-type="row"><td class="xxlx-borders hanging01"><b>Pathogen-induced</b></td><td class="xxxx-borders">&nbsp;</td><td class="xxxx-borders">&nbsp;</td><td class="xxxr-borders">&nbsp;</td></tr><tr data-type="row"><td class="xxlx-borders hanging01 shading">Bacterial sepsis</td><td class="xxxx-borders shading">Hematogenous bacterial infection</td><td class="xxxx-borders hanging01 shading">Heterogeneous and multifactorial drivers</td><td class="xxxr-borders shading">Intravenous antibiotics</td></tr><tr data-type="row"><td class="xxlx-borders hanging01">EBV-associated HLH</td><td class="xxxx-borders hanging01">EBV infection in patient with genetic susceptibility</td><td class="xxxx-borders hanging01">Interferon-γ, TNF, CD8+ T cells</td><td class="xxxr-borders hanging01">B-cell–depleting therapy, glucocorticoids</td></tr><tr data-type="row"><td class="xxlx-borders hanging01 shading">HHV-8–associated MCD</td><td class="xxxx-borders hanging01 shading">HHV-8 infection in patient with HIV coinfection, genetic susceptibility, or both</td><td class="xxxx-borders hanging01 shading">Viral interleukin-6, interleukin-6</td><td class="xxxr-borders hanging01 shading">B-cell–depleting therapy</td></tr><tr data-type="row"><td class="xxlx-borders hanging01">Covid-19</td><td class="xxxx-borders hanging01">SARS-CoV-2 infection, potentially in a susceptible person</td><td class="xxxx-borders hanging01">Unknown driver</td><td class="xxxr-borders hanging01">Glucocorticoids</td></tr><tr data-type="row"><td class="xxlx-borders hanging01 shading"><b>Monogenic and autoimmune</b></td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxr-borders shading">&nbsp;</td></tr><tr data-type="row"><td class="xxlx-borders hanging01">Primary HLH</td><td class="xxxx-borders hanging01">Germline mutation in genes regulating granule-mediated cytotoxicity</td><td class="xxxx-borders hanging01">CD8+ T cells, interferon-γ</td><td class="xxxr-borders hanging01">T-cell inhibition or ablation, interferon-γ inhibitor, glucocorticoids</td></tr><tr data-type="row"><td class="xxlx-borders hanging01 shading">Secondary HLH, or MAS</td><td class="xxxx-borders hanging01 shading">Viral cause (EBV or CMV), autoimmune disorder (rheumatoid arthritis or adult-onset Still’s disease), or neoplastic disorder in patient with genetic susceptibility (lymphoma)</td><td class="xxxx-borders hanging01 shading">CD8+ T cells, interferon-γ, interleukin-1β, myeloid-cell autoinflammation</td><td class="xxxr-borders hanging01 shading">Treatment of the underlying cause, in addition to T-cell inhibition or ablation, interleukin-1β inhibitor, JAK1 and JAK2 inhibitors, glucocorticoids</td></tr><tr data-type="row"><td class="xxlx-borders hanging01">Autoinflammatory disorders</td><td class="xxxx-borders hanging01">Germline mutations in genes regulating the innate immune system and inflammasome activation</td><td class="xxxx-borders hanging01">Innate cells, TNF, interleukin-1β</td><td class="xxxr-borders hanging01">Anti-TNF antibody, anti–interleukin-1 antibody</td></tr><tr data-type="row"><td class="xblx-borders hanging01 shading">Idiopathic MCD</td><td class="xbxx-borders hanging01 shading">Unknown cause</td><td class="xbxx-borders hanging01 shading">Interleukin-6, activated T cells, mTOR</td><td class="xbxr-borders hanging01 shading">Anti–interleukin-6 antibody, sirolimus, cyclosporine, cytotoxic chemotherapy, glucocorticoids</td></tr></tbody></table></div><figcaption><div class="caption">Clinical Causes of Cytokine Storm, Pathologic Drivers, and Therapeutic Approaches.<a href="#t2fn1" role="doc-noteref">*</a></div><div class="notes"><div role="doc-footnote" data-has="label"><div class="label">*</div><div id="t2fn1" role="paragraph">CAR denotes chimeric antigen receptor, CMV cytomegalovirus, Covid-19 coronavirus disease 2019, EBV Epstein–Barr virus, HHV-8 human herpesvirus 8, HIV human immunodeficiency virus, HLH hemophagocytic lymphohistiocytosis, JAK1 Janus kinase 1, JAK2 Janus kinase 2, MAS macrophage activation syndrome, MCD multicentric Castleman’s disease, mTOR mammalian target of rapamycin, and SARS-CoV-2 severe acute respiratory syndrome coronavirus 2.</div></div></div></figcaption></figure></div><div role="paragraph">A complex, interconnected network of cell types, signaling pathways, and cytokines is involved in cytokine storm disorders. Interferon-γ, interleukin-1, interleukin-6, TNF, and interleukin-18 are key cytokines that often have elevated levels in cytokine storm and are thought to have central immunopathologic roles. The pattern of cytokine elevations varies on the basis of such factors as the microbiome, genetic features, and underlying disorders.<sup><a href="#core-r30" role="doc-biblioref" data-xml-rid="r30" id="body-ref-r30-1" href-manipulated="true" aria-label="Reference 30">30</a></sup> The specific immune cells that secrete the various cytokines are not fully understood and most likely vary among cytokine storm disorders. Interferon-γ is primarily secreted by activated T cells and NK cells and is a potent activator of macrophages. Clinically, interferon-γ causes fever, chills, headache, dizziness, and fatigue.<sup><a href="#core-r31" role="doc-biblioref" data-xml-rid="r31" id="body-ref-r31" href-manipulated="true" aria-label="Reference 31">31</a></sup> Emapalumab, a monoclonal antibody that binds interferon-γ, was recently approved for the treatment of cytokine storm in patients with primary HLH.<sup><a href="#core-r32" role="doc-biblioref" data-xml-rid="r32" id="body-ref-r32" href-manipulated="true" aria-label="Reference 32">32</a></sup> This agent may also be useful in other cytokine storm disorders, such as macrophage activation syndrome or CAR T-cell–associated cytokine storm, although in the latter case, it may diminish antitumor effects.</div><div role="paragraph">Fever, a clinical hallmark of cytokine storm, can be elicited by interleukin-1, interleukin-6, or TNF through distinct mechanisms. Interleukin-1 is encoded by two genes (<i>IL1A</i> and <i>IL1B</i>), both of which bind to the same interleukin-1 receptor, activating a cascade of intracellular signaling pathways, including nuclear factor κB (NF-κB). The interleukin-1–receptor antagonist anakinra is effective as a single agent and in combination with other agents for the treatment of some forms of cytokine storm.<sup><a href="#core-r33" role="doc-biblioref" data-xml-rid="r33 r34" id="body-ref-r34" href-manipulated="true">33,34</a></sup></div><div role="paragraph">Levels of interleukin-6, an important mediator of the acute inflammatory response and pathophysiological features of cytokine storm, are highly elevated across various underlying immunopathologic disorders<sup><a href="#core-r35" role="doc-biblioref" data-xml-rid="r35 r36" id="body-ref-r36-1" href-manipulated="true">35,36</a></sup> and in mouse models of cytokine storm.<sup><a href="#core-r37" role="doc-biblioref" data-xml-rid="r37" id="body-ref-r37" href-manipulated="true" aria-label="Reference 37">37</a></sup> Both tocilizumab, a monoclonal antibody directed at the interleukin-6 receptor (interleukin-6R), and siltuximab, which neutralizes interleukin-6 directly, have been shown to be effective in a number of cytokine storm disorders, including HLH, idiopathic multicentric Castleman’s disease, and CAR T-cell–induced cytokine storm.<sup><a href="#core-r38" role="doc-biblioref" data-xml-rid="r38" id="body-ref-r38-1" href-manipulated="true" aria-label="Reference 38">38</a></sup></div><div role="paragraph">Interleukin-6 is one of the more complex cytokines, since it is produced by and acts on immune and nonimmune cells across multiple organ systems. It can signal through two main pathways, referred to as classic cis signaling and trans signaling.<sup><a href="#core-r38" role="doc-biblioref" data-xml-rid="r38" id="body-ref-r38-2" href-manipulated="true" aria-label="Reference 38">38</a></sup> The membrane-bound interleukin-6R does not possess intracellular signaling domains but signals instead through interaction with membrane-bound gp130. In cis signaling, soluble interleukin-6 binds to membrane-bound interleukin-6R, forming an interleukin-6–interleukin-6R complex that binds to gp130, which then initiates signaling through its intracellular domain.</div><div role="paragraph">Downstream signal transduction is mediated by JAKs (Janus kinases) and STAT3 (signal transducer and activator of transcription 3), as well as by Akt–mTOR (mammalian target of rapamycin) and MAPK–ERK (mitogen-activated protein kinase–extracellular signal-regulated kinase) pathways. Membrane-bound gp130 is ubiquitously expressed, whereas expression of membrane-bound interleukin-6R is restricted largely to immune cells. Activation of cis signaling results in pleiotropic effects on the immune system, which can contribute to cytokine storm.<sup><a href="#core-r38" role="doc-biblioref" data-xml-rid="r38" id="body-ref-r38-3" href-manipulated="true" aria-label="Reference 38">38</a></sup> In the presence of high circulating levels of interleukin-6, which can be present in cytokine storm, trans signaling occurs through the binding of interleukin-6 to the soluble form of interleukin-6R, forming a complex with a gp130 dimer on potentially all cell surfaces. The resultant interleukin-6–soluble interleukin-6R–gp130–JAK-STAT3 signaling is then activated in cells that do not express the membrane-bound interleukin-6R, such as endothelial cells. This results in systemic hyperinflammation involving secretion of monocyte chemoattractant protein 1 (MCP-1), interleukin-8, and additional interleukin-6, as well as increased vascular endothelial growth factor (VEGF) and reduced E-cadherin expression on endothelial cells, which contribute to vascular hyperpermeability, leakiness, hypotension, and pulmonary dysfunction.<sup><a href="#core-r38" role="doc-biblioref" data-xml-rid="r38" id="body-ref-r38-4" href-manipulated="true" aria-label="Reference 38">38</a></sup></div><div role="paragraph">TNF is a potent, multifunctional, proinflammatory cytokine that belongs to the TNF–TNF receptor superfamily. In addition to inducing fever, augmenting systemic inflammation, and activating antimicrobial responses such as interleukin-6, TNF can induce cellular apoptosis and regulate immunity. TNF and other cytokines in the TNF–TNF receptor superfamily are potent inducers of NF-κB, leading to the expression of multiple proinflammatory genes. In mouse models of toxic shock, TNF is the cytokine driver of superantigen-driven cytokine storm.<sup><a href="#core-r39" role="doc-biblioref" data-xml-rid="r39" id="body-ref-r39" href-manipulated="true" aria-label="Reference 39">39</a></sup> The effectiveness of anti-TNF therapies in certain autoinflammatory-driven cytokine storm conditions points to their potential role in the treatment of cytokine storm, but the limitations and dangers of anti-TNF therapies in patients with sepsis indicate that more work is needed.</div><div role="paragraph">Interleukin-18 is a member of the large interleukin-1 family<sup><a href="#core-r40" role="doc-biblioref" data-xml-rid="r40" id="body-ref-r40" href-manipulated="true" aria-label="Reference 40">40</a></sup> that has recently been associated with cytokine storm disorders. Interleukin-18 and interleukin-1β are activated from precursors by inflammasomes. The inflammasome is a multimolecular cytosolic sensor that detects pathogenic microorganisms and sterile stressors and activates caspase-1 during the process of pyroptosis, which, in turn, causes the inactive precursor forms of interleukin-1β and interleukin-18 to become the active forms.<sup><a href="#core-r41" role="doc-biblioref" data-xml-rid="r41 r42" id="body-ref-r42" href-manipulated="true">41,42</a></sup> Macrophages and dendritic cells are the primary sources of bioactive interleukin-18, which has many proinflammatory effects. Most important, it synergizes with interleukin-12 or interleukin-15 to stimulate secretion of interferon-γ from T cells and NK cells, and thus promotes Th1-type inflammatory responses. The interleukin-18 receptor is constitutively expressed on NK cells and induced on activation in most T cells. Interleukin-1β and interleukin-18 are also potent inducers of interleukin-6 secretion from macrophages.<sup><a href="#core-r43" role="doc-biblioref" data-xml-rid="r43" id="body-ref-r43" href-manipulated="true" aria-label="Reference 43">43</a></sup></div><div role="paragraph">Patients with cytokine storm due to macrophage activation syndrome have high levels of interleukin-18 in serum,<sup><a href="#core-r44" role="doc-biblioref" data-xml-rid="r44" id="body-ref-r44-1" href-manipulated="true" aria-label="Reference 44">44</a></sup> and interleukin-18 is a biomarker of severity that correlates with hyperferritinemia, elevated aminotransferase levels, and disease flare.<sup><a href="#core-r45" role="doc-biblioref" data-xml-rid="r45" id="body-ref-r45" href-manipulated="true" aria-label="Reference 45">45</a></sup> The proinflammatory effects of interleukin-18 are normally kept in check by the interleukin-18–binding protein (IL18BP), which prevents the binding of interleukin-18 to its receptor.<sup><a href="#core-r46" role="doc-biblioref" data-xml-rid="r46" id="body-ref-r46" href-manipulated="true" aria-label="Reference 46">46</a></sup> The ratio of free interleukin-18 to bound interleukin-18–IL18BP complexes in serum is an important indicator of the severity of the macrophage activation syndrome.<sup><a href="#core-r44" role="doc-biblioref" data-xml-rid="r44 r47" id="body-ref-r47" href-manipulated="true">44,47</a></sup> Tadekinig alfa is a recombinant IL18BP currently under investigation as a treatment for hyperinflammation.</div><div role="paragraph">Chemokines are a class of cytokines that contribute to a variety of immune-cell functions, including leukocyte recruitment and trafficking. Dysregulated trafficking during inflammation may have a role in hyperinflammation. Numerous regulatory cytokines such as interleukin-10 and natural cytokine antagonists such as IL1RA serve as buffers to limit systemic off-target effects. Interleukin-10 inhibits the production of TNF, interleukin-1, interleukin-6, and interleukin-12 and down-regulates antigen presentation. Furthermore, in mice lacking interleukin-10, infection leads to cytokine storm.<sup><a href="#core-r48" role="doc-biblioref" data-xml-rid="r48" id="body-ref-r48" href-manipulated="true" aria-label="Reference 48">48</a></sup> Though interleukin-10 and IL1RA are often elevated in cytokine storm, this finding most likely reflects a secondary, albeit insufficient, counterregulatory response to the proinflammatory cytokines. Anakinra is a therapeutic agent that mimics the endogenous immunoregulatory effects of IL1RA.</div><div role="paragraph">Plasma proteins such as complement proteins and other inflammatory mediators can contribute to the pathogenesis of cytokine storm. These soluble proteins recognize pathogens, amplify cellular responses, and provide feedback on cytokine signaling. In fact, cytokines can enhance the production of complement proteins, which in turn can enhance or inhibit cytokine production. Thus, complement can be highly effective in eliminating microbes but can also cause collateral damage if excessive. Hypocomplementemia, resulting from increased consumption by immune complexes, can be observed in cytokine storm.<sup><a href="#core-r49" role="doc-biblioref" data-xml-rid="r49" id="body-ref-r49" href-manipulated="true" aria-label="Reference 49">49</a></sup> Complement inhibitors are under evaluation for the treatment of cytokine storm disorders.</div></section></section><section id="sec-3"><h2>Iatrogenic Cytokine Storm</h2><div role="paragraph">Infusion of CAR T cells engineered to recognize and eliminate CD19+ lymphoma cells can induce cytokine storm, with supraphysiologic levels of interferon-γ and interleukin-6.<sup><a href="#core-r50" role="doc-biblioref" data-xml-rid="r50" id="body-ref-r50" href-manipulated="true" aria-label="Reference 50">50</a></sup> The highly activated CAR T cells are clearly the initiators of the cytokine storm. Although some studies suggest that the driver cytokines are released by CAR T cells, resulting in a positive feedback loop of T-cell activation and inflammatory cytokine release,<sup><a href="#core-r51" role="doc-biblioref" data-xml-rid="r51" id="body-ref-r51-1" href-manipulated="true" aria-label="Reference 51">51</a></sup> recent studies in mice suggest that the cytokines and factors mediating the severity of cytokine storm are produced not by the CAR T cells but by macrophages and can be reversed by interleukin-6 and interleukin-1 blockade.<sup><a href="#core-r52" role="doc-biblioref" data-xml-rid="r52 r53 r54" id="body-ref-r54" href-manipulated="true">52-54</a></sup> Tumor lysis most likely also contributes to the cytokine storm through the induction of pyroptosis in target cells.<sup><a href="#core-r55" role="doc-biblioref" data-xml-rid="r55" id="body-ref-r55" href-manipulated="true" aria-label="Reference 55">55</a></sup> Since interleukin-6 blockade is highly effective at reversing symptoms and organ dysfunction in most patients, it is the likely cytokine driver of cytokine storm induced by CAR T-cell therapy. Glucocorticoids and interleukin-1 inhibition can also be effective in the treatment of this type of cytokine storm.</div><div role="paragraph">Cytokine storm can be observed with other T-cell–engaging immunotherapies as well, such as blinatumomab, a bispecific antibody that binds to CD19+ and CD3+ T cells.<sup><a href="#core-r56" role="doc-biblioref" data-xml-rid="r56" id="body-ref-r56" href-manipulated="true" aria-label="Reference 56">56</a></sup> Like CAR T cells, activated T cells initiate the cytokine storm, and macrophage activation propagates blinatumomab-induced cytokine storm, which also responds to anti–interleukin-6 antibody therapy.<sup><a href="#core-r36" role="doc-biblioref" data-xml-rid="r36" id="body-ref-r36-2" href-manipulated="true" aria-label="Reference 36">36</a></sup> The unfortunate consequences of another T-cell–activating treatment with the anti-CD28 superagonist TGN1412 show that rapid activation of large numbers of T cells can result in severe cytokine storm within minutes after infusion.<sup><a href="#core-r57" role="doc-biblioref" data-xml-rid="r57" id="body-ref-r57" href-manipulated="true" aria-label="Reference 57">57</a></sup> However, cytokine storm does not develop in all patients treated with CAR T cells or blinatumomab, so additional factors, such as CAR structure and design,<sup><a href="#core-r51" role="doc-biblioref" data-xml-rid="r51" id="body-ref-r51-2" href-manipulated="true" aria-label="Reference 51">51</a></sup> disease burden,<sup><a href="#core-r58" role="doc-biblioref" data-xml-rid="r58" id="body-ref-r58" href-manipulated="true" aria-label="Reference 58">58</a></sup> and host genomic background,<sup><a href="#core-r59" role="doc-biblioref" data-xml-rid="r59" id="body-ref-r59" href-manipulated="true" aria-label="Reference 59">59</a></sup> are likely to play a part. In a recent study of NK-cell CAR therapy, there were no reported cases of cytokine storm or even elevated interleukin-6 levels,<sup><a href="#core-r60" role="doc-biblioref" data-xml-rid="r60" id="body-ref-r60" href-manipulated="true" aria-label="Reference 60">60</a></sup> possibly because of lower interleukin-6 production by NK cells than by T cells and different cross-talk with myeloid cells. Additional iatrogenic causes of cytokine storm include rituximab,<sup><a href="#core-r35" role="doc-biblioref" data-xml-rid="r35" id="body-ref-r35-2" href-manipulated="true" aria-label="Reference 35">35</a></sup> gene therapies, immune checkpoint inhibitors, cardiac-bypass surgery,<sup><a href="#core-r61" role="doc-biblioref" data-xml-rid="r61" id="body-ref-r61" href-manipulated="true" aria-label="Reference 61">61</a></sup> and allogeneic stem-cell transplantation, as well as bioterrorism agents such as staphylococcal enterotoxin B and <i>Francisella tularensis</i>.</div></section><section id="sec-4"><h2>Pathogen-Induced Cytokine Storm</h2><div role="paragraph">Cytokine storm can also result from naturally occurring microbial infections. Though data on relative frequencies are limited, infections are most likely the most common trigger of cytokine storm. Distinguishing between appropriate cytokine production for controlling a widespread infection and excessive cytokine production is challenging. Disseminated bacterial infections causing sepsis induce the production of many cytokines that can lead to fever, cell death, coagulopathies, and multiorgan dysfunction. The collateral damage caused by the immune response as it attempts to clear the pathogen can be more deadly than the pathogen itself. Certain bacteria, including streptococcus species and <i>Staphylococcus aureus</i>, can produce superantigens that cross-link the major histocompatibility complex and T-cell receptors, leading to polyclonal activation of T cells, cytokine production, and toxic shock syndrome. Superantigens are the most powerful T-cell mitogens, and bacterial superantigen concentrations of less than 0.1 pg per milliliter are sufficient to stimulate T cells in an uncontrolled manner, resulting in fever, shock, and death.</div><div role="paragraph">In sepsis-associated cytokine storm, it is unclear which immune cell types and cytokines may be responsible for propagating the pathologic hyperinflammation. Antibiotics are the mainstay of treatment. The administration of monoclonal antibodies directed at specific cytokines and the use of apheresis or medical devices to remove cytokines from circulation have had generally disappointing results in clinical trials.<sup><a href="#core-r62" role="doc-biblioref" data-xml-rid="r62" id="body-ref-r62" href-manipulated="true" aria-label="Reference 62">62</a></sup> Although the timing of treatment in these studies may have contributed to the lack of benefit, additional host or pathogen factors may be important, beyond the specifically elevated cytokine levels. For example, reanalysis of a negative trial of interleukin-1β blockade in patients with sepsis identified a subgroup of patients with elevated ferritin levels who seemed to benefit from the treatment.<sup><a href="#core-r63" role="doc-biblioref" data-xml-rid="r63" id="body-ref-r63" href-manipulated="true" aria-label="Reference 63">63</a></sup></div><div role="paragraph">Disseminated viral infections can also induce profound cytokine storm. Patients with hyperinflammatory responses to microbes often have defects in pathogen detection, effector and regulatory mechanisms, or resolution of inflammation. For example, patients lacking functional perforin, which is critical for resolving infections and inflammation, have prolonged CD8+ T-cell production of interferon-γ and TNF, and HLH-associated cytokine storm develops in such patients when they are infected with EBV or cytomegalovirus.<sup><a href="#core-r64" role="doc-biblioref" data-xml-rid="r64" id="body-ref-r64" href-manipulated="true" aria-label="Reference 64">64</a></sup> Experimental models suggest that cytokine storm occurs in these patients from defective perforin-mediated cytolysis that leads to prolonged engagement between lymphocytes and antigen-presenting cells and defective clearance of antigen-bearing dendritic cells, resulting in continuous activation and proliferation of T cells and macrophages, hemophagocytosis, and an autocrine loop of proinflammatory cytokines.<sup><a href="#core-r21" role="doc-biblioref" data-xml-rid="r21 r65 r66 r67" id="body-ref-r67" href-manipulated="true">21,65–67</a></sup> Furthermore, retrospective analyses of data from persons who died from coagulopathies and hemophagocytosis during the H1N1 influenza pandemic of 2009 revealed germline mutations previously associated with HLH-associated cytokine storm.<sup><a href="#core-r30" role="doc-biblioref" data-xml-rid="r30" id="body-ref-r30-2" href-manipulated="true" aria-label="Reference 30">30</a></sup> Thus, the pathogen initiates and T-cell activation propagates cytokine storm in patients with a genetic susceptibility. Cyclosporine and anti–interleukin-6 receptor monoclonal antibody therapy can be effective in some virus-driven forms of HLH-associated cytokine storm, indicating the critical role of T-cell activation and interleukin-6.</div><div role="paragraph">Another pathogen-induced form of cytokine storm is HHV-8–associated multicentric Castleman’s disease. In this disorder, uncontrolled infection with HHV-8 (also known as Kaposi’s sarcoma herpesvirus) leads to a cytokine storm driven primarily by excessive production of human interleukin-6 and viral interleukin-6 by HHV-8–infected plasmablasts.<sup><a href="#core-r68" role="doc-biblioref" data-xml-rid="r68" id="body-ref-r68" href-manipulated="true" aria-label="Reference 68">68</a></sup> Patients with HHV-8–associated multicentric Castleman’s disease are immunocompromised as a result of human immunodeficiency virus infection or a genetic susceptibility, making it difficult to control the HHV-8 infection, which is a common, typically asymptomatic infection in the general population.<sup><a href="#core-r69" role="doc-biblioref" data-xml-rid="r69" id="body-ref-r69" href-manipulated="true" aria-label="Reference 69">69</a></sup> A recent study showed that the effect of tocilizumab in patients with HHV-8–associated multicentric Castleman’s disease was minimal and short-lived, most likely because of viral interleukin-6 signaling that was independent of the neutralized interleukin-6 receptor.<sup><a href="#core-r70" role="doc-biblioref" data-xml-rid="r70" id="body-ref-r70" href-manipulated="true" aria-label="Reference 70">70</a></sup> As with EBV-associated HLH,<sup><a href="#core-r71" role="doc-biblioref" data-xml-rid="r71" id="body-ref-r71" href-manipulated="true" aria-label="Reference 71">71</a></sup> rituximab is highly effective in patients with HHV-8–associated multicentric Castleman’s disease, since B-cell depletion removes the primary reservoir for HHV-8.<sup><a href="#core-r72" role="doc-biblioref" data-xml-rid="r72" id="body-ref-r72" href-manipulated="true" aria-label="Reference 72">72</a></sup> Many additional microbes can trigger cytokine storm, including other herpesviruses, such as herpes simplex virus, and other influenza viruses, such as H5N1.</div><div role="paragraph">Targeted treatment is more challenging in patients with viral infections than in patients with bacterial infections, since fewer antiviral agents are available. Intravenous immune globulin and convalescent plasma are sometimes used to help control the pathogen and provide beneficial immunomodulation. For some viral infections, treating patients with proinflammatory cytokines in the early stages of infection can help to control the virus before detrimental effects of the immune response occur.<sup><a href="#core-r73" role="doc-biblioref" data-xml-rid="r73" id="body-ref-r73" href-manipulated="true" aria-label="Reference 73">73</a></sup></div></section><section id="sec-5"><h2>Monogenic or Autoimmune Cytokine Storm</h2><div role="paragraph">In rare cases, a pathogen triggers cytokine storm in patients with monogenic disorders, and in other cases, cytokine storm has autoimmune, neoplastic, or idiopathic causes. In patients with primary HLH, various autosomal recessive monogenic abnormalities in granule-mediated cytotoxicity lead to cytokine storm. Common pathologic mutations include those occurring in <i>PRF1</i>, <i>UNC13D</i>, <i>STXBP1</i>, <i>RAB27A</i>, <i>STX11</i>, <i>SH2D1A</i>, <i>XIAP</i>, and <i>NLRC4</i>.<sup><a href="#core-r23" role="doc-biblioref" data-xml-rid="r23" id="body-ref-r23-2" href-manipulated="true" aria-label="Reference 23">23</a></sup> In patients with secondary HLH, viral, autoimmune, or neoplastic disorders trigger cytokine storm, and such patients often have heterozygous polymorphisms in the same genes that are altered in primary HLH.<sup><a href="#core-r65" role="doc-biblioref" data-xml-rid="r65 r74" id="body-ref-r74" href-manipulated="true">65,74</a></sup> Elevated levels of interferon-γ, TNF, interleukin-1, interleukin-4, interleukin-6, interleukin-8, interleukin-10, CXCL9, CXCL10, and interleukin-18 are frequently associated with HLH. Anti–interferon-γ antibody therapy with emapalumab has recently been approved for the treatment of primary HLH, as a bridge to allogeneic stem-cell transplantation, which is typically curative.</div><div role="paragraph">The beneficial effects of glucocorticoids, cyclosporine, anti–interleukin-1 antibody, JAK1 and JAK2 inhibitors, anti–interleukin-6 antibody, and cytotoxic chemotherapies in some patients with primary or secondary HLH suggest that pathways targeted by these agents are key to pathogenesis. Cyclophosphamide and etoposide, which are broadly cytotoxic but particularly effective at eliminating activated CD8+ T cells, are often effective in patients with primary HLH, secondary HLH (including macrophage activation syndrome), and corresponding models.<sup><a href="#core-r75" role="doc-biblioref" data-xml-rid="r75" id="body-ref-r75" href-manipulated="true" aria-label="Reference 75">75</a></sup> Etoposide also targets macrophages, including those involved in regulating inflammation, which could be harmful. Generalized T-cell and B-cell ablation with alemtuzumab and T-cell ablation with antithymocyte globulin have been reported; ablation most likely works by depleting the pathogenic CD8+ T cells, among other cell types.<sup><a href="#core-r76" role="doc-biblioref" data-xml-rid="r76" id="body-ref-r76" href-manipulated="true" aria-label="Reference 76">76</a></sup> Nonablative inhibition of T cells with cyclosporine can also be helpful.<sup><a href="#core-r77" role="doc-biblioref" data-xml-rid="r77" id="body-ref-r77" href-manipulated="true" aria-label="Reference 77">77</a></sup></div><div role="paragraph">Autoinflammatory diseases are characterized by seemingly unprovoked inflammation and cytokine storm without signs of infection or autoimmunity. Affected patients have germline mutations in genes regulating the innate immune system and activation of the inflammasome. Several genetic disorders are associated with altered regulation of the innate immune system, including familial Mediterranean fever (<i>MEFV</i>), TNF receptor–associated periodic syndrome (<i>TNFRSF1A</i>), hyperimmunoglobulinemia D with periodic fever syndrome (<i>MVK</i>), familial cold autoinflammatory syndrome (<i>NLRP3</i>), the Muckle–Wells syndrome (<i>NLRP3</i>), neonatal-onset multisystem inflammatory disease (<i>NLRP3</i>), deficiency of ADA2 (<i>CECR1</i>), <i>NLRC4</i> inflammasomopathies, X-linked lymphoproliferative type 2 disorder (<i>XIAP</i>), the Takenouchi–Kosaki syndrome (<i>CDC42</i>), and the Wiskott–Aldrich syndrome (<i>CDC42</i>). Although all patients with these disorders have periodic fevers, only a portion have cytokine storm. Given the primary genetic defects and the effective treatments that are available, innate cells are most likely the primary cell drivers involved, and TNF, interleukin-1, interleukin-18, or a combination of these cytokines probably drives pathogenesis. Patients with genetic immunodeficiency syndromes such as chronic granulomatous disease and STAT1 gain-of-function disease can, paradoxically, present with cytokine storm from overwhelming infections.<sup><a href="#core-r78" role="doc-biblioref" data-xml-rid="r78" id="body-ref-r78" href-manipulated="true" aria-label="Reference 78">78</a></sup></div><div role="paragraph">Idiopathic multicentric Castleman’s disease is another cytokine storm disorder that is similar to HHV-8–associated multicentric Castleman’s disease, but the cause is unknown. Patients with the thrombocytopenia, anasarca, fever, reticulin fibrosis, and organomegaly (TAFRO) subtype tend to have the most severe cytokine storm.<sup><a href="#core-r79" role="doc-biblioref" data-xml-rid="r79" id="body-ref-r79" href-manipulated="true" aria-label="Reference 79">79</a></sup> Although the cause is unknown, interleukin-6 is the driver of pathogenesis in a large portion of patients. As a result, tocilizumab, which targets the interleukin-6 receptor, and siltuximab, which targets interleukin-6 directly, were developed and approved by regulatory agencies in Japan (tocilizumab) and in the United States and dozens of other countries (siltuximab) for the treatment of idiopathic multicentric Castleman’s disease. Both siltuximab and tocilizumab have been shown to resolve disease flares and sustain remission in approximately one third to one half of patients.<sup><a href="#core-r80" role="doc-biblioref" data-xml-rid="r80" id="body-ref-r80" href-manipulated="true" aria-label="Reference 80">80</a></sup> However, some patients with low circulating interleukin-6 levels have a response to interleukin-6 blockade, and some patients with high systemic interleukin-6 levels do not have a response. A seven-protein panel that can predict which patients with idiopathic multicentric Castleman’s disease are most likely to benefit from siltuximab was recently identified and validated (<a href="https://ashpublications.org/blood/article/132/Supplement%201/3716/265269/Serum-Proteomics-Reveals-Distinct-Subtypes?searchresult=1" target="_blank">https://ashpublications.org/blood/article/132/Supplement%201/3716/265269/Serum-Proteomics-Reveals-Distinct-Subtypes?searchresult=1</a>).</div><div role="paragraph">Patients with idiopathic multicentric Castleman’s disease who have progressive organ dysfunction and who do not have a response to anti–interleukin-6 therapy are often treated with combination cytotoxic chemotherapy to nonspecifically eliminate hyperinflammatory cells.<sup><a href="#core-r81" role="doc-biblioref" data-xml-rid="r81" id="body-ref-r81" href-manipulated="true" aria-label="Reference 81">81</a></sup> Other elevated serum cytokines and cellular signaling pathways that could be considered for therapeutic targeting include CXCL13, CXCL10 (interferon-inducible protein 10 [IP-10]), VEGF-A,<sup><a href="#core-r82" role="doc-biblioref" data-xml-rid="r82" id="body-ref-r82" href-manipulated="true" aria-label="Reference 82">82</a></sup> type I interferon,<sup><a href="#core-r83" role="doc-biblioref" data-xml-rid="r83" id="body-ref-r83" href-manipulated="true" aria-label="Reference 83">83</a></sup> mTOR complex 1 (mTORC1),<sup><a href="#core-r84" role="doc-biblioref" data-xml-rid="r84" id="body-ref-r84" href-manipulated="true" aria-label="Reference 84">84</a></sup> and JAK-STAT3. These findings have led to treatment with the mTORC1 inhibitor sirolimus in patients with idiopathic multicentric Castleman’s disease who do not have a response to anti–interleukin-6 therapy.<sup><a href="#core-r85" role="doc-biblioref" data-xml-rid="r85" id="body-ref-r85" href-manipulated="true" aria-label="Reference 85">85</a></sup> Sirolimus therapy is being evaluated in an ongoing clinical trial involving patients with active disease who do not yet have fulminant cytokine storm (ClinicalTrials.gov number, <a href="http://clinicaltrials.gov/show/NCT03933904" target="_blank">NCT03933904</a>).</div></section><section id="sec-6"><h2>Covid-19–Associated Cytokine Storm</h2><div role="paragraph">Covid-19, which is caused by SARS-CoV-2, is characterized by heterogeneous symptoms ranging from mild fatigue to life-threatening pneumonia, cytokine storm, and multiorgan failure. Cytokine storm was also reported in patients with SARS and was associated with poor outcomes.<sup><a href="#core-r86" role="doc-biblioref" data-xml-rid="r86" id="body-ref-r86" href-manipulated="true" aria-label="Reference 86">86</a></sup> Although the mechanisms of lung injury and multiorgan failure in Covid-19 are still under investigation,<sup><a href="#core-r14" role="doc-biblioref" data-xml-rid="r14" id="body-ref-r14-2" href-manipulated="true" aria-label="Reference 14">14</a></sup> reports of hemophagocytosis and elevated cytokine levels — as well as beneficial effects of immunosuppressant agents — in affected patients, particularly those who are the most severely ill, suggest that cytokine storm may contribute to the pathogenesis of Covid-19.<sup><a href="#core-r87" role="doc-biblioref" data-xml-rid="r87 r88" id="body-ref-r88-1" href-manipulated="true">87,88</a></sup></div><div role="paragraph">Serum cytokine levels that are elevated in patients with Covid-19–associated cytokine storm include interleukin-1β, interleukin-6, IP-10, TNF, interferon-γ, macrophage inflammatory protein (MIP) 1α and 1β, and VEGF.<sup><a href="#core-r89" role="doc-biblioref" data-xml-rid="r89 r90" id="body-ref-r90" href-manipulated="true">89,90</a></sup> Higher interleukin-6 levels are strongly associated with shorter survival.<sup><a href="#core-r91" role="doc-biblioref" data-xml-rid="r91" id="body-ref-r91" href-manipulated="true" aria-label="Reference 91">91</a></sup> The relative frequencies of circulating activated CD4+ and CD8+ T cells and plasmablasts are increased in Covid-19.<sup><a href="#core-r92" role="doc-biblioref" data-xml-rid="r92" id="body-ref-r92" href-manipulated="true" aria-label="Reference 92">92</a></sup> In addition to the elevated systemic cytokine levels and activated immune cells, several clinical and laboratory abnormalities, such as elevated CRP and <span data-style="small-caps">d</span>-dimer levels, hypoalbuminemia, renal dysfunction, and effusions, are also observed in Covid-19, as they are in cytokine storm disorders. Laboratory test results reflecting hyperinflammation and tissue damage were found to predict worsening outcomes in Covid-19.<sup><a href="#core-r93" role="doc-biblioref" data-xml-rid="r93" id="body-ref-r93" href-manipulated="true" aria-label="Reference 93">93</a></sup></div><div role="paragraph">Although immunologic dysregulation has been observed in severe cases of Covid-19,<sup><a href="#core-r26" role="doc-biblioref" data-xml-rid="r26" id="body-ref-r26-2" href-manipulated="true" aria-label="Reference 26">26</a></sup> it is not known whether immune hyperactivity or a failure to resolve the inflammatory response because of ongoing viral replication or immune dysregulation underlies severe cases. The correlation between the nasopharyngeal viral load and cytokine levels (e.g., interferon-α, interferon-γ, and TNF), as well as a declining viral load in moderate but not severe cases, suggests that the immune response is positively associated with the viral burden.<sup><a href="#core-r26" role="doc-biblioref" data-xml-rid="r26" id="body-ref-r26-3" href-manipulated="true" aria-label="Reference 26">26</a></sup> Alternatively, the discoveries of inborn errors of type I interferon immunity and autoantibodies against type I interferons in the most severe cases of Covid-19 suggest that an inadequate antiviral response may be contributory in some patients with Covid-19.<sup><a href="#core-r94" role="doc-biblioref" data-xml-rid="r94 r95" id="body-ref-r95" href-manipulated="true">94,95</a></sup> Host immune responses and immune-related symptoms are extremely variable between asymptomatic patients (who have effective control of SARS-CoV-2) and patients with severe Covid-19 (who are unable to control the virus), which suggests that host immune dysregulation contributes to pathogenesis in some cases. Another hypothesized mechanism involves autoimmunity due to molecular mimicry between SARS-CoV-2 and a self-antigen. These mechanisms may be involved in subgroups of patients, such as children with postinfection multisystem inflammatory syndrome, a condition that seems to be ameliorated by immunomodulatory therapies such as intravenous immune globulin, glucocorticoids, and anti–interleukin-1 and anti–interleukin-6 therapies. Patients with multisystem inflammatory syndrome very clearly meet the definition of cytokine storm, since SARS-CoV-2 is no longer present; however, it is unclear whether the cytokine storm is a driver of Covid-19 or a secondary process. Furthermore, it is now clear that patients with SARS-CoV-2 infection can be asymptomatic or can have acute Covid-19 with heterogeneous severity, a chronic course of Covid-19, or multisystem inflammatory syndrome. A critical question concerns the factors that contribute to the severe cytokine storm–like phenotype observed in a small fraction of patients. Coexisting conditions such as hypertension, diabetes, and obesity are associated with more severe cases of Covid-19, possibly because of the preexisting chronic inflammatory state or a lower threshold for the development of organ dysfunction from the immune response.</div><div role="paragraph">Several important differences in therapeutic considerations should be noted between Covid-19–associated cytokine storm and many other cytokine storm disorders. First, cytokine storm triggered by infection with SARS-CoV-2 may require different therapies from those used for cytokine storm due to other causes. Cytokines may be both a key component of the cytokine storm and an essential factor in the antimicrobial response. Thus, blocking cytokine signaling may actually impair clearance of SARS-CoV-2, increase the risk of secondary infections, and lead to worse outcomes, as seen with influenza virus.<sup><a href="#core-r96" role="doc-biblioref" data-xml-rid="r96" id="body-ref-r96" href-manipulated="true" aria-label="Reference 96">96</a></sup> Since interleukin-6 and other cytokines are potentially critical for both a healthy response to SARS-CoV-2 and a detrimental cytokine storm, it is particularly important that the right subgroups of patients with Covid-19 are selected for treatments at the right time. Despite positive anecdotal reports, two large, randomized, controlled trials of anti–interleukin-6 receptor antibody therapies did not show a survival benefit in hospitalized patients with Covid-19.<sup><a href="#core-r97" role="doc-biblioref" data-xml-rid="r97 r98" id="body-ref-r98" href-manipulated="true">97,98</a></sup></div><div role="paragraph">Second, the primary site of infection and disease most likely contributes to differences in immune responses and mechanisms underlying the cytokine storm, which have implications for treatment. For example, selective elimination of the primary viral reservoir is beneficial in patients with HHV-8–associated multicentric Castleman’s disease but is not possible in patients with Covid-19.</div><div role="paragraph">Third, lymphopenia is not often observed in cytokine storm disorders, but it is a hallmark of severe Covid-19. It is currently unclear whether the lymphopenia observed in Covid-19 is due to tissue infiltration or destruction of lymphocytes.</div><div role="paragraph">Fourth, clotting issues can occur across cytokine storm disorders, but thromboembolic events appear to be more frequent in Covid-19–associated cytokine storm.<sup><a href="#core-r99" role="doc-biblioref" data-xml-rid="r99" id="body-ref-r99" href-manipulated="true" aria-label="Reference 99">99</a></sup> Finally, although cytokine panels have not been measured simultaneously on the same platform across Covid-19–associated cytokine storm and other cytokine storm disorders, preliminary results suggest that circulating levels of several cytokines, such as interleukin-6, as well as other inflammatory markers, such as ferritin, are less severely elevated in Covid-19 than in some of the other cytokine storm disorders.<sup><a href="#core-r26" role="doc-biblioref" data-xml-rid="r26" id="body-ref-r26-4" href-manipulated="true" aria-label="Reference 26">26</a></sup> Levels of inflammatory mediators in pulmonary tissue during infection with SARS-CoV-2 remain unknown.</div><div role="paragraph">Despite the many unknowns, a recent randomized, controlled trial showing that dexamethasone reduces mortality among the most severe cases of Covid-19, characterized by elevated CRP levels and supplemental oxygen requirements, and potentially worsens outcomes in milder cases suggests that excessive, late-stage inflammation contributes to mortality.<sup><a href="#core-r88" role="doc-biblioref" data-xml-rid="r88" id="body-ref-r88-2" href-manipulated="true" aria-label="Reference 88">88</a></sup> A meta-analysis of seven randomized trials showed that 28-day all-cause mortality in critically ill patients with Covid-19 was lower among those who were treated with glucocorticoids than among those who received usual care or placebo.<sup><a href="#core-r100" role="doc-biblioref" data-xml-rid="r100" id="body-ref-r100" href-manipulated="true" aria-label="Reference 100">100</a></sup> An observational study suggesting that patients with Covid-19 have a good response to glucocorticoids when the CRP level is high but a poor response when the level is low is consistent with these findings.<sup><a href="#core-r101" role="doc-biblioref" data-xml-rid="r101" id="body-ref-r101" href-manipulated="true" aria-label="Reference 101">101</a></sup> Further support comes from positive anecdotal reports of targeted antagonists against interleukin-1, granulocyte–macrophage colony-stimulating factor, and JAK1 and JAK2 in patients with Covid-19.<sup><a href="#core-r102" role="doc-biblioref" data-xml-rid="r102 r103 r104 r105" id="body-ref-r105" href-manipulated="true">102-105</a></sup> Likewise, the observation that proinflammatory agents such as inhaled interferon-β have a positive effect if given early in the disease course is consistent with a model in which immunostimulation that enhances antiviral activity is helpful early (and probably harmful late), whereas immunosuppression is helpful late and harmful early. As with dexamethasone, the timing of treatment and selection of subgroups of patients included in studies will most likely have an effect on outcomes.</div><div role="paragraph">Despite unknowns regarding the role of immune dysregulation and cytokine storm in Covid-19, hundreds of immunomodulatory drugs are currently under investigation.<sup><a href="#core-r102" role="doc-biblioref" data-xml-rid="r102" id="body-ref-r102-2" href-manipulated="true" aria-label="Reference 102">102</a></sup> Many of these treatments have been used for other cytokine storm disorders. Canakinumab, an anti–interleukin-1β monoclonal antibody, and anakinra are both being studied for Covid-19–induced ARDS. Acalabrutinib, a selective inhibitor of Bruton tyrosine kinase that regulates B-cell and macrophage signaling and activation, may have promise for dampening the hyperinflammatory response in Covid-19.<sup><a href="#core-r106" role="doc-biblioref" data-xml-rid="r106" id="body-ref-r106" href-manipulated="true" aria-label="Reference 106">106</a></sup> JAK1 and JAK2 inhibitors, which are approved for the treatment of a number of autoimmune and neoplastic conditions, have the potential to inhibit signaling downstream of type I interferon, interleukin-6 (and other gp130 family receptors), interferon-γ, and interleukin-2, among other cytokines.<sup><a href="#core-r107" role="doc-biblioref" data-xml-rid="r107" id="body-ref-r107" href-manipulated="true" aria-label="Reference 107">107</a></sup> Much like anti–interleukin-6 antibody therapy, inhibition of Bruton tyrosine kinase and JAK could prove to be damaging or unhelpful if given too soon, when the immune response to SARS-CoV-2 is critical in controlling viral replication and clearance.</div></section><section id="sec-7"><h2>Therapeutics</h2><div role="paragraph">The general treatment strategy for cytokine storm involves supportive care to maintain critical organ function, control of the underlying disease and elimination of triggers for abnormal immune system activation, and targeted immunomodulation or nonspecific immunosuppression to limit the collateral damage of the activated immune system. As noted throughout this review, a number of drugs are effective across multiple disorders under the cytokine storm umbrella and still more may be effective in multiple conditions that have not yet been studied.</div><div role="paragraph">Given the growing number of new therapeutics targeting various aspects of the immune system and our ability to probe the biologic mechanisms of disease, further research should focus on the identification of drugs that can be used across cytokine storm disorders and precision diagnostics for selecting the right drugs for the right patients, regardless of the underlying condition.<sup><a href="#core-r108" role="doc-biblioref" data-xml-rid="r108 r109" id="body-ref-r109" href-manipulated="true">108,109</a></sup> A study involving patients with systemic juvenile idiopathic arthritis revealed subgroups of patients with cytokine profiles in which interleukin-6 and interleukin-18 predominated, pointing toward available therapeutic approaches.<sup><a href="#core-r110" role="doc-biblioref" data-xml-rid="r110" id="body-ref-r110" href-manipulated="true" aria-label="Reference 110">110</a></sup> Likewise, biomarkers were recently shown to effectively predict which patients with adult-onset Still’s disease would have a response to anakinra or tocilizumab.<sup><a href="#core-r111" role="doc-biblioref" data-xml-rid="r111" id="body-ref-r111" href-manipulated="true" aria-label="Reference 111">111</a></sup> The progress made in precision oncology suggests that similar efforts across cytokine storm disorders are warranted to identify specific therapeutic targets and signatures of response to certain drugs that cross disease boundaries. JAK signaling is an interesting target in cytokine storm, because multiple cytokine–receptor pairs can be targeted simultaneously, an approach that may be effective for multiple diseases driven by different cytokines. In addition, plasma exchange and plasma filtration columns for the adsorption of cytokines are both under evaluation for cytokine storm disorders.</div><div role="paragraph">It is important to consider several factors in managing cytokine storm. Neutralization of a particular cytokine whose level is elevated in the circulation with an existing agent (anti–interleukin-6, anti-TNF, anti–interferon-γ, or anti–interleukin-1β antibody) will not always be effective, and blocking a cytokine with a low or normal circulating level can be effective if it is a key component of the hyperinflammatory circuit or if its level is potentially elevated in tissue. In addition, the various therapies mentioned in this review have distinctive side-effect and risk profiles. All targeted agents have target-specific risks, and combination therapy has more potential risks than single-agent therapy. Furthermore, pathologic hyperinflammation itself is an immunodeficiency that can put patients at risk for infections, and immunosuppressive agents most likely increase the risk further. In this age of cytokine profiling and individualized medicine, patients must be monitored and given appropriate prophylaxis when treated empirically, and randomized, controlled trials should always be performed to assess efficacy and safety.</div><div role="paragraph">Advancing the research and treatment of cytokine storm will require pooling of samples for “omics” studies and collaboration among experts across conditions. The introduction of an <i>International Classification of Diseases, 10th Revision</i>, code for cytokine release syndrome in 2021 should facilitate electronic health record–based research into its natural history, pathogenesis, and treatments. Once sufficient scientific progress has been achieved toward biomarker-guided, individualized treatment of cytokine storm, reliable, quick, and accessible assays will be needed to measure soluble mediators of inflammation in plasma and tissues.</div></section><section id="sec-8"><h2>Summary</h2><div role="paragraph">Mild, secondary organ dysfunction during an inflammatory response is evolutionarily acceptable if it allows the host to overcome the infection and survive. If the inflammatory response causes excessive organ dysfunction that puts host survival and reproductive fitness at risk (in the absence of ventilatory support and dialysis), then it is pathologic. Extensive regulatory mechanisms exist that modulate the immune response and prevent cytokine storm. Nevertheless, the disorder can still occur due to iatrogenic causes, pathogens, cancers, autoimmunity, and autoinflammatory mechanisms. Distinguishing between protective inflammatory responses and pathologic cytokine storm has important implications for treatment and is quite challenging. No unifying definition of cytokine storm exists, and there is much disagreement about what the definition should be and whether specific conditions such as Covid-19 should be included in the spectrum of cytokine storm disorders. We propose a unifying definition for cytokine storm that is based on the following criteria: elevated circulating cytokine levels, acute systemic inflammatory symptoms, and secondary organ dysfunction beyond that which could be attributed to a normal response to a pathogen, if a pathogen is present. Targeted therapeutic approaches to cytokine storm associated with idiopathic multicentric Castleman’s disease, HLH, or CAR T-cell therapy have turned deadly conditions into often reversible states. Given advances in “multi-omic” profiling and therapeutic modulation of the immune system, as well as concerted efforts to work across the cytokine storm umbrella, we expect to see continued improvements in outcomes.</div></section>



        
        
</div></section><section id="backmatter" data-extent="backmatter" data-location="articleTab_article"><div class="core-container"><section id="backnotes" data-location="notes_article"><h2>Notes</h2><div role="paragraph"><a href="#ap1">Disclosure forms</a> provided by the authors are available at NEJM.org.</div><div role="paragraph">We thank our colleagues Michael Jordan, Taku Kambayashi, Ivan Maillard, Sheila Pierson, Ruth-Anne Langan Pai, Dan Rader, Patricia Tsao, Frits van Rhee, Dermot Kelleher, Shanmuganthan Chandrakasan, Amber Cohen, Alexis Phillips, John Wherry, and Charles Dinarello for their critical review and feedback.</div></section><section id="supplementary-materials" class="core-supplementary-materials"><h2>Supplementary Material</h2><div role="list"><div id="ap1" class="core-supplementary-material" role="listitem"><div class="core-description"><span class="core-label">Disclosure Forms</span> <span class="core-filename">(nejmra2026131_disclosures.pdf)</span></div><div class="core-link"><ul><li><a href="/doi/suppl/10.1056/NEJMra2026131/suppl_file/nejmra2026131_disclosures.pdf" download="nejmra2026131_disclosures.pdf" data-interactiontype="multimedia_download" data-multimedia-type="Supplementary Material" data-behavior="trackDownloadEvent" data-multimedia-filename="nejmra2026131_disclosures.pdf" data-doi="10.1056/NEJMra2026131">Download</a></li><li>193.92 KB</li></ul></div></div></div></section><section id="bibliography" class="core-reference-list" role="doc-bibliography" data-location="references_article"><h2>References</h2><div role="list" data-method="clamp" id="collapsible-text"><div role="listitem" data-has="label"><div class="label">1.</div><div id="r1" class="citations"><div class="citation"><div class="citation-content">Morgan RA, Yang JC, Kitano M, Dudley ME, Laurencot CM, Rosenberg SA. Case report of a serious adverse event following the administration of T cells transduced with a chimeric antigen receptor recognizing ERBB2. <em>Mol Ther</em> 2010;18:843-851.</div><div class="external-links"><div class="to-citation__wrapper"><a class="to-citation" href="#body-ref-r1"><i aria-hidden="true" class="icon-return"></i><span>Go to Citation</span></a></div><div class="core-xlink-crossref"><a href="https://doi.org/10.1038/mt.2010.24" target="_blank">Crossref</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/20179677/" target="_blank">PubMed</a></div><div class="core-xlink-isi"><a href="https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;DestApp=WOS_CPL&amp;UsrCustomerID=5e3815c904498985e796fc91436abd9a&amp;SrcAuth=atyponcel&amp;SrcApp=literatum&amp;DestLinkType=FullRecord&amp;KeyUT=000276636800024" target="_blank">Web of Science</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=Case+report+of+a+serious+adverse+event+following+the+administration+of+T+cells+transduced+with+a+chimeric+antigen+receptor+recognizing+ERBB2.&amp;publication_year=2010&amp;journal=Mol+Ther&amp;pages=843-851&amp;doi=10.1038%2Fmt.2010.24&amp;pmid=20179677" target="_blank">Google Scholar</a></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">2.</div><div id="r2" class="citations"><div class="citation"><div class="citation-content">Ferrara JL, Abhyankar S, Gilliland DG. Cytokine storm of graft-versus-host disease: a critical effector role for interleukin-1. <em>Transplant Proc</em> 1993;25:1216-1217.</div><div class="external-links"><div class="to-citation__wrapper"><a class="to-citation" href="#body-ref-r2"><i aria-hidden="true" class="icon-return"></i><span>Go to Citation</span></a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/8442093/" target="_blank">PubMed</a></div><div class="core-xlink-isi"><a href="https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;DestApp=WOS_CPL&amp;UsrCustomerID=5e3815c904498985e796fc91436abd9a&amp;SrcAuth=atyponcel&amp;SrcApp=literatum&amp;DestLinkType=FullRecord&amp;KeyUT=A1993KN62200156" target="_blank">Web of Science</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=Cytokine+storm+of+graft-versus-host+disease%3A+a+critical+effector+role+for+interleukin-1.&amp;publication_year=1993&amp;journal=Transplant+Proc&amp;pages=1216-1217&amp;pmid=8442093" target="_blank">Google Scholar</a></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">3.</div><div id="r3" class="citations"><div class="citation"><div class="citation-content">Chatenoud L, Ferran C, Bach JF. The anti-CD3-induced syndrome: a consequence of massive in vivo cell activation. <em>Curr Top Microbiol Immunol</em> 1991;174:121-134.</div><div class="external-links"><div class="to-citation__wrapper"><a class="to-citation" href="#body-ref-r3"><i aria-hidden="true" class="icon-return"></i><span>Go to Citation</span></a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/1839376/" target="_blank">PubMed</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=The+anti-CD3-induced+syndrome%3A+a+consequence+of+massive+in+vivo+cell+activation.&amp;publication_year=1991&amp;journal=Curr+Top+Microbiol+Immunol&amp;pages=121-134&amp;pmid=1839376" target="_blank">Google Scholar</a></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">4.</div><div id="r4" class="citations"><div class="citation"><div class="citation-content">Coley WB. The treatment of malignant tumors by repeated inoculations of erysipelas: with a report of ten original cases. <em>Am J Med Sci</em> 1893;105:487-511.</div><div class="external-links"><div class="to-citation__wrapper"><a class="to-citation" href="#body-ref-r4"><i aria-hidden="true" class="icon-return"></i><span>Go to Citation</span></a></div><div class="core-xlink-crossref"><a href="https://doi.org/10.1097/00000441-189305000-00001" target="_blank">Crossref</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=The+treatment+of+malignant+tumors+by+repeated+inoculations+of+erysipelas%3A+with+a+report+of+ten+original+cases.&amp;publication_year=1893&amp;journal=Am+J+Med+Sci&amp;pages=487-511&amp;doi=10.1097%2F00000441-189305000-00001" target="_blank">Google Scholar</a></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">5.</div><div id="r5" class="citations"><div class="citation"><div class="citation-content">Pechous RD, Sivaraman V, Price PA, Stasulli NM, Goldman WE. Early host cell targets of Yersinia pestis during primary pneumonic plague. <em>PLoS Pathog</em> 2013;9(10):e1003679-e1003679.</div><div class="external-links"><div class="to-citation__wrapper"><a class="to-citation" href="#body-ref-r5"><i aria-hidden="true" class="icon-return"></i><span>Go to Citation</span></a></div><div class="core-xlink-crossref"><a href="https://doi.org/10.1371/journal.ppat.1003679" target="_blank">Crossref</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/24098126/" target="_blank">PubMed</a></div><div class="core-xlink-isi"><a href="https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;DestApp=WOS_CPL&amp;UsrCustomerID=5e3815c904498985e796fc91436abd9a&amp;SrcAuth=atyponcel&amp;SrcApp=literatum&amp;DestLinkType=FullRecord&amp;KeyUT=000330383800049" target="_blank">Web of Science</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=Early+host+cell+targets+of+Yersinia+pestis+during+primary+pneumonic+plague.&amp;publication_year=2013&amp;journal=PLoS+Pathog&amp;pages=e1003679-e1003679&amp;doi=10.1371%2Fjournal.ppat.1003679&amp;pmid=24098126" target="_blank">Google Scholar</a></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">6.</div><div id="r6" class="citations"><div class="citation"><div class="citation-content">Kash JC, Tumpey TM, Proll SC, et al. Genomic analysis of increased host immune and cell death responses induced by 1918 influenza virus. <em>Nature</em> 2006;443:578-581.</div><div class="external-links"><div class="to-citation__wrapper"><a class="to-citation" href="#body-ref-r6"><i aria-hidden="true" class="icon-return"></i><span>Go to Citation</span></a></div><div class="core-xlink-crossref"><a href="https://doi.org/10.1038/nature05181" target="_blank">Crossref</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/17006449/" target="_blank">PubMed</a></div><div class="core-xlink-isi"><a href="https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;DestApp=WOS_CPL&amp;UsrCustomerID=5e3815c904498985e796fc91436abd9a&amp;SrcAuth=atyponcel&amp;SrcApp=literatum&amp;DestLinkType=FullRecord&amp;KeyUT=000240988200044" target="_blank">Web of Science</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=Genomic+analysis+of+increased+host+immune+and+cell+death+responses+induced+by+1918+influenza+virus.&amp;publication_year=2006&amp;journal=Nature&amp;pages=578-581&amp;doi=10.1038%2Fnature05181&amp;pmid=17006449" target="_blank">Google Scholar</a></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">7.</div><div id="r7" class="citations"><div class="citation"><div class="citation-content">Lee DW, Santomasso BD, Locke FL, et al. ASTCT consensus grading for cytokine release syndrome and neurologic toxicity associated with immune effector cells. <em>Biol Blood Marrow Transplant</em> 2019;25:625-638.</div><div class="external-links"><div class="to-citation__wrapper"><button aria-controls="to-citation__accordion-r7" aria-expanded="false" aria-label="Toggle citations menu" class="to-citation__toggle"><i aria-hidden="true" class="icon-plus"></i><span data-expand-title="Hide Citations" data-collapsed-title="Show Citations" class="accordion__toggle__title"></span></button></div><div class="core-xlink-crossref"><a href="https://doi.org/10.1016/j.bbmt.2018.12.758" target="_blank">Crossref</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/30592986/" target="_blank">PubMed</a></div><div class="core-xlink-isi"><a href="https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;DestApp=WOS_CPL&amp;UsrCustomerID=5e3815c904498985e796fc91436abd9a&amp;SrcAuth=atyponcel&amp;SrcApp=literatum&amp;DestLinkType=FullRecord&amp;KeyUT=000465364900001" target="_blank">Web of Science</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=ASTCT+consensus+grading+for+cytokine+release+syndrome+and+neurologic+toxicity+associated+with+immune+effector+cells.&amp;publication_year=2019&amp;journal=Biol+Blood+Marrow+Transplant&amp;pages=625-638&amp;doi=10.1016%2Fj.bbmt.2018.12.758&amp;pmid=30592986" target="_blank">Google Scholar</a></div><div role="menu" aria-label="links" class="to-citation__accordion no-separator" id="to-citation__accordion-r7" style="display: none;"><ul role="none"><li role="none"><a class="to-citation" href="#body-ref-r7-1" role="menuitem"><i aria-hidden="true" class="icon-return"></i><span>a [...] iatrogenic causes of cytokine storm alone. </span></a></li><li role="none"><a class="to-citation" href="#body-ref-r7-2" role="menuitem"><i aria-hidden="true" class="icon-return"></i><span>b [...] on the cause and treatments administered. </span></a></li><li role="none"><a class="to-citation" href="#body-ref-r7-3" role="menuitem"><i aria-hidden="true" class="icon-return"></i><span>c [...] release syndrome–associated encephalopathy. </span></a></li><li role="none"><a class="to-citation" href="#body-ref-r7-4" role="menuitem"><i aria-hidden="true" class="icon-return"></i><span>d [...] scale used to assess the current severity. </span></a></li></ul></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">8.</div><div id="r8" class="citations"><div class="citation"><div class="citation-content">Grupp SA, Kalos M, Barrett D, et al. Chimeric antigen receptor-modified T cells for acute lymphoid leukemia. <em>N Engl J Med</em> 2013;368:1509-1518.</div><div class="external-links"><div class="to-citation__wrapper"><button aria-controls="to-citation__accordion-r8" aria-expanded="false" aria-label="Toggle citations menu" class="to-citation__toggle"><i aria-hidden="true" class="icon-plus"></i><span data-expand-title="Hide Citations" data-collapsed-title="Show Citations" class="accordion__toggle__title"></span></button></div><div class="core-xlink-crossref"><a href="/servlet/linkout?suffix=e_1_3_4_9_2&amp;dbid=4&amp;doi=10.1056%2FNEJMra2026131&amp;key=10.1056%2FNEJMoa1215134&amp;site=mms-site" target="_blank">Crossref</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/23527958/" target="_blank">PubMed</a></div><div class="core-xlink-isi"><a href="https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;DestApp=WOS_CPL&amp;UsrCustomerID=5e3815c904498985e796fc91436abd9a&amp;SrcAuth=atyponcel&amp;SrcApp=literatum&amp;DestLinkType=FullRecord&amp;KeyUT=000317603300008" target="_blank">Web of Science</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=Chimeric+antigen+receptor-modified+T+cells+for+acute+lymphoid+leukemia.&amp;publication_year=2013&amp;journal=N+Engl+J+Med&amp;pages=1509-1518&amp;doi=10.1056%2FNEJMoa1215134&amp;pmid=23527958" target="_blank">Google Scholar</a></div><div role="menu" aria-label="links" class="to-citation__accordion no-separator" id="to-citation__accordion-r8" style="display: none;"><ul role="none"><li role="none"><a class="to-citation" href="#body-ref-r8-1" role="menuitem"><i aria-hidden="true" class="icon-return"></i><span>a [...] fever may be high grade in severe cases. </span></a></li><li role="none"><a class="to-citation" href="#body-ref-r8-2" role="menuitem"><i aria-hidden="true" class="icon-return"></i><span>b [...] and several other cytokine storm disorders. </span></a></li></ul></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">9.</div><div id="r9" class="citations"><div class="citation"><div class="citation-content">Templin C, Ghadri JR, Diekmann J, et al. Clinical features and outcomes of takotsubo (stress) cardiomyopathy. <em>N Engl J Med</em> 2015;373:929-938.</div><div class="external-links"><div class="to-citation__wrapper"><a class="to-citation" href="#body-ref-r9"><i aria-hidden="true" class="icon-return"></i><span>Go to Citation</span></a></div><div class="core-xlink-crossref"><a href="/servlet/linkout?suffix=e_1_3_4_10_2&amp;dbid=4&amp;doi=10.1056%2FNEJMra2026131&amp;key=10.1056%2FNEJMoa1406761&amp;site=mms-site" target="_blank">Crossref</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/26332547/" target="_blank">PubMed</a></div><div class="core-xlink-isi"><a href="https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;DestApp=WOS_CPL&amp;UsrCustomerID=5e3815c904498985e796fc91436abd9a&amp;SrcAuth=atyponcel&amp;SrcApp=literatum&amp;DestLinkType=FullRecord&amp;KeyUT=000360439500008" target="_blank">Web of Science</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=Clinical+features+and+outcomes+of+takotsubo+%28stress%29+cardiomyopathy.&amp;publication_year=2015&amp;journal=N+Engl+J+Med&amp;pages=929-938&amp;doi=10.1056%2FNEJMoa1406761&amp;pmid=26332547" target="_blank">Google Scholar</a></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">10.</div><div id="r10" class="citations"><div class="citation"><div class="citation-content">Schwartzentruber DJ. Guidelines for the safe administration of high-dose interleukin-2. <em>J Immunother</em> 2001;24:287-293.</div><div class="external-links"><div class="to-citation__wrapper"><a class="to-citation" href="#body-ref-r10"><i aria-hidden="true" class="icon-return"></i><span>Go to Citation</span></a></div><div class="core-xlink-crossref"><a href="https://doi.org/10.1097/00002371-200107000-00004" target="_blank">Crossref</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/11565830/" target="_blank">PubMed</a></div><div class="core-xlink-isi"><a href="https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;DestApp=WOS_CPL&amp;UsrCustomerID=5e3815c904498985e796fc91436abd9a&amp;SrcAuth=atyponcel&amp;SrcApp=literatum&amp;DestLinkType=FullRecord&amp;KeyUT=000170839700004" target="_blank">Web of Science</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=Guidelines+for+the+safe+administration+of+high-dose+interleukin-2.&amp;publication_year=2001&amp;journal=J+Immunother&amp;pages=287-293&amp;doi=10.1097%2F00002371-200107000-00004&amp;pmid=11565830" target="_blank">Google Scholar</a></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">11.</div><div id="r11" class="citations"><div class="citation"><div class="citation-content">Lee DW, Gardner R, Porter DL, et al. Current concepts in the diagnosis and management of cytokine release syndrome. <em>Blood</em> 2014;124:188-195.</div><div class="external-links"><div class="to-citation__wrapper"><a class="to-citation" href="#body-ref-r11"><i aria-hidden="true" class="icon-return"></i><span>Go to Citation</span></a></div><div class="core-xlink-crossref"><a href="https://doi.org/10.1182/blood-2014-05-552729" target="_blank">Crossref</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/24876563/" target="_blank">PubMed</a></div><div class="core-xlink-isi"><a href="https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;DestApp=WOS_CPL&amp;UsrCustomerID=5e3815c904498985e796fc91436abd9a&amp;SrcAuth=atyponcel&amp;SrcApp=literatum&amp;DestLinkType=FullRecord&amp;KeyUT=000342618600011" target="_blank">Web of Science</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=Current+concepts+in+the+diagnosis+and+management+of+cytokine+release+syndrome.&amp;publication_year=2014&amp;journal=Blood&amp;pages=188-195&amp;doi=10.1182%2Fblood-2014-05-552729&amp;pmid=24876563" target="_blank">Google Scholar</a></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">12.</div><div id="r12" class="citations"><div class="citation"><div class="citation-content">Diorio C, Shaw PA, Pequignot E, et al. Diagnostic biomarkers to differentiate sepsis from cytokine release syndrome in critically ill children. <em>Blood Adv</em> 2020;4:5174-5183.</div><div class="external-links"><div class="to-citation__wrapper"><a class="to-citation" href="#body-ref-r12"><i aria-hidden="true" class="icon-return"></i><span>Go to Citation</span></a></div><div class="core-xlink-crossref"><a href="https://doi.org/10.1182/bloodadvances.2020002592" target="_blank">Crossref</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/33095872/" target="_blank">PubMed</a></div><div class="core-xlink-isi"><a href="https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;DestApp=WOS_CPL&amp;UsrCustomerID=5e3815c904498985e796fc91436abd9a&amp;SrcAuth=atyponcel&amp;SrcApp=literatum&amp;DestLinkType=FullRecord&amp;KeyUT=000582796200020" target="_blank">Web of Science</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=Diagnostic+biomarkers+to+differentiate+sepsis+from+cytokine+release+syndrome+in+critically+ill+children.&amp;publication_year=2020&amp;journal=Blood+Adv&amp;pages=5174-5183&amp;doi=10.1182%2Fbloodadvances.2020002592&amp;pmid=33095872" target="_blank">Google Scholar</a></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">13.</div><div id="r13" class="citations"><div class="citation"><div class="citation-content">Teachey DT, Lacey SF, Shaw PA, et al. Identification of predictive biomarkers for cytokine release syndrome after chimeric antigen receptor T-cell therapy for acute lymphoblastic leukemia. <em>Cancer Discov</em> 2016;6:664-679.</div><div class="external-links"><div class="to-citation__wrapper"><a class="to-citation" href="#body-ref-r13"><i aria-hidden="true" class="icon-return"></i><span>Go to Citation</span></a></div><div class="core-xlink-crossref"><a href="https://doi.org/10.1158/2159-8290.CD-16-0040" target="_blank">Crossref</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/27076371/" target="_blank">PubMed</a></div><div class="core-xlink-isi"><a href="https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;DestApp=WOS_CPL&amp;UsrCustomerID=5e3815c904498985e796fc91436abd9a&amp;SrcAuth=atyponcel&amp;SrcApp=literatum&amp;DestLinkType=FullRecord&amp;KeyUT=000377426800018" target="_blank">Web of Science</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=Identification+of+predictive+biomarkers+for+cytokine+release+syndrome+after+chimeric+antigen+receptor+T-cell+therapy+for+acute+lymphoblastic+leukemia.&amp;publication_year=2016&amp;journal=Cancer+Discov&amp;pages=664-679&amp;doi=10.1158%2F2159-8290.CD-16-0040&amp;pmid=27076371" target="_blank">Google Scholar</a></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">14.</div><div id="r14" class="citations"><div class="citation"><div class="citation-content">Sinha P, Matthay MA, Calfee CS. Is a “cytokine storm” relevant to COVID-19? <em>JAMA Intern Med</em> 2020;180:1152-1154.</div><div class="external-links"><div class="to-citation__wrapper"><button aria-controls="to-citation__accordion-r14" aria-expanded="false" aria-label="Toggle citations menu" class="to-citation__toggle"><i aria-hidden="true" class="icon-plus"></i><span data-expand-title="Hide Citations" data-collapsed-title="Show Citations" class="accordion__toggle__title"></span></button></div><div class="core-xlink-crossref"><a href="https://doi.org/10.1001/jamainternmed.2020.3313" target="_blank">Crossref</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/32602883/" target="_blank">PubMed</a></div><div class="core-xlink-isi"><a href="https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;DestApp=WOS_CPL&amp;UsrCustomerID=5e3815c904498985e796fc91436abd9a&amp;SrcAuth=atyponcel&amp;SrcApp=literatum&amp;DestLinkType=FullRecord&amp;KeyUT=000571868600004" target="_blank">Web of Science</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=Is+a+%E2%80%9Ccytokine+storm%E2%80%9D+relevant+to+COVID-19%3F&amp;publication_year=2020&amp;journal=JAMA+Intern+Med&amp;pages=1152-1154&amp;doi=10.1001%2Fjamainternmed.2020.3313&amp;pmid=32602883" target="_blank">Google Scholar</a></div><div role="menu" aria-label="links" class="to-citation__accordion no-separator" id="to-citation__accordion-r14" style="display: none;"><ul role="none"><li role="none"><a class="to-citation" href="#body-ref-r14-1" role="menuitem"><i aria-hidden="true" class="icon-return"></i><span>a [...] of a unifying definition for cytokine storm </span></a></li><li role="none"><a class="to-citation" href="#body-ref-r14-2" role="menuitem"><i aria-hidden="true" class="icon-return"></i><span>b [...] in Covid-19 are still under investigation, </span></a></li></ul></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">15.</div><div id="r15" class="citations"><div class="citation"><div class="citation-content">Hashimoto D, Chow A, Noizat C, et al. Tissue-resident macrophages self-maintain locally throughout adult life with minimal contribution from circulating monocytes. <em>Immunity</em> 2013;38:792-804.</div><div class="external-links"><div class="to-citation__wrapper"><a class="to-citation" href="#body-ref-r15"><i aria-hidden="true" class="icon-return"></i><span>Go to Citation</span></a></div><div class="core-xlink-crossref"><a href="https://doi.org/10.1016/j.immuni.2013.04.004" target="_blank">Crossref</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/23601688/" target="_blank">PubMed</a></div><div class="core-xlink-isi"><a href="https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;DestApp=WOS_CPL&amp;UsrCustomerID=5e3815c904498985e796fc91436abd9a&amp;SrcAuth=atyponcel&amp;SrcApp=literatum&amp;DestLinkType=FullRecord&amp;KeyUT=000330942100020" target="_blank">Web of Science</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=Tissue-resident+macrophages+self-maintain+locally+throughout+adult+life+with+minimal+contribution+from+circulating+monocytes.&amp;publication_year=2013&amp;journal=Immunity&amp;pages=792-804&amp;doi=10.1016%2Fj.immuni.2013.04.004&amp;pmid=23601688" target="_blank">Google Scholar</a></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">16.</div><div id="r16" class="citations"><div class="citation"><div class="citation-content">Zoller EE, Lykens JE, Terrell CE, et al. Hemophagocytosis causes a consumptive anemia of inflammation. <em>J Exp Med</em> 2011;208:1203-1214.</div><div class="external-links"><div class="to-citation__wrapper"><a class="to-citation" href="#body-ref-r16"><i aria-hidden="true" class="icon-return"></i><span>Go to Citation</span></a></div><div class="core-xlink-crossref"><a href="https://doi.org/10.1084/jem.20102538" target="_blank">Crossref</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/21624938/" target="_blank">PubMed</a></div><div class="core-xlink-isi"><a href="https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;DestApp=WOS_CPL&amp;UsrCustomerID=5e3815c904498985e796fc91436abd9a&amp;SrcAuth=atyponcel&amp;SrcApp=literatum&amp;DestLinkType=FullRecord&amp;KeyUT=000291424200008" target="_blank">Web of Science</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=Hemophagocytosis+causes+a+consumptive+anemia+of+inflammation.&amp;publication_year=2011&amp;journal=J+Exp+Med&amp;pages=1203-1214&amp;doi=10.1084%2Fjem.20102538&amp;pmid=21624938" target="_blank">Google Scholar</a></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">17.</div><div id="r17" class="citations"><div class="citation"><div class="citation-content">Perez N, Virelizier J-L, Arenzana-Seisdedos F, Fischer A, Griscelli C. Impaired natural killer activity in lymphohistiocytosis syndrome. <em>J Pediatr</em> 1984;104:569-573.</div><div class="external-links"><div class="to-citation__wrapper"><a class="to-citation" href="#body-ref-r17"><i aria-hidden="true" class="icon-return"></i><span>Go to Citation</span></a></div><div class="core-xlink-crossref"><a href="https://doi.org/10.1016/S0022-3476(84)80549-1" target="_blank">Crossref</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/6368780/" target="_blank">PubMed</a></div><div class="core-xlink-isi"><a href="https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;DestApp=WOS_CPL&amp;UsrCustomerID=5e3815c904498985e796fc91436abd9a&amp;SrcAuth=atyponcel&amp;SrcApp=literatum&amp;DestLinkType=FullRecord&amp;KeyUT=A1984SM07900015" target="_blank">Web of Science</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=Impaired+natural+killer+activity+in+lymphohistiocytosis+syndrome.&amp;publication_year=1984&amp;journal=J+Pediatr&amp;pages=569-573&amp;doi=10.1016%2FS0022-3476%2884%2980549-1&amp;pmid=6368780" target="_blank">Google Scholar</a></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">18.</div><div id="r18" class="citations"><div class="citation"><div class="citation-content">Sallusto F. Heterogeneity of human CD4+ T cells against microbes. <em>Annu Rev Immunol</em> 2016;34:317-334.</div><div class="external-links"><div class="to-citation__wrapper"><a class="to-citation" href="#body-ref-r18"><i aria-hidden="true" class="icon-return"></i><span>Go to Citation</span></a></div><div class="core-xlink-crossref"><a href="https://doi.org/10.1146/annurev-immunol-032414-112056" target="_blank">Crossref</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/27168241/" target="_blank">PubMed</a></div><div class="core-xlink-isi"><a href="https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;DestApp=WOS_CPL&amp;UsrCustomerID=5e3815c904498985e796fc91436abd9a&amp;SrcAuth=atyponcel&amp;SrcApp=literatum&amp;DestLinkType=FullRecord&amp;KeyUT=000376011300012" target="_blank">Web of Science</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=Heterogeneity+of+human+CD4%2B+T+cells+against+microbes.&amp;publication_year=2016&amp;journal=Annu+Rev+Immunol&amp;pages=317-334&amp;doi=10.1146%2Fannurev-immunol-032414-112056&amp;pmid=27168241" target="_blank">Google Scholar</a></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">19.</div><div id="r19" class="citations"><div class="citation"><div class="citation-content">Mosmann TR, Coffman RL. TH1 and TH2 cells: different patterns of lymphokine secretion lead to different functional properties. <em>Annu Rev Immunol</em> 1989;7:145-173.</div><div class="external-links"><div class="to-citation__wrapper"><a class="to-citation" href="#body-ref-r19"><i aria-hidden="true" class="icon-return"></i><span>Go to Citation</span></a></div><div class="core-xlink-crossref"><a href="https://doi.org/10.1146/annurev.iy.07.040189.001045" target="_blank">Crossref</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/2523712/" target="_blank">PubMed</a></div><div class="core-xlink-isi"><a href="https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;DestApp=WOS_CPL&amp;UsrCustomerID=5e3815c904498985e796fc91436abd9a&amp;SrcAuth=atyponcel&amp;SrcApp=literatum&amp;DestLinkType=FullRecord&amp;KeyUT=A1989U071000007" target="_blank">Web of Science</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=TH1+and+TH2+cells%3A+different+patterns+of+lymphokine+secretion+lead+to+different+functional+properties.&amp;publication_year=1989&amp;journal=Annu+Rev+Immunol&amp;pages=145-173&amp;doi=10.1146%2Fannurev.iy.07.040189.001045&amp;pmid=2523712" target="_blank">Google Scholar</a></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">20.</div><div id="r20" class="citations"><div class="citation"><div class="citation-content">Crayne CB, Albeituni S, Nichols KE, Cron RQ. The immunology of macrophage activation syndrome. <em>Front Immunol</em> 2019;10:119-119.</div><div class="external-links"><div class="to-citation__wrapper"><a class="to-citation" href="#body-ref-r20"><i aria-hidden="true" class="icon-return"></i><span>Go to Citation</span></a></div><div class="core-xlink-crossref"><a href="https://doi.org/10.3389/fimmu.2019.00119" target="_blank">Crossref</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/30774631/" target="_blank">PubMed</a></div><div class="core-xlink-isi"><a href="https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;DestApp=WOS_CPL&amp;UsrCustomerID=5e3815c904498985e796fc91436abd9a&amp;SrcAuth=atyponcel&amp;SrcApp=literatum&amp;DestLinkType=FullRecord&amp;KeyUT=000457363400001" target="_blank">Web of Science</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=The+immunology+of+macrophage+activation+syndrome.&amp;publication_year=2019&amp;journal=Front+Immunol&amp;pages=119-119&amp;doi=10.3389%2Ffimmu.2019.00119&amp;pmid=30774631" target="_blank">Google Scholar</a></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">21.</div><div id="r21" class="citations"><div class="citation"><div class="citation-content">Jordan MB, Hildeman D, Kappler J, Marrack P. An animal model of hemophagocytic lymphohistiocytosis (HLH): CD8+ T cells and interferon gamma are essential for the disorder. <em>Blood</em> 2004;104:735-743.</div><div class="external-links"><div class="to-citation__wrapper"><button aria-controls="to-citation__accordion-r21" aria-expanded="false" aria-label="Toggle citations menu" class="to-citation__toggle"><i aria-hidden="true" class="icon-plus"></i><span data-expand-title="Hide Citations" data-collapsed-title="Show Citations" class="accordion__toggle__title"></span></button></div><div class="core-xlink-crossref"><a href="https://doi.org/10.1182/blood-2003-10-3413" target="_blank">Crossref</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/15069016/" target="_blank">PubMed</a></div><div class="core-xlink-isi"><a href="https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;DestApp=WOS_CPL&amp;UsrCustomerID=5e3815c904498985e796fc91436abd9a&amp;SrcAuth=atyponcel&amp;SrcApp=literatum&amp;DestLinkType=FullRecord&amp;KeyUT=000222886400028" target="_blank">Web of Science</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=An+animal+model+of+hemophagocytic+lymphohistiocytosis+%28HLH%29%3A+CD8%2B+T+cells+and+interferon+gamma+are+essential+for+the+disorder.&amp;publication_year=2004&amp;journal=Blood&amp;pages=735-743&amp;doi=10.1182%2Fblood-2003-10-3413&amp;pmid=15069016" target="_blank">Google Scholar</a></div><div role="menu" aria-label="links" class="to-citation__accordion no-separator" id="to-citation__accordion-r21" style="display: none;"><ul role="none"><li role="none"><a class="to-citation" href="#body-ref-r23-1" role="menuitem"><i aria-hidden="true" class="icon-return"></i><span>a [...] a cascade of inflammatory tissue damage. </span></a></li><li role="none"><a class="to-citation" href="#body-ref-r67" role="menuitem"><i aria-hidden="true" class="icon-return"></i><span>b [...] loop of proinflammatory cytokines. </span></a></li></ul></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">22.</div><div id="r22" class="citations"><div class="citation"><div class="citation-content">Zhang K, Jordan MB, Marsh RA, et al. Hypomorphic mutations in PRF1, MUNC13-4, and STXBP2 are associated with adult-onset familial HLH. <em>Blood</em> 2011;118:5794-5798.</div><div class="external-links"><div class="to-citation__wrapper"><a class="to-citation" href="#body-ref-r23-1"><i aria-hidden="true" class="icon-return"></i><span>Go to Citation</span></a></div><div class="core-xlink-crossref"><a href="https://doi.org/10.1182/blood-2011-07-370148" target="_blank">Crossref</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/21881043/" target="_blank">PubMed</a></div><div class="core-xlink-isi"><a href="https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;DestApp=WOS_CPL&amp;UsrCustomerID=5e3815c904498985e796fc91436abd9a&amp;SrcAuth=atyponcel&amp;SrcApp=literatum&amp;DestLinkType=FullRecord&amp;KeyUT=000297576600018" target="_blank">Web of Science</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=Hypomorphic+mutations+in+PRF1%2C+MUNC13-4%2C+and+STXBP2+are+associated+with+adult-onset+familial+HLH.&amp;publication_year=2011&amp;journal=Blood&amp;pages=5794-5798&amp;doi=10.1182%2Fblood-2011-07-370148&amp;pmid=21881043" target="_blank">Google Scholar</a></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">23.</div><div id="r23" class="citations"><div class="citation"><div class="citation-content">Schulert GS, Cron RQ. The genetics of macrophage activation syndrome. <em>Genes Immun</em> 2020;21:169-181.</div><div class="external-links"><div class="to-citation__wrapper"><button aria-controls="to-citation__accordion-r23" aria-expanded="false" aria-label="Toggle citations menu" class="to-citation__toggle"><i aria-hidden="true" class="icon-plus"></i><span data-expand-title="Hide Citations" data-collapsed-title="Show Citations" class="accordion__toggle__title"></span></button></div><div class="core-xlink-crossref"><a href="https://doi.org/10.1038/s41435-020-0098-4" target="_blank">Crossref</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/32291394/" target="_blank">PubMed</a></div><div class="core-xlink-isi"><a href="https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;DestApp=WOS_CPL&amp;UsrCustomerID=5e3815c904498985e796fc91436abd9a&amp;SrcAuth=atyponcel&amp;SrcApp=literatum&amp;DestLinkType=FullRecord&amp;KeyUT=000526883300001" target="_blank">Web of Science</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=The+genetics+of+macrophage+activation+syndrome.&amp;publication_year=2020&amp;journal=Genes+Immun&amp;pages=169-181&amp;doi=10.1038%2Fs41435-020-0098-4&amp;pmid=32291394" target="_blank">Google Scholar</a></div><div role="menu" aria-label="links" class="to-citation__accordion no-separator" id="to-citation__accordion-r23" style="display: none;"><ul role="none"><li role="none"><a class="to-citation" href="#body-ref-r23-1" role="menuitem"><i aria-hidden="true" class="icon-return"></i><span>a [...] a cascade of inflammatory tissue damage. </span></a></li><li role="none"><a class="to-citation" href="#body-ref-r23-2" role="menuitem"><i aria-hidden="true" class="icon-return"></i><span>b [...] NLRC4. </span></a></li></ul></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">24.</div><div id="r24" class="citations"><div class="citation"><div class="citation-content">Korn T, Bettelli E, Oukka M, Kuchroo VK. IL-17 and Th17 cells. <em>Annu Rev Immunol</em> 2009;27:485-517.</div><div class="external-links"><div class="to-citation__wrapper"><a class="to-citation" href="#body-ref-r24"><i aria-hidden="true" class="icon-return"></i><span>Go to Citation</span></a></div><div class="core-xlink-crossref"><a href="https://doi.org/10.1146/annurev.immunol.021908.132710" target="_blank">Crossref</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/19132915/" target="_blank">PubMed</a></div><div class="core-xlink-isi"><a href="https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;DestApp=WOS_CPL&amp;UsrCustomerID=5e3815c904498985e796fc91436abd9a&amp;SrcAuth=atyponcel&amp;SrcApp=literatum&amp;DestLinkType=FullRecord&amp;KeyUT=000268071600018" target="_blank">Web of Science</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=IL-17+and+Th17+cells.&amp;publication_year=2009&amp;journal=Annu+Rev+Immunol&amp;pages=485-517&amp;doi=10.1146%2Fannurev.immunol.021908.132710&amp;pmid=19132915" target="_blank">Google Scholar</a></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">25.</div><div id="r25" class="citations"><div class="citation"><div class="citation-content">Avau A, Mitera T, Put S, et al. Systemic juvenile idiopathic arthritis-like syndrome in mice following stimulation of the immune system with Freund’s complete adjuvant: regulation by interferon-γ. <em>Arthritis Rheumatol</em> 2014;66:1340-1351.</div><div class="external-links"><div class="to-citation__wrapper"><a class="to-citation" href="#body-ref-r25"><i aria-hidden="true" class="icon-return"></i><span>Go to Citation</span></a></div><div class="core-xlink-crossref"><a href="https://doi.org/10.1002/art.38359" target="_blank">Crossref</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/24470407/" target="_blank">PubMed</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=Systemic+juvenile+idiopathic+arthritis-like+syndrome+in+mice+following+stimulation+of+the+immune+system+with+Freund%E2%80%99s+complete+adjuvant%3A+regulation+by+interferon-%CE%B3.&amp;publication_year=2014&amp;journal=Arthritis+Rheumatol&amp;pages=1340-1351&amp;doi=10.1002%2Fart.38359&amp;pmid=24470407" target="_blank">Google Scholar</a></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">26.</div><div id="r26" class="citations"><div class="citation"><div class="citation-content">Lucas C, Wong P, Klein J, et al. Longitudinal analyses reveal immunological misfiring in severe COVID-19. <em>Nature</em> 2020;584:463-469.</div><div class="external-links"><div class="to-citation__wrapper"><button aria-controls="to-citation__accordion-r26" aria-expanded="false" aria-label="Toggle citations menu" class="to-citation__toggle"><i aria-hidden="true" class="icon-plus"></i><span data-expand-title="Hide Citations" data-collapsed-title="Show Citations" class="accordion__toggle__title"></span></button></div><div class="core-xlink-crossref"><a href="https://doi.org/10.1038/s41586-020-2588-y" target="_blank">Crossref</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/32717743/" target="_blank">PubMed</a></div><div class="core-xlink-isi"><a href="https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;DestApp=WOS_CPL&amp;UsrCustomerID=5e3815c904498985e796fc91436abd9a&amp;SrcAuth=atyponcel&amp;SrcApp=literatum&amp;DestLinkType=FullRecord&amp;KeyUT=000559369800001" target="_blank">Web of Science</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=Longitudinal+analyses+reveal+immunological+misfiring+in+severe+COVID-19.&amp;publication_year=2020&amp;journal=Nature&amp;pages=463-469&amp;doi=10.1038%2Fs41586-020-2588-y&amp;pmid=32717743" target="_blank">Google Scholar</a></div><div role="menu" aria-label="links" class="to-citation__accordion no-separator" id="to-citation__accordion-r26" style="display: none;"><ul role="none"><li role="none"><a class="to-citation open-in-viewer" href="#t1" role="menuitem" data-target="#fv-body-ref-r26-1"><i aria-hidden="true" class="icon-return"></i><span>a [...] with type I interferon in Covid-19 </span></a></li><li role="none"><a class="to-citation" href="#body-ref-r26-2" role="menuitem"><i aria-hidden="true" class="icon-return"></i><span>b [...] been observed in severe cases of Covid-19, </span></a></li><li role="none"><a class="to-citation" href="#body-ref-r26-3" role="menuitem"><i aria-hidden="true" class="icon-return"></i><span>c [...] associated with the viral burden. </span></a></li><li role="none"><a class="to-citation" href="#body-ref-r26-4" role="menuitem"><i aria-hidden="true" class="icon-return"></i><span>d [...] some of the other cytokine storm disorders. </span></a></li></ul></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">27.</div><div id="r27" class="citations"><div class="citation"><div class="citation-content">Doherty GM, Lange JR, Langstein HN, Alexander HR, Buresh CM, Norton JA. Evidence for IFN-gamma as a mediator of the lethality of endotoxin and tumor necrosis factor-alpha. <em>J Immunol</em> 1992;149:1666-1670.</div><div class="external-links"><div class="to-citation__wrapper"><a class="to-citation" href="#body-ref-r29"><i aria-hidden="true" class="icon-return"></i><span>Go to Citation</span></a></div><div class="core-xlink-crossref"><a href="https://doi.org/10.4049/jimmunol.149.5.1666" target="_blank">Crossref</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/1506688/" target="_blank">PubMed</a></div><div class="core-xlink-isi"><a href="https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;DestApp=WOS_CPL&amp;UsrCustomerID=5e3815c904498985e796fc91436abd9a&amp;SrcAuth=atyponcel&amp;SrcApp=literatum&amp;DestLinkType=FullRecord&amp;KeyUT=A1992JJ89000027" target="_blank">Web of Science</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=Evidence+for+IFN-gamma+as+a+mediator+of+the+lethality+of+endotoxin+and+tumor+necrosis+factor-alpha.&amp;publication_year=1992&amp;journal=J+Immunol&amp;pages=1666-1670&amp;doi=10.4049%2Fjimmunol.149.5.1666&amp;pmid=1506688" target="_blank">Google Scholar</a></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">28.</div><div id="r28" class="citations"><div class="citation"><div class="citation-content">Cohen J. IL-12 deaths: explanation and a puzzle. <em>Science</em> 1995;270:908-908.</div><div class="external-links"><div class="to-citation__wrapper"><a class="to-citation" href="#body-ref-r29"><i aria-hidden="true" class="icon-return"></i><span>Go to Citation</span></a></div><div class="core-xlink-crossref"><a href="https://doi.org/10.1126/science.270.5238.908a" target="_blank">Crossref</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/7481785/" target="_blank">PubMed</a></div><div class="core-xlink-isi"><a href="https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;DestApp=WOS_CPL&amp;UsrCustomerID=5e3815c904498985e796fc91436abd9a&amp;SrcAuth=atyponcel&amp;SrcApp=literatum&amp;DestLinkType=FullRecord&amp;KeyUT=A1995TD87800016" target="_blank">Web of Science</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=IL-12+deaths%3A+explanation+and+a+puzzle.&amp;publication_year=1995&amp;journal=Science&amp;pages=908-908&amp;doi=10.1126%2Fscience.270.5238.908a&amp;pmid=7481785" target="_blank">Google Scholar</a></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">29.</div><div id="r29" class="citations"><div class="citation"><div class="citation-content">Atkins MB. Interleukin-2: clinical applications. <em>Semin Oncol</em> 2002;29:Suppl 7:12-17.</div><div class="external-links"><div class="to-citation__wrapper"><a class="to-citation" href="#body-ref-r29"><i aria-hidden="true" class="icon-return"></i><span>Go to Citation</span></a></div><div class="core-xlink-crossref"><a href="https://doi.org/10.1053/sonc.2002.33077" target="_blank">Crossref</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/12068383/" target="_blank">PubMed</a></div><div class="core-xlink-isi"><a href="https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;DestApp=WOS_CPL&amp;UsrCustomerID=5e3815c904498985e796fc91436abd9a&amp;SrcAuth=atyponcel&amp;SrcApp=literatum&amp;DestLinkType=FullRecord&amp;KeyUT=000176311500003" target="_blank">Web of Science</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=Interleukin-2%3A+clinical+applications.&amp;publication_year=2002&amp;journal=Semin+Oncol&amp;pages=12-17&amp;doi=10.1053%2Fsonc.2002.33077&amp;pmid=12068383" target="_blank">Google Scholar</a></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">30.</div><div id="r30" class="citations"><div class="citation"><div class="citation-content">Schulert GS, Zhang M, Fall N, et al. Whole-exome sequencing reveals mutations in genes linked to hemophagocytic lymphohistiocytosis and macrophage activation syndrome in fatal cases of H1N1 influenza. <em>J Infect Dis</em> 2016;213:1180-1188.</div><div class="external-links"><div class="to-citation__wrapper"><button aria-controls="to-citation__accordion-r30" aria-expanded="false" aria-label="Toggle citations menu" class="to-citation__toggle"><i aria-hidden="true" class="icon-plus"></i><span data-expand-title="Hide Citations" data-collapsed-title="Show Citations" class="accordion__toggle__title"></span></button></div><div class="core-xlink-crossref"><a href="https://doi.org/10.1093/infdis/jiv550" target="_blank">Crossref</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/26597256/" target="_blank">PubMed</a></div><div class="core-xlink-isi"><a href="https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;DestApp=WOS_CPL&amp;UsrCustomerID=5e3815c904498985e796fc91436abd9a&amp;SrcAuth=atyponcel&amp;SrcApp=literatum&amp;DestLinkType=FullRecord&amp;KeyUT=000374186300018" target="_blank">Web of Science</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=Whole-exome+sequencing+reveals+mutations+in+genes+linked+to+hemophagocytic+lymphohistiocytosis+and+macrophage+activation+syndrome+in+fatal+cases+of+H1N1+influenza.&amp;publication_year=2016&amp;journal=J+Infect+Dis&amp;pages=1180-1188&amp;doi=10.1093%2Finfdis%2Fjiv550&amp;pmid=26597256" target="_blank">Google Scholar</a></div><div role="menu" aria-label="links" class="to-citation__accordion no-separator" id="to-citation__accordion-r30" style="display: none;"><ul role="none"><li role="none"><a class="to-citation" href="#body-ref-r30-1" role="menuitem"><i aria-hidden="true" class="icon-return"></i><span>a [...] genetic features, and underlying disorders. </span></a></li><li role="none"><a class="to-citation" href="#body-ref-r30-2" role="menuitem"><i aria-hidden="true" class="icon-return"></i><span>b [...] with HLH-associated cytokine storm. </span></a></li></ul></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">31.</div><div id="r31" class="citations"><div class="citation"><div class="citation-content">Vadhan-Raj S, Nathan CF, Sherwin SA, Oettgen HF, Krown SE. Phase I trial of recombinant interferon gamma by 1-hour i.v. infusion. <em>Cancer Treat Rep</em> 1986;70:609-614.</div><div class="external-links"><div class="to-citation__wrapper"><a class="to-citation" href="#body-ref-r31"><i aria-hidden="true" class="icon-return"></i><span>Go to Citation</span></a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/3085930/" target="_blank">PubMed</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=Phase+I+trial+of+recombinant+interferon+gamma+by+1-hour+i.v.+infusion.&amp;publication_year=1986&amp;journal=Cancer+Treat+Rep&amp;pages=609-614&amp;pmid=3085930" target="_blank">Google Scholar</a></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">32.</div><div id="r32" class="citations"><div class="citation"><div class="citation-content">Locatelli F, Jordan MB, Allen C, et al. Emapalumab in children with primary hemophagocytic lymphohistiocytosis. <em>N Engl J Med</em> 2020;382:1811-1822.</div><div class="external-links"><div class="to-citation__wrapper"><a class="to-citation" href="#body-ref-r32"><i aria-hidden="true" class="icon-return"></i><span>Go to Citation</span></a></div><div class="core-xlink-crossref"><a href="/servlet/linkout?suffix=e_1_3_4_33_2&amp;dbid=4&amp;doi=10.1056%2FNEJMra2026131&amp;key=10.1056%2FNEJMoa1911326&amp;site=mms-site" target="_blank">Crossref</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/32374962/" target="_blank">PubMed</a></div><div class="core-xlink-isi"><a href="https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;DestApp=WOS_CPL&amp;UsrCustomerID=5e3815c904498985e796fc91436abd9a&amp;SrcAuth=atyponcel&amp;SrcApp=literatum&amp;DestLinkType=FullRecord&amp;KeyUT=000533411000012" target="_blank">Web of Science</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=Emapalumab+in+children+with+primary+hemophagocytic+lymphohistiocytosis.&amp;publication_year=2020&amp;journal=N+Engl+J+Med&amp;pages=1811-1822&amp;doi=10.1056%2FNEJMoa1911326&amp;pmid=32374962" target="_blank">Google Scholar</a></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">33.</div><div id="r33" class="citations"><div class="citation"><div class="citation-content">Eloseily EM, Weiser P, Crayne CB, et al. Benefit of anakinra in treating pediatric secondary hemophagocytic lymphohistiocytosis. <em>Arthritis Rheumatol</em> 2020;72:326-334.</div><div class="external-links"><div class="to-citation__wrapper"><a class="to-citation" href="#body-ref-r34"><i aria-hidden="true" class="icon-return"></i><span>Go to Citation</span></a></div><div class="core-xlink-crossref"><a href="https://doi.org/10.1002/art.41103" target="_blank">Crossref</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/31513353/" target="_blank">PubMed</a></div><div class="core-xlink-isi"><a href="https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;DestApp=WOS_CPL&amp;UsrCustomerID=5e3815c904498985e796fc91436abd9a&amp;SrcAuth=atyponcel&amp;SrcApp=literatum&amp;DestLinkType=FullRecord&amp;KeyUT=000504346400001" target="_blank">Web of Science</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=Benefit+of+anakinra+in+treating+pediatric+secondary+hemophagocytic+lymphohistiocytosis.&amp;publication_year=2020&amp;journal=Arthritis+Rheumatol&amp;pages=326-334&amp;doi=10.1002%2Fart.41103&amp;pmid=31513353" target="_blank">Google Scholar</a></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">34.</div><div id="r34" class="citations"><div class="citation"><div class="citation-content">Durand M, Troyanov Y, Laflamme P, Gregoire G. Macrophage activation syndrome treated with anakinra. <em>J Rheumatol</em> 2010;37:879-880.</div><div class="external-links"><div class="to-citation__wrapper"><a class="to-citation" href="#body-ref-r34"><i aria-hidden="true" class="icon-return"></i><span>Go to Citation</span></a></div><div class="core-xlink-crossref"><a href="https://doi.org/10.3899/jrheum.091046" target="_blank">Crossref</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/20360206/" target="_blank">PubMed</a></div><div class="core-xlink-isi"><a href="https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;DestApp=WOS_CPL&amp;UsrCustomerID=5e3815c904498985e796fc91436abd9a&amp;SrcAuth=atyponcel&amp;SrcApp=literatum&amp;DestLinkType=FullRecord&amp;KeyUT=000276783900032" target="_blank">Web of Science</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=Macrophage+activation+syndrome+treated+with+anakinra.&amp;publication_year=2010&amp;journal=J+Rheumatol&amp;pages=879-880&amp;doi=10.3899%2Fjrheum.091046&amp;pmid=20360206" target="_blank">Google Scholar</a></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">35.</div><div id="r35" class="citations"><div class="citation"><div class="citation-content">Winkler U, Jensen M, Manzke O, Schulz H, Diehl V, Engert A. Cytokine-release syndrome in patients with B-cell chronic lymphocytic leukemia and high lymphocyte counts after treatment with an anti-CD20 monoclonal antibody (rituximab, IDEC-C2B8). <em>Blood</em> 1999;94:2217-2224.</div><div class="external-links"><div class="to-citation__wrapper"><button aria-controls="to-citation__accordion-r35" aria-expanded="false" aria-label="Toggle citations menu" class="to-citation__toggle"><i aria-hidden="true" class="icon-plus"></i><span data-expand-title="Hide Citations" data-collapsed-title="Show Citations" class="accordion__toggle__title"></span></button></div><div class="core-xlink-crossref"><a href="https://doi.org/10.1182/blood.V94.7.2217.419k02_2217_2224" target="_blank">Crossref</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/10498591/" target="_blank">PubMed</a></div><div class="core-xlink-isi"><a href="https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;DestApp=WOS_CPL&amp;UsrCustomerID=5e3815c904498985e796fc91436abd9a&amp;SrcAuth=atyponcel&amp;SrcApp=literatum&amp;DestLinkType=FullRecord&amp;KeyUT=000082935000007" target="_blank">Web of Science</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=Cytokine-release+syndrome+in+patients+with+B-cell+chronic+lymphocytic+leukemia+and+high+lymphocyte+counts+after+treatment+with+an+anti-CD20+monoclonal+antibody+%28rituximab%2C+IDEC-C2B8%29.&amp;publication_year=1999&amp;journal=Blood&amp;pages=2217-2224&amp;doi=10.1182%2Fblood.V94.7.2217.419k02_2217_2224&amp;pmid=10498591" target="_blank">Google Scholar</a></div><div role="menu" aria-label="links" class="to-citation__accordion no-separator" id="to-citation__accordion-r35" style="display: none;"><ul role="none"><li role="none"><a class="to-citation" href="#body-ref-r36-1" role="menuitem"><i aria-hidden="true" class="icon-return"></i><span>a [...] underlying immunopathologic disorders </span></a></li><li role="none"><a class="to-citation" href="#body-ref-r35-2" role="menuitem"><i aria-hidden="true" class="icon-return"></i><span>b [...] causes of cytokine storm include rituximab, </span></a></li></ul></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">36.</div><div id="r36" class="citations"><div class="citation"><div class="citation-content">Teachey DT, Rheingold SR, Maude SL, et al. Cytokine release syndrome after blinatumomab treatment related to abnormal macrophage activation and ameliorated with cytokine-directed therapy. <em>Blood</em> 2013;121:5154-5157.</div><div class="external-links"><div class="to-citation__wrapper"><button aria-controls="to-citation__accordion-r36" aria-expanded="false" aria-label="Toggle citations menu" class="to-citation__toggle"><i aria-hidden="true" class="icon-plus"></i><span data-expand-title="Hide Citations" data-collapsed-title="Show Citations" class="accordion__toggle__title"></span></button></div><div class="core-xlink-crossref"><a href="https://doi.org/10.1182/blood-2013-02-485623" target="_blank">Crossref</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/23678006/" target="_blank">PubMed</a></div><div class="core-xlink-isi"><a href="https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;DestApp=WOS_CPL&amp;UsrCustomerID=5e3815c904498985e796fc91436abd9a&amp;SrcAuth=atyponcel&amp;SrcApp=literatum&amp;DestLinkType=FullRecord&amp;KeyUT=000321900700010" target="_blank">Web of Science</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=Cytokine+release+syndrome+after+blinatumomab+treatment+related+to+abnormal+macrophage+activation+and+ameliorated+with+cytokine-directed+therapy.&amp;publication_year=2013&amp;journal=Blood&amp;pages=5154-5157&amp;doi=10.1182%2Fblood-2013-02-485623&amp;pmid=23678006" target="_blank">Google Scholar</a></div><div role="menu" aria-label="links" class="to-citation__accordion no-separator" id="to-citation__accordion-r36" style="display: none;"><ul role="none"><li role="none"><a class="to-citation" href="#body-ref-r36-1" role="menuitem"><i aria-hidden="true" class="icon-return"></i><span>a [...] underlying immunopathologic disorders </span></a></li><li role="none"><a class="to-citation" href="#body-ref-r36-2" role="menuitem"><i aria-hidden="true" class="icon-return"></i><span>b [...] to anti–interleukin-6 antibody therapy. </span></a></li></ul></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">37.</div><div id="r37" class="citations"><div class="citation"><div class="citation-content">van der Stegen SJ, Davies DM, Wilkie S, et al. Preclinical in vivo modeling of cytokine release syndrome induced by ErbB-retargeted human T cells: identifying a window of therapeutic opportunity? <em>J Immunol</em> 2013;191:4589-4598.</div><div class="external-links"><div class="to-citation__wrapper"><a class="to-citation" href="#body-ref-r37"><i aria-hidden="true" class="icon-return"></i><span>Go to Citation</span></a></div><div class="core-xlink-crossref"><a href="https://doi.org/10.4049/jimmunol.1301523" target="_blank">Crossref</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/24062490/" target="_blank">PubMed</a></div><div class="core-xlink-isi"><a href="https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;DestApp=WOS_CPL&amp;UsrCustomerID=5e3815c904498985e796fc91436abd9a&amp;SrcAuth=atyponcel&amp;SrcApp=literatum&amp;DestLinkType=FullRecord&amp;KeyUT=000325929000016" target="_blank">Web of Science</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=Preclinical+in+vivo+modeling+of+cytokine+release+syndrome+induced+by+ErbB-retargeted+human+T+cells%3A+identifying+a+window+of+therapeutic+opportunity%3F&amp;publication_year=2013&amp;journal=J+Immunol&amp;pages=4589-4598&amp;doi=10.4049%2Fjimmunol.1301523&amp;pmid=24062490" target="_blank">Google Scholar</a></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">38.</div><div id="r38" class="citations"><div class="citation"><div class="citation-content">Kang S, Tanaka T, Narazaki M, Kishimoto T. Targeting interleukin-6 signaling in clinic. <em>Immunity</em> 2019;50:1007-1023.</div><div class="external-links"><div class="to-citation__wrapper"><button aria-controls="to-citation__accordion-r38" aria-expanded="false" aria-label="Toggle citations menu" class="to-citation__toggle"><i aria-hidden="true" class="icon-plus"></i><span data-expand-title="Hide Citations" data-collapsed-title="Show Citations" class="accordion__toggle__title"></span></button></div><div class="core-xlink-crossref"><a href="https://doi.org/10.1016/j.immuni.2019.03.026" target="_blank">Crossref</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/30995492/" target="_blank">PubMed</a></div><div class="core-xlink-isi"><a href="https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;DestApp=WOS_CPL&amp;UsrCustomerID=5e3815c904498985e796fc91436abd9a&amp;SrcAuth=atyponcel&amp;SrcApp=literatum&amp;DestLinkType=FullRecord&amp;KeyUT=000464660800016" target="_blank">Web of Science</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=Targeting+interleukin-6+signaling+in+clinic.&amp;publication_year=2019&amp;journal=Immunity&amp;pages=1007-1023&amp;doi=10.1016%2Fj.immuni.2019.03.026&amp;pmid=30995492" target="_blank">Google Scholar</a></div><div role="menu" aria-label="links" class="to-citation__accordion no-separator" id="to-citation__accordion-r38" style="display: none;"><ul role="none"><li role="none"><a class="to-citation" href="#body-ref-r38-1" role="menuitem"><i aria-hidden="true" class="icon-return"></i><span>a [...] and CAR T-cell–induced cytokine storm. </span></a></li><li role="none"><a class="to-citation" href="#body-ref-r38-2" role="menuitem"><i aria-hidden="true" class="icon-return"></i><span>b [...] classic cis signaling and trans signaling. </span></a></li><li role="none"><a class="to-citation" href="#body-ref-r38-3" role="menuitem"><i aria-hidden="true" class="icon-return"></i><span>c [...] which can contribute to cytokine storm. </span></a></li><li role="none"><a class="to-citation" href="#body-ref-r38-4" role="menuitem"><i aria-hidden="true" class="icon-return"></i><span>d [...] hypotension, and pulmonary dysfunction. </span></a></li></ul></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">39.</div><div id="r39" class="citations"><div class="citation"><div class="citation-content">Faulkner L, Cooper A, Fantino C, Altmann DM, Sriskandan S. The mechanism of superantigen-mediated toxic shock: not a simple Th1 cytokine storm. <em>J Immunol</em> 2005;175:6870-6877.</div><div class="external-links"><div class="to-citation__wrapper"><a class="to-citation" href="#body-ref-r39"><i aria-hidden="true" class="icon-return"></i><span>Go to Citation</span></a></div><div class="core-xlink-crossref"><a href="https://doi.org/10.4049/jimmunol.175.10.6870" target="_blank">Crossref</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/16272345/" target="_blank">PubMed</a></div><div class="core-xlink-isi"><a href="https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;DestApp=WOS_CPL&amp;UsrCustomerID=5e3815c904498985e796fc91436abd9a&amp;SrcAuth=atyponcel&amp;SrcApp=literatum&amp;DestLinkType=FullRecord&amp;KeyUT=000233126300073" target="_blank">Web of Science</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=The+mechanism+of+superantigen-mediated+toxic+shock%3A+not+a+simple+Th1+cytokine+storm.&amp;publication_year=2005&amp;journal=J+Immunol&amp;pages=6870-6877&amp;doi=10.4049%2Fjimmunol.175.10.6870&amp;pmid=16272345" target="_blank">Google Scholar</a></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">40.</div><div id="r40" class="citations"><div class="citation"><div class="citation-content">Garlanda C, Dinarello CA, Mantovani A. The interleukin-1 family: back to the future. <em>Immunity</em> 2013;39:1003-1018.</div><div class="external-links"><div class="to-citation__wrapper"><a class="to-citation" href="#body-ref-r40"><i aria-hidden="true" class="icon-return"></i><span>Go to Citation</span></a></div><div class="core-xlink-crossref"><a href="https://doi.org/10.1016/j.immuni.2013.11.010" target="_blank">Crossref</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/24332029/" target="_blank">PubMed</a></div><div class="core-xlink-isi"><a href="https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;DestApp=WOS_CPL&amp;UsrCustomerID=5e3815c904498985e796fc91436abd9a&amp;SrcAuth=atyponcel&amp;SrcApp=literatum&amp;DestLinkType=FullRecord&amp;KeyUT=000330951000008" target="_blank">Web of Science</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=The+interleukin-1+family%3A+back+to+the+future.&amp;publication_year=2013&amp;journal=Immunity&amp;pages=1003-1018&amp;doi=10.1016%2Fj.immuni.2013.11.010&amp;pmid=24332029" target="_blank">Google Scholar</a></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">41.</div><div id="r41" class="citations"><div class="citation"><div class="citation-content">Martinon F, Pétrilli V, Mayor A, Tardivel A, Tschopp J. Gout-associated uric acid crystals activate the NALP3 inflammasome. <em>Nature</em> 2006;440:237-241.</div><div class="external-links"><div class="to-citation__wrapper"><a class="to-citation" href="#body-ref-r42"><i aria-hidden="true" class="icon-return"></i><span>Go to Citation</span></a></div><div class="core-xlink-crossref"><a href="https://doi.org/10.1038/nature04516" target="_blank">Crossref</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/16407889/" target="_blank">PubMed</a></div><div class="core-xlink-isi"><a href="https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;DestApp=WOS_CPL&amp;UsrCustomerID=5e3815c904498985e796fc91436abd9a&amp;SrcAuth=atyponcel&amp;SrcApp=literatum&amp;DestLinkType=FullRecord&amp;KeyUT=000235839500052" target="_blank">Web of Science</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=Gout-associated+uric+acid+crystals+activate+the+NALP3+inflammasome.&amp;publication_year=2006&amp;journal=Nature&amp;pages=237-241&amp;doi=10.1038%2Fnature04516&amp;pmid=16407889" target="_blank">Google Scholar</a></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">42.</div><div id="r42" class="citations"><div class="citation"><div class="citation-content">Frank D, Vince JE. Pyroptosis versus necroptosis: similarities, differences, and crosstalk. <em>Cell Death Differ</em> 2019;26:99-114.</div><div class="external-links"><div class="to-citation__wrapper"><a class="to-citation" href="#body-ref-r42"><i aria-hidden="true" class="icon-return"></i><span>Go to Citation</span></a></div><div class="core-xlink-crossref"><a href="https://doi.org/10.1038/s41418-018-0212-6" target="_blank">Crossref</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/30341423/" target="_blank">PubMed</a></div><div class="core-xlink-isi"><a href="https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;DestApp=WOS_CPL&amp;UsrCustomerID=5e3815c904498985e796fc91436abd9a&amp;SrcAuth=atyponcel&amp;SrcApp=literatum&amp;DestLinkType=FullRecord&amp;KeyUT=000453235500009" target="_blank">Web of Science</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=Pyroptosis+versus+necroptosis%3A+similarities%2C+differences%2C+and+crosstalk.&amp;publication_year=2019&amp;journal=Cell+Death+Differ&amp;pages=99-114&amp;doi=10.1038%2Fs41418-018-0212-6&amp;pmid=30341423" target="_blank">Google Scholar</a></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">43.</div><div id="r43" class="citations"><div class="citation"><div class="citation-content">Netea MG, Kullberg BJ, Verschueren I, Van Der Meer JW. Interleukin-18 induces production of proinflammatory cytokines in mice: no intermediate role for the cytokines of the tumor necrosis factor family and interleukin-1beta. <em>Eur J Immunol</em> 2000;30:3057-3060.</div><div class="external-links"><div class="to-citation__wrapper"><a class="to-citation" href="#body-ref-r43"><i aria-hidden="true" class="icon-return"></i><span>Go to Citation</span></a></div><div class="core-xlink-crossref"><a href="https://doi.org/10.1002/1521-4141(200010)30:10%3C3057::AID-IMMU3057%3E3.0.CO;2-P" target="_blank">Crossref</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/11069090/" target="_blank">PubMed</a></div><div class="core-xlink-isi"><a href="https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;DestApp=WOS_CPL&amp;UsrCustomerID=5e3815c904498985e796fc91436abd9a&amp;SrcAuth=atyponcel&amp;SrcApp=literatum&amp;DestLinkType=FullRecord&amp;KeyUT=000089978200038" target="_blank">Web of Science</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=Interleukin-18+induces+production+of+proinflammatory+cytokines+in+mice%3A+no+intermediate+role+for+the+cytokines+of+the+tumor+necrosis+factor+family+and+interleukin-1beta.&amp;publication_year=2000&amp;journal=Eur+J+Immunol&amp;pages=3057-3060&amp;doi=10.1002%2F1521-4141%28200010%2930%3A10%253C3057%3A%3AAID-IMMU3057%253E3.0.CO%3B2-P&amp;pmid=11069090" target="_blank">Google Scholar</a></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">44.</div><div id="r44" class="citations"><div class="citation"><div class="citation-content">Mazodier K, Marin V, Novick D, et al. Severe imbalance of IL-18/IL-18BP in patients with secondary hemophagocytic syndrome. <em>Blood</em> 2005;106:3483-3489.</div><div class="external-links"><div class="to-citation__wrapper"><button aria-controls="to-citation__accordion-r44" aria-expanded="false" aria-label="Toggle citations menu" class="to-citation__toggle"><i aria-hidden="true" class="icon-plus"></i><span data-expand-title="Hide Citations" data-collapsed-title="Show Citations" class="accordion__toggle__title"></span></button></div><div class="core-xlink-crossref"><a href="https://doi.org/10.1182/blood-2005-05-1980" target="_blank">Crossref</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/16020503/" target="_blank">PubMed</a></div><div class="core-xlink-isi"><a href="https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;DestApp=WOS_CPL&amp;UsrCustomerID=5e3815c904498985e796fc91436abd9a&amp;SrcAuth=atyponcel&amp;SrcApp=literatum&amp;DestLinkType=FullRecord&amp;KeyUT=000233187700033" target="_blank">Web of Science</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=Severe+imbalance+of+IL-18%2FIL-18BP+in+patients+with+secondary+hemophagocytic+syndrome.&amp;publication_year=2005&amp;journal=Blood&amp;pages=3483-3489&amp;doi=10.1182%2Fblood-2005-05-1980&amp;pmid=16020503" target="_blank">Google Scholar</a></div><div role="menu" aria-label="links" class="to-citation__accordion no-separator" id="to-citation__accordion-r44" style="display: none;"><ul role="none"><li role="none"><a class="to-citation" href="#body-ref-r44-1" role="menuitem"><i aria-hidden="true" class="icon-return"></i><span>a [...] high levels of interleukin-18 in serum, </span></a></li><li role="none"><a class="to-citation" href="#body-ref-r47" role="menuitem"><i aria-hidden="true" class="icon-return"></i><span>b [...] of the macrophage activation syndrome. </span></a></li></ul></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">45.</div><div id="r45" class="citations"><div class="citation"><div class="citation-content">Shimizu M, Yokoyama T, Yamada K, et al. Distinct cytokine profiles of systemic-onset juvenile idiopathic arthritis-associated macrophage activation syndrome with particular emphasis on the role of interleukin-18 in its pathogenesis. <em>Rheumatology (Oxford)</em> 2010;49:1645-1653.</div><div class="external-links"><div class="to-citation__wrapper"><a class="to-citation" href="#body-ref-r45"><i aria-hidden="true" class="icon-return"></i><span>Go to Citation</span></a></div><div class="core-xlink-crossref"><a href="https://doi.org/10.1093/rheumatology/keq133" target="_blank">Crossref</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/20472718/" target="_blank">PubMed</a></div><div class="core-xlink-isi"><a href="https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;DestApp=WOS_CPL&amp;UsrCustomerID=5e3815c904498985e796fc91436abd9a&amp;SrcAuth=atyponcel&amp;SrcApp=literatum&amp;DestLinkType=FullRecord&amp;KeyUT=000280904400006" target="_blank">Web of Science</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=Distinct+cytokine+profiles+of+systemic-onset+juvenile+idiopathic+arthritis-associated+macrophage+activation+syndrome+with+particular+emphasis+on+the+role+of+interleukin-18+in+its+pathogenesis.&amp;publication_year=2010&amp;journal=Rheumatology+%28Oxford%29&amp;pages=1645-1653&amp;doi=10.1093%2Frheumatology%2Fkeq133&amp;pmid=20472718" target="_blank">Google Scholar</a></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">46.</div><div id="r46" class="citations"><div class="citation"><div class="citation-content">Dinarello CA, Novick D, Kim S, Kaplanski G. Interleukin-18 and IL-18 binding protein. <em>Front Immunol</em> 2013;4:289-289.</div><div class="external-links"><div class="to-citation__wrapper"><a class="to-citation" href="#body-ref-r46"><i aria-hidden="true" class="icon-return"></i><span>Go to Citation</span></a></div><div class="core-xlink-crossref"><a href="https://doi.org/10.3389/fimmu.2013.00289" target="_blank">Crossref</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/24115947/" target="_blank">PubMed</a></div><div class="core-xlink-isi"><a href="https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;DestApp=WOS_CPL&amp;UsrCustomerID=5e3815c904498985e796fc91436abd9a&amp;SrcAuth=atyponcel&amp;SrcApp=literatum&amp;DestLinkType=FullRecord&amp;KeyUT=000209374100284" target="_blank">Web of Science</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=Interleukin-18+and+IL-18+binding+protein.&amp;publication_year=2013&amp;journal=Front+Immunol&amp;pages=289-289&amp;doi=10.3389%2Ffimmu.2013.00289&amp;pmid=24115947" target="_blank">Google Scholar</a></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">47.</div><div id="r47" class="citations"><div class="citation"><div class="citation-content">Novick D, Kim S, Kaplanski G, Dinarello CA. Interleukin-18, more than a Th1 cytokine. <em>Semin Immunol</em> 2013;25:439-448.</div><div class="external-links"><div class="to-citation__wrapper"><a class="to-citation" href="#body-ref-r47"><i aria-hidden="true" class="icon-return"></i><span>Go to Citation</span></a></div><div class="core-xlink-crossref"><a href="https://doi.org/10.1016/j.smim.2013.10.014" target="_blank">Crossref</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/24275602/" target="_blank">PubMed</a></div><div class="core-xlink-isi"><a href="https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;DestApp=WOS_CPL&amp;UsrCustomerID=5e3815c904498985e796fc91436abd9a&amp;SrcAuth=atyponcel&amp;SrcApp=literatum&amp;DestLinkType=FullRecord&amp;KeyUT=000330752000007" target="_blank">Web of Science</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=Interleukin-18%2C+more+than+a+Th1+cytokine.&amp;publication_year=2013&amp;journal=Semin+Immunol&amp;pages=439-448&amp;doi=10.1016%2Fj.smim.2013.10.014&amp;pmid=24275602" target="_blank">Google Scholar</a></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">48.</div><div id="r48" class="citations"><div class="citation"><div class="citation-content">Behrens EM, Canna SW, Slade K, et al. Repeated TLR9 stimulation results in macrophage activation syndrome-like disease in mice. <em>J Clin Invest</em> 2011;121:2264-2277.</div><div class="external-links"><div class="to-citation__wrapper"><a class="to-citation" href="#body-ref-r48"><i aria-hidden="true" class="icon-return"></i><span>Go to Citation</span></a></div><div class="core-xlink-crossref"><a href="https://doi.org/10.1172/JCI43157" target="_blank">Crossref</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/21576823/" target="_blank">PubMed</a></div><div class="core-xlink-isi"><a href="https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;DestApp=WOS_CPL&amp;UsrCustomerID=5e3815c904498985e796fc91436abd9a&amp;SrcAuth=atyponcel&amp;SrcApp=literatum&amp;DestLinkType=FullRecord&amp;KeyUT=000291234300026" target="_blank">Web of Science</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=Repeated+TLR9+stimulation+results+in+macrophage+activation+syndrome-like+disease+in+mice.&amp;publication_year=2011&amp;journal=J+Clin+Invest&amp;pages=2264-2277&amp;doi=10.1172%2FJCI43157&amp;pmid=21576823" target="_blank">Google Scholar</a></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">49.</div><div id="r49" class="citations"><div class="citation"><div class="citation-content">Gorelik M, Torok KS, Kietz DA, Hirsch R. Hypocomplementemia associated with macrophage activation syndrome in systemic juvenile idiopathic arthritis and adult onset Still’s disease: 3 cases. <em>J Rheumatol</em> 2011;38:396-397.</div><div class="external-links"><div class="to-citation__wrapper"><a class="to-citation" href="#body-ref-r49"><i aria-hidden="true" class="icon-return"></i><span>Go to Citation</span></a></div><div class="core-xlink-crossref"><a href="https://doi.org/10.3899/jrheum.100833" target="_blank">Crossref</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/21285182/" target="_blank">PubMed</a></div><div class="core-xlink-isi"><a href="https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;DestApp=WOS_CPL&amp;UsrCustomerID=5e3815c904498985e796fc91436abd9a&amp;SrcAuth=atyponcel&amp;SrcApp=literatum&amp;DestLinkType=FullRecord&amp;KeyUT=000287173000036" target="_blank">Web of Science</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=Hypocomplementemia+associated+with+macrophage+activation+syndrome+in+systemic+juvenile+idiopathic+arthritis+and+adult+onset+Still%E2%80%99s+disease%3A+3+cases.&amp;publication_year=2011&amp;journal=J+Rheumatol&amp;pages=396-397&amp;doi=10.3899%2Fjrheum.100833&amp;pmid=21285182" target="_blank">Google Scholar</a></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">50.</div><div id="r50" class="citations"><div class="citation"><div class="citation-content">Porter DL, Hwang WT, Frey NV, et al. Chimeric antigen receptor T cells persist and induce sustained remissions in relapsed refractory chronic lymphocytic leukemia. <em>Sci Transl Med</em> 2015;7:303ra139-303ra139.</div><div class="external-links"><div class="to-citation__wrapper"><a class="to-citation" href="#body-ref-r50"><i aria-hidden="true" class="icon-return"></i><span>Go to Citation</span></a></div><div class="core-xlink-crossref"><a href="https://doi.org/10.1126/scitranslmed.aac5415" target="_blank">Crossref</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/26333935/" target="_blank">PubMed</a></div><div class="core-xlink-isi"><a href="https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;DestApp=WOS_CPL&amp;UsrCustomerID=5e3815c904498985e796fc91436abd9a&amp;SrcAuth=atyponcel&amp;SrcApp=literatum&amp;DestLinkType=FullRecord&amp;KeyUT=000360943200004" target="_blank">Web of Science</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=Chimeric+antigen+receptor+T+cells+persist+and+induce+sustained+remissions+in+relapsed+refractory+chronic+lymphocytic+leukemia.&amp;publication_year=2015&amp;journal=Sci+Transl+Med&amp;pages=303ra139-303ra139&amp;doi=10.1126%2Fscitranslmed.aac5415&amp;pmid=26333935" target="_blank">Google Scholar</a></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">51.</div><div id="r51" class="citations"><div class="citation"><div class="citation-content">Xu XJ, Tang YM. Cytokine release syndrome in cancer immunotherapy with chimeric antigen receptor engineered T cells. <em>Cancer Lett</em> 2014;343:172-178.</div><div class="external-links"><div class="to-citation__wrapper"><button aria-controls="to-citation__accordion-r51" aria-expanded="false" aria-label="Toggle citations menu" class="to-citation__toggle"><i aria-hidden="true" class="icon-plus"></i><span data-expand-title="Hide Citations" data-collapsed-title="Show Citations" class="accordion__toggle__title"></span></button></div><div class="core-xlink-crossref"><a href="https://doi.org/10.1016/j.canlet.2013.10.004" target="_blank">Crossref</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/24141191/" target="_blank">PubMed</a></div><div class="core-xlink-isi"><a href="https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;DestApp=WOS_CPL&amp;UsrCustomerID=5e3815c904498985e796fc91436abd9a&amp;SrcAuth=atyponcel&amp;SrcApp=literatum&amp;DestLinkType=FullRecord&amp;KeyUT=000331589600004" target="_blank">Web of Science</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=Cytokine+release+syndrome+in+cancer+immunotherapy+with+chimeric+antigen+receptor+engineered+T+cells.&amp;publication_year=2014&amp;journal=Cancer+Lett&amp;pages=172-178&amp;doi=10.1016%2Fj.canlet.2013.10.004&amp;pmid=24141191" target="_blank">Google Scholar</a></div><div role="menu" aria-label="links" class="to-citation__accordion no-separator" id="to-citation__accordion-r51" style="display: none;"><ul role="none"><li role="none"><a class="to-citation" href="#body-ref-r51-1" role="menuitem"><i aria-hidden="true" class="icon-return"></i><span>a [...] and inflammatory cytokine release, </span></a></li><li role="none"><a class="to-citation" href="#body-ref-r51-2" role="menuitem"><i aria-hidden="true" class="icon-return"></i><span>b [...] factors, such as CAR structure and design, </span></a></li></ul></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">52.</div><div id="r52" class="citations"><div class="citation"><div class="citation-content">Singh N, Hofmann TJ, Gershenson Z, et al. Monocyte lineage-derived IL-6 does not affect chimeric antigen receptor T-cell function. <em>Cytotherapy</em> 2017;19:867-880.</div><div class="external-links"><div class="to-citation__wrapper"><a class="to-citation" href="#body-ref-r54"><i aria-hidden="true" class="icon-return"></i><span>Go to Citation</span></a></div><div class="core-xlink-crossref"><a href="https://doi.org/10.1016/j.jcyt.2017.04.001" target="_blank">Crossref</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/28506444/" target="_blank">PubMed</a></div><div class="core-xlink-isi"><a href="https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;DestApp=WOS_CPL&amp;UsrCustomerID=5e3815c904498985e796fc91436abd9a&amp;SrcAuth=atyponcel&amp;SrcApp=literatum&amp;DestLinkType=FullRecord&amp;KeyUT=000403976600010" target="_blank">Web of Science</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=Monocyte+lineage-derived+IL-6+does+not+affect+chimeric+antigen+receptor+T-cell+function.&amp;publication_year=2017&amp;journal=Cytotherapy&amp;pages=867-880&amp;doi=10.1016%2Fj.jcyt.2017.04.001&amp;pmid=28506444" target="_blank">Google Scholar</a></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">53.</div><div id="r53" class="citations"><div class="citation"><div class="citation-content">Giavridis T, van der Stegen SJC, Eyquem J, Hamieh M, Piersigilli A, Sadelain M. CAR T cell-induced cytokine release syndrome is mediated by macrophages and abated by IL-1 blockade. <em>Nat Med</em> 2018;24:731-738.</div><div class="external-links"><div class="to-citation__wrapper"><a class="to-citation" href="#body-ref-r54"><i aria-hidden="true" class="icon-return"></i><span>Go to Citation</span></a></div><div class="core-xlink-crossref"><a href="https://doi.org/10.1038/s41591-018-0041-7" target="_blank">Crossref</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/29808005/" target="_blank">PubMed</a></div><div class="core-xlink-isi"><a href="https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;DestApp=WOS_CPL&amp;UsrCustomerID=5e3815c904498985e796fc91436abd9a&amp;SrcAuth=atyponcel&amp;SrcApp=literatum&amp;DestLinkType=FullRecord&amp;KeyUT=000434281300018" target="_blank">Web of Science</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=CAR+T+cell-induced+cytokine+release+syndrome+is+mediated+by+macrophages+and+abated+by+IL-1+blockade.&amp;publication_year=2018&amp;journal=Nat+Med&amp;pages=731-738&amp;doi=10.1038%2Fs41591-018-0041-7&amp;pmid=29808005" target="_blank">Google Scholar</a></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">54.</div><div id="r54" class="citations"><div class="citation"><div class="citation-content">Norelli M, Camisa B, Barbiera G, et al. Monocyte-derived IL-1 and IL-6 are differentially required for cytokine-release syndrome and neurotoxicity due to CAR T cells. <em>Nat Med</em> 2018;24:739-748.</div><div class="external-links"><div class="to-citation__wrapper"><a class="to-citation" href="#body-ref-r54"><i aria-hidden="true" class="icon-return"></i><span>Go to Citation</span></a></div><div class="core-xlink-crossref"><a href="https://doi.org/10.1038/s41591-018-0036-4" target="_blank">Crossref</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/29808007/" target="_blank">PubMed</a></div><div class="core-xlink-isi"><a href="https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;DestApp=WOS_CPL&amp;UsrCustomerID=5e3815c904498985e796fc91436abd9a&amp;SrcAuth=atyponcel&amp;SrcApp=literatum&amp;DestLinkType=FullRecord&amp;KeyUT=000434281300019" target="_blank">Web of Science</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=Monocyte-derived+IL-1+and+IL-6+are+differentially+required+for+cytokine-release+syndrome+and+neurotoxicity+due+to+CAR+T+cells.&amp;publication_year=2018&amp;journal=Nat+Med&amp;pages=739-748&amp;doi=10.1038%2Fs41591-018-0036-4&amp;pmid=29808007" target="_blank">Google Scholar</a></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">55.</div><div id="r55" class="citations"><div class="citation"><div class="citation-content">Liu Y, Fang Y, Chen X, et al. Gasdermin E-mediated target cell pyroptosis by CAR T cells triggers cytokine release syndrome. <em>Sci Immunol</em> 2020;5(43):eaax7969-eaax7969.</div><div class="external-links"><div class="to-citation__wrapper"><a class="to-citation" href="#body-ref-r55"><i aria-hidden="true" class="icon-return"></i><span>Go to Citation</span></a></div><div class="core-xlink-crossref"><a href="https://doi.org/10.1126/sciimmunol.aax7969" target="_blank">Crossref</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/31953257/" target="_blank">PubMed</a></div><div class="core-xlink-isi"><a href="https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;DestApp=WOS_CPL&amp;UsrCustomerID=5e3815c904498985e796fc91436abd9a&amp;SrcAuth=atyponcel&amp;SrcApp=literatum&amp;DestLinkType=FullRecord&amp;KeyUT=000512348000007" target="_blank">Web of Science</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=Gasdermin+E-mediated+target+cell+pyroptosis+by+CAR+T+cells+triggers+cytokine+release+syndrome.&amp;publication_year=2020&amp;journal=Sci+Immunol&amp;pages=eaax7969-eaax7969&amp;doi=10.1126%2Fsciimmunol.aax7969&amp;pmid=31953257" target="_blank">Google Scholar</a></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">56.</div><div id="r56" class="citations"><div class="citation"><div class="citation-content">Topp MS, Gökbuget N, Stein AS, et al. Safety and activity of blinatumomab for adult patients with relapsed or refractory B-precursor acute lymphoblastic leukaemia: a multicentre, single-arm, phase 2 study. <em>Lancet Oncol</em> 2015;16:57-66.</div><div class="external-links"><div class="to-citation__wrapper"><a class="to-citation" href="#body-ref-r56"><i aria-hidden="true" class="icon-return"></i><span>Go to Citation</span></a></div><div class="core-xlink-crossref"><a href="https://doi.org/10.1016/S1470-2045(14)71170-2" target="_blank">Crossref</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/25524800/" target="_blank">PubMed</a></div><div class="core-xlink-isi"><a href="https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;DestApp=WOS_CPL&amp;UsrCustomerID=5e3815c904498985e796fc91436abd9a&amp;SrcAuth=atyponcel&amp;SrcApp=literatum&amp;DestLinkType=FullRecord&amp;KeyUT=000346912800045" target="_blank">Web of Science</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=Safety+and+activity+of+blinatumomab+for+adult+patients+with+relapsed+or+refractory+B-precursor+acute+lymphoblastic+leukaemia%3A+a+multicentre%2C+single-arm%2C+phase+2+study.&amp;publication_year=2015&amp;journal=Lancet+Oncol&amp;pages=57-66&amp;doi=10.1016%2FS1470-2045%2814%2971170-2&amp;pmid=25524800" target="_blank">Google Scholar</a></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">57.</div><div id="r57" class="citations"><div class="citation"><div class="citation-content">Suntharalingam G, Perry MR, Ward S, et al. Cytokine storm in a phase 1 trial of the anti-CD28 monoclonal antibody TGN1412. <em>N Engl J Med</em> 2006;355:1018-1028.</div><div class="external-links"><div class="to-citation__wrapper"><a class="to-citation" href="#body-ref-r57"><i aria-hidden="true" class="icon-return"></i><span>Go to Citation</span></a></div><div class="core-xlink-crossref"><a href="/servlet/linkout?suffix=e_1_3_4_58_2&amp;dbid=4&amp;doi=10.1056%2FNEJMra2026131&amp;key=10.1056%2FNEJMoa063842&amp;site=mms-site" target="_blank">Crossref</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/16908486/" target="_blank">PubMed</a></div><div class="core-xlink-isi"><a href="https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;DestApp=WOS_CPL&amp;UsrCustomerID=5e3815c904498985e796fc91436abd9a&amp;SrcAuth=atyponcel&amp;SrcApp=literatum&amp;DestLinkType=FullRecord&amp;KeyUT=000240273300007" target="_blank">Web of Science</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=Cytokine+storm+in+a+phase+1+trial+of+the+anti-CD28+monoclonal+antibody+TGN1412.&amp;publication_year=2006&amp;journal=N+Engl+J+Med&amp;pages=1018-1028&amp;doi=10.1056%2FNEJMoa063842&amp;pmid=16908486" target="_blank">Google Scholar</a></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">58.</div><div id="r58" class="citations"><div class="citation"><div class="citation-content">Frey NV, Porter DL. Cytokine release syndrome with novel therapeutics for acute lymphoblastic leukemia. <em>Hematology Am Soc Hematol Educ Program</em> 2016;2016:567-572.</div><div class="external-links"><div class="to-citation__wrapper"><a class="to-citation" href="#body-ref-r58"><i aria-hidden="true" class="icon-return"></i><span>Go to Citation</span></a></div><div class="core-xlink-crossref"><a href="https://doi.org/10.1182/asheducation-2016.1.567" target="_blank">Crossref</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/27913530/" target="_blank">PubMed</a></div><div class="core-xlink-isi"><a href="https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;DestApp=WOS_CPL&amp;UsrCustomerID=5e3815c904498985e796fc91436abd9a&amp;SrcAuth=atyponcel&amp;SrcApp=literatum&amp;DestLinkType=FullRecord&amp;KeyUT=000418326700076" target="_blank">Web of Science</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=Cytokine+release+syndrome+with+novel+therapeutics+for+acute+lymphoblastic+leukemia.&amp;publication_year=2016&amp;journal=Hematology+Am+Soc+Hematol+Educ+Program&amp;pages=567-572&amp;doi=10.1182%2Fasheducation-2016.1.567&amp;pmid=27913530" target="_blank">Google Scholar</a></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">59.</div><div id="r59" class="citations"><div class="citation"><div class="citation-content">Dahmer MK, Randolph A, Vitali S, Quasney MW. Genetic polymorphisms in sepsis. <em>Pediatr Crit Care Med</em> 2005;6:Suppl:S61-S73.</div><div class="external-links"><div class="to-citation__wrapper"><a class="to-citation" href="#body-ref-r59"><i aria-hidden="true" class="icon-return"></i><span>Go to Citation</span></a></div><div class="core-xlink-crossref"><a href="https://doi.org/10.1097/01.PCC.0000161970.44470.C7" target="_blank">Crossref</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/15857562/" target="_blank">PubMed</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=Genetic+polymorphisms+in+sepsis.&amp;publication_year=2005&amp;journal=Pediatr+Crit+Care+Med&amp;pages=S61-S73&amp;doi=10.1097%2F01.PCC.0000161970.44470.C7&amp;pmid=15857562" target="_blank">Google Scholar</a></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">60.</div><div id="r60" class="citations"><div class="citation"><div class="citation-content">Liu E, Marin D, Banerjee P, et al. Use of CAR-transduced natural killer cells in CD19-positive lymphoid tumors. <em>N Engl J Med</em> 2020;382:545-553.</div><div class="external-links"><div class="to-citation__wrapper"><a class="to-citation" href="#body-ref-r60"><i aria-hidden="true" class="icon-return"></i><span>Go to Citation</span></a></div><div class="core-xlink-crossref"><a href="/servlet/linkout?suffix=e_1_3_4_61_2&amp;dbid=4&amp;doi=10.1056%2FNEJMra2026131&amp;key=10.1056%2FNEJMoa1910607&amp;site=mms-site" target="_blank">Crossref</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/32023374/" target="_blank">PubMed</a></div><div class="core-xlink-isi"><a href="https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;DestApp=WOS_CPL&amp;UsrCustomerID=5e3815c904498985e796fc91436abd9a&amp;SrcAuth=atyponcel&amp;SrcApp=literatum&amp;DestLinkType=FullRecord&amp;KeyUT=000511997100009" target="_blank">Web of Science</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=Use+of+CAR-transduced+natural+killer+cells+in+CD19-positive+lymphoid+tumors.&amp;publication_year=2020&amp;journal=N+Engl+J+Med&amp;pages=545-553&amp;doi=10.1056%2FNEJMoa1910607&amp;pmid=32023374" target="_blank">Google Scholar</a></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">61.</div><div id="r61" class="citations"><div class="citation"><div class="citation-content">Nebelsiek T, Beiras-Fernandez A, Kilger E, Möhnle P, Weis F. Routine use of corticosteroids to prevent inflammation response in cardiac surgery. <em>Recent Pat Cardiovasc Drug Discov</em> 2012;7:170-174.</div><div class="external-links"><div class="to-citation__wrapper"><a class="to-citation" href="#body-ref-r61"><i aria-hidden="true" class="icon-return"></i><span>Go to Citation</span></a></div><div class="core-xlink-crossref"><a href="https://doi.org/10.2174/157489012803832829" target="_blank">Crossref</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/23035828/" target="_blank">PubMed</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=Routine+use+of+corticosteroids+to+prevent+inflammation+response+in+cardiac+surgery.&amp;publication_year=2012&amp;journal=Recent+Pat+Cardiovasc+Drug+Discov&amp;pages=170-174&amp;doi=10.2174%2F157489012803832829&amp;pmid=23035828" target="_blank">Google Scholar</a></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">62.</div><div id="r62" class="citations"><div class="citation"><div class="citation-content">Fisher CJ Jr, Dhainaut JF, Opal SM, et al. Recombinant human interleukin 1 receptor antagonist in the treatment of patients with sepsis syndrome: results from a randomized, double-blind, placebo-controlled trial. <em>JAMA</em> 1994;271:1836-1843.</div><div class="external-links"><div class="to-citation__wrapper"><a class="to-citation" href="#body-ref-r62"><i aria-hidden="true" class="icon-return"></i><span>Go to Citation</span></a></div><div class="core-xlink-crossref"><a href="https://doi.org/10.1001/jama.1994.03510470040032" target="_blank">Crossref</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/8196140/" target="_blank">PubMed</a></div><div class="core-xlink-isi"><a href="https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;DestApp=WOS_CPL&amp;UsrCustomerID=5e3815c904498985e796fc91436abd9a&amp;SrcAuth=atyponcel&amp;SrcApp=literatum&amp;DestLinkType=FullRecord&amp;KeyUT=A1994NP95900027" target="_blank">Web of Science</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=Recombinant+human+interleukin+1+receptor+antagonist+in+the+treatment+of+patients+with+sepsis+syndrome%3A+results+from+a+randomized%2C+double-blind%2C+placebo-controlled+trial.&amp;publication_year=1994&amp;journal=JAMA&amp;pages=1836-1843&amp;doi=10.1001%2Fjama.1994.03510470040032&amp;pmid=8196140" target="_blank">Google Scholar</a></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">63.</div><div id="r63" class="citations"><div class="citation"><div class="citation-content">Shakoory B, Carcillo JA, Chatham WW, et al. Interleukin-1 receptor blockade is associated with reduced mortality in sepsis patients with features of macrophage activation syndrome: reanalysis of a prior phase III trial. <em>Crit Care Med</em> 2016;44:275-281.</div><div class="external-links"><div class="to-citation__wrapper"><a class="to-citation" href="#body-ref-r63"><i aria-hidden="true" class="icon-return"></i><span>Go to Citation</span></a></div><div class="core-xlink-crossref"><a href="https://doi.org/10.1097/CCM.0000000000001402" target="_blank">Crossref</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/26584195/" target="_blank">PubMed</a></div><div class="core-xlink-isi"><a href="https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;DestApp=WOS_CPL&amp;UsrCustomerID=5e3815c904498985e796fc91436abd9a&amp;SrcAuth=atyponcel&amp;SrcApp=literatum&amp;DestLinkType=FullRecord&amp;KeyUT=000368503700005" target="_blank">Web of Science</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=Interleukin-1+receptor+blockade+is+associated+with+reduced+mortality+in+sepsis+patients+with+features+of+macrophage+activation+syndrome%3A+reanalysis+of+a+prior+phase+III+trial.&amp;publication_year=2016&amp;journal=Crit+Care+Med&amp;pages=275-281&amp;doi=10.1097%2FCCM.0000000000001402&amp;pmid=26584195" target="_blank">Google Scholar</a></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">64.</div><div id="r64" class="citations"><div class="citation"><div class="citation-content">Lykens JE, Terrell CE, Zoller EE, Risma K, Jordan MB. Perforin is a critical physiologic regulator of T-cell activation. <em>Blood</em> 2011;118:618-626.</div><div class="external-links"><div class="to-citation__wrapper"><a class="to-citation" href="#body-ref-r64"><i aria-hidden="true" class="icon-return"></i><span>Go to Citation</span></a></div><div class="core-xlink-crossref"><a href="https://doi.org/10.1182/blood-2010-12-324533" target="_blank">Crossref</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/21606480/" target="_blank">PubMed</a></div><div class="core-xlink-isi"><a href="https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;DestApp=WOS_CPL&amp;UsrCustomerID=5e3815c904498985e796fc91436abd9a&amp;SrcAuth=atyponcel&amp;SrcApp=literatum&amp;DestLinkType=FullRecord&amp;KeyUT=000292967300023" target="_blank">Web of Science</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=Perforin+is+a+critical+physiologic+regulator+of+T-cell+activation.&amp;publication_year=2011&amp;journal=Blood&amp;pages=618-626&amp;doi=10.1182%2Fblood-2010-12-324533&amp;pmid=21606480" target="_blank">Google Scholar</a></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">65.</div><div id="r65" class="citations"><div class="citation"><div class="citation-content">Zhang M, Bracaglia C, Prencipe G, et al. A heterozygous RAB27A mutation associated with delayed cytolytic granule polarization and hemophagocytic lymphohistiocytosis. <em>J Immunol</em> 2016;196:2492-2503.</div><div class="external-links"><div class="to-citation__wrapper"><button aria-controls="to-citation__accordion-r65" aria-expanded="false" aria-label="Toggle citations menu" class="to-citation__toggle"><i aria-hidden="true" class="icon-plus"></i><span data-expand-title="Hide Citations" data-collapsed-title="Show Citations" class="accordion__toggle__title"></span></button></div><div class="core-xlink-crossref"><a href="https://doi.org/10.4049/jimmunol.1501284" target="_blank">Crossref</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/26880764/" target="_blank">PubMed</a></div><div class="core-xlink-isi"><a href="https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;DestApp=WOS_CPL&amp;UsrCustomerID=5e3815c904498985e796fc91436abd9a&amp;SrcAuth=atyponcel&amp;SrcApp=literatum&amp;DestLinkType=FullRecord&amp;KeyUT=000372338100008" target="_blank">Web of Science</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=A+heterozygous+RAB27A+mutation+associated+with+delayed+cytolytic+granule+polarization+and+hemophagocytic+lymphohistiocytosis.&amp;publication_year=2016&amp;journal=J+Immunol&amp;pages=2492-2503&amp;doi=10.4049%2Fjimmunol.1501284&amp;pmid=26880764" target="_blank">Google Scholar</a></div><div role="menu" aria-label="links" class="to-citation__accordion no-separator" id="to-citation__accordion-r65" style="display: none;"><ul role="none"><li role="none"><a class="to-citation" href="#body-ref-r67" role="menuitem"><i aria-hidden="true" class="icon-return"></i><span>a [...] loop of proinflammatory cytokines. </span></a></li><li role="none"><a class="to-citation" href="#body-ref-r74" role="menuitem"><i aria-hidden="true" class="icon-return"></i><span>b [...] same genes that are altered in primary HLH. </span></a></li></ul></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">66.</div><div id="r66" class="citations"><div class="citation"><div class="citation-content">Terrell CE, Jordan MB. Perforin deficiency impairs a critical immunoregulatory loop involving murine CD8(+) T cells and dendritic cells. <em>Blood</em> 2013;121:5184-5191.</div><div class="external-links"><div class="to-citation__wrapper"><a class="to-citation" href="#body-ref-r67"><i aria-hidden="true" class="icon-return"></i><span>Go to Citation</span></a></div><div class="core-xlink-crossref"><a href="https://doi.org/10.1182/blood-2013-04-495309" target="_blank">Crossref</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/23660960/" target="_blank">PubMed</a></div><div class="core-xlink-isi"><a href="https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;DestApp=WOS_CPL&amp;UsrCustomerID=5e3815c904498985e796fc91436abd9a&amp;SrcAuth=atyponcel&amp;SrcApp=literatum&amp;DestLinkType=FullRecord&amp;KeyUT=000321900700014" target="_blank">Web of Science</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=Perforin+deficiency+impairs+a+critical+immunoregulatory+loop+involving+murine+CD8%28%2B%29+T+cells+and+dendritic+cells.&amp;publication_year=2013&amp;journal=Blood&amp;pages=5184-5191&amp;doi=10.1182%2Fblood-2013-04-495309&amp;pmid=23660960" target="_blank">Google Scholar</a></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">67.</div><div id="r67" class="citations"><div class="citation"><div class="citation-content">Pachlopnik Schmid J, Ho C-H, Chrétien F, et al. Neutralization of IFNgamma defeats haemophagocytosis in LCMV-infected perforin- and Rab27a-deficient mice. <em>EMBO Mol Med</em> 2009;1:112-124.</div><div class="external-links"><div class="to-citation__wrapper"><a class="to-citation" href="#body-ref-r67"><i aria-hidden="true" class="icon-return"></i><span>Go to Citation</span></a></div><div class="core-xlink-crossref"><a href="https://doi.org/10.1002/emmm.200900009" target="_blank">Crossref</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/20049711/" target="_blank">PubMed</a></div><div class="core-xlink-isi"><a href="https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;DestApp=WOS_CPL&amp;UsrCustomerID=5e3815c904498985e796fc91436abd9a&amp;SrcAuth=atyponcel&amp;SrcApp=literatum&amp;DestLinkType=FullRecord&amp;KeyUT=000273563000007" target="_blank">Web of Science</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=Neutralization+of+IFNgamma+defeats+haemophagocytosis+in+LCMV-infected+perforin-+and+Rab27a-deficient+mice.&amp;publication_year=2009&amp;journal=EMBO+Mol+Med&amp;pages=112-124&amp;doi=10.1002%2Femmm.200900009&amp;pmid=20049711" target="_blank">Google Scholar</a></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">68.</div><div id="r68" class="citations"><div class="citation"><div class="citation-content">Polizzotto MN, Uldrick TS, Wang V, et al. Human and viral interleukin-6 and other cytokines in Kaposi sarcoma herpesvirus-associated multicentric Castleman disease. <em>Blood</em> 2013;122:4189-4198.</div><div class="external-links"><div class="to-citation__wrapper"><a class="to-citation" href="#body-ref-r68"><i aria-hidden="true" class="icon-return"></i><span>Go to Citation</span></a></div><div class="core-xlink-crossref"><a href="https://doi.org/10.1182/blood-2013-08-519959" target="_blank">Crossref</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/24174627/" target="_blank">PubMed</a></div><div class="core-xlink-isi"><a href="https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;DestApp=WOS_CPL&amp;UsrCustomerID=5e3815c904498985e796fc91436abd9a&amp;SrcAuth=atyponcel&amp;SrcApp=literatum&amp;DestLinkType=FullRecord&amp;KeyUT=000329741000013" target="_blank">Web of Science</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=Human+and+viral+interleukin-6+and+other+cytokines+in+Kaposi+sarcoma+herpesvirus-associated+multicentric+Castleman+disease.&amp;publication_year=2013&amp;journal=Blood&amp;pages=4189-4198&amp;doi=10.1182%2Fblood-2013-08-519959&amp;pmid=24174627" target="_blank">Google Scholar</a></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">69.</div><div id="r69" class="citations"><div class="citation"><div class="citation-content">Dispenzieri A, Fajgenbaum DC. Overview of Castleman disease. <em>Blood</em> 2020;135:1353-1364.</div><div class="external-links"><div class="to-citation__wrapper"><a class="to-citation" href="#body-ref-r69"><i aria-hidden="true" class="icon-return"></i><span>Go to Citation</span></a></div><div class="core-xlink-crossref"><a href="https://doi.org/10.1182/blood.2019000931" target="_blank">Crossref</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/32106302/" target="_blank">PubMed</a></div><div class="core-xlink-isi"><a href="https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;DestApp=WOS_CPL&amp;UsrCustomerID=5e3815c904498985e796fc91436abd9a&amp;SrcAuth=atyponcel&amp;SrcApp=literatum&amp;DestLinkType=FullRecord&amp;KeyUT=000527355300009" target="_blank">Web of Science</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=Overview+of+Castleman+disease.&amp;publication_year=2020&amp;journal=Blood&amp;pages=1353-1364&amp;doi=10.1182%2Fblood.2019000931&amp;pmid=32106302" target="_blank">Google Scholar</a></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">70.</div><div id="r70" class="citations"><div class="citation"><div class="citation-content">Ramaswami R, Lurain K, Peer CJ, et al. Tocilizumab in patients with symptomatic Kaposi sarcoma herpesvirus-associated multicentric Castleman disease. <em>Blood</em> 2020;135:2316-2319.</div><div class="external-links"><div class="to-citation__wrapper"><a class="to-citation" href="#body-ref-r70"><i aria-hidden="true" class="icon-return"></i><span>Go to Citation</span></a></div><div class="core-xlink-crossref"><a href="https://doi.org/10.1182/blood.2019004602" target="_blank">Crossref</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/32276276/" target="_blank">PubMed</a></div><div class="core-xlink-isi"><a href="https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;DestApp=WOS_CPL&amp;UsrCustomerID=5e3815c904498985e796fc91436abd9a&amp;SrcAuth=atyponcel&amp;SrcApp=literatum&amp;DestLinkType=FullRecord&amp;KeyUT=000571484400016" target="_blank">Web of Science</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=Tocilizumab+in+patients+with+symptomatic+Kaposi+sarcoma+herpesvirus-associated+multicentric+Castleman+disease.&amp;publication_year=2020&amp;journal=Blood&amp;pages=2316-2319&amp;doi=10.1182%2Fblood.2019004602&amp;pmid=32276276" target="_blank">Google Scholar</a></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">71.</div><div id="r71" class="citations"><div class="citation"><div class="citation-content">Chellapandian D, Das R, Zelley K, et al. Treatment of Epstein Barr virus-induced haemophagocytic lymphohistiocytosis with rituximab-containing chemo-immunotherapeutic regimens. <em>Br J Haematol</em> 2013;162:376-382.</div><div class="external-links"><div class="to-citation__wrapper"><a class="to-citation" href="#body-ref-r71"><i aria-hidden="true" class="icon-return"></i><span>Go to Citation</span></a></div><div class="core-xlink-crossref"><a href="https://doi.org/10.1111/bjh.12386" target="_blank">Crossref</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/23692048/" target="_blank">PubMed</a></div><div class="core-xlink-isi"><a href="https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;DestApp=WOS_CPL&amp;UsrCustomerID=5e3815c904498985e796fc91436abd9a&amp;SrcAuth=atyponcel&amp;SrcApp=literatum&amp;DestLinkType=FullRecord&amp;KeyUT=000321568800011" target="_blank">Web of Science</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=Treatment+of+Epstein+Barr+virus-induced+haemophagocytic+lymphohistiocytosis+with+rituximab-containing+chemo-immunotherapeutic+regimens.&amp;publication_year=2013&amp;journal=Br+J+Haematol&amp;pages=376-382&amp;doi=10.1111%2Fbjh.12386&amp;pmid=23692048" target="_blank">Google Scholar</a></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">72.</div><div id="r72" class="citations"><div class="citation"><div class="citation-content">Dalla Pria A, Pinato D, Roe J, Naresh K, Nelson M, Bower M. Relapse of HHV8-positive multicentric Castleman disease following rituximab-based therapy in HIV-positive patients. <em>Blood</em> 2017;129:2143-2147.</div><div class="external-links"><div class="to-citation__wrapper"><a class="to-citation" href="#body-ref-r72"><i aria-hidden="true" class="icon-return"></i><span>Go to Citation</span></a></div><div class="core-xlink-crossref"><a href="https://doi.org/10.1182/blood-2016-10-747477" target="_blank">Crossref</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/28143881/" target="_blank">PubMed</a></div><div class="core-xlink-isi"><a href="https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;DestApp=WOS_CPL&amp;UsrCustomerID=5e3815c904498985e796fc91436abd9a&amp;SrcAuth=atyponcel&amp;SrcApp=literatum&amp;DestLinkType=FullRecord&amp;KeyUT=000399008200019" target="_blank">Web of Science</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=Relapse+of+HHV8-positive+multicentric+Castleman+disease+following+rituximab-based+therapy+in+HIV-positive+patients.&amp;publication_year=2017&amp;journal=Blood&amp;pages=2143-2147&amp;doi=10.1182%2Fblood-2016-10-747477&amp;pmid=28143881" target="_blank">Google Scholar</a></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">73.</div><div id="r73" class="citations"><div class="citation"><div class="citation-content">Grajales-Reyes GE, Colonna M. Interferon responses in viral pneumonias. <em>Science</em> 2020;369:626-627.</div><div class="external-links"><div class="to-citation__wrapper"><a class="to-citation" href="#body-ref-r73"><i aria-hidden="true" class="icon-return"></i><span>Go to Citation</span></a></div><div class="core-xlink-crossref"><a href="https://doi.org/10.1126/science.abd2208" target="_blank">Crossref</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/32764056/" target="_blank">PubMed</a></div><div class="core-xlink-isi"><a href="https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;DestApp=WOS_CPL&amp;UsrCustomerID=5e3815c904498985e796fc91436abd9a&amp;SrcAuth=atyponcel&amp;SrcApp=literatum&amp;DestLinkType=FullRecord&amp;KeyUT=000559184400025" target="_blank">Web of Science</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=Interferon+responses+in+viral+pneumonias.&amp;publication_year=2020&amp;journal=Science&amp;pages=626-627&amp;doi=10.1126%2Fscience.abd2208&amp;pmid=32764056" target="_blank">Google Scholar</a></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">74.</div><div id="r74" class="citations"><div class="citation"><div class="citation-content">Kaufman KM, Linghu B, Szustakowski JD, et al. Whole-exome sequencing reveals overlap between macrophage activation syndrome in systemic juvenile idiopathic arthritis and familial hemophagocytic lymphohistiocytosis. <em>Arthritis Rheumatol</em> 2014;66:3486-3495.</div><div class="external-links"><div class="to-citation__wrapper"><a class="to-citation" href="#body-ref-r74"><i aria-hidden="true" class="icon-return"></i><span>Go to Citation</span></a></div><div class="core-xlink-crossref"><a href="https://doi.org/10.1002/art.38793" target="_blank">Crossref</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/25047945/" target="_blank">PubMed</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=Whole-exome+sequencing+reveals+overlap+between+macrophage+activation+syndrome+in+systemic+juvenile+idiopathic+arthritis+and+familial+hemophagocytic+lymphohistiocytosis.&amp;publication_year=2014&amp;journal=Arthritis+Rheumatol&amp;pages=3486-3495&amp;doi=10.1002%2Fart.38793&amp;pmid=25047945" target="_blank">Google Scholar</a></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">75.</div><div id="r75" class="citations"><div class="citation"><div class="citation-content">Johnson TS, Terrell CE, Millen SH, Katz JD, Hildeman DA, Jordan MB. Etoposide selectively ablates activated T cells to control the immunoregulatory disorder hemophagocytic lymphohistiocytosis. <em>J Immunol</em> 2014;192:84-91.</div><div class="external-links"><div class="to-citation__wrapper"><a class="to-citation" href="#body-ref-r75"><i aria-hidden="true" class="icon-return"></i><span>Go to Citation</span></a></div><div class="core-xlink-crossref"><a href="https://doi.org/10.4049/jimmunol.1302282" target="_blank">Crossref</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/24259502/" target="_blank">PubMed</a></div><div class="core-xlink-isi"><a href="https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;DestApp=WOS_CPL&amp;UsrCustomerID=5e3815c904498985e796fc91436abd9a&amp;SrcAuth=atyponcel&amp;SrcApp=literatum&amp;DestLinkType=FullRecord&amp;KeyUT=000328950700009" target="_blank">Web of Science</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=Etoposide+selectively+ablates+activated+T+cells+to+control+the+immunoregulatory+disorder+hemophagocytic+lymphohistiocytosis.&amp;publication_year=2014&amp;journal=J+Immunol&amp;pages=84-91&amp;doi=10.4049%2Fjimmunol.1302282&amp;pmid=24259502" target="_blank">Google Scholar</a></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">76.</div><div id="r76" class="citations"><div class="citation"><div class="citation-content">Marsh RA, Allen CE, McClain KL, et al. Salvage therapy of refractory hemophagocytic lymphohistiocytosis with alemtuzumab. <em>Pediatr Blood Cancer</em> 2013;60:101-109.</div><div class="external-links"><div class="to-citation__wrapper"><a class="to-citation" href="#body-ref-r76"><i aria-hidden="true" class="icon-return"></i><span>Go to Citation</span></a></div><div class="core-xlink-crossref"><a href="https://doi.org/10.1002/pbc.24188" target="_blank">Crossref</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/22522603/" target="_blank">PubMed</a></div><div class="core-xlink-isi"><a href="https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;DestApp=WOS_CPL&amp;UsrCustomerID=5e3815c904498985e796fc91436abd9a&amp;SrcAuth=atyponcel&amp;SrcApp=literatum&amp;DestLinkType=FullRecord&amp;KeyUT=000311167800019" target="_blank">Web of Science</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=Salvage+therapy+of+refractory+hemophagocytic+lymphohistiocytosis+with+alemtuzumab.&amp;publication_year=2013&amp;journal=Pediatr+Blood+Cancer&amp;pages=101-109&amp;doi=10.1002%2Fpbc.24188&amp;pmid=22522603" target="_blank">Google Scholar</a></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">77.</div><div id="r77" class="citations"><div class="citation"><div class="citation-content">Mouy R, Stephan JL, Pillet P, Haddad E, Hubert P, Prieur AM. Efficacy of cyclosporine A in the treatment of macrophage activation syndrome in juvenile arthritis: report of five cases. <em>J Pediatr</em> 1996;129:750-754.</div><div class="external-links"><div class="to-citation__wrapper"><a class="to-citation" href="#body-ref-r77"><i aria-hidden="true" class="icon-return"></i><span>Go to Citation</span></a></div><div class="core-xlink-crossref"><a href="https://doi.org/10.1016/S0022-3476(96)70160-9" target="_blank">Crossref</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/8917244/" target="_blank">PubMed</a></div><div class="core-xlink-isi"><a href="https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;DestApp=WOS_CPL&amp;UsrCustomerID=5e3815c904498985e796fc91436abd9a&amp;SrcAuth=atyponcel&amp;SrcApp=literatum&amp;DestLinkType=FullRecord&amp;KeyUT=A1996VR95700025" target="_blank">Web of Science</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=Efficacy+of+cyclosporine+A+in+the+treatment+of+macrophage+activation+syndrome+in+juvenile+arthritis%3A+report+of+five+cases.&amp;publication_year=1996&amp;journal=J+Pediatr&amp;pages=750-754&amp;doi=10.1016%2FS0022-3476%2896%2970160-9&amp;pmid=8917244" target="_blank">Google Scholar</a></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">78.</div><div id="r78" class="citations"><div class="citation"><div class="citation-content">Faitelson Y, Grunebaum E. Hemophagocytic lymphohistiocytosis and primary immune deficiency disorders. <em>Clin Immunol</em> 2014;155:118-125.</div><div class="external-links"><div class="to-citation__wrapper"><a class="to-citation" href="#body-ref-r78"><i aria-hidden="true" class="icon-return"></i><span>Go to Citation</span></a></div><div class="core-xlink-crossref"><a href="https://doi.org/10.1016/j.clim.2014.09.008" target="_blank">Crossref</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/25241079/" target="_blank">PubMed</a></div><div class="core-xlink-isi"><a href="https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;DestApp=WOS_CPL&amp;UsrCustomerID=5e3815c904498985e796fc91436abd9a&amp;SrcAuth=atyponcel&amp;SrcApp=literatum&amp;DestLinkType=FullRecord&amp;KeyUT=000343638400015" target="_blank">Web of Science</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=Hemophagocytic+lymphohistiocytosis+and+primary+immune+deficiency+disorders.&amp;publication_year=2014&amp;journal=Clin+Immunol&amp;pages=118-125&amp;doi=10.1016%2Fj.clim.2014.09.008&amp;pmid=25241079" target="_blank">Google Scholar</a></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">79.</div><div id="r79" class="citations"><div class="citation"><div class="citation-content">Iwaki N, Fajgenbaum DC, Nabel CS, et al. Clinicopathologic analysis of TAFRO syndrome demonstrates a distinct subtype of HHV-8-negative multicentric Castleman disease. <em>Am J Hematol</em> 2016;91:220-226.</div><div class="external-links"><div class="to-citation__wrapper"><a class="to-citation" href="#body-ref-r79"><i aria-hidden="true" class="icon-return"></i><span>Go to Citation</span></a></div><div class="core-xlink-crossref"><a href="https://doi.org/10.1002/ajh.24242" target="_blank">Crossref</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/26805758/" target="_blank">PubMed</a></div><div class="core-xlink-isi"><a href="https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;DestApp=WOS_CPL&amp;UsrCustomerID=5e3815c904498985e796fc91436abd9a&amp;SrcAuth=atyponcel&amp;SrcApp=literatum&amp;DestLinkType=FullRecord&amp;KeyUT=000369430800017" target="_blank">Web of Science</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=Clinicopathologic+analysis+of+TAFRO+syndrome+demonstrates+a+distinct+subtype+of+HHV-8-negative+multicentric+Castleman+disease.&amp;publication_year=2016&amp;journal=Am+J+Hematol&amp;pages=220-226&amp;doi=10.1002%2Fajh.24242&amp;pmid=26805758" target="_blank">Google Scholar</a></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">80.</div><div id="r80" class="citations"><div class="citation"><div class="citation-content">Nishimoto N, Kanakura Y, Aozasa K, et al. Humanized anti-interleukin-6 receptor antibody treatment of multicentric Castleman disease. <em>Blood</em> 2005;106:2627-2632.</div><div class="external-links"><div class="to-citation__wrapper"><a class="to-citation" href="#body-ref-r80"><i aria-hidden="true" class="icon-return"></i><span>Go to Citation</span></a></div><div class="core-xlink-crossref"><a href="https://doi.org/10.1182/blood-2004-12-4602" target="_blank">Crossref</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/15998837/" target="_blank">PubMed</a></div><div class="core-xlink-isi"><a href="https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;DestApp=WOS_CPL&amp;UsrCustomerID=5e3815c904498985e796fc91436abd9a&amp;SrcAuth=atyponcel&amp;SrcApp=literatum&amp;DestLinkType=FullRecord&amp;KeyUT=000232466000014" target="_blank">Web of Science</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=Humanized+anti-interleukin-6+receptor+antibody+treatment+of+multicentric+Castleman+disease.&amp;publication_year=2005&amp;journal=Blood&amp;pages=2627-2632&amp;doi=10.1182%2Fblood-2004-12-4602&amp;pmid=15998837" target="_blank">Google Scholar</a></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">81.</div><div id="r81" class="citations"><div class="citation"><div class="citation-content">van Rhee F, Voorhees P, Dispenzieri A, et al. International, evidence-based consensus treatment guidelines for idiopathic multicentric Castleman disease. <em>Blood</em> 2018;132:2115-2124.</div><div class="external-links"><div class="to-citation__wrapper"><a class="to-citation" href="#body-ref-r81"><i aria-hidden="true" class="icon-return"></i><span>Go to Citation</span></a></div><div class="core-xlink-crossref"><a href="https://doi.org/10.1182/blood-2018-07-862334" target="_blank">Crossref</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/30181172/" target="_blank">PubMed</a></div><div class="core-xlink-isi"><a href="https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;DestApp=WOS_CPL&amp;UsrCustomerID=5e3815c904498985e796fc91436abd9a&amp;SrcAuth=atyponcel&amp;SrcApp=literatum&amp;DestLinkType=FullRecord&amp;KeyUT=000450194500005" target="_blank">Web of Science</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=International%2C+evidence-based+consensus+treatment+guidelines+for+idiopathic+multicentric+Castleman+disease.&amp;publication_year=2018&amp;journal=Blood&amp;pages=2115-2124&amp;doi=10.1182%2Fblood-2018-07-862334&amp;pmid=30181172" target="_blank">Google Scholar</a></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">82.</div><div id="r82" class="citations"><div class="citation"><div class="citation-content">Pierson SK, Stonestrom AJ, Shilling D, et al. Plasma proteomics identifies a ‘chemokine storm’ in idiopathic multicentric Castleman disease. <em>Am J Hematol</em> 2018;93:902-912.</div><div class="external-links"><div class="to-citation__wrapper"><a class="to-citation" href="#body-ref-r82"><i aria-hidden="true" class="icon-return"></i><span>Go to Citation</span></a></div><div class="core-xlink-crossref"><a href="https://doi.org/10.1002/ajh.25123" target="_blank">Crossref</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/29675946/" target="_blank">PubMed</a></div><div class="core-xlink-isi"><a href="https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;DestApp=WOS_CPL&amp;UsrCustomerID=5e3815c904498985e796fc91436abd9a&amp;SrcAuth=atyponcel&amp;SrcApp=literatum&amp;DestLinkType=FullRecord&amp;KeyUT=000437829500018" target="_blank">Web of Science</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=Plasma+proteomics+identifies+a+%E2%80%98chemokine+storm%E2%80%99+in+idiopathic+multicentric+Castleman+disease.&amp;publication_year=2018&amp;journal=Am+J+Hematol&amp;pages=902-912&amp;doi=10.1002%2Fajh.25123&amp;pmid=29675946" target="_blank">Google Scholar</a></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">83.</div><div id="r83" class="citations"><div class="citation"><div class="citation-content">Langan Pai R-A, Sada Japp A, Gonzalez M, et al. Type I IFN response associated with mTOR activation in the TAFRO subtype of idiopathic multicentric Castleman disease. <em>JCI Insight</em> 2020;5(9):e135031-e135031.</div><div class="external-links"><div class="to-citation__wrapper"><a class="to-citation" href="#body-ref-r83"><i aria-hidden="true" class="icon-return"></i><span>Go to Citation</span></a></div><div class="core-xlink-crossref"><a href="https://doi.org/10.1172/jci.insight.135031" target="_blank">Crossref</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/32376796/" target="_blank">PubMed</a></div><div class="core-xlink-isi"><a href="https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;DestApp=WOS_CPL&amp;UsrCustomerID=5e3815c904498985e796fc91436abd9a&amp;SrcAuth=atyponcel&amp;SrcApp=literatum&amp;DestLinkType=FullRecord&amp;KeyUT=000531472400010" target="_blank">Web of Science</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=Type+I+IFN+response+associated+with+mTOR+activation+in+the+TAFRO+subtype+of+idiopathic+multicentric+Castleman+disease.&amp;publication_year=2020&amp;journal=JCI+Insight&amp;pages=e135031-e135031&amp;doi=10.1172%2Fjci.insight.135031&amp;pmid=32376796" target="_blank">Google Scholar</a></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">84.</div><div id="r84" class="citations"><div class="citation"><div class="citation-content">Arenas DJ, Floess K, Kobrin D, et al. Increased mTOR activation in idiopathic multicentric Castleman disease. <em>Blood</em> 2020;135:1673-1684.</div><div class="external-links"><div class="to-citation__wrapper"><a class="to-citation" href="#body-ref-r84"><i aria-hidden="true" class="icon-return"></i><span>Go to Citation</span></a></div><div class="core-xlink-crossref"><a href="https://doi.org/10.1182/blood.2019002792" target="_blank">Crossref</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/32206779/" target="_blank">PubMed</a></div><div class="core-xlink-isi"><a href="https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;DestApp=WOS_CPL&amp;UsrCustomerID=5e3815c904498985e796fc91436abd9a&amp;SrcAuth=atyponcel&amp;SrcApp=literatum&amp;DestLinkType=FullRecord&amp;KeyUT=000534369200012" target="_blank">Web of Science</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=Increased+mTOR+activation+in+idiopathic+multicentric+Castleman+disease.&amp;publication_year=2020&amp;journal=Blood&amp;pages=1673-1684&amp;doi=10.1182%2Fblood.2019002792&amp;pmid=32206779" target="_blank">Google Scholar</a></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">85.</div><div id="r85" class="citations"><div class="citation"><div class="citation-content">Fajgenbaum DC, Langan R-A, Sada Japp A, et al. Identifying and targeting pathogenic PI3K/AKT/mTOR signaling in IL-6-blockade-refractory idiopathic multicentric Castleman disease. <em>J Clin Invest</em> 2019;129:4451-4463.</div><div class="external-links"><div class="to-citation__wrapper"><a class="to-citation" href="#body-ref-r85"><i aria-hidden="true" class="icon-return"></i><span>Go to Citation</span></a></div><div class="core-xlink-crossref"><a href="https://doi.org/10.1172/JCI126091" target="_blank">Crossref</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/31408438/" target="_blank">PubMed</a></div><div class="core-xlink-isi"><a href="https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;DestApp=WOS_CPL&amp;UsrCustomerID=5e3815c904498985e796fc91436abd9a&amp;SrcAuth=atyponcel&amp;SrcApp=literatum&amp;DestLinkType=FullRecord&amp;KeyUT=000488537800047" target="_blank">Web of Science</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=Identifying+and+targeting+pathogenic+PI3K%2FAKT%2FmTOR+signaling+in+IL-6-blockade-refractory+idiopathic+multicentric+Castleman+disease.&amp;publication_year=2019&amp;journal=J+Clin+Invest&amp;pages=4451-4463&amp;doi=10.1172%2FJCI126091&amp;pmid=31408438" target="_blank">Google Scholar</a></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">86.</div><div id="r86" class="citations"><div class="citation"><div class="citation-content">Huang K-J, Su I-J, Theron M, et al. An interferon-gamma-related cytokine storm in SARS patients. <em>J Med Virol</em> 2005;75:185-194.</div><div class="external-links"><div class="to-citation__wrapper"><a class="to-citation" href="#body-ref-r86"><i aria-hidden="true" class="icon-return"></i><span>Go to Citation</span></a></div><div class="core-xlink-crossref"><a href="https://doi.org/10.1002/jmv.20255" target="_blank">Crossref</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/15602737/" target="_blank">PubMed</a></div><div class="core-xlink-isi"><a href="https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;DestApp=WOS_CPL&amp;UsrCustomerID=5e3815c904498985e796fc91436abd9a&amp;SrcAuth=atyponcel&amp;SrcApp=literatum&amp;DestLinkType=FullRecord&amp;KeyUT=000226009400002" target="_blank">Web of Science</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=An+interferon-gamma-related+cytokine+storm+in+SARS+patients.&amp;publication_year=2005&amp;journal=J+Med+Virol&amp;pages=185-194&amp;doi=10.1002%2Fjmv.20255&amp;pmid=15602737" target="_blank">Google Scholar</a></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">87.</div><div id="r87" class="citations"><div class="citation"><div class="citation-content">Moore JB, June CH. Cytokine release syndrome in severe COVID-19. <em>Science</em> 2020;368:473-474.</div><div class="external-links"><div class="to-citation__wrapper"><a class="to-citation" href="#body-ref-r88-1"><i aria-hidden="true" class="icon-return"></i><span>Go to Citation</span></a></div><div class="core-xlink-crossref"><a href="https://doi.org/10.1126/science.abb8925" target="_blank">Crossref</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/32303591/" target="_blank">PubMed</a></div><div class="core-xlink-isi"><a href="https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;DestApp=WOS_CPL&amp;UsrCustomerID=5e3815c904498985e796fc91436abd9a&amp;SrcAuth=atyponcel&amp;SrcApp=literatum&amp;DestLinkType=FullRecord&amp;KeyUT=000531178400028" target="_blank">Web of Science</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=Cytokine+release+syndrome+in+severe+COVID-19.&amp;publication_year=2020&amp;journal=Science&amp;pages=473-474&amp;doi=10.1126%2Fscience.abb8925&amp;pmid=32303591" target="_blank">Google Scholar</a></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">88.</div><div id="r88" class="citations"><div class="citation"><div class="citation-content">The RECOVERY Collaborative Group. Dexamethasone in hospitalized patients with Covid-19 — preliminary report. <em>N Engl J Med</em>.</div><div class="external-links"><div class="to-citation__wrapper"><button aria-controls="to-citation__accordion-r88" aria-expanded="false" aria-label="Toggle citations menu" class="to-citation__toggle"><i aria-hidden="true" class="icon-plus"></i><span data-expand-title="Hide Citations" data-collapsed-title="Show Citations" class="accordion__toggle__title"></span></button></div><div class="core-xlink-crossref"><a href="/servlet/linkout?suffix=e_1_3_4_89_2&amp;dbid=4&amp;doi=10.1056%2FNEJMra2026131&amp;key=10.1056%2FNEJMoa2021436&amp;site=mms-site" target="_blank">Crossref</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/32678530/" target="_blank">PubMed</a></div><div class="core-xlink-isi"><a href="https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;DestApp=WOS_CPL&amp;UsrCustomerID=5e3815c904498985e796fc91436abd9a&amp;SrcAuth=atyponcel&amp;SrcApp=literatum&amp;DestLinkType=FullRecord&amp;KeyUT=000584372000001" target="_blank">Web of Science</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=Dexamethasone+in+hospitalized+patients+with+Covid-19+%E2%80%94+preliminary+report.&amp;journal=N+Engl+J+Med&amp;doi=10.1056%2FNEJMoa2021436&amp;pmid=32678530" target="_blank">Google Scholar</a></div><div role="menu" aria-label="links" class="to-citation__accordion no-separator" id="to-citation__accordion-r88" style="display: none;"><ul role="none"><li role="none"><a class="to-citation" href="#body-ref-r88-1" role="menuitem"><i aria-hidden="true" class="icon-return"></i><span>a [...] contribute to the pathogenesis of Covid-19. </span></a></li><li role="none"><a class="to-citation" href="#body-ref-r88-2" role="menuitem"><i aria-hidden="true" class="icon-return"></i><span>b [...] inflammation contributes to mortality. </span></a></li></ul></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">89.</div><div id="r89" class="citations"><div class="citation"><div class="citation-content">Huang C, Wang Y, Li X, et al. Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China. <em>Lancet</em> 2020;395:497-506.</div><div class="external-links"><div class="to-citation__wrapper"><a class="to-citation" href="#body-ref-r90"><i aria-hidden="true" class="icon-return"></i><span>Go to Citation</span></a></div><div class="core-xlink-crossref"><a href="https://doi.org/10.1016/S0140-6736(20)30183-5" target="_blank">Crossref</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/31986264/" target="_blank">PubMed</a></div><div class="core-xlink-isi"><a href="https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;DestApp=WOS_CPL&amp;UsrCustomerID=5e3815c904498985e796fc91436abd9a&amp;SrcAuth=atyponcel&amp;SrcApp=literatum&amp;DestLinkType=FullRecord&amp;KeyUT=000514576900032" target="_blank">Web of Science</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=Clinical+features+of+patients+infected+with+2019+novel+coronavirus+in+Wuhan%2C+China.&amp;publication_year=2020&amp;journal=Lancet&amp;pages=497-506&amp;doi=10.1016%2FS0140-6736%2820%2930183-5&amp;pmid=31986264" target="_blank">Google Scholar</a></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">90.</div><div id="r90" class="citations"><div class="citation"><div class="citation-content">Zhu Z, Cai T, Fan L, et al. Clinical value of immune-inflammatory parameters to assess the severity of coronavirus disease 2019. <em>Int J Infect Dis</em> 2020;95:332-339.</div><div class="external-links"><div class="to-citation__wrapper"><a class="to-citation" href="#body-ref-r90"><i aria-hidden="true" class="icon-return"></i><span>Go to Citation</span></a></div><div class="core-xlink-crossref"><a href="https://doi.org/10.1016/j.ijid.2020.04.041" target="_blank">Crossref</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/32334118/" target="_blank">PubMed</a></div><div class="core-xlink-isi"><a href="https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;DestApp=WOS_CPL&amp;UsrCustomerID=5e3815c904498985e796fc91436abd9a&amp;SrcAuth=atyponcel&amp;SrcApp=literatum&amp;DestLinkType=FullRecord&amp;KeyUT=000540737100060" target="_blank">Web of Science</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=Clinical+value+of+immune-inflammatory+parameters+to+assess+the+severity+of+coronavirus+disease+2019.&amp;publication_year=2020&amp;journal=Int+J+Infect+Dis&amp;pages=332-339&amp;doi=10.1016%2Fj.ijid.2020.04.041&amp;pmid=32334118" target="_blank">Google Scholar</a></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">91.</div><div id="r91" class="citations"><div class="citation"><div class="citation-content">Del Valle DM, Kim-Schulze S, Huang H-H, et al. An inflammatory cytokine signature predicts COVID-19 severity and survival. <em>Nat Med</em> 2020;26:1636-1643.</div><div class="external-links"><div class="to-citation__wrapper"><a class="to-citation" href="#body-ref-r91"><i aria-hidden="true" class="icon-return"></i><span>Go to Citation</span></a></div><div class="core-xlink-crossref"><a href="https://doi.org/10.1038/s41591-020-1051-9" target="_blank">Crossref</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/32839624/" target="_blank">PubMed</a></div><div class="core-xlink-isi"><a href="https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;DestApp=WOS_CPL&amp;UsrCustomerID=5e3815c904498985e796fc91436abd9a&amp;SrcAuth=atyponcel&amp;SrcApp=literatum&amp;DestLinkType=FullRecord&amp;KeyUT=000562338700004" target="_blank">Web of Science</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=An+inflammatory+cytokine+signature+predicts+COVID-19+severity+and+survival.&amp;publication_year=2020&amp;journal=Nat+Med&amp;pages=1636-1643&amp;doi=10.1038%2Fs41591-020-1051-9&amp;pmid=32839624" target="_blank">Google Scholar</a></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">92.</div><div id="r92" class="citations"><div class="citation"><div class="citation-content">Mathew D, Giles JR, Baxter AE, et al. Deep immune profiling of COVID-19 patients reveals distinct immunotypes with therapeutic implications. <em>Science</em> 2020;369(6508):eabc8511-eabc8511.</div><div class="external-links"><div class="to-citation__wrapper"><a class="to-citation" href="#body-ref-r92"><i aria-hidden="true" class="icon-return"></i><span>Go to Citation</span></a></div><div class="core-xlink-crossref"><a href="https://doi.org/10.1126/science.abc8511" target="_blank">Crossref</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/32669297/" target="_blank">PubMed</a></div><div class="core-xlink-isi"><a href="https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;DestApp=WOS_CPL&amp;UsrCustomerID=5e3815c904498985e796fc91436abd9a&amp;SrcAuth=atyponcel&amp;SrcApp=literatum&amp;DestLinkType=FullRecord&amp;KeyUT=000567525400046" target="_blank">Web of Science</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=Deep+immune+profiling+of+COVID-19+patients+reveals+distinct+immunotypes+with+therapeutic+implications.&amp;publication_year=2020&amp;journal=Science&amp;pages=eabc8511-eabc8511&amp;doi=10.1126%2Fscience.abc8511&amp;pmid=32669297" target="_blank">Google Scholar</a></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">93.</div><div id="r93" class="citations"><div class="citation"><div class="citation-content">Caricchio R, Gallucci M, Dass C, et al. Preliminary predictive criteria for COVID-19 cytokine storm. <em>Ann Rheum Dis</em> 2020 September 25 (Epub ahead of print).</div><div class="external-links"><div class="to-citation__wrapper"><a class="to-citation" href="#body-ref-r93"><i aria-hidden="true" class="icon-return"></i><span>Go to Citation</span></a></div><div class="core-xlink-crossref"><a href="https://doi.org/10.1136/annrheumdis-2020-218323" target="_blank">Crossref</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/32978237/" target="_blank">PubMed</a></div><div class="core-xlink-isi"><a href="https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;DestApp=WOS_CPL&amp;UsrCustomerID=5e3815c904498985e796fc91436abd9a&amp;SrcAuth=atyponcel&amp;SrcApp=literatum&amp;DestLinkType=FullRecord&amp;KeyUT=000607296800025" target="_blank">Web of Science</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=Preliminary+predictive+criteria+for+COVID-19+cytokine+storm.&amp;publication_year=2020&amp;journal=Ann+Rheum+Dis&amp;doi=10.1136%2Fannrheumdis-2020-218323&amp;pmid=32978237" target="_blank">Google Scholar</a></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">94.</div><div id="r94" class="citations"><div class="citation"><div class="citation-content">Zhang Q, Bastard P, Liu Z, et al. Inborn errors of type I IFN immunity in patients with life-threatening COVID-19. <em>Science</em> 2020 September 24 (Epub ahead of print).</div><div class="external-links"><div class="to-citation__wrapper"><a class="to-citation" href="#body-ref-r95"><i aria-hidden="true" class="icon-return"></i><span>Go to Citation</span></a></div><div class="core-xlink-crossref"><a href="https://doi.org/10.1126/science.abd4570" target="_blank">Crossref</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/32972995/" target="_blank">PubMed</a></div><div class="core-xlink-isi"><a href="https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;DestApp=WOS_CPL&amp;UsrCustomerID=5e3815c904498985e796fc91436abd9a&amp;SrcAuth=atyponcel&amp;SrcApp=literatum&amp;DestLinkType=FullRecord&amp;KeyUT=000581077200034" target="_blank">Web of Science</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=Inborn+errors+of+type+I+IFN+immunity+in+patients+with+life-threatening+COVID-19.&amp;publication_year=2020&amp;journal=Science&amp;doi=10.1126%2Fscience.abd4570&amp;pmid=32972995" target="_blank">Google Scholar</a></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">95.</div><div id="r95" class="citations"><div class="citation"><div class="citation-content">Bastard P, Rosen LB, Zhang Q, et al. Auto-antibodies against type I IFNs in patients with life-threatening COVID-19. <em>Science</em> 2020 September 24 (Epub ahead of print).</div><div class="external-links"><div class="to-citation__wrapper"><a class="to-citation" href="#body-ref-r95"><i aria-hidden="true" class="icon-return"></i><span>Go to Citation</span></a></div><div class="core-xlink-crossref"><a href="https://doi.org/10.1126/science.abd4585" target="_blank">Crossref</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/32972996/" target="_blank">PubMed</a></div><div class="core-xlink-isi"><a href="https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;DestApp=WOS_CPL&amp;UsrCustomerID=5e3815c904498985e796fc91436abd9a&amp;SrcAuth=atyponcel&amp;SrcApp=literatum&amp;DestLinkType=FullRecord&amp;KeyUT=000581077200035" target="_blank">Web of Science</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=Auto-antibodies+against+type+I+IFNs+in+patients+with+life-threatening+COVID-19.&amp;publication_year=2020&amp;journal=Science&amp;doi=10.1126%2Fscience.abd4585&amp;pmid=32972996" target="_blank">Google Scholar</a></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">96.</div><div id="r96" class="citations"><div class="citation"><div class="citation-content">Lauder SN, Jones E, Smart K, et al. Interleukin-6 limits influenza-induced inflammation and protects against fatal lung pathology. <em>Eur J Immunol</em> 2013;43:2613-2625.</div><div class="external-links"><div class="to-citation__wrapper"><a class="to-citation" href="#body-ref-r96"><i aria-hidden="true" class="icon-return"></i><span>Go to Citation</span></a></div><div class="core-xlink-crossref"><a href="https://doi.org/10.1002/eji.201243018" target="_blank">Crossref</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/23857287/" target="_blank">PubMed</a></div><div class="core-xlink-isi"><a href="https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;DestApp=WOS_CPL&amp;UsrCustomerID=5e3815c904498985e796fc91436abd9a&amp;SrcAuth=atyponcel&amp;SrcApp=literatum&amp;DestLinkType=FullRecord&amp;KeyUT=000329155200012" target="_blank">Web of Science</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=Interleukin-6+limits+influenza-induced+inflammation+and+protects+against+fatal+lung+pathology.&amp;publication_year=2013&amp;journal=Eur+J+Immunol&amp;pages=2613-2625&amp;doi=10.1002%2Feji.201243018&amp;pmid=23857287" target="_blank">Google Scholar</a></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">97.</div><div id="r97" class="citations"><div class="citation"><div class="citation-content">Hermine O, Mariette X, Tharaux PL, et al. Effect of tocilizumab vs usual care in adults hospitalized with COVID-19 and moderate or severe pneumonia: a randomized clinical trial. <em>JAMA Intern Med</em> 2020 October 20 (Epub ahead of print).</div><div class="external-links"><div class="to-citation__wrapper"><a class="to-citation" href="#body-ref-r98"><i aria-hidden="true" class="icon-return"></i><span>Go to Citation</span></a></div><div class="core-xlink-crossref"><a href="https://doi.org/10.1001/jamainternmed.2020.6820" target="_blank">Crossref</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/33080017/" target="_blank">PubMed</a></div><div class="core-xlink-isi"><a href="https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;DestApp=WOS_CPL&amp;UsrCustomerID=5e3815c904498985e796fc91436abd9a&amp;SrcAuth=atyponcel&amp;SrcApp=literatum&amp;DestLinkType=FullRecord&amp;KeyUT=000587482200001" target="_blank">Web of Science</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=Effect+of+tocilizumab+vs+usual+care+in+adults+hospitalized+with+COVID-19+and+moderate+or+severe+pneumonia%3A+a+randomized+clinical+trial.&amp;publication_year=2020&amp;journal=JAMA+Intern+Med&amp;doi=10.1001%2Fjamainternmed.2020.6820&amp;pmid=33080017" target="_blank">Google Scholar</a></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">98.</div><div id="r98" class="citations"><div class="citation"><div class="citation-content">Stone JH, Frigault MJ, Serling-Boyd NJ, et al. Efficacy of tocilizumab in patients hospitalized with Covid-19. <em>N Engl J Med</em> 2020 October 21 DOI: 10.1056/NEJMoa2028836.</div><div class="external-links"><div class="to-citation__wrapper"><a class="to-citation" href="#body-ref-r98"><i aria-hidden="true" class="icon-return"></i><span>Go to Citation</span></a></div><div class="core-xlink-crossref"><a href="/servlet/linkout?suffix=e_1_3_4_99_2&amp;dbid=4&amp;doi=10.1056%2FNEJMra2026131&amp;key=10.1056%2FNEJMoa2028836&amp;site=mms-site" target="_blank">Crossref</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/33085857/" target="_blank">PubMed</a></div><div class="core-xlink-isi"><a href="https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;DestApp=WOS_CPL&amp;UsrCustomerID=5e3815c904498985e796fc91436abd9a&amp;SrcAuth=atyponcel&amp;SrcApp=literatum&amp;DestLinkType=FullRecord&amp;KeyUT=000627165900012" target="_blank">Web of Science</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=Efficacy+of+tocilizumab+in+patients+hospitalized+with+Covid-19.&amp;publication_year=2020&amp;journal=N+Engl+J+Med&amp;doi=10.1056%2FNEJMoa2028836&amp;pmid=33085857" target="_blank">Google Scholar</a></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">99.</div><div id="r99" class="citations"><div class="citation"><div class="citation-content">Klok FA, Kruip MJHA, van der Meer NJM, et al. Confirmation of the high cumulative incidence of thrombotic complications in critically ill ICU patients with COVID-19: an updated analysis. <em>Thromb Res</em> 2020;191:148-150.</div><div class="external-links"><div class="to-citation__wrapper"><a class="to-citation" href="#body-ref-r99"><i aria-hidden="true" class="icon-return"></i><span>Go to Citation</span></a></div><div class="core-xlink-crossref"><a href="https://doi.org/10.1016/j.thromres.2020.04.041" target="_blank">Crossref</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/32381264/" target="_blank">PubMed</a></div><div class="core-xlink-isi"><a href="https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;DestApp=WOS_CPL&amp;UsrCustomerID=5e3815c904498985e796fc91436abd9a&amp;SrcAuth=atyponcel&amp;SrcApp=literatum&amp;DestLinkType=FullRecord&amp;KeyUT=000582054800029" target="_blank">Web of Science</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=Confirmation+of+the+high+cumulative+incidence+of+thrombotic+complications+in+critically+ill+ICU+patients+with+COVID-19%3A+an+updated+analysis.&amp;publication_year=2020&amp;journal=Thromb+Res&amp;pages=148-150&amp;doi=10.1016%2Fj.thromres.2020.04.041&amp;pmid=32381264" target="_blank">Google Scholar</a></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">100.</div><div id="r100" class="citations"><div class="citation"><div class="citation-content">Sterne JAC, Murthy S, Diaz JV, et al. Association between administration of systemic corticosteroids and mortality among critically ill patients with COVID-19: a meta-analysis. <em>JAMA</em> 2020;324:1330-1341.</div><div class="external-links"><div class="to-citation__wrapper"><a class="to-citation" href="#body-ref-r100"><i aria-hidden="true" class="icon-return"></i><span>Go to Citation</span></a></div><div class="core-xlink-crossref"><a href="https://doi.org/10.1001/jama.2020.17023" target="_blank">Crossref</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/32876694/" target="_blank">PubMed</a></div><div class="core-xlink-isi"><a href="https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;DestApp=WOS_CPL&amp;UsrCustomerID=5e3815c904498985e796fc91436abd9a&amp;SrcAuth=atyponcel&amp;SrcApp=literatum&amp;DestLinkType=FullRecord&amp;KeyUT=000590156000017" target="_blank">Web of Science</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=Association+between+administration+of+systemic+corticosteroids+and+mortality+among+critically+ill+patients+with+COVID-19%3A+a+meta-analysis.&amp;publication_year=2020&amp;journal=JAMA&amp;pages=1330-1341&amp;doi=10.1001%2Fjama.2020.17023&amp;pmid=32876694" target="_blank">Google Scholar</a></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">101.</div><div id="r101" class="citations"><div class="citation"><div class="citation-content">Keller MJ, Kitsis EA, Arora S, et al. Effect of systemic glucocorticoids on mortality or mechanical ventilation in patients with COVID-19. <em>J Hosp Med</em> 2020;15:489-493.</div><div class="external-links"><div class="to-citation__wrapper"><a class="to-citation" href="#body-ref-r101"><i aria-hidden="true" class="icon-return"></i><span>Go to Citation</span></a></div><div class="core-xlink-crossref"><a href="https://doi.org/10.12788/jhm.3497" target="_blank">Crossref</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/32804611/" target="_blank">PubMed</a></div><div class="core-xlink-isi"><a href="https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;DestApp=WOS_CPL&amp;UsrCustomerID=5e3815c904498985e796fc91436abd9a&amp;SrcAuth=atyponcel&amp;SrcApp=literatum&amp;DestLinkType=FullRecord&amp;KeyUT=000553411500007" target="_blank">Web of Science</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=Effect+of+systemic+glucocorticoids+on+mortality+or+mechanical+ventilation+in+patients+with+COVID-19.&amp;publication_year=2020&amp;journal=J+Hosp+Med&amp;pages=489-493&amp;doi=10.12788%2Fjhm.3497&amp;pmid=32804611" target="_blank">Google Scholar</a></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">102.</div><div id="r102" class="citations"><div class="citation"><div class="citation-content">Fajgenbaum DC, Khor JS, Gorzewski A, et al. Treatments administered to the first 9152 reported cases of COVID-19: a systematic review. <em>Infect Dis Ther</em> 2020;9:435-449.</div><div class="external-links"><div class="to-citation__wrapper"><button aria-controls="to-citation__accordion-r102" aria-expanded="false" aria-label="Toggle citations menu" class="to-citation__toggle"><i aria-hidden="true" class="icon-plus"></i><span data-expand-title="Hide Citations" data-collapsed-title="Show Citations" class="accordion__toggle__title"></span></button></div><div class="core-xlink-crossref"><a href="https://doi.org/10.1007/s40121-020-00303-8" target="_blank">Crossref</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/32462545/" target="_blank">PubMed</a></div><div class="core-xlink-isi"><a href="https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;DestApp=WOS_CPL&amp;UsrCustomerID=5e3815c904498985e796fc91436abd9a&amp;SrcAuth=atyponcel&amp;SrcApp=literatum&amp;DestLinkType=FullRecord&amp;KeyUT=000553933300001" target="_blank">Web of Science</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=Treatments+administered+to+the+first+9152+reported+cases+of+COVID-19%3A+a+systematic+review.&amp;publication_year=2020&amp;journal=Infect+Dis+Ther&amp;pages=435-449&amp;doi=10.1007%2Fs40121-020-00303-8&amp;pmid=32462545" target="_blank">Google Scholar</a></div><div role="menu" aria-label="links" class="to-citation__accordion no-separator" id="to-citation__accordion-r102" style="display: none;"><ul role="none"><li role="none"><a class="to-citation" href="#body-ref-r105" role="menuitem"><i aria-hidden="true" class="icon-return"></i><span>a [...] JAK1 and JAK2 in patients with Covid-19. </span></a></li><li role="none"><a class="to-citation" href="#body-ref-r102-2" role="menuitem"><i aria-hidden="true" class="icon-return"></i><span>b [...] drugs are currently under investigation. </span></a></li></ul></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">103.</div><div id="r103" class="citations"><div class="citation"><div class="citation-content">De Luca G, Cavalli G, Campochiaro C, et al. GM-CSF blockade with mavrilimumab in severe COVID-19 pneumonia and systemic hyperinflammation: a single-centre, prospective cohort study. <em>Lancet Rheumatol</em> 2020;2(8):e465-e473.</div><div class="external-links"><div class="to-citation__wrapper"><a class="to-citation" href="#body-ref-r105"><i aria-hidden="true" class="icon-return"></i><span>Go to Citation</span></a></div><div class="core-xlink-crossref"><a href="https://doi.org/10.1016/S2665-9913(20)30170-3" target="_blank">Crossref</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/32835256/" target="_blank">PubMed</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=GM-CSF+blockade+with+mavrilimumab+in+severe+COVID-19+pneumonia+and+systemic+hyperinflammation%3A+a+single-centre%2C+prospective+cohort+study.&amp;publication_year=2020&amp;journal=Lancet+Rheumatol&amp;pages=e465-e473&amp;doi=10.1016%2FS2665-9913%2820%2930170-3&amp;pmid=32835256" target="_blank">Google Scholar</a></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">104.</div><div id="r104" class="citations"><div class="citation"><div class="citation-content">Bronte V, Ugel S, Tinazzi E, et al. Baricitinib restrains the immune dysregulation in patients with severe COVID-19. <em>J Clin Invest</em> 2020 November 03 (Epub ahead of print).</div><div class="external-links"><div class="to-citation__wrapper"><a class="to-citation" href="#body-ref-r105"><i aria-hidden="true" class="icon-return"></i><span>Go to Citation</span></a></div><div class="core-xlink-crossref"><a href="https://doi.org/10.1172/JCI141772" target="_blank">Crossref</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/32809969/" target="_blank">PubMed</a></div><div class="core-xlink-isi"><a href="https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;DestApp=WOS_CPL&amp;UsrCustomerID=5e3815c904498985e796fc91436abd9a&amp;SrcAuth=atyponcel&amp;SrcApp=literatum&amp;DestLinkType=FullRecord&amp;KeyUT=000600281700001" target="_blank">Web of Science</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=Baricitinib+restrains+the+immune+dysregulation+in+patients+with+severe+COVID-19.&amp;publication_year=2020&amp;journal=J+Clin+Invest&amp;doi=10.1172%2FJCI141772&amp;pmid=32809969" target="_blank">Google Scholar</a></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">105.</div><div id="r105" class="citations"><div class="citation"><div class="citation-content">Rodriguez-Garcia JL, Sanchez-Nievas G, Arevalo-Serrano J, Garcia-Gomez C, Jimenez-Vizuete JM, Martinez-Alfaro E. Baricitinib improves respiratory function in patients treated with corticosteroids for SARS-CoV-2 pneumonia: an observational cohort study. <em>Rheumatology (Oxford)</em> 2020 October 06 (Epub ahead of print).</div><div class="external-links"><div class="to-citation__wrapper"><a class="to-citation" href="#body-ref-r105"><i aria-hidden="true" class="icon-return"></i><span>Go to Citation</span></a></div><div class="core-xlink-crossref"><a href="https://doi.org/10.1093/rheumatology/keaa587" target="_blank">Crossref</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/33020836/" target="_blank">PubMed</a></div><div class="core-xlink-isi"><a href="https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;DestApp=WOS_CPL&amp;UsrCustomerID=5e3815c904498985e796fc91436abd9a&amp;SrcAuth=atyponcel&amp;SrcApp=literatum&amp;DestLinkType=FullRecord&amp;KeyUT=000610050100068" target="_blank">Web of Science</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=Baricitinib+improves+respiratory+function+in+patients+treated+with+corticosteroids+for+SARS-CoV-2+pneumonia%3A+an+observational+cohort+study.&amp;publication_year=2020&amp;journal=Rheumatology+%28Oxford%29&amp;doi=10.1093%2Frheumatology%2Fkeaa587&amp;pmid=33020836" target="_blank">Google Scholar</a></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">106.</div><div id="r106" class="citations"><div class="citation"><div class="citation-content">Roschewski M, Lionakis MS, Sharman JP, et al. Inhibition of Bruton tyrosine kinase in patients with severe COVID-19. <em>Sci Immunol</em> 2020;5(48):eabd0110-eabd0110.</div><div class="external-links"><div class="to-citation__wrapper"><a class="to-citation" href="#body-ref-r106"><i aria-hidden="true" class="icon-return"></i><span>Go to Citation</span></a></div><div class="core-xlink-crossref"><a href="https://doi.org/10.1126/sciimmunol.abd0110" target="_blank">Crossref</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/32503877/" target="_blank">PubMed</a></div><div class="core-xlink-isi"><a href="https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;DestApp=WOS_CPL&amp;UsrCustomerID=5e3815c904498985e796fc91436abd9a&amp;SrcAuth=atyponcel&amp;SrcApp=literatum&amp;DestLinkType=FullRecord&amp;KeyUT=000546993600010" target="_blank">Web of Science</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=Inhibition+of+Bruton+tyrosine+kinase+in+patients+with+severe+COVID-19.&amp;publication_year=2020&amp;journal=Sci+Immunol&amp;pages=eabd0110-eabd0110&amp;doi=10.1126%2Fsciimmunol.abd0110&amp;pmid=32503877" target="_blank">Google Scholar</a></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">107.</div><div id="r107" class="citations"><div class="citation"><div class="citation-content">Zhang W, Zhao Y, Zhang F, et al. The use of anti-inflammatory drugs in the treatment of people with severe coronavirus disease 2019 (COVID-19): the perspectives of clinical immunologists from China. <em>Clin Immunol</em> 2020;214:108393-108393.</div><div class="external-links"><div class="to-citation__wrapper"><a class="to-citation" href="#body-ref-r107"><i aria-hidden="true" class="icon-return"></i><span>Go to Citation</span></a></div><div class="core-xlink-crossref"><a href="https://doi.org/10.1016/j.clim.2020.108393" target="_blank">Crossref</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/32222466/" target="_blank">PubMed</a></div><div class="core-xlink-isi"><a href="https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;DestApp=WOS_CPL&amp;UsrCustomerID=5e3815c904498985e796fc91436abd9a&amp;SrcAuth=atyponcel&amp;SrcApp=literatum&amp;DestLinkType=FullRecord&amp;KeyUT=000530692800022" target="_blank">Web of Science</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=The+use+of+anti-inflammatory+drugs+in+the+treatment+of+people+with+severe+coronavirus+disease+2019+%28COVID-19%29%3A+the+perspectives+of+clinical+immunologists+from+China.&amp;publication_year=2020&amp;journal=Clin+Immunol&amp;pages=108393-108393&amp;doi=10.1016%2Fj.clim.2020.108393&amp;pmid=32222466" target="_blank">Google Scholar</a></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">108.</div><div id="r108" class="citations"><div class="citation"><div class="citation-content">Behrens EM, Koretzky GA. Review: cytokine storm syndrome: looking toward the precision medicine era. <em>Arthritis Rheumatol</em> 2017;69:1135-1143.</div><div class="external-links"><div class="to-citation__wrapper"><a class="to-citation" href="#body-ref-r109"><i aria-hidden="true" class="icon-return"></i><span>Go to Citation</span></a></div><div class="core-xlink-crossref"><a href="https://doi.org/10.1002/art.40071" target="_blank">Crossref</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/28217930/" target="_blank">PubMed</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=Review%3A+cytokine+storm+syndrome%3A+looking+toward+the+precision+medicine+era.&amp;publication_year=2017&amp;journal=Arthritis+Rheumatol&amp;pages=1135-1143&amp;doi=10.1002%2Fart.40071&amp;pmid=28217930" target="_blank">Google Scholar</a></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">109.</div><div id="r109" class="citations"><div class="citation"><div class="citation-content">de Jesus AA, Hou Y, Brooks S, et al. Distinct interferon signatures and cytokine patterns define additional systemic autoinflammatory diseases. <em>J Clin Invest</em> 2020;130:1669-1682.</div><div class="external-links"><div class="to-citation__wrapper"><a class="to-citation" href="#body-ref-r109"><i aria-hidden="true" class="icon-return"></i><span>Go to Citation</span></a></div><div class="core-xlink-crossref"><a href="https://doi.org/10.1172/JCI129301" target="_blank">Crossref</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/31874111/" target="_blank">PubMed</a></div><div class="core-xlink-isi"><a href="https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;DestApp=WOS_CPL&amp;UsrCustomerID=5e3815c904498985e796fc91436abd9a&amp;SrcAuth=atyponcel&amp;SrcApp=literatum&amp;DestLinkType=FullRecord&amp;KeyUT=000530101000019" target="_blank">Web of Science</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=Distinct+interferon+signatures+and+cytokine+patterns+define+additional+systemic+autoinflammatory+diseases.&amp;publication_year=2020&amp;journal=J+Clin+Invest&amp;pages=1669-1682&amp;doi=10.1172%2FJCI129301&amp;pmid=31874111" target="_blank">Google Scholar</a></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">110.</div><div id="r110" class="citations"><div class="citation"><div class="citation-content">Shimizu M, Nakagishi Y, Yachie A. Distinct subsets of patients with systemic juvenile idiopathic arthritis based on their cytokine profiles. <em>Cytokine</em> 2013;61:345-348.</div><div class="external-links"><div class="to-citation__wrapper"><a class="to-citation" href="#body-ref-r110"><i aria-hidden="true" class="icon-return"></i><span>Go to Citation</span></a></div><div class="core-xlink-crossref"><a href="https://doi.org/10.1016/j.cyto.2012.11.025" target="_blank">Crossref</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/23276493/" target="_blank">PubMed</a></div><div class="core-xlink-isi"><a href="https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;DestApp=WOS_CPL&amp;UsrCustomerID=5e3815c904498985e796fc91436abd9a&amp;SrcAuth=atyponcel&amp;SrcApp=literatum&amp;DestLinkType=FullRecord&amp;KeyUT=000314742800003" target="_blank">Web of Science</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=Distinct+subsets+of+patients+with+systemic+juvenile+idiopathic+arthritis+based+on+their+cytokine+profiles.&amp;publication_year=2013&amp;journal=Cytokine&amp;pages=345-348&amp;doi=10.1016%2Fj.cyto.2012.11.025&amp;pmid=23276493" target="_blank">Google Scholar</a></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">111.</div><div id="r111" class="citations"><div class="citation"><div class="citation-content">Vercruysse F, Barnetche T, Lazaro E, et al. Adult-onset Still’s disease biological treatment strategy may depend on the phenotypic dichotomy. <em>Arthritis Res Ther</em> 2019;21:53-53.</div><div class="external-links"><div class="to-citation__wrapper"><a class="to-citation" href="#body-ref-r111"><i aria-hidden="true" class="icon-return"></i><span>Go to Citation</span></a></div><div class="core-xlink-crossref"><a href="https://doi.org/10.1186/s13075-019-1838-6" target="_blank">Crossref</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/30755262/" target="_blank">PubMed</a></div><div class="core-xlink-isi"><a href="https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;DestApp=WOS_CPL&amp;UsrCustomerID=5e3815c904498985e796fc91436abd9a&amp;SrcAuth=atyponcel&amp;SrcApp=literatum&amp;DestLinkType=FullRecord&amp;KeyUT=000458723300003" target="_blank">Web of Science</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=Adult-onset+Still%E2%80%99s+disease+biological+treatment+strategy+may+depend+on+the+phenotypic+dichotomy.&amp;publication_year=2019&amp;journal=Arthritis+Res+Ther&amp;pages=53-53&amp;doi=10.1186%2Fs13075-019-1838-6&amp;pmid=30755262" target="_blank">Google Scholar</a></div></div></div></div></div></div><div class="citations-truncation"><button data-label-expand="Show all references" data-label-collapse="Show fewer" data-label-remaining="references remaining" class="btn btn--secondary" aria-expanded="false" aria-controls="collapsible-text"><span>Show all references</span></button></div></section></div></section></div><div class="core-collateral"><div id="core-collateral-info" role="tabpanel" data-core-tabs="core-collateral-info" tabindex="-1" aria-labelledby="pane-core-collateral-info"><header><h2 id="pane-core-collateral-info"><i class="icon-info" aria-hidden="true"></i>Information &amp; Authors</h2><button data-close="collateral" aria-label="Close"><i class="icon-close"></i></button></header><div role="tablist"><button aria-controls="tab-information" role="tab" id="tab-information-label" aria-selected="true" class="active">Information</button><button aria-controls="tab-contributors" role="tab" id="tab-contributors-label" tabindex="-1" aria-selected="false">Authors</button></div><section id="tab-information" aria-labelledby="tab-information-label" role="tabpanel" tabindex="0"><h3>Information</h3><section class="core-self-citation"><h4>Published In</h4><div class="core-journal-presentation"><div class="core-journal-description"><div property="isPartOf" typeof="Periodical"><span property="name">New England Journal of Medicine</span></div><div class="core-enumeration"><a href="/toc/nejm/383/23"><span property="isPartOf" typeof="PublicationVolume">Volume <span property="volumeNumber">383</span></span> • <span property="isPartOf" typeof="PublicationIssue">Number <span property="issueNumber">23</span></span> • <span property="datePublished">December 3, 2020</span></a></div><div class="core-pagination"><span class="heading">Pages</span>: <span class="content"><span property="pageStart">2255</span>-<span property="pageEnd">2273</span></span></div></div></div></section><section class="core-editors"><h4 class="heading">Editor</h4><div role="list"><span role="listitem" property="editor" typeof="Person"><span property="givenName">Dan L.</span> <span property="familyName">Longo</span>, <span property="honorificSuffix">M.D.</span>, <span property="jobTitle">Editor</span></span></div></section><section class="core-copyright"><h4>Copyright</h4><div role="paragraph">Copyright © 2020 Massachusetts Medical Society. All rights reserved.</div><div>For personal use only. Any commercial reuse of NEJM Group content requires <a href="mailto:permissions@nejm.org">permission</a>.</div></section><section data-translation="YXQYra2026131" class="core-component-translation"><h4>Translation</h4><div role="paragraph"><a target="_blank" href="https://nejmqianyan.cn/article/YXQYra2026131?sg=AbW1N">Chinese Translation 中文翻译</a></div></section><section class="core-history"><h4>History</h4><div><b class="core-label">Published online</b>: December 2, 2020</div><div><b class="core-label">Published in issue</b>: December 3, 2020</div></section><section data-location="recirc_topics_article" class="core-classifications"><h4>Topics</h4><div class="keywords"><ol><li><a href="/browse/topic/allergy-immunology-general" alt="View article keyword Allergy/Immunology General" data-interactiontype="article_recirculation_click">Allergy/Immunology General</a></li><li role="presentation" aria-hidden="true" class="list-line-break"></li><li><a href="/browse/topic/coronavirus" alt="View article keyword Coronavirus" data-interactiontype="article_recirculation_click">Coronavirus</a></li><li role="presentation" aria-hidden="true" class="list-line-break"></li><li><a href="/browse/topic/critical-care" alt="View article keyword Critical Care" data-interactiontype="article_recirculation_click">Critical Care</a></li><li role="presentation" aria-hidden="true" class="list-line-break"></li><li><a href="/browse/topic/hematology-oncology-general" alt="View article keyword Hematology/Oncology General" data-interactiontype="article_recirculation_click">Hematology/Oncology General</a></li><li role="presentation" aria-hidden="true" class="list-line-break"></li><li><a href="/browse/topic/infectious-disease-general" alt="View article keyword Infectious Disease General" data-interactiontype="article_recirculation_click">Infectious Disease General</a></li><li role="presentation" aria-hidden="true" class="list-line-break"></li><li><a href="/browse/topic/pulmonary-critical-care-general" alt="View article keyword Pulmonary/Critical Care General" data-interactiontype="article_recirculation_click">Pulmonary/Critical Care General</a></li><li role="presentation" aria-hidden="true" class="list-line-break"></li><li><a href="/browse/topic/shock" alt="View article keyword Shock" data-interactiontype="article_recirculation_click">Shock</a></li><li role="presentation" aria-hidden="true" class="list-line-break"></li></ol></div></section></section><section id="tab-contributors" aria-labelledby="tab-contributors-label" role="tabpanel" tabindex="-1"><h3>Authors</h3><section class="core-authors"><h4>Authors</h4><div role="paragraph"><span property="author" typeof="Person"><span property="givenName">David C.</span> <span property="familyName">Fajgenbaum</span>, <span property="honorificSuffix">M.D.</span> <a class="orcid-id" href="https://orcid.org/0000-0002-7367-8184" property="identifier" aria-label="ORCID identifier" target="_blank">https://orcid.org/0000-0002-7367-8184</a></span>, and <span property="author" typeof="Person"><span property="givenName">Carl H.</span> <span property="familyName">June</span>, <span property="honorificSuffix">M.D.</span> <a class="orcid-id" href="https://orcid.org/0000-0003-0241-3557" property="identifier" aria-label="ORCID identifier" target="_blank">https://orcid.org/0000-0003-0241-3557</a></span></div></section><section class="core-affiliations"><h4>Affiliations</h4><div property="affiliation" typeof="Organization"><span property="name">From the Department of Medicine, Division of Translational Medicine and Human Genetics, Center for Cytokine Storm Treatment and Laboratory (D.C.F.), and the Center for Cellular Immunotherapies and the Parker Institute for Cancer Immunotherapy (C.H.J.), Perelman School of Medicine, University of Pennsylvania, Philadelphia.</span></div></section><section class="core-authors-notes"><h4>Notes</h4><div role="doc-footnote">Address reprint requests to Dr. Fajgenbaum at <a href="mailto:davidfa@pennmedicine.upenn.edu">davidfa@pennmedicine.upenn.edu</a> or to Dr. June at <a href="mailto:cjune@upenn.edu">cjune@upenn.edu</a>.</div></section></section></div><div id="core-collateral-metrics" role="tabpanel" data-core-tabs="core-collateral-metrics" tabindex="-1" aria-labelledby="pane-core-collateral-metrics"><header><h2 id="pane-core-collateral-metrics"><i class="icon-timeline" aria-hidden="true"></i>Metrics &amp; Citations</h2><button data-close="collateral" aria-label="Close"><i class="icon-close"></i></button></header><div role="tablist"><button aria-controls="tab-metrics-inner" role="tab" id="tab-metrics-inner-label" aria-selected="true" class="active" data-interactiontype="article_tab" data-tabname="metricsWindow">Metrics</button><button aria-controls="tab-citations" role="tab" id="tab-citations-label" tabindex="-1" aria-selected="false" data-interactiontype="article_tab" data-tabname="metricsWindow">Citations<span class="citations-count">2240</span></button></div><section id="tab-metrics-inner" aria-labelledby="tab-metrics-inner-label" role="tabpanel" tabindex="0"><h3>Metrics</h3><section>









    
    
        <div data-widget-def="UX3HTMLWidget" data-widget-id="95ea9f58-ec0e-4db2-b2ab-280fc876af53" data-location="article_metrics_article">
        



        
            <h4 class="">
                Altmetrics
            </h4>
        
        <div data-badge-details="right" data-badge-type="large-donut" data-doi="10.1056/NEJMra2026131" data-hide-no-mentions="true" data-link-target="_blank" class="altmetric-embed" data-uuid="d4983148-a086-5d21-0820-99588d14db60"><div style="overflow:hidden;">
    <div class="altmetric-normal-legend">
        <a target="_blank" href="https://www.altmetric.com/details.php?domain=www.nejm.org&amp;citation_id=95340890" style="display:inline-block;">
                <img alt="Article has an altmetric score of 1888" src="https://badges.altmetric.com/?size=320&amp;score=1888&amp;types=mabctwfu" width="180" height="180" style="border:0; margin:0; max-width: none;">
        </a>
        <p class="altmetric-see-more-details" style="padding-top: 10px; text-align: center;"><a target="_blank" href="https://www.altmetric.com/details.php?domain=www.nejm.org&amp;citation_id=95340890">See more details</a></p>
    </div>
    <div id="_altmetric_popover_el_d4983148-a086-5d21-0820-99588d14db60" class="altmetric-embed right" style="margin:0; padding:0; display:inline-block; float:left; position:relative;">
        <div class="altmetric_container">
            <div class="altmetric-embed altmetric-popover-inner right">
                <div style="padding:0; margin: 0;" class="altmetric-embed altmetric-popover-content">
                        <div style="padding-left: 10px; line-height:18px; border-left: 16px solid #FF0000;">
      <a class="link-to-altmetric-details-tab" target="_blank" href="https://www.altmetric.com/details.php?domain=www.nejm.org&amp;citation_id=95340890&amp;tab=news">
          Picked up by <b>105</b> news outlets
      </a>
    </div>
    <div style="padding-left: 10px; line-height:18px; border-left: 16px solid #ffd140;">
      <a class="link-to-altmetric-details-tab" target="_blank" href="https://www.altmetric.com/details.php?domain=www.nejm.org&amp;citation_id=95340890&amp;tab=blogs">
          Blogged by <b>4</b>
      </a>
    </div>
    <div style="padding-left: 10px; line-height:18px; border-left: 16px solid #74CFED;">
      <a class="link-to-altmetric-details-tab" target="_blank" href="https://www.altmetric.com/details.php?domain=www.nejm.org&amp;citation_id=95340890&amp;tab=twitter">
          Posted by <b>1753</b> X users
      </a>
    </div>
    <div style="padding-left: 10px; line-height:18px; border-left: 16px solid #f27700;">
      <a class="link-to-altmetric-details-tab" target="_blank" href="https://www.altmetric.com/details.php?domain=www.nejm.org&amp;citation_id=95340890&amp;tab=patents">
          Referenced in <b>7</b> patents
      </a>
    </div>
    <div style="padding-left: 10px; line-height:18px; border-left: 16px solid #2445bd;">
      <a class="link-to-altmetric-details-tab" target="_blank" href="https://www.altmetric.com/details.php?domain=www.nejm.org&amp;citation_id=95340890&amp;tab=facebook">
          On <b>10</b> Facebook pages
      </a>
    </div>
    <div style="padding-left: 10px; line-height:18px; border-left: 16px solid #958899;">
      <a class="link-to-altmetric-details-tab" target="_blank" href="https://www.altmetric.com/details.php?domain=www.nejm.org&amp;citation_id=95340890&amp;tab=wikipedia">
          Referenced in <b>4</b> Wikipedia pages
      </a>
    </div>
    <div style="padding-left: 10px; line-height:18px; border-left: 16px solid #A1E3E4;">
      <a class="link-to-altmetric-details-tab" target="_blank" href="https://www.altmetric.com/details.php?domain=www.nejm.org&amp;citation_id=95340890&amp;tab=guidelines">
          Referenced in <b>2</b> clinical guideline sources
      </a>
    </div>
    <div style="padding-left: 10px; line-height:18px; border-left: 16px solid #70B1FF;">
      <a class="link-to-altmetric-details-tab" target="_blank" href="https://www.altmetric.com/details.php?domain=www.nejm.org&amp;citation_id=95340890&amp;tab=bluesky">
          Referenced by <b>3</b> Bluesky users
      </a>
    </div>

    <div class="altmetric-embed readers" style="margin-top: 10px;">
          <div class="altmetric-embed tip_mendeley" style="padding-left: 10px; line-height:18px; border-left: 16px solid #A60000;">
              <b>2489</b> readers on Mendeley
          </div>
    </div>

                </div>
            </div>
        </div>
    </div>
</div></div>
<script async="" type="text/javascript" src="https://d1bxh8uas1mnw7.cloudfront.net/assets/embed.js" nonce="94d65ade13caf211-SJC"></script>

        </div>
    

</section></section><section id="tab-citations" aria-labelledby="tab-citations-label" role="tabpanel" tabindex="-1"><h3>Citations</h3><section>



        
            <h4 class="">
                Export citation
            </h4>
        
        <div class="citation-download cd-sec">
<p class="citation-download_msg">Select the format you want to export the citation of this publication.</p>
<form action="/action/downloadCitation" name="frmCitmgr" method="post" target="_self" class="citation-download_form"><input type="hidden" name="doi" value="10.1056/NEJMra2026131"> <input type="hidden" name="downloadFileName" value="csp_383_"> <input type="hidden" name="include" value="abs">
<div class="dropdown dropdown-selectable dropdown-selectable--form-control"><input type="hidden" name="format" value=""> <label class="form-label">Format*</label> <button id="slct_format" type="button" data-toggle="dropdown" aria-haspopup="true" aria-expanded="false" class="btn dropdown-toggle d-flex align-items-center justify-content-between">Please Select </button>
<div aria-labelledby="slct_format" role="listbox" class="dropdown-menu"><a href="#" data-value="ris" class="dropdown-item">RIS (ProCite, Reference Manager)</a><a href="#" data-value="endnote" class="dropdown-item">EndNote</a><a href="#" data-value="bibtex" class="dropdown-item">BibTex</a><a href="#" data-value="medlars" class="dropdown-item">Medlars</a><a href="#" data-value="refworks" class="dropdown-item">RefWorks</a></div>
<div class="invalid-feedback">Please select an item in the list</div>
</div>
<div class="citation-download_checkbox"><label class="checkbox--primary"><input type="checkbox" name="direct" value="true"><span class="checkbox--primary-icons"><span class="checkbox--primary-unchecked"><span class="icon-component "><svg aria-hidden="true"><use xlink:href="/specs/products/mms-nextgen/mms/releasedAssets/icons/icons.spritemap.svg#toggles-checboxUnchecked"></use></svg></span></span><span class="checkbox--primary-checked"><span class="icon-component "><svg aria-hidden="true"><use xlink:href="/specs/products/mms-nextgen/mms/releasedAssets/icons/icons.spritemap.svg#toggles-checboxChecked"></use></svg></span></span></span><span class="checkbox--primary-label"><span class="checkbox--primary-label-text">Direct Import</span></span></label></div>
<div class="citation-download_btn"><button type="submit" name="submit" value="Download" class="ng-btn_default ng-btn_iconLeft" data-interactiontype="article_tools_citation_download" data-multimedia-type="Citation"><span class="icon-component "><svg aria-hidden="true"><use xlink:href="/specs/products/mms-nextgen/mms/releasedAssets/icons/icons.spritemap.svg#citations"></use></svg></span><span class="ng-btn_text">Export citation</span></button></div>
</form></div>
</section><section>









    
    
        <div data-widget-def="UX3CitedByWidget" data-widget-id="efb4df9a-8e1a-47f9-bfb7-271959277a9f" data-location="citedby_article">
        



        
            <h4 class="">
                Cited by
            </h4>
        
        <section id="cited-by" class="cited-by"><div class="cited-by__wrapper"><div id="cited-by__content" class="cited-by__content"><ol data-source="/pb/widgets/citedBy?page=1&amp;widgetId=efb4df9a-8e1a-47f9-bfb7-271959277a9f&amp;pbContext=%3BrequestedJournal%3Ajournal%3Anejm%3Bpage%3Astring%3AArticle%2FChapter+View%3Bctype%3Astring%3AJournal+Content%3Bissue%3Aissue%3Adoi%5C%3A10.1056%2Fnejm_2020.383.issue-23%3Barticle%3Aarticle%3Adoi%5C%3A10.1056%2FNEJMra2026131%3Bwgroup%3Astring%3AMMS+NextGen+Website+Group%3BpageGroup%3Astring%3APublication+Pages%3BsubPage%3Astring%3AFull+Text%3Bwebsite%3Awebsite%3Amms-site%3Bjournal%3Ajournal%3Anejms" data-lazyload="false" data-total="2240" class="cited-by__list list-unstyled"><li class="cited-by__entry border-bottom pb-16 mb-24"><ul class="cited-by__entry__authors list-inline"><li class="list-inline-item cited-by__entry__author">Honglin Huang, </li><li class="list-inline-item cited-by__entry__author">Qiaomei Ke, </li><li class="list-inline-item cited-by__entry__author">Ningxi Li, </li><li class="list-inline-item cited-by__entry__author">Ziman Yang, </li><li class="list-inline-item cited-by__entry__author">Jinyang Shen, </li><li class="list-inline-item cited-by__entry__author">Li Zeng, </li><li class="list-inline-item cited-by__entry__author">Qianyi Zeng, </li><li class="list-inline-item cited-by__entry__author">Xiaodan Wei, </li><li class="list-inline-item cited-by__entry__author">Hong Yang, </li><li class="list-inline-item cited-by__entry__author">Dengfeng Wang, </li><li class="list-inline-item cited-by__entry__author">Yiyao Liu, </li><li class="list-inline-item cited-by__entry__author">Chunhui Wu, </li></ul><span class="cited-by__entry__title">Advanced biomaterials and delivery modalities to alleviate cancer therapy-induced inflammation, </span><span class="cited-by__entry__series-title">Biomaterials, </span><span class="cited-by__entry__volume"><strong>324</strong>, </span><span class="cited-by__entry__page-range">(123419), </span><span class="cited-by__entry__pub-date">(2026).</span><a href="https://doi.org/10.1016/j.biomaterials.2025.123419" title="Crossref" target="_blank" class="cited-by__entry__doi">https://doi.org/10.1016/j.biomaterials.2025.123419</a><div class="cited-by__entry__extra-links"><a href="https://doi.org/10.1016/j.biomaterials.2025.123419" target="_blank" class="cited-by__entry__visitable">Crossref</a></div></li><li class="cited-by__entry border-bottom pb-16 mb-24"><ul class="cited-by__entry__authors list-inline"><li class="list-inline-item cited-by__entry__author">Camila Neiva Porto Silva, </li><li class="list-inline-item cited-by__entry__author">Joelson Germano Crispim, </li><li class="list-inline-item cited-by__entry__author">Michelly Cristiny Pereira, </li><li class="list-inline-item cited-by__entry__author">Maira Galdino da Rocha Pitta, </li><li class="list-inline-item cited-by__entry__author">Moacyr Jesus Barreto de Melo Rêgo, </li><li class="list-inline-item cited-by__entry__author">Michelle Melgarejo da Rosa, </li></ul><span class="cited-by__entry__title">The communication between chikungunya infection and the central nervous system, </span><span class="cited-by__entry__series-title">Microbial Pathogenesis, </span><span class="cited-by__entry__volume"><strong>206</strong>, </span><span class="cited-by__entry__page-range">(107747), </span><span class="cited-by__entry__pub-date">(2025).</span><a href="https://doi.org/10.1016/j.micpath.2025.107747" title="Crossref" target="_blank" class="cited-by__entry__doi">https://doi.org/10.1016/j.micpath.2025.107747</a><div class="cited-by__entry__extra-links"><a href="https://doi.org/10.1016/j.micpath.2025.107747" target="_blank" class="cited-by__entry__visitable">Crossref</a></div></li><li class="cited-by__entry border-bottom pb-16 mb-24"><ul class="cited-by__entry__authors list-inline"><li class="list-inline-item cited-by__entry__author">Vidya Raju, </li><li class="list-inline-item cited-by__entry__author">Revanth Reddy, </li><li class="list-inline-item cited-by__entry__author">Arzhang Cyrus Javan, </li><li class="list-inline-item cited-by__entry__author">Behnam Hajihossainlou, </li><li class="list-inline-item cited-by__entry__author">Ralph Weissleder, </li><li class="list-inline-item cited-by__entry__author">Anthony Guiseppi-Elie, </li><li class="list-inline-item cited-by__entry__author">Katsuo Kurabayashi, </li><li class="list-inline-item cited-by__entry__author">Simon A. Jones, </li><li class="list-inline-item cited-by__entry__author">Rose T. Faghih, </li></ul><span class="cited-by__entry__title">Tracking inflammation status for improving patient prognosis: A review of current methods, unmet clinical needs and opportunities, </span><span class="cited-by__entry__series-title">Biotechnology Advances, </span><span class="cited-by__entry__volume"><strong>82</strong>, </span><span class="cited-by__entry__page-range">(108592), </span><span class="cited-by__entry__pub-date">(2025).</span><a href="https://doi.org/10.1016/j.biotechadv.2025.108592" title="Crossref" target="_blank" class="cited-by__entry__doi">https://doi.org/10.1016/j.biotechadv.2025.108592</a><div class="cited-by__entry__extra-links"><a href="https://doi.org/10.1016/j.biotechadv.2025.108592" target="_blank" class="cited-by__entry__visitable">Crossref</a></div></li><li class="cited-by__entry border-bottom pb-16 mb-24"><ul class="cited-by__entry__authors list-inline"><li class="list-inline-item cited-by__entry__author">Shareef Mohammed Buvvaji, </li><li class="list-inline-item cited-by__entry__author">Vinod Joshi, </li><li class="list-inline-item cited-by__entry__author">Annette Angel, </li><li class="list-inline-item cited-by__entry__author">Bennet Angel, </li><li class="list-inline-item cited-by__entry__author">Poorna Khaneja, </li><li class="list-inline-item cited-by__entry__author">Ramesh Joshi, </li></ul><span class="cited-by__entry__title">Intracellular alterations, vacuolization and bypass mechanism by SARS-CoV-2 infection could be the possible basis of respiratory distress and hypoxia, </span><span class="cited-by__entry__series-title">Tissue and Cell, </span><span class="cited-by__entry__volume"><strong>95</strong>, </span><span class="cited-by__entry__page-range">(102896), </span><span class="cited-by__entry__pub-date">(2025).</span><a href="https://doi.org/10.1016/j.tice.2025.102896" title="Crossref" target="_blank" class="cited-by__entry__doi">https://doi.org/10.1016/j.tice.2025.102896</a><div class="cited-by__entry__extra-links"><a href="https://doi.org/10.1016/j.tice.2025.102896" target="_blank" class="cited-by__entry__visitable">Crossref</a></div></li><li class="cited-by__entry border-bottom pb-16 mb-24"><ul class="cited-by__entry__authors list-inline"><li class="list-inline-item cited-by__entry__author">Antonio Tonutti, </li><li class="list-inline-item cited-by__entry__author">Francesca Motta, </li><li class="list-inline-item cited-by__entry__author">Natasa Isailovic, </li><li class="list-inline-item cited-by__entry__author">Carlo Selmi, </li><li class="list-inline-item cited-by__entry__author">Suraj Timilsina, </li><li class="list-inline-item cited-by__entry__author">Merrill Eric Gershwin, </li><li class="list-inline-item cited-by__entry__author">Maria De Santis, </li></ul><span class="cited-by__entry__title">Mechanistic considerations linking SARS-CoV-2 infection, inflammation, and the loss of immune tolerance, </span><span class="cited-by__entry__series-title">Current Opinion in Immunology, </span><span class="cited-by__entry__volume"><strong>95</strong>, </span><span class="cited-by__entry__page-range">(102567), </span><span class="cited-by__entry__pub-date">(2025).</span><a href="https://doi.org/10.1016/j.coi.2025.102567" title="Crossref" target="_blank" class="cited-by__entry__doi">https://doi.org/10.1016/j.coi.2025.102567</a><div class="cited-by__entry__extra-links"><a href="https://doi.org/10.1016/j.coi.2025.102567" target="_blank" class="cited-by__entry__visitable">Crossref</a></div></li><li class="cited-by__entry border-bottom pb-16 mb-24"><ul class="cited-by__entry__authors list-inline"><li class="list-inline-item cited-by__entry__author">Yixu Wang, </li><li class="list-inline-item cited-by__entry__author">Jin Zhang, </li><li class="list-inline-item cited-by__entry__author">Sihan Xu, </li><li class="list-inline-item cited-by__entry__author">Junjie Li, </li><li class="list-inline-item cited-by__entry__author">Wenjuan Liu, </li><li class="list-inline-item cited-by__entry__author">Min Jiang, </li><li class="list-inline-item cited-by__entry__author">Gang Bai, </li></ul><span class="cited-by__entry__title">Psoralen alleviates acute lung injury by covalently targeting Cys106 of HMGB1 in macrophages to inhibit inflammatory responses, </span><span class="cited-by__entry__series-title">Phytomedicine, </span><span class="cited-by__entry__volume"><strong>142</strong>, </span><span class="cited-by__entry__page-range">(156807), </span><span class="cited-by__entry__pub-date">(2025).</span><a href="https://doi.org/10.1016/j.phymed.2025.156807" title="Crossref" target="_blank" class="cited-by__entry__doi">https://doi.org/10.1016/j.phymed.2025.156807</a><div class="cited-by__entry__extra-links"><a href="https://doi.org/10.1016/j.phymed.2025.156807" target="_blank" class="cited-by__entry__visitable">Crossref</a></div></li><li class="cited-by__entry border-bottom pb-16 mb-24"><ul class="cited-by__entry__authors list-inline"><li class="list-inline-item cited-by__entry__author">Francesco Castagna, </li><li class="list-inline-item cited-by__entry__author">Mandeep R. Mehra, </li><li class="list-inline-item cited-by__entry__author">Christoph G.S. Nabzdyk, </li><li class="list-inline-item cited-by__entry__author">Michael M. Givertz, </li></ul><span class="cited-by__entry__title">Vasoplegia Syndrome After Cardiac Surgery, </span><span class="cited-by__entry__series-title">JACC: Heart Failure, </span><span class="cited-by__entry__volume"><strong>13</strong>, </span><span class="cited-by__entry__issue">7, </span><span class="cited-by__entry__page-range">(102482), </span><span class="cited-by__entry__pub-date">(2025).</span><a href="https://doi.org/10.1016/j.jchf.2025.02.028" title="Crossref" target="_blank" class="cited-by__entry__doi">https://doi.org/10.1016/j.jchf.2025.02.028</a><div class="cited-by__entry__extra-links"><a href="https://doi.org/10.1016/j.jchf.2025.02.028" target="_blank" class="cited-by__entry__visitable">Crossref</a></div></li><li class="cited-by__entry border-bottom pb-16 mb-24"><ul class="cited-by__entry__authors list-inline"><li class="list-inline-item cited-by__entry__author">Abid H. Banday, </li></ul><span class="cited-by__entry__title">Harnessing the immune system and developing targeted vaccines: Overall strategies of leveraging the body’s natural defense mechanisms to enhance cancer treatment, </span><span class="cited-by__entry__series-title">Regenerative Medicine Reports, </span><span class="cited-by__entry__pub-date">(2025).</span><a href="https://doi.org/10.4103/REGENMED.REGENMED-D-25-00011" title="Crossref" target="_blank" class="cited-by__entry__doi">https://doi.org/10.4103/REGENMED.REGENMED-D-25-00011</a><div class="cited-by__entry__extra-links"><a href="https://doi.org/10.4103/REGENMED.REGENMED-D-25-00011" target="_blank" class="cited-by__entry__visitable">Crossref</a></div></li><li class="cited-by__entry border-bottom pb-16 mb-24"><ul class="cited-by__entry__authors list-inline"><li class="list-inline-item cited-by__entry__author">Stephen J. Balevic, </li><li class="list-inline-item cited-by__entry__author">Daniel Gonzalez, </li><li class="list-inline-item cited-by__entry__author">P. Brian Smith, </li><li class="list-inline-item cited-by__entry__author">William G. Powderly, </li><li class="list-inline-item cited-by__entry__author">Andreas Schmid, </li><li class="list-inline-item cited-by__entry__author">Ashley Kang, </li><li class="list-inline-item cited-by__entry__author">Matthew W. McCarthy, </li><li class="list-inline-item cited-by__entry__author">Linda K. Shaw, </li><li class="list-inline-item cited-by__entry__author">Christopher J. Lindsell, </li><li class="list-inline-item cited-by__entry__author">Sam Bozzette, </li><li class="list-inline-item cited-by__entry__author">Richard M. W. Hoetelmans, </li><li class="list-inline-item cited-by__entry__author">Christoph P. Hornik, </li><li class="list-inline-item cited-by__entry__author">Daniel K. Benjamin Jr, </li></ul><span class="cited-by__entry__title">Infliximab Pharmacokinetics, Dosing, and Response in Hospitalized Patients with COVID‐19 Pneumonia: A Secondary Analysis of a Multinational Randomized Clinical Trial (ACTIV‐1 IM), </span><span class="cited-by__entry__series-title">The Journal of Clinical Pharmacology, </span><span class="cited-by__entry__pub-date">(2025).</span><a href="https://doi.org/10.1002/jcph.70057" title="Crossref" target="_blank" class="cited-by__entry__doi">https://doi.org/10.1002/jcph.70057</a><div class="cited-by__entry__extra-links"><a href="https://doi.org/10.1002/jcph.70057" target="_blank" class="cited-by__entry__visitable">Crossref</a></div></li><li class="cited-by__entry border-bottom pb-16 mb-24"><ul class="cited-by__entry__authors list-inline"><li class="list-inline-item cited-by__entry__author">Rachid Noureddine, </li><li class="list-inline-item cited-by__entry__author">Asmaa Haddaji, </li><li class="list-inline-item cited-by__entry__author">Hanâ Baba, </li><li class="list-inline-item cited-by__entry__author">Ahd Ouladlahsen, </li><li class="list-inline-item cited-by__entry__author">Safaa Aqillouch, </li><li class="list-inline-item cited-by__entry__author">Oumaima Laazaazia, </li><li class="list-inline-item cited-by__entry__author">Achraf Aainouss, </li><li class="list-inline-item cited-by__entry__author">Hind Dehbi, </li><li class="list-inline-item cited-by__entry__author">Sayeh Ezzikouri, </li></ul><span class="cited-by__entry__title">
              Genetic Variations in
              TLR2
              and
              TLR4
              Genes and Their Association With COVID‐19 Severity and Inflammatory Markers in the Moroccan Population
            , </span><span class="cited-by__entry__series-title">International Journal of Immunogenetics, </span><span class="cited-by__entry__pub-date">(2025).</span><a href="https://doi.org/10.1111/iji.70002" title="Crossref" target="_blank" class="cited-by__entry__doi">https://doi.org/10.1111/iji.70002</a><div class="cited-by__entry__extra-links"><a href="https://doi.org/10.1111/iji.70002" target="_blank" class="cited-by__entry__visitable">Crossref</a></div></li><li class="cited-by__entry--see-more"><a href="javascript:void(0)" data-source="/pb/widgets/citedBy?page=1&amp;widgetId=efb4df9a-8e1a-47f9-bfb7-271959277a9f&amp;pbContext=%3BrequestedJournal%3Ajournal%3Anejm%3Bpage%3Astring%3AArticle%2FChapter+View%3Bctype%3Astring%3AJournal+Content%3Bissue%3Aissue%3Adoi%5C%3A10.1056%2Fnejm_2020.383.issue-23%3Barticle%3Aarticle%3Adoi%5C%3A10.1056%2FNEJMra2026131%3Bwgroup%3Astring%3AMMS+NextGen+Website+Group%3BpageGroup%3Astring%3APublication+Pages%3BsubPage%3Astring%3AFull+Text%3Bwebsite%3Awebsite%3Amms-site%3Bjournal%3Ajournal%3Anejms" class="cited-by__see-more">See more</a></li></ol></div><div class="cited-by__spinner justify-content-center align-items-center d-none"><div role="status" class="spinner-border text-gray"><span class="sr-only">Loading...</span></div></div></div></section>

        </div>
    

</section></section></div><div id="core-collateral-fulltext-options" role="tabpanel" data-core-tabs="core-collateral-fulltext-options" tabindex="-1" aria-labelledby="pane-core-collateral-fulltext-options"><header><h2 id="pane-core-collateral-fulltext-options"><i class="icon-eye" aria-hidden="true"></i>View Options</h2><button data-close="collateral" aria-label="Close"><i class="icon-close"></i></button></header><div class="section--wrapper"><h3>View options</h3><section class="format--pdf"><h4> <abbr title="Portable Document Format">PDF</abbr></h4><a href="https://www.nejm.org/doi/pdf/10.1056/NEJMra2026131" class="btn btn--pdf" aria-label="View PDF" data-behavior="trackDownloadEvent" data-doi="10.1056/NEJMra2026131" data-interactiontype="article_tools_download_pdf" data-multimedia-type="Article PDF" data-multimedia-filename="nejmra2026131.pdf"><i aria-hidden="true" class="icon-pdf"></i><span>View PDF</span></a></section></div><!-- Its needed to duplicate this for PB check Collateral.js as well--></div><div id="core-collateral-media" role="tabpanel" data-core-tabs="core-collateral-media" tabindex="-1" aria-labelledby="pane-core-collateral-media"><header><h2 id="pane-core-collateral-media"><i class="icon-photo" aria-hidden="true"></i>Media</h2><button data-close="collateral" aria-label="Close"><i class="icon-close"></i></button></header><div role="tablist"><button aria-controls="tab-figures" role="tab" id="tab-figures-label" aria-selected="true" class="active">Figures</button><button aria-controls="tab-other" role="tab" id="tab-other-label" tabindex="-1" aria-selected="false" class="inactive" aria-disabled="true">Other</button></div><section id="tab-figures" aria-labelledby="tab-figures-label" role="tabpanel" tabindex="0"><h3>Figures</h3><div class="text-right"><a class="btn btn--inverse  open-in-viewer" href="#figures"><span>Open all in viewer</span><i class="icon-open_in_new" aria-hidden="true"></i></a></div><div id="core-f1"><figure class="graphic"><a class="open-in-viewer" href="#f1" data-index="0" data-interactiontype="multimedia_click" data-multimedia-type="Figure" data-multimedia-filename="nejmra2026131_f1.jpg"><img src="/cms/10.1056/NEJMra2026131/asset/909f0648-4b51-4338-9760-cefa7aab4ca6/assets/images/large/nejmra2026131_f1.jpg" height="2206" width="2640" aria-labelledby="f1" loading="lazy"></a><figcaption><div class="caption">Clinical Presentation of Cytokine Storm.</div><div class="notes"><div role="doc-footnote">A wide range of clinical and laboratory abnormalities can be observed in cytokine storm. However, all cases involve elevated circulating cytokine levels, acute systemic inflammatory symptoms, and secondary organ dysfunction (often renal, hepatic, or pulmonary). ARDS denotes acute respiratory distress syndrome, CRP C-reactive protein, and VEGF vascular endothelial growth factor.</div></div></figcaption></figure><div class="external-links"><a class="pill__to-original" href="#f1"><i class="icon-return" aria-hidden="true"></i><span>Go to Figure</span></a><a class="open-in-viewer" href="#f1" data-interactiontype="multimedia_click" data-multimedia-type="Figure" data-multimedia-filename="nejmra2026131_f1.jpg"><span>Open in Viewer</span><i class="icon-expand" aria-hidden="true"></i></a></div></div><div id="core-f2"><figure class="graphic"><a class="open-in-viewer" href="#f2" data-index="0" data-interactiontype="multimedia_click" data-multimedia-type="Figure" data-multimedia-filename="nejmra2026131_f2.jpg"><img src="/cms/10.1056/NEJMra2026131/asset/90086a76-be54-4325-874f-c36584350de8/assets/images/large/nejmra2026131_f2.jpg" height="3341" width="2640" aria-labelledby="f2" loading="lazy"></a><figcaption><div class="caption">Pathophysiological Features of Cytokine Storm.</div><div class="notes"><div role="doc-footnote">Cytokine storm can occur as a result of inappropriate recognition (e.g., in hypersensitivity) or ineffective recognition with immune evasion (e.g., in Epstein–Barr virus [EBV]–associated hemophagocytic lymphohistiocytosis [HLH]), an inappropriate response with an exaggerated effector response and cytokine production (e.g., in chimeric antigen receptor [CAR] T-cell therapy) or an ineffective response due to immune evasion (e.g., in sepsis), or failure to terminate homeostasis or return to homeostasis (e.g., in HLH). Examples of drugs that can inhibit signaling pathways are shown in boxes. Covid-19 denotes coronavirus disease 2019, CS cytokine storm, IL1RA interleukin-1–receptor antagonist, IP-10 interferon-inducible protein 10, JAK-STAT3 Janus kinase–signal transducer and activator of transcription 3, MAPK mitogen-activated protein kinase, MCP-1 monocyte chemotactic protein 1, MIP-1α macrophage inflammatory protein 1α, mTOR mammalian target of rapamycin, NF-κB nuclear factor κB, TNF tumor necrosis factor, and Tregs regulatory T cells.</div></div></figcaption></figure><div class="external-links"><a class="pill__to-original" href="#f2"><i class="icon-return" aria-hidden="true"></i><span>Go to Figure</span></a><a class="open-in-viewer" href="#f2" data-interactiontype="multimedia_click" data-multimedia-type="Figure" data-multimedia-filename="nejmra2026131_f2.jpg"><span>Open in Viewer</span><i class="icon-expand" aria-hidden="true"></i></a></div></div><div id="core-f3"><figure class="graphic"><a class="open-in-viewer" href="#f3" data-index="0" data-interactiontype="multimedia_click" data-multimedia-type="Figure" data-multimedia-filename="nejmra2026131_f3.jpg"><img src="/cms/10.1056/NEJMra2026131/asset/7aaf6482-acae-4bdc-8a34-aeafb104077d/assets/images/large/nejmra2026131_f3.jpg" height="1605" width="2640" aria-labelledby="f3" loading="lazy"></a><figcaption><div class="caption">T-Cell Effector Subgroups Involved in Cytokine Storm.</div><div class="notes"><div role="doc-footnote">The master transcription factors (T-bet, GATA-3, PU.1, RORγT, and eomesodermin [eomes]), effector molecules, and cell targets are shown for the following T-cell subgroups: types 1, 2, 9, and 17 helper T (Th1, Th2, Th9, and Th17, respectively) cells and cytotoxic T lymphocytes.</div></div></figcaption></figure><div class="external-links"><a class="pill__to-original" href="#f3"><i class="icon-return" aria-hidden="true"></i><span>Go to Figure</span></a><a class="open-in-viewer" href="#f3" data-interactiontype="multimedia_click" data-multimedia-type="Figure" data-multimedia-filename="nejmra2026131_f3.jpg"><span>Open in Viewer</span><i class="icon-expand" aria-hidden="true"></i></a></div></div></section><section id="tab-other" aria-labelledby="tab-other-label" role="tabpanel" tabindex="-1"><h3>Other</h3></section></div><div id="core-collateral-tables" role="tabpanel" data-core-tabs="core-collateral-tables" tabindex="-1" aria-labelledby="pane-core-collateral-tables"><header><h2 id="pane-core-collateral-tables"><i class="icon-tables" aria-hidden="true"></i>Tables</h2><button data-close="collateral" aria-label="Close"><i class="icon-close"></i></button></header><!-- There is no content. --><div class="section--wrapper"><div class="text-right"><a class="btn btn--inverse  open-in-viewer" href="#tables"><span>Open all in viewer</span><i class="icon-open_in_new" aria-hidden="true"></i></a></div><div id="core-t1"><figure class="table"><a class="open-in-viewer" href="#t1" data-index="0" data-interactiontype="multimedia_click" data-multimedia-type="Table" data-multimedia-filename="nejmra2026131_t1.jpg"><div class="graphic-wrap" data-presentation="suppressed-in-viewer"><img src="/cms/10.1056/NEJMra2026131/asset/d37b4562-4a3c-4afe-afb6-e6a499ad5023/assets/images/large/nejmra2026131_t1.jpg" height="2618" width="1999" loading="lazy"></div><div class="table-wrap catalyst-standard" data-presentation="suppressed-in-flow"><table data-shading="custom"><thead><tr class="head1" data-type="row head1"><th class="txlx-borders" data-xml-align="left">Mediator</th><th class="txxx-borders">Main Cell Source</th><th class="txxr-borders">Type and Function</th></tr></thead><tbody><tr data-type="row"><td class="xxlx-borders hanging01 shading"><b>Cytokines and growth factors</b></td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxr-borders shading">&nbsp;</td></tr><tr data-type="row"><td class="xxlx-borders hanging01">Interleukin-1</td><td class="xxxx-borders hanging01">Macrophages, epithelial cells; pyroptotic cells</td><td class="xxxr-borders hanging01">Proinflammatory alarmin cytokine; pyrogenic function, macrophage and Th17 cell activation</td></tr><tr data-type="row"><td class="xxlx-borders hanging01 shading">Interleukin-2</td><td class="xxxx-borders shading">T cells</td><td class="xxxr-borders hanging01 shading">Effector T-cell and regulatory T-cell growth factor</td></tr><tr data-type="row"><td class="xxlx-borders hanging01">Interleukin-6</td><td class="xxxx-borders">Macrophages, T cells, endothelial cells</td><td class="xxxr-borders hanging01">Proinflammatory cytokine; pyrogenic function, increased antibody production, induction of acute-phase reactants</td></tr><tr data-type="row"><td class="xxlx-borders hanging01 shading">Interleukin-9</td><td class="xxxx-borders shading">Th9 cells</td><td class="xxxr-borders hanging01 shading">Protection from helminth infections, activation of mast cells, association with type I interferon in Covid-19<sup><a href="#core-r26" role="doc-biblioref" data-xml-rid="r26" id="core-ref-r26-1" href-manipulated="true" aria-label="Reference 26">26</a></sup></td></tr><tr data-type="row"><td class="xxlx-borders hanging01">Interleukin-10</td><td class="xxxx-borders">Regulatory T cells, Th9 cells</td><td class="xxxr-borders hanging01">Antiinflammatory cytokine; inhibition of Th1 cells and cytokine release</td></tr><tr data-type="row"><td class="xxlx-borders hanging01 shading">Interleukin-12</td><td class="xxxx-borders shading">Dendritic cells, macrophages</td><td class="xxxr-borders hanging01 shading">Activation of the Th1 pathway; induction of interferon-γ from Th1 cells, CTLs, and NK cells; acting in synergy with interleukin-18</td></tr><tr data-type="row"><td class="xxlx-borders hanging01">Interleukin-17</td><td class="xxxx-borders hanging01">Th17 cells, NK cells, group 3 innate lymphoid cells</td><td class="xxxr-borders hanging01">Promoting neutrophilic inflammation, protection from bacterial and fungal infections</td></tr><tr data-type="row"><td class="xxlx-borders hanging01 shading">Interleukin-18</td><td class="xxxx-borders hanging01 shading">Monocytes, macrophages, dendritic cells</td><td class="xxxr-borders hanging01 shading">Proinflammatory alarmin cytokine; activation of Th1 pathway, acting in synergy with interleukin-12</td></tr><tr data-type="row"><td class="xxlx-borders hanging01">Interleukin-33</td><td class="xxxx-borders hanging01">Macrophages, dendritic cells, mast cells, epithelial cells</td><td class="xxxr-borders hanging01">Proinflammatory alarmin cytokine; amplification of Th1 and Th2 cells, activation of NK cells, CTLs, and mast cells</td></tr><tr data-type="row"><td class="xxlx-borders hanging01 shading">Interferon-γ</td><td class="xxxx-borders hanging01 shading">Th1 cells, CTLs, group 1 innate lymphoid cells, and NK cells</td><td class="xxxr-borders hanging01 shading">Proinflammatory cytokine; activation of macrophages</td></tr><tr data-type="row"><td class="xxlx-borders hanging01">Tumor necrosis factor</td><td class="xxxx-borders">Macrophages, T cells, NK cells, mast cells</td><td class="xxxr-borders hanging01">Increasing vascular permeability; pyrogenic function</td></tr><tr data-type="row"><td class="xxlx-borders hanging01 shading">GM-CSF</td><td class="xxxx-borders shading">Th17 cells</td><td class="xxxr-borders shading">Proinflammatory cytokine</td></tr><tr data-type="row"><td class="xxlx-borders hanging01">VEGF</td><td class="xxxx-borders">Macrophages</td><td class="xxxr-borders">Angiogenesis</td></tr><tr data-type="row"><td class="xxlx-borders hanging01 shading"><b>Chemokines</b></td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxr-borders shading">&nbsp;</td></tr><tr data-type="row"><td class="xxlx-borders hanging01">Interleukin-8 (CXCL8)</td><td class="xxxx-borders">Macrophages, epithelial cells</td><td class="xxxr-borders">Recruitment of neutrophils</td></tr><tr data-type="row"><td class="xxlx-borders hanging01 shading">MIG (CXCL9)</td><td class="xxxx-borders hanging01 shading">Monocytes, endothelial cells, keratinocytes</td><td class="xxxr-borders hanging01 shading">Interferon-inducible chemokine; recruitment of Th1 cells, NK cells, plasmacytoid dendritic cells</td></tr><tr data-type="row"><td class="xxlx-borders hanging01">IP-10 (CXCL10)</td><td class="xxxx-borders hanging01">Monocytes, endothelial cells, keratinocytes</td><td class="xxxr-borders hanging01">Interferon-inducible chemokine; recruitment of macrophages, Th1 cells, NK cells</td></tr><tr data-type="row"><td class="xxlx-borders hanging01 shading">MCP-1 (CCL2)</td><td class="xxxx-borders hanging01 shading">Macrophages, dendritic cells, cardiac myocytes</td><td class="xxxr-borders hanging01 shading">Recruitment of Th2 cells, monocytes, dendritic cells, basophils</td></tr><tr data-type="row"><td class="xxlx-borders hanging01">MIP-1α (CCL3)</td><td class="xxxx-borders hanging01">Monocytes, neutrophils, dendritic cells, NK cells, mast cells</td><td class="xxxr-borders hanging01">Recruitment of macrophages, Th1 cells, NK cells, eosinophils, dendritic cells; pyrogenic function</td></tr><tr data-type="row"><td class="xxlx-borders hanging01 shading">MIP-1β (CCL4)</td><td class="xxxx-borders shading">Macrophages, neutrophils, endothelium</td><td class="xxxr-borders hanging01 shading">Recruitment of macrophages, Th1 cells, NK cells, dendritic cells</td></tr><tr data-type="row"><td class="xxlx-borders hanging01">BLC (CXCL13)</td><td class="xxxx-borders">B cells, follicular dendritic cells</td><td class="xxxr-borders hanging01">Recruitment of B cells, CD4 T cells, dendritic cells<a href="#core-t1fn2" role="doc-noteref">†</a></td></tr><tr data-type="row"><td class="xxlx-borders hanging01 shading"><b>Plasma proteins</b></td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxr-borders shading">&nbsp;</td></tr><tr data-type="row"><td class="xxlx-borders hanging01">CRP</td><td class="xxxx-borders">Hepatocytes</td><td class="xxxr-borders hanging01">Monomeric CRP increases interleukin-8 and MCP-1 secretion; interleukin-6 increases CRP expression</td></tr><tr data-type="row"><td class="xxlx-borders hanging01 shading">Complement</td><td class="xxxx-borders shading">Hepatocytes, other cells</td><td class="xxxr-borders hanging01 shading">Complement activation contributes to tissue damage in cytokine storm; complement inhibition can reduce immunopathologic effects of cytokine storm</td></tr><tr data-type="row"><td class="xblx-borders hanging01">Ferritin</td><td class="xbxx-borders">Ubiquitous</td><td class="xbxr-borders">Primary site of iron storage in cells</td></tr></tbody></table></div><figcaption><div class="notes"><div role="doc-footnote" data-has="label"><div class="label">*</div><div id="core-t1fn1" role="paragraph" data-to-manipulate="true">BLC denotes B-lymphocyte chemoattractant; Covid-19 coronavirus disease 2019; CRP C-reactive protein; CTLs cytotoxic T lymphocytes; CXCL C-X-C motif chemokine ligand; GM-CSF granulocyte–macrophage colony-stimulating factor; IP-10 interferon-inducible protein 10; MCP-1 monocyte chemoattractant protein 1; MIG monokine induced by interferon-γ; MIP-1α and MIP-1β macrophage inflammatory protein 1α and 1β, respectively; NK natural killer; Th1, Th2, Th9, and Th17 cells types 1, 2, 9, and 17 helper T cells, respectively; and VEGF vascular endothelial growth factor.</div></div><div role="doc-footnote" data-has="label"><div class="label">†</div><div id="core-t1fn2" role="paragraph" data-to-manipulate="true">In idiopathic multicentric Castleman’s disease, the levels of CXCL13 are the most elevated of all the cytokines or chemokines.</div></div></div></figcaption></a><figcaption><div class="caption">Soluble Mediators in Cytokine Storm.<a href="#core-t1fn1" role="doc-noteref">*</a></div></figcaption></figure><div class="external-links"><a class="pill__to-original" href="#t1"><i class="icon-return" aria-hidden="true"></i><span>Go to Table</span></a><a class="open-in-viewer" href="#t1" data-interactiontype="multimedia_click" data-multimedia-type="Table" data-multimedia-filename="nejmra2026131_t1.jpg"><span>Open in Viewer</span><i class="icon-expand" aria-hidden="true"></i></a></div></div><div id="core-t2"><figure class="table"><a class="open-in-viewer" href="#t2" data-index="0" data-interactiontype="multimedia_click" data-multimedia-type="Table" data-multimedia-filename="nejmra2026131_t2.jpg"><div class="graphic-wrap" data-presentation="suppressed-in-viewer"><img src="/cms/10.1056/NEJMra2026131/asset/ed1d87f1-fbe3-4da7-a16d-548275efabdc/assets/images/large/nejmra2026131_t2.jpg" height="1831" width="1999" loading="lazy"></div><div class="table-wrap catalyst-standard" data-presentation="suppressed-in-flow"><table data-shading="custom"><thead><tr class="head1" data-type="row head1"><th class="txlx-borders" data-xml-align="left">Type of Cytokine Storm and Trigger</th><th class="txxx-borders">Cause</th><th class="txxx-borders">Pathologic Cellular or Cytokine Driver</th><th class="txxr-borders">Common Therapeutic Approaches</th></tr></thead><tbody><tr data-type="row"><td class="xxlx-borders hanging01 shading"><b>Iatrogenic</b></td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxr-borders shading">&nbsp;</td></tr><tr data-type="row"><td class="xxlx-borders hanging01">CAR T-cell therapy</td><td class="xxxx-borders hanging01">Infusion of CAR T cells</td><td class="xxxx-borders hanging01">Macrophages, CAR T cells, interleukin-6, interleukin-1β</td><td class="xxxr-borders hanging01">Anti–interleukin-6 antibody, glucocorticoids</td></tr><tr data-type="row"><td class="xxlx-borders hanging01 shading">Blinatumomab</td><td class="xxxx-borders hanging01 shading">Infusion of CD19- and CD3-specific T-cell receptor–engaging antibody</td><td class="xxxx-borders hanging01 shading">Activated T cells, macrophages, interleukin-6</td><td class="xxxr-borders hanging01 shading">Anti–interleukin-6 antibody, glucocorticoids</td></tr><tr data-type="row"><td class="xxlx-borders hanging01"><b>Pathogen-induced</b></td><td class="xxxx-borders">&nbsp;</td><td class="xxxx-borders">&nbsp;</td><td class="xxxr-borders">&nbsp;</td></tr><tr data-type="row"><td class="xxlx-borders hanging01 shading">Bacterial sepsis</td><td class="xxxx-borders shading">Hematogenous bacterial infection</td><td class="xxxx-borders hanging01 shading">Heterogeneous and multifactorial drivers</td><td class="xxxr-borders shading">Intravenous antibiotics</td></tr><tr data-type="row"><td class="xxlx-borders hanging01">EBV-associated HLH</td><td class="xxxx-borders hanging01">EBV infection in patient with genetic susceptibility</td><td class="xxxx-borders hanging01">Interferon-γ, TNF, CD8+ T cells</td><td class="xxxr-borders hanging01">B-cell–depleting therapy, glucocorticoids</td></tr><tr data-type="row"><td class="xxlx-borders hanging01 shading">HHV-8–associated MCD</td><td class="xxxx-borders hanging01 shading">HHV-8 infection in patient with HIV coinfection, genetic susceptibility, or both</td><td class="xxxx-borders hanging01 shading">Viral interleukin-6, interleukin-6</td><td class="xxxr-borders hanging01 shading">B-cell–depleting therapy</td></tr><tr data-type="row"><td class="xxlx-borders hanging01">Covid-19</td><td class="xxxx-borders hanging01">SARS-CoV-2 infection, potentially in a susceptible person</td><td class="xxxx-borders hanging01">Unknown driver</td><td class="xxxr-borders hanging01">Glucocorticoids</td></tr><tr data-type="row"><td class="xxlx-borders hanging01 shading"><b>Monogenic and autoimmune</b></td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxr-borders shading">&nbsp;</td></tr><tr data-type="row"><td class="xxlx-borders hanging01">Primary HLH</td><td class="xxxx-borders hanging01">Germline mutation in genes regulating granule-mediated cytotoxicity</td><td class="xxxx-borders hanging01">CD8+ T cells, interferon-γ</td><td class="xxxr-borders hanging01">T-cell inhibition or ablation, interferon-γ inhibitor, glucocorticoids</td></tr><tr data-type="row"><td class="xxlx-borders hanging01 shading">Secondary HLH, or MAS</td><td class="xxxx-borders hanging01 shading">Viral cause (EBV or CMV), autoimmune disorder (rheumatoid arthritis or adult-onset Still’s disease), or neoplastic disorder in patient with genetic susceptibility (lymphoma)</td><td class="xxxx-borders hanging01 shading">CD8+ T cells, interferon-γ, interleukin-1β, myeloid-cell autoinflammation</td><td class="xxxr-borders hanging01 shading">Treatment of the underlying cause, in addition to T-cell inhibition or ablation, interleukin-1β inhibitor, JAK1 and JAK2 inhibitors, glucocorticoids</td></tr><tr data-type="row"><td class="xxlx-borders hanging01">Autoinflammatory disorders</td><td class="xxxx-borders hanging01">Germline mutations in genes regulating the innate immune system and inflammasome activation</td><td class="xxxx-borders hanging01">Innate cells, TNF, interleukin-1β</td><td class="xxxr-borders hanging01">Anti-TNF antibody, anti–interleukin-1 antibody</td></tr><tr data-type="row"><td class="xblx-borders hanging01 shading">Idiopathic MCD</td><td class="xbxx-borders hanging01 shading">Unknown cause</td><td class="xbxx-borders hanging01 shading">Interleukin-6, activated T cells, mTOR</td><td class="xbxr-borders hanging01 shading">Anti–interleukin-6 antibody, sirolimus, cyclosporine, cytotoxic chemotherapy, glucocorticoids</td></tr></tbody></table></div><figcaption><div class="notes"><div role="doc-footnote" data-has="label"><div class="label">*</div><div id="core-t2fn1" role="paragraph" data-to-manipulate="true">CAR denotes chimeric antigen receptor, CMV cytomegalovirus, Covid-19 coronavirus disease 2019, EBV Epstein–Barr virus, HHV-8 human herpesvirus 8, HIV human immunodeficiency virus, HLH hemophagocytic lymphohistiocytosis, JAK1 Janus kinase 1, JAK2 Janus kinase 2, MAS macrophage activation syndrome, MCD multicentric Castleman’s disease, mTOR mammalian target of rapamycin, and SARS-CoV-2 severe acute respiratory syndrome coronavirus 2.</div></div></div></figcaption></a><figcaption><div class="caption">Clinical Causes of Cytokine Storm, Pathologic Drivers, and Therapeutic Approaches.<a href="#core-t2fn1" role="doc-noteref">*</a></div></figcaption></figure><div class="external-links"><a class="pill__to-original" href="#t2"><i class="icon-return" aria-hidden="true"></i><span>Go to Table</span></a><a class="open-in-viewer" href="#t2" data-interactiontype="multimedia_click" data-multimedia-type="Table" data-multimedia-filename="nejmra2026131_t2.jpg"><span>Open in Viewer</span><i class="icon-expand" aria-hidden="true"></i></a></div></div></div></div><div id="core-collateral-share" role="tabpanel" data-core-tabs="core-collateral-share" tabindex="-1" aria-labelledby="pane-core-collateral-share"><header><h2 id="pane-core-collateral-share"><i class="icon-share" aria-hidden="true"></i>Share</h2><button data-close="collateral" aria-label="Close"><i class="icon-close"></i></button></header><h3>Share</h3><div class="section--wrapper"><section><h4>CONTENT LINK</h4><div id="share-self"><p data-id="article-share-self-link" class="share-self__source">https://www.nejm.org/doi/full/10.1056/NEJMra2026131</p><button data-id="article-share-access" aria-label="CONTENT LINK" class="share-self__action btn btn--inverse"><i aria-hidden="true" class="icon-copy-o"></i><span>Copy Link</span></button><div aria-live="polite" class="share-self__status"><p class="share-self__success"><i aria-hidden="true" class="icon-check_circle"></i><span>Copied!</span></p><p class="share-self__failed"><i aria-hidden="true" class="icon-x_btnclose"></i><span>Copying failed.</span></p></div></div></section><section data-location="share_tools_article"><h4>Share</h4><div class="share-buttons a2a a2a_kit" style="line-height: 16px;"><a href="/#facebook" aria-label="Share on Facebook" data-id="article-share-facebook" rel="nofollow noopener" role="link" target="_blank" title="Share on Facebook" class="btn btn--facebook a2a_button_facebook" data-interactiontype="social"><i aria-hidden="true" class="icon-facebook"></i><span>Facebook</span></a><a href="/#twitter" aria-label="Share on X (formerly Twitter)" data-id="article-share-twitter" rel="nofollow noopener" role="link" target="_blank" title="Share on X (formerly Twitter)" class="btn btn--twitter a2a_button_twitter" data-interactiontype="social"><i aria-hidden="true" class="icon-twitter"></i><span>X (formerly Twitter)</span></a><a href="/#linkedin" aria-label="Share on LinkedIn" data-id="article-share-linkedin" rel="nofollow noopener" role="link" target="_blank" title="Share on LinkedIn" class="btn btn--linkedin a2a_button_linkedin" data-interactiontype="social"><i aria-hidden="true" class="icon-linkedin"></i><span>LinkedIn</span></a><a href="/#email" aria-label="Share on email" data-id="article-share-email" rel="nofollow noopener" role="link" target="_blank" title="Share on email" class="btn btn--email a2a_button_email" data-interactiontype="content_email_click"><i aria-hidden="true" class="icon-mail"></i><span>email</span></a><a href="/#bluesky" aria-label="Share on Bluesky" data-id="article-share-bluesky" rel="nofollow noopener" role="link" target="_blank" title="Share on Bluesky" class="btn btn--bluesky a2a_button_bluesky" data-interactiontype="social"><i aria-hidden="true" class="icon-bluesky"></i><span>Bluesky</span></a></div></section></div></div><div data-location="references_article" id="core-collateral-references" role="tabpanel" aria-labelledby="pane-core-collateral-references" data-core-tabs="core-collateral-references" tabindex="-1"><header><h2 id="pane-core-collateral-references"><i aria-hidden="true" class="icon-references"></i>References</h2><button data-close="collateral" aria-label="Close"><i class="icon-close"></i></button></header><h3>References</h3><div role="list" class="section--wrapper"><div role="listitem" data-has="label"><div class="label">1.</div><div id="core-r1" class="citations"><div class="citation"><div class="citation-content">Morgan RA, Yang JC, Kitano M, Dudley ME, Laurencot CM, Rosenberg SA. Case report of a serious adverse event following the administration of T cells transduced with a chimeric antigen receptor recognizing ERBB2. <em>Mol Ther</em> 2010;18:843-851.</div><div class="external-links"><div class="to-citation__wrapper"><a class="to-citation" href="#body-ref-r1"><i aria-hidden="true" class="icon-return"></i><span>Go to Citation</span></a></div><div class="core-xlink-crossref"><a href="https://doi.org/10.1038/mt.2010.24" target="_blank">Crossref</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/20179677/" target="_blank">PubMed</a></div><div class="core-xlink-isi"><a href="https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;DestApp=WOS_CPL&amp;UsrCustomerID=5e3815c904498985e796fc91436abd9a&amp;SrcAuth=atyponcel&amp;SrcApp=literatum&amp;DestLinkType=FullRecord&amp;KeyUT=000276636800024" target="_blank">Web of Science</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=Case+report+of+a+serious+adverse+event+following+the+administration+of+T+cells+transduced+with+a+chimeric+antigen+receptor+recognizing+ERBB2.&amp;publication_year=2010&amp;journal=Mol+Ther&amp;pages=843-851&amp;doi=10.1038%2Fmt.2010.24&amp;pmid=20179677" target="_blank">Google Scholar</a></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">2.</div><div id="core-r2" class="citations"><div class="citation"><div class="citation-content">Ferrara JL, Abhyankar S, Gilliland DG. Cytokine storm of graft-versus-host disease: a critical effector role for interleukin-1. <em>Transplant Proc</em> 1993;25:1216-1217.</div><div class="external-links"><div class="to-citation__wrapper"><a class="to-citation" href="#body-ref-r2"><i aria-hidden="true" class="icon-return"></i><span>Go to Citation</span></a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/8442093/" target="_blank">PubMed</a></div><div class="core-xlink-isi"><a href="https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;DestApp=WOS_CPL&amp;UsrCustomerID=5e3815c904498985e796fc91436abd9a&amp;SrcAuth=atyponcel&amp;SrcApp=literatum&amp;DestLinkType=FullRecord&amp;KeyUT=A1993KN62200156" target="_blank">Web of Science</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=Cytokine+storm+of+graft-versus-host+disease%3A+a+critical+effector+role+for+interleukin-1.&amp;publication_year=1993&amp;journal=Transplant+Proc&amp;pages=1216-1217&amp;pmid=8442093" target="_blank">Google Scholar</a></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">3.</div><div id="core-r3" class="citations"><div class="citation"><div class="citation-content">Chatenoud L, Ferran C, Bach JF. The anti-CD3-induced syndrome: a consequence of massive in vivo cell activation. <em>Curr Top Microbiol Immunol</em> 1991;174:121-134.</div><div class="external-links"><div class="to-citation__wrapper"><a class="to-citation" href="#body-ref-r3"><i aria-hidden="true" class="icon-return"></i><span>Go to Citation</span></a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/1839376/" target="_blank">PubMed</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=The+anti-CD3-induced+syndrome%3A+a+consequence+of+massive+in+vivo+cell+activation.&amp;publication_year=1991&amp;journal=Curr+Top+Microbiol+Immunol&amp;pages=121-134&amp;pmid=1839376" target="_blank">Google Scholar</a></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">4.</div><div id="core-r4" class="citations"><div class="citation"><div class="citation-content">Coley WB. The treatment of malignant tumors by repeated inoculations of erysipelas: with a report of ten original cases. <em>Am J Med Sci</em> 1893;105:487-511.</div><div class="external-links"><div class="to-citation__wrapper"><a class="to-citation" href="#body-ref-r4"><i aria-hidden="true" class="icon-return"></i><span>Go to Citation</span></a></div><div class="core-xlink-crossref"><a href="https://doi.org/10.1097/00000441-189305000-00001" target="_blank">Crossref</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=The+treatment+of+malignant+tumors+by+repeated+inoculations+of+erysipelas%3A+with+a+report+of+ten+original+cases.&amp;publication_year=1893&amp;journal=Am+J+Med+Sci&amp;pages=487-511&amp;doi=10.1097%2F00000441-189305000-00001" target="_blank">Google Scholar</a></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">5.</div><div id="core-r5" class="citations"><div class="citation"><div class="citation-content">Pechous RD, Sivaraman V, Price PA, Stasulli NM, Goldman WE. Early host cell targets of Yersinia pestis during primary pneumonic plague. <em>PLoS Pathog</em> 2013;9(10):e1003679-e1003679.</div><div class="external-links"><div class="to-citation__wrapper"><a class="to-citation" href="#body-ref-r5"><i aria-hidden="true" class="icon-return"></i><span>Go to Citation</span></a></div><div class="core-xlink-crossref"><a href="https://doi.org/10.1371/journal.ppat.1003679" target="_blank">Crossref</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/24098126/" target="_blank">PubMed</a></div><div class="core-xlink-isi"><a href="https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;DestApp=WOS_CPL&amp;UsrCustomerID=5e3815c904498985e796fc91436abd9a&amp;SrcAuth=atyponcel&amp;SrcApp=literatum&amp;DestLinkType=FullRecord&amp;KeyUT=000330383800049" target="_blank">Web of Science</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=Early+host+cell+targets+of+Yersinia+pestis+during+primary+pneumonic+plague.&amp;publication_year=2013&amp;journal=PLoS+Pathog&amp;pages=e1003679-e1003679&amp;doi=10.1371%2Fjournal.ppat.1003679&amp;pmid=24098126" target="_blank">Google Scholar</a></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">6.</div><div id="core-r6" class="citations"><div class="citation"><div class="citation-content">Kash JC, Tumpey TM, Proll SC, et al. Genomic analysis of increased host immune and cell death responses induced by 1918 influenza virus. <em>Nature</em> 2006;443:578-581.</div><div class="external-links"><div class="to-citation__wrapper"><a class="to-citation" href="#body-ref-r6"><i aria-hidden="true" class="icon-return"></i><span>Go to Citation</span></a></div><div class="core-xlink-crossref"><a href="https://doi.org/10.1038/nature05181" target="_blank">Crossref</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/17006449/" target="_blank">PubMed</a></div><div class="core-xlink-isi"><a href="https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;DestApp=WOS_CPL&amp;UsrCustomerID=5e3815c904498985e796fc91436abd9a&amp;SrcAuth=atyponcel&amp;SrcApp=literatum&amp;DestLinkType=FullRecord&amp;KeyUT=000240988200044" target="_blank">Web of Science</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=Genomic+analysis+of+increased+host+immune+and+cell+death+responses+induced+by+1918+influenza+virus.&amp;publication_year=2006&amp;journal=Nature&amp;pages=578-581&amp;doi=10.1038%2Fnature05181&amp;pmid=17006449" target="_blank">Google Scholar</a></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">7.</div><div id="core-r7" class="citations"><div class="citation"><div class="citation-content">Lee DW, Santomasso BD, Locke FL, et al. ASTCT consensus grading for cytokine release syndrome and neurologic toxicity associated with immune effector cells. <em>Biol Blood Marrow Transplant</em> 2019;25:625-638.</div><div class="external-links"><div class="to-citation__wrapper"><button aria-controls="to-citation__accordion-r7-core" aria-expanded="false" aria-label="Toggle citations menu" class="to-citation__toggle"><i aria-hidden="true" class="icon-plus"></i><span data-expand-title="Hide Citations" data-collapsed-title="Show Citations" class="accordion__toggle__title"></span></button></div><div class="core-xlink-crossref"><a href="https://doi.org/10.1016/j.bbmt.2018.12.758" target="_blank">Crossref</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/30592986/" target="_blank">PubMed</a></div><div class="core-xlink-isi"><a href="https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;DestApp=WOS_CPL&amp;UsrCustomerID=5e3815c904498985e796fc91436abd9a&amp;SrcAuth=atyponcel&amp;SrcApp=literatum&amp;DestLinkType=FullRecord&amp;KeyUT=000465364900001" target="_blank">Web of Science</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=ASTCT+consensus+grading+for+cytokine+release+syndrome+and+neurologic+toxicity+associated+with+immune+effector+cells.&amp;publication_year=2019&amp;journal=Biol+Blood+Marrow+Transplant&amp;pages=625-638&amp;doi=10.1016%2Fj.bbmt.2018.12.758&amp;pmid=30592986" target="_blank">Google Scholar</a></div><div role="menu" aria-label="links" class="to-citation__accordion no-separator" id="to-citation__accordion-r7-core" style="display: none;"><ul role="none"><li role="none"><a class="to-citation" href="#body-ref-r7-1" role="menuitem"><i aria-hidden="true" class="icon-return"></i><span>a [...] iatrogenic causes of cytokine storm alone. </span></a></li><li role="none"><a class="to-citation" href="#body-ref-r7-2" role="menuitem"><i aria-hidden="true" class="icon-return"></i><span>b [...] on the cause and treatments administered. </span></a></li><li role="none"><a class="to-citation" href="#body-ref-r7-3" role="menuitem"><i aria-hidden="true" class="icon-return"></i><span>c [...] release syndrome–associated encephalopathy. </span></a></li><li role="none"><a class="to-citation" href="#body-ref-r7-4" role="menuitem"><i aria-hidden="true" class="icon-return"></i><span>d [...] scale used to assess the current severity. </span></a></li></ul></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">8.</div><div id="core-r8" class="citations"><div class="citation"><div class="citation-content">Grupp SA, Kalos M, Barrett D, et al. Chimeric antigen receptor-modified T cells for acute lymphoid leukemia. <em>N Engl J Med</em> 2013;368:1509-1518.</div><div class="external-links"><div class="to-citation__wrapper"><button aria-controls="to-citation__accordion-r8-core" aria-expanded="false" aria-label="Toggle citations menu" class="to-citation__toggle"><i aria-hidden="true" class="icon-plus"></i><span data-expand-title="Hide Citations" data-collapsed-title="Show Citations" class="accordion__toggle__title"></span></button></div><div class="core-xlink-crossref"><a href="/servlet/linkout?suffix=e_1_3_4_9_2&amp;dbid=4&amp;doi=10.1056%2FNEJMra2026131&amp;key=10.1056%2FNEJMoa1215134&amp;site=mms-site" target="_blank">Crossref</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/23527958/" target="_blank">PubMed</a></div><div class="core-xlink-isi"><a href="https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;DestApp=WOS_CPL&amp;UsrCustomerID=5e3815c904498985e796fc91436abd9a&amp;SrcAuth=atyponcel&amp;SrcApp=literatum&amp;DestLinkType=FullRecord&amp;KeyUT=000317603300008" target="_blank">Web of Science</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=Chimeric+antigen+receptor-modified+T+cells+for+acute+lymphoid+leukemia.&amp;publication_year=2013&amp;journal=N+Engl+J+Med&amp;pages=1509-1518&amp;doi=10.1056%2FNEJMoa1215134&amp;pmid=23527958" target="_blank">Google Scholar</a></div><div role="menu" aria-label="links" class="to-citation__accordion no-separator" id="to-citation__accordion-r8-core" style="display: none;"><ul role="none"><li role="none"><a class="to-citation" href="#body-ref-r8-1" role="menuitem"><i aria-hidden="true" class="icon-return"></i><span>a [...] fever may be high grade in severe cases. </span></a></li><li role="none"><a class="to-citation" href="#body-ref-r8-2" role="menuitem"><i aria-hidden="true" class="icon-return"></i><span>b [...] and several other cytokine storm disorders. </span></a></li></ul></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">9.</div><div id="core-r9" class="citations"><div class="citation"><div class="citation-content">Templin C, Ghadri JR, Diekmann J, et al. Clinical features and outcomes of takotsubo (stress) cardiomyopathy. <em>N Engl J Med</em> 2015;373:929-938.</div><div class="external-links"><div class="to-citation__wrapper"><a class="to-citation" href="#body-ref-r9"><i aria-hidden="true" class="icon-return"></i><span>Go to Citation</span></a></div><div class="core-xlink-crossref"><a href="/servlet/linkout?suffix=e_1_3_4_10_2&amp;dbid=4&amp;doi=10.1056%2FNEJMra2026131&amp;key=10.1056%2FNEJMoa1406761&amp;site=mms-site" target="_blank">Crossref</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/26332547/" target="_blank">PubMed</a></div><div class="core-xlink-isi"><a href="https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;DestApp=WOS_CPL&amp;UsrCustomerID=5e3815c904498985e796fc91436abd9a&amp;SrcAuth=atyponcel&amp;SrcApp=literatum&amp;DestLinkType=FullRecord&amp;KeyUT=000360439500008" target="_blank">Web of Science</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=Clinical+features+and+outcomes+of+takotsubo+%28stress%29+cardiomyopathy.&amp;publication_year=2015&amp;journal=N+Engl+J+Med&amp;pages=929-938&amp;doi=10.1056%2FNEJMoa1406761&amp;pmid=26332547" target="_blank">Google Scholar</a></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">10.</div><div id="core-r10" class="citations"><div class="citation"><div class="citation-content">Schwartzentruber DJ. Guidelines for the safe administration of high-dose interleukin-2. <em>J Immunother</em> 2001;24:287-293.</div><div class="external-links"><div class="to-citation__wrapper"><a class="to-citation" href="#body-ref-r10"><i aria-hidden="true" class="icon-return"></i><span>Go to Citation</span></a></div><div class="core-xlink-crossref"><a href="https://doi.org/10.1097/00002371-200107000-00004" target="_blank">Crossref</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/11565830/" target="_blank">PubMed</a></div><div class="core-xlink-isi"><a href="https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;DestApp=WOS_CPL&amp;UsrCustomerID=5e3815c904498985e796fc91436abd9a&amp;SrcAuth=atyponcel&amp;SrcApp=literatum&amp;DestLinkType=FullRecord&amp;KeyUT=000170839700004" target="_blank">Web of Science</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=Guidelines+for+the+safe+administration+of+high-dose+interleukin-2.&amp;publication_year=2001&amp;journal=J+Immunother&amp;pages=287-293&amp;doi=10.1097%2F00002371-200107000-00004&amp;pmid=11565830" target="_blank">Google Scholar</a></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">11.</div><div id="core-r11" class="citations"><div class="citation"><div class="citation-content">Lee DW, Gardner R, Porter DL, et al. Current concepts in the diagnosis and management of cytokine release syndrome. <em>Blood</em> 2014;124:188-195.</div><div class="external-links"><div class="to-citation__wrapper"><a class="to-citation" href="#body-ref-r11"><i aria-hidden="true" class="icon-return"></i><span>Go to Citation</span></a></div><div class="core-xlink-crossref"><a href="https://doi.org/10.1182/blood-2014-05-552729" target="_blank">Crossref</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/24876563/" target="_blank">PubMed</a></div><div class="core-xlink-isi"><a href="https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;DestApp=WOS_CPL&amp;UsrCustomerID=5e3815c904498985e796fc91436abd9a&amp;SrcAuth=atyponcel&amp;SrcApp=literatum&amp;DestLinkType=FullRecord&amp;KeyUT=000342618600011" target="_blank">Web of Science</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=Current+concepts+in+the+diagnosis+and+management+of+cytokine+release+syndrome.&amp;publication_year=2014&amp;journal=Blood&amp;pages=188-195&amp;doi=10.1182%2Fblood-2014-05-552729&amp;pmid=24876563" target="_blank">Google Scholar</a></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">12.</div><div id="core-r12" class="citations"><div class="citation"><div class="citation-content">Diorio C, Shaw PA, Pequignot E, et al. Diagnostic biomarkers to differentiate sepsis from cytokine release syndrome in critically ill children. <em>Blood Adv</em> 2020;4:5174-5183.</div><div class="external-links"><div class="to-citation__wrapper"><a class="to-citation" href="#body-ref-r12"><i aria-hidden="true" class="icon-return"></i><span>Go to Citation</span></a></div><div class="core-xlink-crossref"><a href="https://doi.org/10.1182/bloodadvances.2020002592" target="_blank">Crossref</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/33095872/" target="_blank">PubMed</a></div><div class="core-xlink-isi"><a href="https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;DestApp=WOS_CPL&amp;UsrCustomerID=5e3815c904498985e796fc91436abd9a&amp;SrcAuth=atyponcel&amp;SrcApp=literatum&amp;DestLinkType=FullRecord&amp;KeyUT=000582796200020" target="_blank">Web of Science</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=Diagnostic+biomarkers+to+differentiate+sepsis+from+cytokine+release+syndrome+in+critically+ill+children.&amp;publication_year=2020&amp;journal=Blood+Adv&amp;pages=5174-5183&amp;doi=10.1182%2Fbloodadvances.2020002592&amp;pmid=33095872" target="_blank">Google Scholar</a></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">13.</div><div id="core-r13" class="citations"><div class="citation"><div class="citation-content">Teachey DT, Lacey SF, Shaw PA, et al. Identification of predictive biomarkers for cytokine release syndrome after chimeric antigen receptor T-cell therapy for acute lymphoblastic leukemia. <em>Cancer Discov</em> 2016;6:664-679.</div><div class="external-links"><div class="to-citation__wrapper"><a class="to-citation" href="#body-ref-r13"><i aria-hidden="true" class="icon-return"></i><span>Go to Citation</span></a></div><div class="core-xlink-crossref"><a href="https://doi.org/10.1158/2159-8290.CD-16-0040" target="_blank">Crossref</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/27076371/" target="_blank">PubMed</a></div><div class="core-xlink-isi"><a href="https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;DestApp=WOS_CPL&amp;UsrCustomerID=5e3815c904498985e796fc91436abd9a&amp;SrcAuth=atyponcel&amp;SrcApp=literatum&amp;DestLinkType=FullRecord&amp;KeyUT=000377426800018" target="_blank">Web of Science</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=Identification+of+predictive+biomarkers+for+cytokine+release+syndrome+after+chimeric+antigen+receptor+T-cell+therapy+for+acute+lymphoblastic+leukemia.&amp;publication_year=2016&amp;journal=Cancer+Discov&amp;pages=664-679&amp;doi=10.1158%2F2159-8290.CD-16-0040&amp;pmid=27076371" target="_blank">Google Scholar</a></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">14.</div><div id="core-r14" class="citations"><div class="citation"><div class="citation-content">Sinha P, Matthay MA, Calfee CS. Is a “cytokine storm” relevant to COVID-19? <em>JAMA Intern Med</em> 2020;180:1152-1154.</div><div class="external-links"><div class="to-citation__wrapper"><button aria-controls="to-citation__accordion-r14-core" aria-expanded="false" aria-label="Toggle citations menu" class="to-citation__toggle"><i aria-hidden="true" class="icon-plus"></i><span data-expand-title="Hide Citations" data-collapsed-title="Show Citations" class="accordion__toggle__title"></span></button></div><div class="core-xlink-crossref"><a href="https://doi.org/10.1001/jamainternmed.2020.3313" target="_blank">Crossref</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/32602883/" target="_blank">PubMed</a></div><div class="core-xlink-isi"><a href="https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;DestApp=WOS_CPL&amp;UsrCustomerID=5e3815c904498985e796fc91436abd9a&amp;SrcAuth=atyponcel&amp;SrcApp=literatum&amp;DestLinkType=FullRecord&amp;KeyUT=000571868600004" target="_blank">Web of Science</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=Is+a+%E2%80%9Ccytokine+storm%E2%80%9D+relevant+to+COVID-19%3F&amp;publication_year=2020&amp;journal=JAMA+Intern+Med&amp;pages=1152-1154&amp;doi=10.1001%2Fjamainternmed.2020.3313&amp;pmid=32602883" target="_blank">Google Scholar</a></div><div role="menu" aria-label="links" class="to-citation__accordion no-separator" id="to-citation__accordion-r14-core" style="display: none;"><ul role="none"><li role="none"><a class="to-citation" href="#body-ref-r14-1" role="menuitem"><i aria-hidden="true" class="icon-return"></i><span>a [...] of a unifying definition for cytokine storm </span></a></li><li role="none"><a class="to-citation" href="#body-ref-r14-2" role="menuitem"><i aria-hidden="true" class="icon-return"></i><span>b [...] in Covid-19 are still under investigation, </span></a></li></ul></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">15.</div><div id="core-r15" class="citations"><div class="citation"><div class="citation-content">Hashimoto D, Chow A, Noizat C, et al. Tissue-resident macrophages self-maintain locally throughout adult life with minimal contribution from circulating monocytes. <em>Immunity</em> 2013;38:792-804.</div><div class="external-links"><div class="to-citation__wrapper"><a class="to-citation" href="#body-ref-r15"><i aria-hidden="true" class="icon-return"></i><span>Go to Citation</span></a></div><div class="core-xlink-crossref"><a href="https://doi.org/10.1016/j.immuni.2013.04.004" target="_blank">Crossref</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/23601688/" target="_blank">PubMed</a></div><div class="core-xlink-isi"><a href="https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;DestApp=WOS_CPL&amp;UsrCustomerID=5e3815c904498985e796fc91436abd9a&amp;SrcAuth=atyponcel&amp;SrcApp=literatum&amp;DestLinkType=FullRecord&amp;KeyUT=000330942100020" target="_blank">Web of Science</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=Tissue-resident+macrophages+self-maintain+locally+throughout+adult+life+with+minimal+contribution+from+circulating+monocytes.&amp;publication_year=2013&amp;journal=Immunity&amp;pages=792-804&amp;doi=10.1016%2Fj.immuni.2013.04.004&amp;pmid=23601688" target="_blank">Google Scholar</a></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">16.</div><div id="core-r16" class="citations"><div class="citation"><div class="citation-content">Zoller EE, Lykens JE, Terrell CE, et al. Hemophagocytosis causes a consumptive anemia of inflammation. <em>J Exp Med</em> 2011;208:1203-1214.</div><div class="external-links"><div class="to-citation__wrapper"><a class="to-citation" href="#body-ref-r16"><i aria-hidden="true" class="icon-return"></i><span>Go to Citation</span></a></div><div class="core-xlink-crossref"><a href="https://doi.org/10.1084/jem.20102538" target="_blank">Crossref</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/21624938/" target="_blank">PubMed</a></div><div class="core-xlink-isi"><a href="https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;DestApp=WOS_CPL&amp;UsrCustomerID=5e3815c904498985e796fc91436abd9a&amp;SrcAuth=atyponcel&amp;SrcApp=literatum&amp;DestLinkType=FullRecord&amp;KeyUT=000291424200008" target="_blank">Web of Science</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=Hemophagocytosis+causes+a+consumptive+anemia+of+inflammation.&amp;publication_year=2011&amp;journal=J+Exp+Med&amp;pages=1203-1214&amp;doi=10.1084%2Fjem.20102538&amp;pmid=21624938" target="_blank">Google Scholar</a></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">17.</div><div id="core-r17" class="citations"><div class="citation"><div class="citation-content">Perez N, Virelizier J-L, Arenzana-Seisdedos F, Fischer A, Griscelli C. Impaired natural killer activity in lymphohistiocytosis syndrome. <em>J Pediatr</em> 1984;104:569-573.</div><div class="external-links"><div class="to-citation__wrapper"><a class="to-citation" href="#body-ref-r17"><i aria-hidden="true" class="icon-return"></i><span>Go to Citation</span></a></div><div class="core-xlink-crossref"><a href="https://doi.org/10.1016/S0022-3476(84)80549-1" target="_blank">Crossref</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/6368780/" target="_blank">PubMed</a></div><div class="core-xlink-isi"><a href="https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;DestApp=WOS_CPL&amp;UsrCustomerID=5e3815c904498985e796fc91436abd9a&amp;SrcAuth=atyponcel&amp;SrcApp=literatum&amp;DestLinkType=FullRecord&amp;KeyUT=A1984SM07900015" target="_blank">Web of Science</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=Impaired+natural+killer+activity+in+lymphohistiocytosis+syndrome.&amp;publication_year=1984&amp;journal=J+Pediatr&amp;pages=569-573&amp;doi=10.1016%2FS0022-3476%2884%2980549-1&amp;pmid=6368780" target="_blank">Google Scholar</a></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">18.</div><div id="core-r18" class="citations"><div class="citation"><div class="citation-content">Sallusto F. Heterogeneity of human CD4+ T cells against microbes. <em>Annu Rev Immunol</em> 2016;34:317-334.</div><div class="external-links"><div class="to-citation__wrapper"><a class="to-citation" href="#body-ref-r18"><i aria-hidden="true" class="icon-return"></i><span>Go to Citation</span></a></div><div class="core-xlink-crossref"><a href="https://doi.org/10.1146/annurev-immunol-032414-112056" target="_blank">Crossref</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/27168241/" target="_blank">PubMed</a></div><div class="core-xlink-isi"><a href="https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;DestApp=WOS_CPL&amp;UsrCustomerID=5e3815c904498985e796fc91436abd9a&amp;SrcAuth=atyponcel&amp;SrcApp=literatum&amp;DestLinkType=FullRecord&amp;KeyUT=000376011300012" target="_blank">Web of Science</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=Heterogeneity+of+human+CD4%2B+T+cells+against+microbes.&amp;publication_year=2016&amp;journal=Annu+Rev+Immunol&amp;pages=317-334&amp;doi=10.1146%2Fannurev-immunol-032414-112056&amp;pmid=27168241" target="_blank">Google Scholar</a></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">19.</div><div id="core-r19" class="citations"><div class="citation"><div class="citation-content">Mosmann TR, Coffman RL. TH1 and TH2 cells: different patterns of lymphokine secretion lead to different functional properties. <em>Annu Rev Immunol</em> 1989;7:145-173.</div><div class="external-links"><div class="to-citation__wrapper"><a class="to-citation" href="#body-ref-r19"><i aria-hidden="true" class="icon-return"></i><span>Go to Citation</span></a></div><div class="core-xlink-crossref"><a href="https://doi.org/10.1146/annurev.iy.07.040189.001045" target="_blank">Crossref</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/2523712/" target="_blank">PubMed</a></div><div class="core-xlink-isi"><a href="https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;DestApp=WOS_CPL&amp;UsrCustomerID=5e3815c904498985e796fc91436abd9a&amp;SrcAuth=atyponcel&amp;SrcApp=literatum&amp;DestLinkType=FullRecord&amp;KeyUT=A1989U071000007" target="_blank">Web of Science</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=TH1+and+TH2+cells%3A+different+patterns+of+lymphokine+secretion+lead+to+different+functional+properties.&amp;publication_year=1989&amp;journal=Annu+Rev+Immunol&amp;pages=145-173&amp;doi=10.1146%2Fannurev.iy.07.040189.001045&amp;pmid=2523712" target="_blank">Google Scholar</a></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">20.</div><div id="core-r20" class="citations"><div class="citation"><div class="citation-content">Crayne CB, Albeituni S, Nichols KE, Cron RQ. The immunology of macrophage activation syndrome. <em>Front Immunol</em> 2019;10:119-119.</div><div class="external-links"><div class="to-citation__wrapper"><a class="to-citation" href="#body-ref-r20"><i aria-hidden="true" class="icon-return"></i><span>Go to Citation</span></a></div><div class="core-xlink-crossref"><a href="https://doi.org/10.3389/fimmu.2019.00119" target="_blank">Crossref</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/30774631/" target="_blank">PubMed</a></div><div class="core-xlink-isi"><a href="https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;DestApp=WOS_CPL&amp;UsrCustomerID=5e3815c904498985e796fc91436abd9a&amp;SrcAuth=atyponcel&amp;SrcApp=literatum&amp;DestLinkType=FullRecord&amp;KeyUT=000457363400001" target="_blank">Web of Science</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=The+immunology+of+macrophage+activation+syndrome.&amp;publication_year=2019&amp;journal=Front+Immunol&amp;pages=119-119&amp;doi=10.3389%2Ffimmu.2019.00119&amp;pmid=30774631" target="_blank">Google Scholar</a></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">21.</div><div id="core-r21" class="citations"><div class="citation"><div class="citation-content">Jordan MB, Hildeman D, Kappler J, Marrack P. An animal model of hemophagocytic lymphohistiocytosis (HLH): CD8+ T cells and interferon gamma are essential for the disorder. <em>Blood</em> 2004;104:735-743.</div><div class="external-links"><div class="to-citation__wrapper"><button aria-controls="to-citation__accordion-r21-core" aria-expanded="false" aria-label="Toggle citations menu" class="to-citation__toggle"><i aria-hidden="true" class="icon-plus"></i><span data-expand-title="Hide Citations" data-collapsed-title="Show Citations" class="accordion__toggle__title"></span></button></div><div class="core-xlink-crossref"><a href="https://doi.org/10.1182/blood-2003-10-3413" target="_blank">Crossref</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/15069016/" target="_blank">PubMed</a></div><div class="core-xlink-isi"><a href="https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;DestApp=WOS_CPL&amp;UsrCustomerID=5e3815c904498985e796fc91436abd9a&amp;SrcAuth=atyponcel&amp;SrcApp=literatum&amp;DestLinkType=FullRecord&amp;KeyUT=000222886400028" target="_blank">Web of Science</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=An+animal+model+of+hemophagocytic+lymphohistiocytosis+%28HLH%29%3A+CD8%2B+T+cells+and+interferon+gamma+are+essential+for+the+disorder.&amp;publication_year=2004&amp;journal=Blood&amp;pages=735-743&amp;doi=10.1182%2Fblood-2003-10-3413&amp;pmid=15069016" target="_blank">Google Scholar</a></div><div role="menu" aria-label="links" class="to-citation__accordion no-separator" id="to-citation__accordion-r21-core" style="display: none;"><ul role="none"><li role="none"><a class="to-citation" href="#body-ref-r23-1" role="menuitem"><i aria-hidden="true" class="icon-return"></i><span>a [...] a cascade of inflammatory tissue damage. </span></a></li><li role="none"><a class="to-citation" href="#body-ref-r67" role="menuitem"><i aria-hidden="true" class="icon-return"></i><span>b [...] loop of proinflammatory cytokines. </span></a></li></ul></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">22.</div><div id="core-r22" class="citations"><div class="citation"><div class="citation-content">Zhang K, Jordan MB, Marsh RA, et al. Hypomorphic mutations in PRF1, MUNC13-4, and STXBP2 are associated with adult-onset familial HLH. <em>Blood</em> 2011;118:5794-5798.</div><div class="external-links"><div class="to-citation__wrapper"><a class="to-citation" href="#body-ref-r23-1"><i aria-hidden="true" class="icon-return"></i><span>Go to Citation</span></a></div><div class="core-xlink-crossref"><a href="https://doi.org/10.1182/blood-2011-07-370148" target="_blank">Crossref</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/21881043/" target="_blank">PubMed</a></div><div class="core-xlink-isi"><a href="https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;DestApp=WOS_CPL&amp;UsrCustomerID=5e3815c904498985e796fc91436abd9a&amp;SrcAuth=atyponcel&amp;SrcApp=literatum&amp;DestLinkType=FullRecord&amp;KeyUT=000297576600018" target="_blank">Web of Science</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=Hypomorphic+mutations+in+PRF1%2C+MUNC13-4%2C+and+STXBP2+are+associated+with+adult-onset+familial+HLH.&amp;publication_year=2011&amp;journal=Blood&amp;pages=5794-5798&amp;doi=10.1182%2Fblood-2011-07-370148&amp;pmid=21881043" target="_blank">Google Scholar</a></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">23.</div><div id="core-r23" class="citations"><div class="citation"><div class="citation-content">Schulert GS, Cron RQ. The genetics of macrophage activation syndrome. <em>Genes Immun</em> 2020;21:169-181.</div><div class="external-links"><div class="to-citation__wrapper"><button aria-controls="to-citation__accordion-r23-core" aria-expanded="false" aria-label="Toggle citations menu" class="to-citation__toggle"><i aria-hidden="true" class="icon-plus"></i><span data-expand-title="Hide Citations" data-collapsed-title="Show Citations" class="accordion__toggle__title"></span></button></div><div class="core-xlink-crossref"><a href="https://doi.org/10.1038/s41435-020-0098-4" target="_blank">Crossref</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/32291394/" target="_blank">PubMed</a></div><div class="core-xlink-isi"><a href="https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;DestApp=WOS_CPL&amp;UsrCustomerID=5e3815c904498985e796fc91436abd9a&amp;SrcAuth=atyponcel&amp;SrcApp=literatum&amp;DestLinkType=FullRecord&amp;KeyUT=000526883300001" target="_blank">Web of Science</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=The+genetics+of+macrophage+activation+syndrome.&amp;publication_year=2020&amp;journal=Genes+Immun&amp;pages=169-181&amp;doi=10.1038%2Fs41435-020-0098-4&amp;pmid=32291394" target="_blank">Google Scholar</a></div><div role="menu" aria-label="links" class="to-citation__accordion no-separator" id="to-citation__accordion-r23-core" style="display: none;"><ul role="none"><li role="none"><a class="to-citation" href="#body-ref-r23-1" role="menuitem"><i aria-hidden="true" class="icon-return"></i><span>a [...] a cascade of inflammatory tissue damage. </span></a></li><li role="none"><a class="to-citation" href="#body-ref-r23-2" role="menuitem"><i aria-hidden="true" class="icon-return"></i><span>b [...] NLRC4. </span></a></li></ul></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">24.</div><div id="core-r24" class="citations"><div class="citation"><div class="citation-content">Korn T, Bettelli E, Oukka M, Kuchroo VK. IL-17 and Th17 cells. <em>Annu Rev Immunol</em> 2009;27:485-517.</div><div class="external-links"><div class="to-citation__wrapper"><a class="to-citation" href="#body-ref-r24"><i aria-hidden="true" class="icon-return"></i><span>Go to Citation</span></a></div><div class="core-xlink-crossref"><a href="https://doi.org/10.1146/annurev.immunol.021908.132710" target="_blank">Crossref</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/19132915/" target="_blank">PubMed</a></div><div class="core-xlink-isi"><a href="https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;DestApp=WOS_CPL&amp;UsrCustomerID=5e3815c904498985e796fc91436abd9a&amp;SrcAuth=atyponcel&amp;SrcApp=literatum&amp;DestLinkType=FullRecord&amp;KeyUT=000268071600018" target="_blank">Web of Science</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=IL-17+and+Th17+cells.&amp;publication_year=2009&amp;journal=Annu+Rev+Immunol&amp;pages=485-517&amp;doi=10.1146%2Fannurev.immunol.021908.132710&amp;pmid=19132915" target="_blank">Google Scholar</a></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">25.</div><div id="core-r25" class="citations"><div class="citation"><div class="citation-content">Avau A, Mitera T, Put S, et al. Systemic juvenile idiopathic arthritis-like syndrome in mice following stimulation of the immune system with Freund’s complete adjuvant: regulation by interferon-γ. <em>Arthritis Rheumatol</em> 2014;66:1340-1351.</div><div class="external-links"><div class="to-citation__wrapper"><a class="to-citation" href="#body-ref-r25"><i aria-hidden="true" class="icon-return"></i><span>Go to Citation</span></a></div><div class="core-xlink-crossref"><a href="https://doi.org/10.1002/art.38359" target="_blank">Crossref</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/24470407/" target="_blank">PubMed</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=Systemic+juvenile+idiopathic+arthritis-like+syndrome+in+mice+following+stimulation+of+the+immune+system+with+Freund%E2%80%99s+complete+adjuvant%3A+regulation+by+interferon-%CE%B3.&amp;publication_year=2014&amp;journal=Arthritis+Rheumatol&amp;pages=1340-1351&amp;doi=10.1002%2Fart.38359&amp;pmid=24470407" target="_blank">Google Scholar</a></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">26.</div><div id="core-r26" class="citations"><div class="citation"><div class="citation-content">Lucas C, Wong P, Klein J, et al. Longitudinal analyses reveal immunological misfiring in severe COVID-19. <em>Nature</em> 2020;584:463-469.</div><div class="external-links"><div class="to-citation__wrapper"><button aria-controls="to-citation__accordion-r26-core" aria-expanded="false" aria-label="Toggle citations menu" class="to-citation__toggle"><i aria-hidden="true" class="icon-plus"></i><span data-expand-title="Hide Citations" data-collapsed-title="Show Citations" class="accordion__toggle__title"></span></button></div><div class="core-xlink-crossref"><a href="https://doi.org/10.1038/s41586-020-2588-y" target="_blank">Crossref</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/32717743/" target="_blank">PubMed</a></div><div class="core-xlink-isi"><a href="https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;DestApp=WOS_CPL&amp;UsrCustomerID=5e3815c904498985e796fc91436abd9a&amp;SrcAuth=atyponcel&amp;SrcApp=literatum&amp;DestLinkType=FullRecord&amp;KeyUT=000559369800001" target="_blank">Web of Science</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=Longitudinal+analyses+reveal+immunological+misfiring+in+severe+COVID-19.&amp;publication_year=2020&amp;journal=Nature&amp;pages=463-469&amp;doi=10.1038%2Fs41586-020-2588-y&amp;pmid=32717743" target="_blank">Google Scholar</a></div><div role="menu" aria-label="links" class="to-citation__accordion no-separator" id="to-citation__accordion-r26-core" style="display: none;"><ul role="none"><li role="none"><a class="to-citation open-in-viewer" href="#t1" role="menuitem" data-target="#fv-body-ref-r26-1"><i aria-hidden="true" class="icon-return"></i><span>a [...] with type I interferon in Covid-19 </span></a></li><li role="none"><a class="to-citation" href="#body-ref-r26-2" role="menuitem"><i aria-hidden="true" class="icon-return"></i><span>b [...] been observed in severe cases of Covid-19, </span></a></li><li role="none"><a class="to-citation" href="#body-ref-r26-3" role="menuitem"><i aria-hidden="true" class="icon-return"></i><span>c [...] associated with the viral burden. </span></a></li><li role="none"><a class="to-citation" href="#body-ref-r26-4" role="menuitem"><i aria-hidden="true" class="icon-return"></i><span>d [...] some of the other cytokine storm disorders. </span></a></li></ul></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">27.</div><div id="core-r27" class="citations"><div class="citation"><div class="citation-content">Doherty GM, Lange JR, Langstein HN, Alexander HR, Buresh CM, Norton JA. Evidence for IFN-gamma as a mediator of the lethality of endotoxin and tumor necrosis factor-alpha. <em>J Immunol</em> 1992;149:1666-1670.</div><div class="external-links"><div class="to-citation__wrapper"><a class="to-citation" href="#body-ref-r29"><i aria-hidden="true" class="icon-return"></i><span>Go to Citation</span></a></div><div class="core-xlink-crossref"><a href="https://doi.org/10.4049/jimmunol.149.5.1666" target="_blank">Crossref</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/1506688/" target="_blank">PubMed</a></div><div class="core-xlink-isi"><a href="https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;DestApp=WOS_CPL&amp;UsrCustomerID=5e3815c904498985e796fc91436abd9a&amp;SrcAuth=atyponcel&amp;SrcApp=literatum&amp;DestLinkType=FullRecord&amp;KeyUT=A1992JJ89000027" target="_blank">Web of Science</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=Evidence+for+IFN-gamma+as+a+mediator+of+the+lethality+of+endotoxin+and+tumor+necrosis+factor-alpha.&amp;publication_year=1992&amp;journal=J+Immunol&amp;pages=1666-1670&amp;doi=10.4049%2Fjimmunol.149.5.1666&amp;pmid=1506688" target="_blank">Google Scholar</a></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">28.</div><div id="core-r28" class="citations"><div class="citation"><div class="citation-content">Cohen J. IL-12 deaths: explanation and a puzzle. <em>Science</em> 1995;270:908-908.</div><div class="external-links"><div class="to-citation__wrapper"><a class="to-citation" href="#body-ref-r29"><i aria-hidden="true" class="icon-return"></i><span>Go to Citation</span></a></div><div class="core-xlink-crossref"><a href="https://doi.org/10.1126/science.270.5238.908a" target="_blank">Crossref</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/7481785/" target="_blank">PubMed</a></div><div class="core-xlink-isi"><a href="https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;DestApp=WOS_CPL&amp;UsrCustomerID=5e3815c904498985e796fc91436abd9a&amp;SrcAuth=atyponcel&amp;SrcApp=literatum&amp;DestLinkType=FullRecord&amp;KeyUT=A1995TD87800016" target="_blank">Web of Science</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=IL-12+deaths%3A+explanation+and+a+puzzle.&amp;publication_year=1995&amp;journal=Science&amp;pages=908-908&amp;doi=10.1126%2Fscience.270.5238.908a&amp;pmid=7481785" target="_blank">Google Scholar</a></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">29.</div><div id="core-r29" class="citations"><div class="citation"><div class="citation-content">Atkins MB. Interleukin-2: clinical applications. <em>Semin Oncol</em> 2002;29:Suppl 7:12-17.</div><div class="external-links"><div class="to-citation__wrapper"><a class="to-citation" href="#body-ref-r29"><i aria-hidden="true" class="icon-return"></i><span>Go to Citation</span></a></div><div class="core-xlink-crossref"><a href="https://doi.org/10.1053/sonc.2002.33077" target="_blank">Crossref</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/12068383/" target="_blank">PubMed</a></div><div class="core-xlink-isi"><a href="https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;DestApp=WOS_CPL&amp;UsrCustomerID=5e3815c904498985e796fc91436abd9a&amp;SrcAuth=atyponcel&amp;SrcApp=literatum&amp;DestLinkType=FullRecord&amp;KeyUT=000176311500003" target="_blank">Web of Science</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=Interleukin-2%3A+clinical+applications.&amp;publication_year=2002&amp;journal=Semin+Oncol&amp;pages=12-17&amp;doi=10.1053%2Fsonc.2002.33077&amp;pmid=12068383" target="_blank">Google Scholar</a></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">30.</div><div id="core-r30" class="citations"><div class="citation"><div class="citation-content">Schulert GS, Zhang M, Fall N, et al. Whole-exome sequencing reveals mutations in genes linked to hemophagocytic lymphohistiocytosis and macrophage activation syndrome in fatal cases of H1N1 influenza. <em>J Infect Dis</em> 2016;213:1180-1188.</div><div class="external-links"><div class="to-citation__wrapper"><button aria-controls="to-citation__accordion-r30-core" aria-expanded="false" aria-label="Toggle citations menu" class="to-citation__toggle"><i aria-hidden="true" class="icon-plus"></i><span data-expand-title="Hide Citations" data-collapsed-title="Show Citations" class="accordion__toggle__title"></span></button></div><div class="core-xlink-crossref"><a href="https://doi.org/10.1093/infdis/jiv550" target="_blank">Crossref</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/26597256/" target="_blank">PubMed</a></div><div class="core-xlink-isi"><a href="https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;DestApp=WOS_CPL&amp;UsrCustomerID=5e3815c904498985e796fc91436abd9a&amp;SrcAuth=atyponcel&amp;SrcApp=literatum&amp;DestLinkType=FullRecord&amp;KeyUT=000374186300018" target="_blank">Web of Science</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=Whole-exome+sequencing+reveals+mutations+in+genes+linked+to+hemophagocytic+lymphohistiocytosis+and+macrophage+activation+syndrome+in+fatal+cases+of+H1N1+influenza.&amp;publication_year=2016&amp;journal=J+Infect+Dis&amp;pages=1180-1188&amp;doi=10.1093%2Finfdis%2Fjiv550&amp;pmid=26597256" target="_blank">Google Scholar</a></div><div role="menu" aria-label="links" class="to-citation__accordion no-separator" id="to-citation__accordion-r30-core" style="display: none;"><ul role="none"><li role="none"><a class="to-citation" href="#body-ref-r30-1" role="menuitem"><i aria-hidden="true" class="icon-return"></i><span>a [...] genetic features, and underlying disorders. </span></a></li><li role="none"><a class="to-citation" href="#body-ref-r30-2" role="menuitem"><i aria-hidden="true" class="icon-return"></i><span>b [...] with HLH-associated cytokine storm. </span></a></li></ul></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">31.</div><div id="core-r31" class="citations"><div class="citation"><div class="citation-content">Vadhan-Raj S, Nathan CF, Sherwin SA, Oettgen HF, Krown SE. Phase I trial of recombinant interferon gamma by 1-hour i.v. infusion. <em>Cancer Treat Rep</em> 1986;70:609-614.</div><div class="external-links"><div class="to-citation__wrapper"><a class="to-citation" href="#body-ref-r31"><i aria-hidden="true" class="icon-return"></i><span>Go to Citation</span></a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/3085930/" target="_blank">PubMed</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=Phase+I+trial+of+recombinant+interferon+gamma+by+1-hour+i.v.+infusion.&amp;publication_year=1986&amp;journal=Cancer+Treat+Rep&amp;pages=609-614&amp;pmid=3085930" target="_blank">Google Scholar</a></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">32.</div><div id="core-r32" class="citations"><div class="citation"><div class="citation-content">Locatelli F, Jordan MB, Allen C, et al. Emapalumab in children with primary hemophagocytic lymphohistiocytosis. <em>N Engl J Med</em> 2020;382:1811-1822.</div><div class="external-links"><div class="to-citation__wrapper"><a class="to-citation" href="#body-ref-r32"><i aria-hidden="true" class="icon-return"></i><span>Go to Citation</span></a></div><div class="core-xlink-crossref"><a href="/servlet/linkout?suffix=e_1_3_4_33_2&amp;dbid=4&amp;doi=10.1056%2FNEJMra2026131&amp;key=10.1056%2FNEJMoa1911326&amp;site=mms-site" target="_blank">Crossref</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/32374962/" target="_blank">PubMed</a></div><div class="core-xlink-isi"><a href="https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;DestApp=WOS_CPL&amp;UsrCustomerID=5e3815c904498985e796fc91436abd9a&amp;SrcAuth=atyponcel&amp;SrcApp=literatum&amp;DestLinkType=FullRecord&amp;KeyUT=000533411000012" target="_blank">Web of Science</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=Emapalumab+in+children+with+primary+hemophagocytic+lymphohistiocytosis.&amp;publication_year=2020&amp;journal=N+Engl+J+Med&amp;pages=1811-1822&amp;doi=10.1056%2FNEJMoa1911326&amp;pmid=32374962" target="_blank">Google Scholar</a></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">33.</div><div id="core-r33" class="citations"><div class="citation"><div class="citation-content">Eloseily EM, Weiser P, Crayne CB, et al. Benefit of anakinra in treating pediatric secondary hemophagocytic lymphohistiocytosis. <em>Arthritis Rheumatol</em> 2020;72:326-334.</div><div class="external-links"><div class="to-citation__wrapper"><a class="to-citation" href="#body-ref-r34"><i aria-hidden="true" class="icon-return"></i><span>Go to Citation</span></a></div><div class="core-xlink-crossref"><a href="https://doi.org/10.1002/art.41103" target="_blank">Crossref</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/31513353/" target="_blank">PubMed</a></div><div class="core-xlink-isi"><a href="https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;DestApp=WOS_CPL&amp;UsrCustomerID=5e3815c904498985e796fc91436abd9a&amp;SrcAuth=atyponcel&amp;SrcApp=literatum&amp;DestLinkType=FullRecord&amp;KeyUT=000504346400001" target="_blank">Web of Science</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=Benefit+of+anakinra+in+treating+pediatric+secondary+hemophagocytic+lymphohistiocytosis.&amp;publication_year=2020&amp;journal=Arthritis+Rheumatol&amp;pages=326-334&amp;doi=10.1002%2Fart.41103&amp;pmid=31513353" target="_blank">Google Scholar</a></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">34.</div><div id="core-r34" class="citations"><div class="citation"><div class="citation-content">Durand M, Troyanov Y, Laflamme P, Gregoire G. Macrophage activation syndrome treated with anakinra. <em>J Rheumatol</em> 2010;37:879-880.</div><div class="external-links"><div class="to-citation__wrapper"><a class="to-citation" href="#body-ref-r34"><i aria-hidden="true" class="icon-return"></i><span>Go to Citation</span></a></div><div class="core-xlink-crossref"><a href="https://doi.org/10.3899/jrheum.091046" target="_blank">Crossref</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/20360206/" target="_blank">PubMed</a></div><div class="core-xlink-isi"><a href="https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;DestApp=WOS_CPL&amp;UsrCustomerID=5e3815c904498985e796fc91436abd9a&amp;SrcAuth=atyponcel&amp;SrcApp=literatum&amp;DestLinkType=FullRecord&amp;KeyUT=000276783900032" target="_blank">Web of Science</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=Macrophage+activation+syndrome+treated+with+anakinra.&amp;publication_year=2010&amp;journal=J+Rheumatol&amp;pages=879-880&amp;doi=10.3899%2Fjrheum.091046&amp;pmid=20360206" target="_blank">Google Scholar</a></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">35.</div><div id="core-r35" class="citations"><div class="citation"><div class="citation-content">Winkler U, Jensen M, Manzke O, Schulz H, Diehl V, Engert A. Cytokine-release syndrome in patients with B-cell chronic lymphocytic leukemia and high lymphocyte counts after treatment with an anti-CD20 monoclonal antibody (rituximab, IDEC-C2B8). <em>Blood</em> 1999;94:2217-2224.</div><div class="external-links"><div class="to-citation__wrapper"><button aria-controls="to-citation__accordion-r35-core" aria-expanded="false" aria-label="Toggle citations menu" class="to-citation__toggle"><i aria-hidden="true" class="icon-plus"></i><span data-expand-title="Hide Citations" data-collapsed-title="Show Citations" class="accordion__toggle__title"></span></button></div><div class="core-xlink-crossref"><a href="https://doi.org/10.1182/blood.V94.7.2217.419k02_2217_2224" target="_blank">Crossref</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/10498591/" target="_blank">PubMed</a></div><div class="core-xlink-isi"><a href="https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;DestApp=WOS_CPL&amp;UsrCustomerID=5e3815c904498985e796fc91436abd9a&amp;SrcAuth=atyponcel&amp;SrcApp=literatum&amp;DestLinkType=FullRecord&amp;KeyUT=000082935000007" target="_blank">Web of Science</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=Cytokine-release+syndrome+in+patients+with+B-cell+chronic+lymphocytic+leukemia+and+high+lymphocyte+counts+after+treatment+with+an+anti-CD20+monoclonal+antibody+%28rituximab%2C+IDEC-C2B8%29.&amp;publication_year=1999&amp;journal=Blood&amp;pages=2217-2224&amp;doi=10.1182%2Fblood.V94.7.2217.419k02_2217_2224&amp;pmid=10498591" target="_blank">Google Scholar</a></div><div role="menu" aria-label="links" class="to-citation__accordion no-separator" id="to-citation__accordion-r35-core" style="display: none;"><ul role="none"><li role="none"><a class="to-citation" href="#body-ref-r36-1" role="menuitem"><i aria-hidden="true" class="icon-return"></i><span>a [...] underlying immunopathologic disorders </span></a></li><li role="none"><a class="to-citation" href="#body-ref-r35-2" role="menuitem"><i aria-hidden="true" class="icon-return"></i><span>b [...] causes of cytokine storm include rituximab, </span></a></li></ul></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">36.</div><div id="core-r36" class="citations"><div class="citation"><div class="citation-content">Teachey DT, Rheingold SR, Maude SL, et al. Cytokine release syndrome after blinatumomab treatment related to abnormal macrophage activation and ameliorated with cytokine-directed therapy. <em>Blood</em> 2013;121:5154-5157.</div><div class="external-links"><div class="to-citation__wrapper"><button aria-controls="to-citation__accordion-r36-core" aria-expanded="false" aria-label="Toggle citations menu" class="to-citation__toggle"><i aria-hidden="true" class="icon-plus"></i><span data-expand-title="Hide Citations" data-collapsed-title="Show Citations" class="accordion__toggle__title"></span></button></div><div class="core-xlink-crossref"><a href="https://doi.org/10.1182/blood-2013-02-485623" target="_blank">Crossref</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/23678006/" target="_blank">PubMed</a></div><div class="core-xlink-isi"><a href="https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;DestApp=WOS_CPL&amp;UsrCustomerID=5e3815c904498985e796fc91436abd9a&amp;SrcAuth=atyponcel&amp;SrcApp=literatum&amp;DestLinkType=FullRecord&amp;KeyUT=000321900700010" target="_blank">Web of Science</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=Cytokine+release+syndrome+after+blinatumomab+treatment+related+to+abnormal+macrophage+activation+and+ameliorated+with+cytokine-directed+therapy.&amp;publication_year=2013&amp;journal=Blood&amp;pages=5154-5157&amp;doi=10.1182%2Fblood-2013-02-485623&amp;pmid=23678006" target="_blank">Google Scholar</a></div><div role="menu" aria-label="links" class="to-citation__accordion no-separator" id="to-citation__accordion-r36-core" style="display: none;"><ul role="none"><li role="none"><a class="to-citation" href="#body-ref-r36-1" role="menuitem"><i aria-hidden="true" class="icon-return"></i><span>a [...] underlying immunopathologic disorders </span></a></li><li role="none"><a class="to-citation" href="#body-ref-r36-2" role="menuitem"><i aria-hidden="true" class="icon-return"></i><span>b [...] to anti–interleukin-6 antibody therapy. </span></a></li></ul></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">37.</div><div id="core-r37" class="citations"><div class="citation"><div class="citation-content">van der Stegen SJ, Davies DM, Wilkie S, et al. Preclinical in vivo modeling of cytokine release syndrome induced by ErbB-retargeted human T cells: identifying a window of therapeutic opportunity? <em>J Immunol</em> 2013;191:4589-4598.</div><div class="external-links"><div class="to-citation__wrapper"><a class="to-citation" href="#body-ref-r37"><i aria-hidden="true" class="icon-return"></i><span>Go to Citation</span></a></div><div class="core-xlink-crossref"><a href="https://doi.org/10.4049/jimmunol.1301523" target="_blank">Crossref</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/24062490/" target="_blank">PubMed</a></div><div class="core-xlink-isi"><a href="https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;DestApp=WOS_CPL&amp;UsrCustomerID=5e3815c904498985e796fc91436abd9a&amp;SrcAuth=atyponcel&amp;SrcApp=literatum&amp;DestLinkType=FullRecord&amp;KeyUT=000325929000016" target="_blank">Web of Science</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=Preclinical+in+vivo+modeling+of+cytokine+release+syndrome+induced+by+ErbB-retargeted+human+T+cells%3A+identifying+a+window+of+therapeutic+opportunity%3F&amp;publication_year=2013&amp;journal=J+Immunol&amp;pages=4589-4598&amp;doi=10.4049%2Fjimmunol.1301523&amp;pmid=24062490" target="_blank">Google Scholar</a></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">38.</div><div id="core-r38" class="citations"><div class="citation"><div class="citation-content">Kang S, Tanaka T, Narazaki M, Kishimoto T. Targeting interleukin-6 signaling in clinic. <em>Immunity</em> 2019;50:1007-1023.</div><div class="external-links"><div class="to-citation__wrapper"><button aria-controls="to-citation__accordion-r38-core" aria-expanded="false" aria-label="Toggle citations menu" class="to-citation__toggle"><i aria-hidden="true" class="icon-plus"></i><span data-expand-title="Hide Citations" data-collapsed-title="Show Citations" class="accordion__toggle__title"></span></button></div><div class="core-xlink-crossref"><a href="https://doi.org/10.1016/j.immuni.2019.03.026" target="_blank">Crossref</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/30995492/" target="_blank">PubMed</a></div><div class="core-xlink-isi"><a href="https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;DestApp=WOS_CPL&amp;UsrCustomerID=5e3815c904498985e796fc91436abd9a&amp;SrcAuth=atyponcel&amp;SrcApp=literatum&amp;DestLinkType=FullRecord&amp;KeyUT=000464660800016" target="_blank">Web of Science</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=Targeting+interleukin-6+signaling+in+clinic.&amp;publication_year=2019&amp;journal=Immunity&amp;pages=1007-1023&amp;doi=10.1016%2Fj.immuni.2019.03.026&amp;pmid=30995492" target="_blank">Google Scholar</a></div><div role="menu" aria-label="links" class="to-citation__accordion no-separator" id="to-citation__accordion-r38-core" style="display: none;"><ul role="none"><li role="none"><a class="to-citation" href="#body-ref-r38-1" role="menuitem"><i aria-hidden="true" class="icon-return"></i><span>a [...] and CAR T-cell–induced cytokine storm. </span></a></li><li role="none"><a class="to-citation" href="#body-ref-r38-2" role="menuitem"><i aria-hidden="true" class="icon-return"></i><span>b [...] classic cis signaling and trans signaling. </span></a></li><li role="none"><a class="to-citation" href="#body-ref-r38-3" role="menuitem"><i aria-hidden="true" class="icon-return"></i><span>c [...] which can contribute to cytokine storm. </span></a></li><li role="none"><a class="to-citation" href="#body-ref-r38-4" role="menuitem"><i aria-hidden="true" class="icon-return"></i><span>d [...] hypotension, and pulmonary dysfunction. </span></a></li></ul></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">39.</div><div id="core-r39" class="citations"><div class="citation"><div class="citation-content">Faulkner L, Cooper A, Fantino C, Altmann DM, Sriskandan S. The mechanism of superantigen-mediated toxic shock: not a simple Th1 cytokine storm. <em>J Immunol</em> 2005;175:6870-6877.</div><div class="external-links"><div class="to-citation__wrapper"><a class="to-citation" href="#body-ref-r39"><i aria-hidden="true" class="icon-return"></i><span>Go to Citation</span></a></div><div class="core-xlink-crossref"><a href="https://doi.org/10.4049/jimmunol.175.10.6870" target="_blank">Crossref</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/16272345/" target="_blank">PubMed</a></div><div class="core-xlink-isi"><a href="https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;DestApp=WOS_CPL&amp;UsrCustomerID=5e3815c904498985e796fc91436abd9a&amp;SrcAuth=atyponcel&amp;SrcApp=literatum&amp;DestLinkType=FullRecord&amp;KeyUT=000233126300073" target="_blank">Web of Science</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=The+mechanism+of+superantigen-mediated+toxic+shock%3A+not+a+simple+Th1+cytokine+storm.&amp;publication_year=2005&amp;journal=J+Immunol&amp;pages=6870-6877&amp;doi=10.4049%2Fjimmunol.175.10.6870&amp;pmid=16272345" target="_blank">Google Scholar</a></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">40.</div><div id="core-r40" class="citations"><div class="citation"><div class="citation-content">Garlanda C, Dinarello CA, Mantovani A. The interleukin-1 family: back to the future. <em>Immunity</em> 2013;39:1003-1018.</div><div class="external-links"><div class="to-citation__wrapper"><a class="to-citation" href="#body-ref-r40"><i aria-hidden="true" class="icon-return"></i><span>Go to Citation</span></a></div><div class="core-xlink-crossref"><a href="https://doi.org/10.1016/j.immuni.2013.11.010" target="_blank">Crossref</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/24332029/" target="_blank">PubMed</a></div><div class="core-xlink-isi"><a href="https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;DestApp=WOS_CPL&amp;UsrCustomerID=5e3815c904498985e796fc91436abd9a&amp;SrcAuth=atyponcel&amp;SrcApp=literatum&amp;DestLinkType=FullRecord&amp;KeyUT=000330951000008" target="_blank">Web of Science</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=The+interleukin-1+family%3A+back+to+the+future.&amp;publication_year=2013&amp;journal=Immunity&amp;pages=1003-1018&amp;doi=10.1016%2Fj.immuni.2013.11.010&amp;pmid=24332029" target="_blank">Google Scholar</a></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">41.</div><div id="core-r41" class="citations"><div class="citation"><div class="citation-content">Martinon F, Pétrilli V, Mayor A, Tardivel A, Tschopp J. Gout-associated uric acid crystals activate the NALP3 inflammasome. <em>Nature</em> 2006;440:237-241.</div><div class="external-links"><div class="to-citation__wrapper"><a class="to-citation" href="#body-ref-r42"><i aria-hidden="true" class="icon-return"></i><span>Go to Citation</span></a></div><div class="core-xlink-crossref"><a href="https://doi.org/10.1038/nature04516" target="_blank">Crossref</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/16407889/" target="_blank">PubMed</a></div><div class="core-xlink-isi"><a href="https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;DestApp=WOS_CPL&amp;UsrCustomerID=5e3815c904498985e796fc91436abd9a&amp;SrcAuth=atyponcel&amp;SrcApp=literatum&amp;DestLinkType=FullRecord&amp;KeyUT=000235839500052" target="_blank">Web of Science</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=Gout-associated+uric+acid+crystals+activate+the+NALP3+inflammasome.&amp;publication_year=2006&amp;journal=Nature&amp;pages=237-241&amp;doi=10.1038%2Fnature04516&amp;pmid=16407889" target="_blank">Google Scholar</a></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">42.</div><div id="core-r42" class="citations"><div class="citation"><div class="citation-content">Frank D, Vince JE. Pyroptosis versus necroptosis: similarities, differences, and crosstalk. <em>Cell Death Differ</em> 2019;26:99-114.</div><div class="external-links"><div class="to-citation__wrapper"><a class="to-citation" href="#body-ref-r42"><i aria-hidden="true" class="icon-return"></i><span>Go to Citation</span></a></div><div class="core-xlink-crossref"><a href="https://doi.org/10.1038/s41418-018-0212-6" target="_blank">Crossref</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/30341423/" target="_blank">PubMed</a></div><div class="core-xlink-isi"><a href="https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;DestApp=WOS_CPL&amp;UsrCustomerID=5e3815c904498985e796fc91436abd9a&amp;SrcAuth=atyponcel&amp;SrcApp=literatum&amp;DestLinkType=FullRecord&amp;KeyUT=000453235500009" target="_blank">Web of Science</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=Pyroptosis+versus+necroptosis%3A+similarities%2C+differences%2C+and+crosstalk.&amp;publication_year=2019&amp;journal=Cell+Death+Differ&amp;pages=99-114&amp;doi=10.1038%2Fs41418-018-0212-6&amp;pmid=30341423" target="_blank">Google Scholar</a></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">43.</div><div id="core-r43" class="citations"><div class="citation"><div class="citation-content">Netea MG, Kullberg BJ, Verschueren I, Van Der Meer JW. Interleukin-18 induces production of proinflammatory cytokines in mice: no intermediate role for the cytokines of the tumor necrosis factor family and interleukin-1beta. <em>Eur J Immunol</em> 2000;30:3057-3060.</div><div class="external-links"><div class="to-citation__wrapper"><a class="to-citation" href="#body-ref-r43"><i aria-hidden="true" class="icon-return"></i><span>Go to Citation</span></a></div><div class="core-xlink-crossref"><a href="https://doi.org/10.1002/1521-4141(200010)30:10%3C3057::AID-IMMU3057%3E3.0.CO;2-P" target="_blank">Crossref</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/11069090/" target="_blank">PubMed</a></div><div class="core-xlink-isi"><a href="https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;DestApp=WOS_CPL&amp;UsrCustomerID=5e3815c904498985e796fc91436abd9a&amp;SrcAuth=atyponcel&amp;SrcApp=literatum&amp;DestLinkType=FullRecord&amp;KeyUT=000089978200038" target="_blank">Web of Science</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=Interleukin-18+induces+production+of+proinflammatory+cytokines+in+mice%3A+no+intermediate+role+for+the+cytokines+of+the+tumor+necrosis+factor+family+and+interleukin-1beta.&amp;publication_year=2000&amp;journal=Eur+J+Immunol&amp;pages=3057-3060&amp;doi=10.1002%2F1521-4141%28200010%2930%3A10%253C3057%3A%3AAID-IMMU3057%253E3.0.CO%3B2-P&amp;pmid=11069090" target="_blank">Google Scholar</a></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">44.</div><div id="core-r44" class="citations"><div class="citation"><div class="citation-content">Mazodier K, Marin V, Novick D, et al. Severe imbalance of IL-18/IL-18BP in patients with secondary hemophagocytic syndrome. <em>Blood</em> 2005;106:3483-3489.</div><div class="external-links"><div class="to-citation__wrapper"><button aria-controls="to-citation__accordion-r44-core" aria-expanded="false" aria-label="Toggle citations menu" class="to-citation__toggle"><i aria-hidden="true" class="icon-plus"></i><span data-expand-title="Hide Citations" data-collapsed-title="Show Citations" class="accordion__toggle__title"></span></button></div><div class="core-xlink-crossref"><a href="https://doi.org/10.1182/blood-2005-05-1980" target="_blank">Crossref</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/16020503/" target="_blank">PubMed</a></div><div class="core-xlink-isi"><a href="https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;DestApp=WOS_CPL&amp;UsrCustomerID=5e3815c904498985e796fc91436abd9a&amp;SrcAuth=atyponcel&amp;SrcApp=literatum&amp;DestLinkType=FullRecord&amp;KeyUT=000233187700033" target="_blank">Web of Science</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=Severe+imbalance+of+IL-18%2FIL-18BP+in+patients+with+secondary+hemophagocytic+syndrome.&amp;publication_year=2005&amp;journal=Blood&amp;pages=3483-3489&amp;doi=10.1182%2Fblood-2005-05-1980&amp;pmid=16020503" target="_blank">Google Scholar</a></div><div role="menu" aria-label="links" class="to-citation__accordion no-separator" id="to-citation__accordion-r44-core" style="display: none;"><ul role="none"><li role="none"><a class="to-citation" href="#body-ref-r44-1" role="menuitem"><i aria-hidden="true" class="icon-return"></i><span>a [...] high levels of interleukin-18 in serum, </span></a></li><li role="none"><a class="to-citation" href="#body-ref-r47" role="menuitem"><i aria-hidden="true" class="icon-return"></i><span>b [...] of the macrophage activation syndrome. </span></a></li></ul></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">45.</div><div id="core-r45" class="citations"><div class="citation"><div class="citation-content">Shimizu M, Yokoyama T, Yamada K, et al. Distinct cytokine profiles of systemic-onset juvenile idiopathic arthritis-associated macrophage activation syndrome with particular emphasis on the role of interleukin-18 in its pathogenesis. <em>Rheumatology (Oxford)</em> 2010;49:1645-1653.</div><div class="external-links"><div class="to-citation__wrapper"><a class="to-citation" href="#body-ref-r45"><i aria-hidden="true" class="icon-return"></i><span>Go to Citation</span></a></div><div class="core-xlink-crossref"><a href="https://doi.org/10.1093/rheumatology/keq133" target="_blank">Crossref</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/20472718/" target="_blank">PubMed</a></div><div class="core-xlink-isi"><a href="https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;DestApp=WOS_CPL&amp;UsrCustomerID=5e3815c904498985e796fc91436abd9a&amp;SrcAuth=atyponcel&amp;SrcApp=literatum&amp;DestLinkType=FullRecord&amp;KeyUT=000280904400006" target="_blank">Web of Science</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=Distinct+cytokine+profiles+of+systemic-onset+juvenile+idiopathic+arthritis-associated+macrophage+activation+syndrome+with+particular+emphasis+on+the+role+of+interleukin-18+in+its+pathogenesis.&amp;publication_year=2010&amp;journal=Rheumatology+%28Oxford%29&amp;pages=1645-1653&amp;doi=10.1093%2Frheumatology%2Fkeq133&amp;pmid=20472718" target="_blank">Google Scholar</a></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">46.</div><div id="core-r46" class="citations"><div class="citation"><div class="citation-content">Dinarello CA, Novick D, Kim S, Kaplanski G. Interleukin-18 and IL-18 binding protein. <em>Front Immunol</em> 2013;4:289-289.</div><div class="external-links"><div class="to-citation__wrapper"><a class="to-citation" href="#body-ref-r46"><i aria-hidden="true" class="icon-return"></i><span>Go to Citation</span></a></div><div class="core-xlink-crossref"><a href="https://doi.org/10.3389/fimmu.2013.00289" target="_blank">Crossref</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/24115947/" target="_blank">PubMed</a></div><div class="core-xlink-isi"><a href="https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;DestApp=WOS_CPL&amp;UsrCustomerID=5e3815c904498985e796fc91436abd9a&amp;SrcAuth=atyponcel&amp;SrcApp=literatum&amp;DestLinkType=FullRecord&amp;KeyUT=000209374100284" target="_blank">Web of Science</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=Interleukin-18+and+IL-18+binding+protein.&amp;publication_year=2013&amp;journal=Front+Immunol&amp;pages=289-289&amp;doi=10.3389%2Ffimmu.2013.00289&amp;pmid=24115947" target="_blank">Google Scholar</a></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">47.</div><div id="core-r47" class="citations"><div class="citation"><div class="citation-content">Novick D, Kim S, Kaplanski G, Dinarello CA. Interleukin-18, more than a Th1 cytokine. <em>Semin Immunol</em> 2013;25:439-448.</div><div class="external-links"><div class="to-citation__wrapper"><a class="to-citation" href="#body-ref-r47"><i aria-hidden="true" class="icon-return"></i><span>Go to Citation</span></a></div><div class="core-xlink-crossref"><a href="https://doi.org/10.1016/j.smim.2013.10.014" target="_blank">Crossref</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/24275602/" target="_blank">PubMed</a></div><div class="core-xlink-isi"><a href="https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;DestApp=WOS_CPL&amp;UsrCustomerID=5e3815c904498985e796fc91436abd9a&amp;SrcAuth=atyponcel&amp;SrcApp=literatum&amp;DestLinkType=FullRecord&amp;KeyUT=000330752000007" target="_blank">Web of Science</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=Interleukin-18%2C+more+than+a+Th1+cytokine.&amp;publication_year=2013&amp;journal=Semin+Immunol&amp;pages=439-448&amp;doi=10.1016%2Fj.smim.2013.10.014&amp;pmid=24275602" target="_blank">Google Scholar</a></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">48.</div><div id="core-r48" class="citations"><div class="citation"><div class="citation-content">Behrens EM, Canna SW, Slade K, et al. Repeated TLR9 stimulation results in macrophage activation syndrome-like disease in mice. <em>J Clin Invest</em> 2011;121:2264-2277.</div><div class="external-links"><div class="to-citation__wrapper"><a class="to-citation" href="#body-ref-r48"><i aria-hidden="true" class="icon-return"></i><span>Go to Citation</span></a></div><div class="core-xlink-crossref"><a href="https://doi.org/10.1172/JCI43157" target="_blank">Crossref</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/21576823/" target="_blank">PubMed</a></div><div class="core-xlink-isi"><a href="https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;DestApp=WOS_CPL&amp;UsrCustomerID=5e3815c904498985e796fc91436abd9a&amp;SrcAuth=atyponcel&amp;SrcApp=literatum&amp;DestLinkType=FullRecord&amp;KeyUT=000291234300026" target="_blank">Web of Science</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=Repeated+TLR9+stimulation+results+in+macrophage+activation+syndrome-like+disease+in+mice.&amp;publication_year=2011&amp;journal=J+Clin+Invest&amp;pages=2264-2277&amp;doi=10.1172%2FJCI43157&amp;pmid=21576823" target="_blank">Google Scholar</a></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">49.</div><div id="core-r49" class="citations"><div class="citation"><div class="citation-content">Gorelik M, Torok KS, Kietz DA, Hirsch R. Hypocomplementemia associated with macrophage activation syndrome in systemic juvenile idiopathic arthritis and adult onset Still’s disease: 3 cases. <em>J Rheumatol</em> 2011;38:396-397.</div><div class="external-links"><div class="to-citation__wrapper"><a class="to-citation" href="#body-ref-r49"><i aria-hidden="true" class="icon-return"></i><span>Go to Citation</span></a></div><div class="core-xlink-crossref"><a href="https://doi.org/10.3899/jrheum.100833" target="_blank">Crossref</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/21285182/" target="_blank">PubMed</a></div><div class="core-xlink-isi"><a href="https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;DestApp=WOS_CPL&amp;UsrCustomerID=5e3815c904498985e796fc91436abd9a&amp;SrcAuth=atyponcel&amp;SrcApp=literatum&amp;DestLinkType=FullRecord&amp;KeyUT=000287173000036" target="_blank">Web of Science</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=Hypocomplementemia+associated+with+macrophage+activation+syndrome+in+systemic+juvenile+idiopathic+arthritis+and+adult+onset+Still%E2%80%99s+disease%3A+3+cases.&amp;publication_year=2011&amp;journal=J+Rheumatol&amp;pages=396-397&amp;doi=10.3899%2Fjrheum.100833&amp;pmid=21285182" target="_blank">Google Scholar</a></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">50.</div><div id="core-r50" class="citations"><div class="citation"><div class="citation-content">Porter DL, Hwang WT, Frey NV, et al. Chimeric antigen receptor T cells persist and induce sustained remissions in relapsed refractory chronic lymphocytic leukemia. <em>Sci Transl Med</em> 2015;7:303ra139-303ra139.</div><div class="external-links"><div class="to-citation__wrapper"><a class="to-citation" href="#body-ref-r50"><i aria-hidden="true" class="icon-return"></i><span>Go to Citation</span></a></div><div class="core-xlink-crossref"><a href="https://doi.org/10.1126/scitranslmed.aac5415" target="_blank">Crossref</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/26333935/" target="_blank">PubMed</a></div><div class="core-xlink-isi"><a href="https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;DestApp=WOS_CPL&amp;UsrCustomerID=5e3815c904498985e796fc91436abd9a&amp;SrcAuth=atyponcel&amp;SrcApp=literatum&amp;DestLinkType=FullRecord&amp;KeyUT=000360943200004" target="_blank">Web of Science</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=Chimeric+antigen+receptor+T+cells+persist+and+induce+sustained+remissions+in+relapsed+refractory+chronic+lymphocytic+leukemia.&amp;publication_year=2015&amp;journal=Sci+Transl+Med&amp;pages=303ra139-303ra139&amp;doi=10.1126%2Fscitranslmed.aac5415&amp;pmid=26333935" target="_blank">Google Scholar</a></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">51.</div><div id="core-r51" class="citations"><div class="citation"><div class="citation-content">Xu XJ, Tang YM. Cytokine release syndrome in cancer immunotherapy with chimeric antigen receptor engineered T cells. <em>Cancer Lett</em> 2014;343:172-178.</div><div class="external-links"><div class="to-citation__wrapper"><button aria-controls="to-citation__accordion-r51-core" aria-expanded="false" aria-label="Toggle citations menu" class="to-citation__toggle"><i aria-hidden="true" class="icon-plus"></i><span data-expand-title="Hide Citations" data-collapsed-title="Show Citations" class="accordion__toggle__title"></span></button></div><div class="core-xlink-crossref"><a href="https://doi.org/10.1016/j.canlet.2013.10.004" target="_blank">Crossref</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/24141191/" target="_blank">PubMed</a></div><div class="core-xlink-isi"><a href="https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;DestApp=WOS_CPL&amp;UsrCustomerID=5e3815c904498985e796fc91436abd9a&amp;SrcAuth=atyponcel&amp;SrcApp=literatum&amp;DestLinkType=FullRecord&amp;KeyUT=000331589600004" target="_blank">Web of Science</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=Cytokine+release+syndrome+in+cancer+immunotherapy+with+chimeric+antigen+receptor+engineered+T+cells.&amp;publication_year=2014&amp;journal=Cancer+Lett&amp;pages=172-178&amp;doi=10.1016%2Fj.canlet.2013.10.004&amp;pmid=24141191" target="_blank">Google Scholar</a></div><div role="menu" aria-label="links" class="to-citation__accordion no-separator" id="to-citation__accordion-r51-core" style="display: none;"><ul role="none"><li role="none"><a class="to-citation" href="#body-ref-r51-1" role="menuitem"><i aria-hidden="true" class="icon-return"></i><span>a [...] and inflammatory cytokine release, </span></a></li><li role="none"><a class="to-citation" href="#body-ref-r51-2" role="menuitem"><i aria-hidden="true" class="icon-return"></i><span>b [...] factors, such as CAR structure and design, </span></a></li></ul></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">52.</div><div id="core-r52" class="citations"><div class="citation"><div class="citation-content">Singh N, Hofmann TJ, Gershenson Z, et al. Monocyte lineage-derived IL-6 does not affect chimeric antigen receptor T-cell function. <em>Cytotherapy</em> 2017;19:867-880.</div><div class="external-links"><div class="to-citation__wrapper"><a class="to-citation" href="#body-ref-r54"><i aria-hidden="true" class="icon-return"></i><span>Go to Citation</span></a></div><div class="core-xlink-crossref"><a href="https://doi.org/10.1016/j.jcyt.2017.04.001" target="_blank">Crossref</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/28506444/" target="_blank">PubMed</a></div><div class="core-xlink-isi"><a href="https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;DestApp=WOS_CPL&amp;UsrCustomerID=5e3815c904498985e796fc91436abd9a&amp;SrcAuth=atyponcel&amp;SrcApp=literatum&amp;DestLinkType=FullRecord&amp;KeyUT=000403976600010" target="_blank">Web of Science</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=Monocyte+lineage-derived+IL-6+does+not+affect+chimeric+antigen+receptor+T-cell+function.&amp;publication_year=2017&amp;journal=Cytotherapy&amp;pages=867-880&amp;doi=10.1016%2Fj.jcyt.2017.04.001&amp;pmid=28506444" target="_blank">Google Scholar</a></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">53.</div><div id="core-r53" class="citations"><div class="citation"><div class="citation-content">Giavridis T, van der Stegen SJC, Eyquem J, Hamieh M, Piersigilli A, Sadelain M. CAR T cell-induced cytokine release syndrome is mediated by macrophages and abated by IL-1 blockade. <em>Nat Med</em> 2018;24:731-738.</div><div class="external-links"><div class="to-citation__wrapper"><a class="to-citation" href="#body-ref-r54"><i aria-hidden="true" class="icon-return"></i><span>Go to Citation</span></a></div><div class="core-xlink-crossref"><a href="https://doi.org/10.1038/s41591-018-0041-7" target="_blank">Crossref</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/29808005/" target="_blank">PubMed</a></div><div class="core-xlink-isi"><a href="https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;DestApp=WOS_CPL&amp;UsrCustomerID=5e3815c904498985e796fc91436abd9a&amp;SrcAuth=atyponcel&amp;SrcApp=literatum&amp;DestLinkType=FullRecord&amp;KeyUT=000434281300018" target="_blank">Web of Science</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=CAR+T+cell-induced+cytokine+release+syndrome+is+mediated+by+macrophages+and+abated+by+IL-1+blockade.&amp;publication_year=2018&amp;journal=Nat+Med&amp;pages=731-738&amp;doi=10.1038%2Fs41591-018-0041-7&amp;pmid=29808005" target="_blank">Google Scholar</a></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">54.</div><div id="core-r54" class="citations"><div class="citation"><div class="citation-content">Norelli M, Camisa B, Barbiera G, et al. Monocyte-derived IL-1 and IL-6 are differentially required for cytokine-release syndrome and neurotoxicity due to CAR T cells. <em>Nat Med</em> 2018;24:739-748.</div><div class="external-links"><div class="to-citation__wrapper"><a class="to-citation" href="#body-ref-r54"><i aria-hidden="true" class="icon-return"></i><span>Go to Citation</span></a></div><div class="core-xlink-crossref"><a href="https://doi.org/10.1038/s41591-018-0036-4" target="_blank">Crossref</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/29808007/" target="_blank">PubMed</a></div><div class="core-xlink-isi"><a href="https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;DestApp=WOS_CPL&amp;UsrCustomerID=5e3815c904498985e796fc91436abd9a&amp;SrcAuth=atyponcel&amp;SrcApp=literatum&amp;DestLinkType=FullRecord&amp;KeyUT=000434281300019" target="_blank">Web of Science</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=Monocyte-derived+IL-1+and+IL-6+are+differentially+required+for+cytokine-release+syndrome+and+neurotoxicity+due+to+CAR+T+cells.&amp;publication_year=2018&amp;journal=Nat+Med&amp;pages=739-748&amp;doi=10.1038%2Fs41591-018-0036-4&amp;pmid=29808007" target="_blank">Google Scholar</a></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">55.</div><div id="core-r55" class="citations"><div class="citation"><div class="citation-content">Liu Y, Fang Y, Chen X, et al. Gasdermin E-mediated target cell pyroptosis by CAR T cells triggers cytokine release syndrome. <em>Sci Immunol</em> 2020;5(43):eaax7969-eaax7969.</div><div class="external-links"><div class="to-citation__wrapper"><a class="to-citation" href="#body-ref-r55"><i aria-hidden="true" class="icon-return"></i><span>Go to Citation</span></a></div><div class="core-xlink-crossref"><a href="https://doi.org/10.1126/sciimmunol.aax7969" target="_blank">Crossref</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/31953257/" target="_blank">PubMed</a></div><div class="core-xlink-isi"><a href="https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;DestApp=WOS_CPL&amp;UsrCustomerID=5e3815c904498985e796fc91436abd9a&amp;SrcAuth=atyponcel&amp;SrcApp=literatum&amp;DestLinkType=FullRecord&amp;KeyUT=000512348000007" target="_blank">Web of Science</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=Gasdermin+E-mediated+target+cell+pyroptosis+by+CAR+T+cells+triggers+cytokine+release+syndrome.&amp;publication_year=2020&amp;journal=Sci+Immunol&amp;pages=eaax7969-eaax7969&amp;doi=10.1126%2Fsciimmunol.aax7969&amp;pmid=31953257" target="_blank">Google Scholar</a></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">56.</div><div id="core-r56" class="citations"><div class="citation"><div class="citation-content">Topp MS, Gökbuget N, Stein AS, et al. Safety and activity of blinatumomab for adult patients with relapsed or refractory B-precursor acute lymphoblastic leukaemia: a multicentre, single-arm, phase 2 study. <em>Lancet Oncol</em> 2015;16:57-66.</div><div class="external-links"><div class="to-citation__wrapper"><a class="to-citation" href="#body-ref-r56"><i aria-hidden="true" class="icon-return"></i><span>Go to Citation</span></a></div><div class="core-xlink-crossref"><a href="https://doi.org/10.1016/S1470-2045(14)71170-2" target="_blank">Crossref</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/25524800/" target="_blank">PubMed</a></div><div class="core-xlink-isi"><a href="https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;DestApp=WOS_CPL&amp;UsrCustomerID=5e3815c904498985e796fc91436abd9a&amp;SrcAuth=atyponcel&amp;SrcApp=literatum&amp;DestLinkType=FullRecord&amp;KeyUT=000346912800045" target="_blank">Web of Science</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=Safety+and+activity+of+blinatumomab+for+adult+patients+with+relapsed+or+refractory+B-precursor+acute+lymphoblastic+leukaemia%3A+a+multicentre%2C+single-arm%2C+phase+2+study.&amp;publication_year=2015&amp;journal=Lancet+Oncol&amp;pages=57-66&amp;doi=10.1016%2FS1470-2045%2814%2971170-2&amp;pmid=25524800" target="_blank">Google Scholar</a></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">57.</div><div id="core-r57" class="citations"><div class="citation"><div class="citation-content">Suntharalingam G, Perry MR, Ward S, et al. Cytokine storm in a phase 1 trial of the anti-CD28 monoclonal antibody TGN1412. <em>N Engl J Med</em> 2006;355:1018-1028.</div><div class="external-links"><div class="to-citation__wrapper"><a class="to-citation" href="#body-ref-r57"><i aria-hidden="true" class="icon-return"></i><span>Go to Citation</span></a></div><div class="core-xlink-crossref"><a href="/servlet/linkout?suffix=e_1_3_4_58_2&amp;dbid=4&amp;doi=10.1056%2FNEJMra2026131&amp;key=10.1056%2FNEJMoa063842&amp;site=mms-site" target="_blank">Crossref</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/16908486/" target="_blank">PubMed</a></div><div class="core-xlink-isi"><a href="https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;DestApp=WOS_CPL&amp;UsrCustomerID=5e3815c904498985e796fc91436abd9a&amp;SrcAuth=atyponcel&amp;SrcApp=literatum&amp;DestLinkType=FullRecord&amp;KeyUT=000240273300007" target="_blank">Web of Science</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=Cytokine+storm+in+a+phase+1+trial+of+the+anti-CD28+monoclonal+antibody+TGN1412.&amp;publication_year=2006&amp;journal=N+Engl+J+Med&amp;pages=1018-1028&amp;doi=10.1056%2FNEJMoa063842&amp;pmid=16908486" target="_blank">Google Scholar</a></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">58.</div><div id="core-r58" class="citations"><div class="citation"><div class="citation-content">Frey NV, Porter DL. Cytokine release syndrome with novel therapeutics for acute lymphoblastic leukemia. <em>Hematology Am Soc Hematol Educ Program</em> 2016;2016:567-572.</div><div class="external-links"><div class="to-citation__wrapper"><a class="to-citation" href="#body-ref-r58"><i aria-hidden="true" class="icon-return"></i><span>Go to Citation</span></a></div><div class="core-xlink-crossref"><a href="https://doi.org/10.1182/asheducation-2016.1.567" target="_blank">Crossref</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/27913530/" target="_blank">PubMed</a></div><div class="core-xlink-isi"><a href="https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;DestApp=WOS_CPL&amp;UsrCustomerID=5e3815c904498985e796fc91436abd9a&amp;SrcAuth=atyponcel&amp;SrcApp=literatum&amp;DestLinkType=FullRecord&amp;KeyUT=000418326700076" target="_blank">Web of Science</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=Cytokine+release+syndrome+with+novel+therapeutics+for+acute+lymphoblastic+leukemia.&amp;publication_year=2016&amp;journal=Hematology+Am+Soc+Hematol+Educ+Program&amp;pages=567-572&amp;doi=10.1182%2Fasheducation-2016.1.567&amp;pmid=27913530" target="_blank">Google Scholar</a></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">59.</div><div id="core-r59" class="citations"><div class="citation"><div class="citation-content">Dahmer MK, Randolph A, Vitali S, Quasney MW. Genetic polymorphisms in sepsis. <em>Pediatr Crit Care Med</em> 2005;6:Suppl:S61-S73.</div><div class="external-links"><div class="to-citation__wrapper"><a class="to-citation" href="#body-ref-r59"><i aria-hidden="true" class="icon-return"></i><span>Go to Citation</span></a></div><div class="core-xlink-crossref"><a href="https://doi.org/10.1097/01.PCC.0000161970.44470.C7" target="_blank">Crossref</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/15857562/" target="_blank">PubMed</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=Genetic+polymorphisms+in+sepsis.&amp;publication_year=2005&amp;journal=Pediatr+Crit+Care+Med&amp;pages=S61-S73&amp;doi=10.1097%2F01.PCC.0000161970.44470.C7&amp;pmid=15857562" target="_blank">Google Scholar</a></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">60.</div><div id="core-r60" class="citations"><div class="citation"><div class="citation-content">Liu E, Marin D, Banerjee P, et al. Use of CAR-transduced natural killer cells in CD19-positive lymphoid tumors. <em>N Engl J Med</em> 2020;382:545-553.</div><div class="external-links"><div class="to-citation__wrapper"><a class="to-citation" href="#body-ref-r60"><i aria-hidden="true" class="icon-return"></i><span>Go to Citation</span></a></div><div class="core-xlink-crossref"><a href="/servlet/linkout?suffix=e_1_3_4_61_2&amp;dbid=4&amp;doi=10.1056%2FNEJMra2026131&amp;key=10.1056%2FNEJMoa1910607&amp;site=mms-site" target="_blank">Crossref</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/32023374/" target="_blank">PubMed</a></div><div class="core-xlink-isi"><a href="https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;DestApp=WOS_CPL&amp;UsrCustomerID=5e3815c904498985e796fc91436abd9a&amp;SrcAuth=atyponcel&amp;SrcApp=literatum&amp;DestLinkType=FullRecord&amp;KeyUT=000511997100009" target="_blank">Web of Science</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=Use+of+CAR-transduced+natural+killer+cells+in+CD19-positive+lymphoid+tumors.&amp;publication_year=2020&amp;journal=N+Engl+J+Med&amp;pages=545-553&amp;doi=10.1056%2FNEJMoa1910607&amp;pmid=32023374" target="_blank">Google Scholar</a></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">61.</div><div id="core-r61" class="citations"><div class="citation"><div class="citation-content">Nebelsiek T, Beiras-Fernandez A, Kilger E, Möhnle P, Weis F. Routine use of corticosteroids to prevent inflammation response in cardiac surgery. <em>Recent Pat Cardiovasc Drug Discov</em> 2012;7:170-174.</div><div class="external-links"><div class="to-citation__wrapper"><a class="to-citation" href="#body-ref-r61"><i aria-hidden="true" class="icon-return"></i><span>Go to Citation</span></a></div><div class="core-xlink-crossref"><a href="https://doi.org/10.2174/157489012803832829" target="_blank">Crossref</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/23035828/" target="_blank">PubMed</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=Routine+use+of+corticosteroids+to+prevent+inflammation+response+in+cardiac+surgery.&amp;publication_year=2012&amp;journal=Recent+Pat+Cardiovasc+Drug+Discov&amp;pages=170-174&amp;doi=10.2174%2F157489012803832829&amp;pmid=23035828" target="_blank">Google Scholar</a></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">62.</div><div id="core-r62" class="citations"><div class="citation"><div class="citation-content">Fisher CJ Jr, Dhainaut JF, Opal SM, et al. Recombinant human interleukin 1 receptor antagonist in the treatment of patients with sepsis syndrome: results from a randomized, double-blind, placebo-controlled trial. <em>JAMA</em> 1994;271:1836-1843.</div><div class="external-links"><div class="to-citation__wrapper"><a class="to-citation" href="#body-ref-r62"><i aria-hidden="true" class="icon-return"></i><span>Go to Citation</span></a></div><div class="core-xlink-crossref"><a href="https://doi.org/10.1001/jama.1994.03510470040032" target="_blank">Crossref</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/8196140/" target="_blank">PubMed</a></div><div class="core-xlink-isi"><a href="https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;DestApp=WOS_CPL&amp;UsrCustomerID=5e3815c904498985e796fc91436abd9a&amp;SrcAuth=atyponcel&amp;SrcApp=literatum&amp;DestLinkType=FullRecord&amp;KeyUT=A1994NP95900027" target="_blank">Web of Science</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=Recombinant+human+interleukin+1+receptor+antagonist+in+the+treatment+of+patients+with+sepsis+syndrome%3A+results+from+a+randomized%2C+double-blind%2C+placebo-controlled+trial.&amp;publication_year=1994&amp;journal=JAMA&amp;pages=1836-1843&amp;doi=10.1001%2Fjama.1994.03510470040032&amp;pmid=8196140" target="_blank">Google Scholar</a></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">63.</div><div id="core-r63" class="citations"><div class="citation"><div class="citation-content">Shakoory B, Carcillo JA, Chatham WW, et al. Interleukin-1 receptor blockade is associated with reduced mortality in sepsis patients with features of macrophage activation syndrome: reanalysis of a prior phase III trial. <em>Crit Care Med</em> 2016;44:275-281.</div><div class="external-links"><div class="to-citation__wrapper"><a class="to-citation" href="#body-ref-r63"><i aria-hidden="true" class="icon-return"></i><span>Go to Citation</span></a></div><div class="core-xlink-crossref"><a href="https://doi.org/10.1097/CCM.0000000000001402" target="_blank">Crossref</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/26584195/" target="_blank">PubMed</a></div><div class="core-xlink-isi"><a href="https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;DestApp=WOS_CPL&amp;UsrCustomerID=5e3815c904498985e796fc91436abd9a&amp;SrcAuth=atyponcel&amp;SrcApp=literatum&amp;DestLinkType=FullRecord&amp;KeyUT=000368503700005" target="_blank">Web of Science</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=Interleukin-1+receptor+blockade+is+associated+with+reduced+mortality+in+sepsis+patients+with+features+of+macrophage+activation+syndrome%3A+reanalysis+of+a+prior+phase+III+trial.&amp;publication_year=2016&amp;journal=Crit+Care+Med&amp;pages=275-281&amp;doi=10.1097%2FCCM.0000000000001402&amp;pmid=26584195" target="_blank">Google Scholar</a></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">64.</div><div id="core-r64" class="citations"><div class="citation"><div class="citation-content">Lykens JE, Terrell CE, Zoller EE, Risma K, Jordan MB. Perforin is a critical physiologic regulator of T-cell activation. <em>Blood</em> 2011;118:618-626.</div><div class="external-links"><div class="to-citation__wrapper"><a class="to-citation" href="#body-ref-r64"><i aria-hidden="true" class="icon-return"></i><span>Go to Citation</span></a></div><div class="core-xlink-crossref"><a href="https://doi.org/10.1182/blood-2010-12-324533" target="_blank">Crossref</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/21606480/" target="_blank">PubMed</a></div><div class="core-xlink-isi"><a href="https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;DestApp=WOS_CPL&amp;UsrCustomerID=5e3815c904498985e796fc91436abd9a&amp;SrcAuth=atyponcel&amp;SrcApp=literatum&amp;DestLinkType=FullRecord&amp;KeyUT=000292967300023" target="_blank">Web of Science</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=Perforin+is+a+critical+physiologic+regulator+of+T-cell+activation.&amp;publication_year=2011&amp;journal=Blood&amp;pages=618-626&amp;doi=10.1182%2Fblood-2010-12-324533&amp;pmid=21606480" target="_blank">Google Scholar</a></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">65.</div><div id="core-r65" class="citations"><div class="citation"><div class="citation-content">Zhang M, Bracaglia C, Prencipe G, et al. A heterozygous RAB27A mutation associated with delayed cytolytic granule polarization and hemophagocytic lymphohistiocytosis. <em>J Immunol</em> 2016;196:2492-2503.</div><div class="external-links"><div class="to-citation__wrapper"><button aria-controls="to-citation__accordion-r65-core" aria-expanded="false" aria-label="Toggle citations menu" class="to-citation__toggle"><i aria-hidden="true" class="icon-plus"></i><span data-expand-title="Hide Citations" data-collapsed-title="Show Citations" class="accordion__toggle__title"></span></button></div><div class="core-xlink-crossref"><a href="https://doi.org/10.4049/jimmunol.1501284" target="_blank">Crossref</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/26880764/" target="_blank">PubMed</a></div><div class="core-xlink-isi"><a href="https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;DestApp=WOS_CPL&amp;UsrCustomerID=5e3815c904498985e796fc91436abd9a&amp;SrcAuth=atyponcel&amp;SrcApp=literatum&amp;DestLinkType=FullRecord&amp;KeyUT=000372338100008" target="_blank">Web of Science</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=A+heterozygous+RAB27A+mutation+associated+with+delayed+cytolytic+granule+polarization+and+hemophagocytic+lymphohistiocytosis.&amp;publication_year=2016&amp;journal=J+Immunol&amp;pages=2492-2503&amp;doi=10.4049%2Fjimmunol.1501284&amp;pmid=26880764" target="_blank">Google Scholar</a></div><div role="menu" aria-label="links" class="to-citation__accordion no-separator" id="to-citation__accordion-r65-core" style="display: none;"><ul role="none"><li role="none"><a class="to-citation" href="#body-ref-r67" role="menuitem"><i aria-hidden="true" class="icon-return"></i><span>a [...] loop of proinflammatory cytokines. </span></a></li><li role="none"><a class="to-citation" href="#body-ref-r74" role="menuitem"><i aria-hidden="true" class="icon-return"></i><span>b [...] same genes that are altered in primary HLH. </span></a></li></ul></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">66.</div><div id="core-r66" class="citations"><div class="citation"><div class="citation-content">Terrell CE, Jordan MB. Perforin deficiency impairs a critical immunoregulatory loop involving murine CD8(+) T cells and dendritic cells. <em>Blood</em> 2013;121:5184-5191.</div><div class="external-links"><div class="to-citation__wrapper"><a class="to-citation" href="#body-ref-r67"><i aria-hidden="true" class="icon-return"></i><span>Go to Citation</span></a></div><div class="core-xlink-crossref"><a href="https://doi.org/10.1182/blood-2013-04-495309" target="_blank">Crossref</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/23660960/" target="_blank">PubMed</a></div><div class="core-xlink-isi"><a href="https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;DestApp=WOS_CPL&amp;UsrCustomerID=5e3815c904498985e796fc91436abd9a&amp;SrcAuth=atyponcel&amp;SrcApp=literatum&amp;DestLinkType=FullRecord&amp;KeyUT=000321900700014" target="_blank">Web of Science</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=Perforin+deficiency+impairs+a+critical+immunoregulatory+loop+involving+murine+CD8%28%2B%29+T+cells+and+dendritic+cells.&amp;publication_year=2013&amp;journal=Blood&amp;pages=5184-5191&amp;doi=10.1182%2Fblood-2013-04-495309&amp;pmid=23660960" target="_blank">Google Scholar</a></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">67.</div><div id="core-r67" class="citations"><div class="citation"><div class="citation-content">Pachlopnik Schmid J, Ho C-H, Chrétien F, et al. Neutralization of IFNgamma defeats haemophagocytosis in LCMV-infected perforin- and Rab27a-deficient mice. <em>EMBO Mol Med</em> 2009;1:112-124.</div><div class="external-links"><div class="to-citation__wrapper"><a class="to-citation" href="#body-ref-r67"><i aria-hidden="true" class="icon-return"></i><span>Go to Citation</span></a></div><div class="core-xlink-crossref"><a href="https://doi.org/10.1002/emmm.200900009" target="_blank">Crossref</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/20049711/" target="_blank">PubMed</a></div><div class="core-xlink-isi"><a href="https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;DestApp=WOS_CPL&amp;UsrCustomerID=5e3815c904498985e796fc91436abd9a&amp;SrcAuth=atyponcel&amp;SrcApp=literatum&amp;DestLinkType=FullRecord&amp;KeyUT=000273563000007" target="_blank">Web of Science</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=Neutralization+of+IFNgamma+defeats+haemophagocytosis+in+LCMV-infected+perforin-+and+Rab27a-deficient+mice.&amp;publication_year=2009&amp;journal=EMBO+Mol+Med&amp;pages=112-124&amp;doi=10.1002%2Femmm.200900009&amp;pmid=20049711" target="_blank">Google Scholar</a></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">68.</div><div id="core-r68" class="citations"><div class="citation"><div class="citation-content">Polizzotto MN, Uldrick TS, Wang V, et al. Human and viral interleukin-6 and other cytokines in Kaposi sarcoma herpesvirus-associated multicentric Castleman disease. <em>Blood</em> 2013;122:4189-4198.</div><div class="external-links"><div class="to-citation__wrapper"><a class="to-citation" href="#body-ref-r68"><i aria-hidden="true" class="icon-return"></i><span>Go to Citation</span></a></div><div class="core-xlink-crossref"><a href="https://doi.org/10.1182/blood-2013-08-519959" target="_blank">Crossref</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/24174627/" target="_blank">PubMed</a></div><div class="core-xlink-isi"><a href="https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;DestApp=WOS_CPL&amp;UsrCustomerID=5e3815c904498985e796fc91436abd9a&amp;SrcAuth=atyponcel&amp;SrcApp=literatum&amp;DestLinkType=FullRecord&amp;KeyUT=000329741000013" target="_blank">Web of Science</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=Human+and+viral+interleukin-6+and+other+cytokines+in+Kaposi+sarcoma+herpesvirus-associated+multicentric+Castleman+disease.&amp;publication_year=2013&amp;journal=Blood&amp;pages=4189-4198&amp;doi=10.1182%2Fblood-2013-08-519959&amp;pmid=24174627" target="_blank">Google Scholar</a></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">69.</div><div id="core-r69" class="citations"><div class="citation"><div class="citation-content">Dispenzieri A, Fajgenbaum DC. Overview of Castleman disease. <em>Blood</em> 2020;135:1353-1364.</div><div class="external-links"><div class="to-citation__wrapper"><a class="to-citation" href="#body-ref-r69"><i aria-hidden="true" class="icon-return"></i><span>Go to Citation</span></a></div><div class="core-xlink-crossref"><a href="https://doi.org/10.1182/blood.2019000931" target="_blank">Crossref</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/32106302/" target="_blank">PubMed</a></div><div class="core-xlink-isi"><a href="https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;DestApp=WOS_CPL&amp;UsrCustomerID=5e3815c904498985e796fc91436abd9a&amp;SrcAuth=atyponcel&amp;SrcApp=literatum&amp;DestLinkType=FullRecord&amp;KeyUT=000527355300009" target="_blank">Web of Science</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=Overview+of+Castleman+disease.&amp;publication_year=2020&amp;journal=Blood&amp;pages=1353-1364&amp;doi=10.1182%2Fblood.2019000931&amp;pmid=32106302" target="_blank">Google Scholar</a></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">70.</div><div id="core-r70" class="citations"><div class="citation"><div class="citation-content">Ramaswami R, Lurain K, Peer CJ, et al. Tocilizumab in patients with symptomatic Kaposi sarcoma herpesvirus-associated multicentric Castleman disease. <em>Blood</em> 2020;135:2316-2319.</div><div class="external-links"><div class="to-citation__wrapper"><a class="to-citation" href="#body-ref-r70"><i aria-hidden="true" class="icon-return"></i><span>Go to Citation</span></a></div><div class="core-xlink-crossref"><a href="https://doi.org/10.1182/blood.2019004602" target="_blank">Crossref</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/32276276/" target="_blank">PubMed</a></div><div class="core-xlink-isi"><a href="https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;DestApp=WOS_CPL&amp;UsrCustomerID=5e3815c904498985e796fc91436abd9a&amp;SrcAuth=atyponcel&amp;SrcApp=literatum&amp;DestLinkType=FullRecord&amp;KeyUT=000571484400016" target="_blank">Web of Science</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=Tocilizumab+in+patients+with+symptomatic+Kaposi+sarcoma+herpesvirus-associated+multicentric+Castleman+disease.&amp;publication_year=2020&amp;journal=Blood&amp;pages=2316-2319&amp;doi=10.1182%2Fblood.2019004602&amp;pmid=32276276" target="_blank">Google Scholar</a></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">71.</div><div id="core-r71" class="citations"><div class="citation"><div class="citation-content">Chellapandian D, Das R, Zelley K, et al. Treatment of Epstein Barr virus-induced haemophagocytic lymphohistiocytosis with rituximab-containing chemo-immunotherapeutic regimens. <em>Br J Haematol</em> 2013;162:376-382.</div><div class="external-links"><div class="to-citation__wrapper"><a class="to-citation" href="#body-ref-r71"><i aria-hidden="true" class="icon-return"></i><span>Go to Citation</span></a></div><div class="core-xlink-crossref"><a href="https://doi.org/10.1111/bjh.12386" target="_blank">Crossref</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/23692048/" target="_blank">PubMed</a></div><div class="core-xlink-isi"><a href="https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;DestApp=WOS_CPL&amp;UsrCustomerID=5e3815c904498985e796fc91436abd9a&amp;SrcAuth=atyponcel&amp;SrcApp=literatum&amp;DestLinkType=FullRecord&amp;KeyUT=000321568800011" target="_blank">Web of Science</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=Treatment+of+Epstein+Barr+virus-induced+haemophagocytic+lymphohistiocytosis+with+rituximab-containing+chemo-immunotherapeutic+regimens.&amp;publication_year=2013&amp;journal=Br+J+Haematol&amp;pages=376-382&amp;doi=10.1111%2Fbjh.12386&amp;pmid=23692048" target="_blank">Google Scholar</a></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">72.</div><div id="core-r72" class="citations"><div class="citation"><div class="citation-content">Dalla Pria A, Pinato D, Roe J, Naresh K, Nelson M, Bower M. Relapse of HHV8-positive multicentric Castleman disease following rituximab-based therapy in HIV-positive patients. <em>Blood</em> 2017;129:2143-2147.</div><div class="external-links"><div class="to-citation__wrapper"><a class="to-citation" href="#body-ref-r72"><i aria-hidden="true" class="icon-return"></i><span>Go to Citation</span></a></div><div class="core-xlink-crossref"><a href="https://doi.org/10.1182/blood-2016-10-747477" target="_blank">Crossref</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/28143881/" target="_blank">PubMed</a></div><div class="core-xlink-isi"><a href="https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;DestApp=WOS_CPL&amp;UsrCustomerID=5e3815c904498985e796fc91436abd9a&amp;SrcAuth=atyponcel&amp;SrcApp=literatum&amp;DestLinkType=FullRecord&amp;KeyUT=000399008200019" target="_blank">Web of Science</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=Relapse+of+HHV8-positive+multicentric+Castleman+disease+following+rituximab-based+therapy+in+HIV-positive+patients.&amp;publication_year=2017&amp;journal=Blood&amp;pages=2143-2147&amp;doi=10.1182%2Fblood-2016-10-747477&amp;pmid=28143881" target="_blank">Google Scholar</a></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">73.</div><div id="core-r73" class="citations"><div class="citation"><div class="citation-content">Grajales-Reyes GE, Colonna M. Interferon responses in viral pneumonias. <em>Science</em> 2020;369:626-627.</div><div class="external-links"><div class="to-citation__wrapper"><a class="to-citation" href="#body-ref-r73"><i aria-hidden="true" class="icon-return"></i><span>Go to Citation</span></a></div><div class="core-xlink-crossref"><a href="https://doi.org/10.1126/science.abd2208" target="_blank">Crossref</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/32764056/" target="_blank">PubMed</a></div><div class="core-xlink-isi"><a href="https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;DestApp=WOS_CPL&amp;UsrCustomerID=5e3815c904498985e796fc91436abd9a&amp;SrcAuth=atyponcel&amp;SrcApp=literatum&amp;DestLinkType=FullRecord&amp;KeyUT=000559184400025" target="_blank">Web of Science</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=Interferon+responses+in+viral+pneumonias.&amp;publication_year=2020&amp;journal=Science&amp;pages=626-627&amp;doi=10.1126%2Fscience.abd2208&amp;pmid=32764056" target="_blank">Google Scholar</a></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">74.</div><div id="core-r74" class="citations"><div class="citation"><div class="citation-content">Kaufman KM, Linghu B, Szustakowski JD, et al. Whole-exome sequencing reveals overlap between macrophage activation syndrome in systemic juvenile idiopathic arthritis and familial hemophagocytic lymphohistiocytosis. <em>Arthritis Rheumatol</em> 2014;66:3486-3495.</div><div class="external-links"><div class="to-citation__wrapper"><a class="to-citation" href="#body-ref-r74"><i aria-hidden="true" class="icon-return"></i><span>Go to Citation</span></a></div><div class="core-xlink-crossref"><a href="https://doi.org/10.1002/art.38793" target="_blank">Crossref</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/25047945/" target="_blank">PubMed</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=Whole-exome+sequencing+reveals+overlap+between+macrophage+activation+syndrome+in+systemic+juvenile+idiopathic+arthritis+and+familial+hemophagocytic+lymphohistiocytosis.&amp;publication_year=2014&amp;journal=Arthritis+Rheumatol&amp;pages=3486-3495&amp;doi=10.1002%2Fart.38793&amp;pmid=25047945" target="_blank">Google Scholar</a></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">75.</div><div id="core-r75" class="citations"><div class="citation"><div class="citation-content">Johnson TS, Terrell CE, Millen SH, Katz JD, Hildeman DA, Jordan MB. Etoposide selectively ablates activated T cells to control the immunoregulatory disorder hemophagocytic lymphohistiocytosis. <em>J Immunol</em> 2014;192:84-91.</div><div class="external-links"><div class="to-citation__wrapper"><a class="to-citation" href="#body-ref-r75"><i aria-hidden="true" class="icon-return"></i><span>Go to Citation</span></a></div><div class="core-xlink-crossref"><a href="https://doi.org/10.4049/jimmunol.1302282" target="_blank">Crossref</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/24259502/" target="_blank">PubMed</a></div><div class="core-xlink-isi"><a href="https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;DestApp=WOS_CPL&amp;UsrCustomerID=5e3815c904498985e796fc91436abd9a&amp;SrcAuth=atyponcel&amp;SrcApp=literatum&amp;DestLinkType=FullRecord&amp;KeyUT=000328950700009" target="_blank">Web of Science</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=Etoposide+selectively+ablates+activated+T+cells+to+control+the+immunoregulatory+disorder+hemophagocytic+lymphohistiocytosis.&amp;publication_year=2014&amp;journal=J+Immunol&amp;pages=84-91&amp;doi=10.4049%2Fjimmunol.1302282&amp;pmid=24259502" target="_blank">Google Scholar</a></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">76.</div><div id="core-r76" class="citations"><div class="citation"><div class="citation-content">Marsh RA, Allen CE, McClain KL, et al. Salvage therapy of refractory hemophagocytic lymphohistiocytosis with alemtuzumab. <em>Pediatr Blood Cancer</em> 2013;60:101-109.</div><div class="external-links"><div class="to-citation__wrapper"><a class="to-citation" href="#body-ref-r76"><i aria-hidden="true" class="icon-return"></i><span>Go to Citation</span></a></div><div class="core-xlink-crossref"><a href="https://doi.org/10.1002/pbc.24188" target="_blank">Crossref</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/22522603/" target="_blank">PubMed</a></div><div class="core-xlink-isi"><a href="https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;DestApp=WOS_CPL&amp;UsrCustomerID=5e3815c904498985e796fc91436abd9a&amp;SrcAuth=atyponcel&amp;SrcApp=literatum&amp;DestLinkType=FullRecord&amp;KeyUT=000311167800019" target="_blank">Web of Science</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=Salvage+therapy+of+refractory+hemophagocytic+lymphohistiocytosis+with+alemtuzumab.&amp;publication_year=2013&amp;journal=Pediatr+Blood+Cancer&amp;pages=101-109&amp;doi=10.1002%2Fpbc.24188&amp;pmid=22522603" target="_blank">Google Scholar</a></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">77.</div><div id="core-r77" class="citations"><div class="citation"><div class="citation-content">Mouy R, Stephan JL, Pillet P, Haddad E, Hubert P, Prieur AM. Efficacy of cyclosporine A in the treatment of macrophage activation syndrome in juvenile arthritis: report of five cases. <em>J Pediatr</em> 1996;129:750-754.</div><div class="external-links"><div class="to-citation__wrapper"><a class="to-citation" href="#body-ref-r77"><i aria-hidden="true" class="icon-return"></i><span>Go to Citation</span></a></div><div class="core-xlink-crossref"><a href="https://doi.org/10.1016/S0022-3476(96)70160-9" target="_blank">Crossref</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/8917244/" target="_blank">PubMed</a></div><div class="core-xlink-isi"><a href="https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;DestApp=WOS_CPL&amp;UsrCustomerID=5e3815c904498985e796fc91436abd9a&amp;SrcAuth=atyponcel&amp;SrcApp=literatum&amp;DestLinkType=FullRecord&amp;KeyUT=A1996VR95700025" target="_blank">Web of Science</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=Efficacy+of+cyclosporine+A+in+the+treatment+of+macrophage+activation+syndrome+in+juvenile+arthritis%3A+report+of+five+cases.&amp;publication_year=1996&amp;journal=J+Pediatr&amp;pages=750-754&amp;doi=10.1016%2FS0022-3476%2896%2970160-9&amp;pmid=8917244" target="_blank">Google Scholar</a></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">78.</div><div id="core-r78" class="citations"><div class="citation"><div class="citation-content">Faitelson Y, Grunebaum E. Hemophagocytic lymphohistiocytosis and primary immune deficiency disorders. <em>Clin Immunol</em> 2014;155:118-125.</div><div class="external-links"><div class="to-citation__wrapper"><a class="to-citation" href="#body-ref-r78"><i aria-hidden="true" class="icon-return"></i><span>Go to Citation</span></a></div><div class="core-xlink-crossref"><a href="https://doi.org/10.1016/j.clim.2014.09.008" target="_blank">Crossref</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/25241079/" target="_blank">PubMed</a></div><div class="core-xlink-isi"><a href="https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;DestApp=WOS_CPL&amp;UsrCustomerID=5e3815c904498985e796fc91436abd9a&amp;SrcAuth=atyponcel&amp;SrcApp=literatum&amp;DestLinkType=FullRecord&amp;KeyUT=000343638400015" target="_blank">Web of Science</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=Hemophagocytic+lymphohistiocytosis+and+primary+immune+deficiency+disorders.&amp;publication_year=2014&amp;journal=Clin+Immunol&amp;pages=118-125&amp;doi=10.1016%2Fj.clim.2014.09.008&amp;pmid=25241079" target="_blank">Google Scholar</a></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">79.</div><div id="core-r79" class="citations"><div class="citation"><div class="citation-content">Iwaki N, Fajgenbaum DC, Nabel CS, et al. Clinicopathologic analysis of TAFRO syndrome demonstrates a distinct subtype of HHV-8-negative multicentric Castleman disease. <em>Am J Hematol</em> 2016;91:220-226.</div><div class="external-links"><div class="to-citation__wrapper"><a class="to-citation" href="#body-ref-r79"><i aria-hidden="true" class="icon-return"></i><span>Go to Citation</span></a></div><div class="core-xlink-crossref"><a href="https://doi.org/10.1002/ajh.24242" target="_blank">Crossref</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/26805758/" target="_blank">PubMed</a></div><div class="core-xlink-isi"><a href="https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;DestApp=WOS_CPL&amp;UsrCustomerID=5e3815c904498985e796fc91436abd9a&amp;SrcAuth=atyponcel&amp;SrcApp=literatum&amp;DestLinkType=FullRecord&amp;KeyUT=000369430800017" target="_blank">Web of Science</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=Clinicopathologic+analysis+of+TAFRO+syndrome+demonstrates+a+distinct+subtype+of+HHV-8-negative+multicentric+Castleman+disease.&amp;publication_year=2016&amp;journal=Am+J+Hematol&amp;pages=220-226&amp;doi=10.1002%2Fajh.24242&amp;pmid=26805758" target="_blank">Google Scholar</a></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">80.</div><div id="core-r80" class="citations"><div class="citation"><div class="citation-content">Nishimoto N, Kanakura Y, Aozasa K, et al. Humanized anti-interleukin-6 receptor antibody treatment of multicentric Castleman disease. <em>Blood</em> 2005;106:2627-2632.</div><div class="external-links"><div class="to-citation__wrapper"><a class="to-citation" href="#body-ref-r80"><i aria-hidden="true" class="icon-return"></i><span>Go to Citation</span></a></div><div class="core-xlink-crossref"><a href="https://doi.org/10.1182/blood-2004-12-4602" target="_blank">Crossref</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/15998837/" target="_blank">PubMed</a></div><div class="core-xlink-isi"><a href="https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;DestApp=WOS_CPL&amp;UsrCustomerID=5e3815c904498985e796fc91436abd9a&amp;SrcAuth=atyponcel&amp;SrcApp=literatum&amp;DestLinkType=FullRecord&amp;KeyUT=000232466000014" target="_blank">Web of Science</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=Humanized+anti-interleukin-6+receptor+antibody+treatment+of+multicentric+Castleman+disease.&amp;publication_year=2005&amp;journal=Blood&amp;pages=2627-2632&amp;doi=10.1182%2Fblood-2004-12-4602&amp;pmid=15998837" target="_blank">Google Scholar</a></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">81.</div><div id="core-r81" class="citations"><div class="citation"><div class="citation-content">van Rhee F, Voorhees P, Dispenzieri A, et al. International, evidence-based consensus treatment guidelines for idiopathic multicentric Castleman disease. <em>Blood</em> 2018;132:2115-2124.</div><div class="external-links"><div class="to-citation__wrapper"><a class="to-citation" href="#body-ref-r81"><i aria-hidden="true" class="icon-return"></i><span>Go to Citation</span></a></div><div class="core-xlink-crossref"><a href="https://doi.org/10.1182/blood-2018-07-862334" target="_blank">Crossref</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/30181172/" target="_blank">PubMed</a></div><div class="core-xlink-isi"><a href="https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;DestApp=WOS_CPL&amp;UsrCustomerID=5e3815c904498985e796fc91436abd9a&amp;SrcAuth=atyponcel&amp;SrcApp=literatum&amp;DestLinkType=FullRecord&amp;KeyUT=000450194500005" target="_blank">Web of Science</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=International%2C+evidence-based+consensus+treatment+guidelines+for+idiopathic+multicentric+Castleman+disease.&amp;publication_year=2018&amp;journal=Blood&amp;pages=2115-2124&amp;doi=10.1182%2Fblood-2018-07-862334&amp;pmid=30181172" target="_blank">Google Scholar</a></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">82.</div><div id="core-r82" class="citations"><div class="citation"><div class="citation-content">Pierson SK, Stonestrom AJ, Shilling D, et al. Plasma proteomics identifies a ‘chemokine storm’ in idiopathic multicentric Castleman disease. <em>Am J Hematol</em> 2018;93:902-912.</div><div class="external-links"><div class="to-citation__wrapper"><a class="to-citation" href="#body-ref-r82"><i aria-hidden="true" class="icon-return"></i><span>Go to Citation</span></a></div><div class="core-xlink-crossref"><a href="https://doi.org/10.1002/ajh.25123" target="_blank">Crossref</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/29675946/" target="_blank">PubMed</a></div><div class="core-xlink-isi"><a href="https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;DestApp=WOS_CPL&amp;UsrCustomerID=5e3815c904498985e796fc91436abd9a&amp;SrcAuth=atyponcel&amp;SrcApp=literatum&amp;DestLinkType=FullRecord&amp;KeyUT=000437829500018" target="_blank">Web of Science</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=Plasma+proteomics+identifies+a+%E2%80%98chemokine+storm%E2%80%99+in+idiopathic+multicentric+Castleman+disease.&amp;publication_year=2018&amp;journal=Am+J+Hematol&amp;pages=902-912&amp;doi=10.1002%2Fajh.25123&amp;pmid=29675946" target="_blank">Google Scholar</a></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">83.</div><div id="core-r83" class="citations"><div class="citation"><div class="citation-content">Langan Pai R-A, Sada Japp A, Gonzalez M, et al. Type I IFN response associated with mTOR activation in the TAFRO subtype of idiopathic multicentric Castleman disease. <em>JCI Insight</em> 2020;5(9):e135031-e135031.</div><div class="external-links"><div class="to-citation__wrapper"><a class="to-citation" href="#body-ref-r83"><i aria-hidden="true" class="icon-return"></i><span>Go to Citation</span></a></div><div class="core-xlink-crossref"><a href="https://doi.org/10.1172/jci.insight.135031" target="_blank">Crossref</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/32376796/" target="_blank">PubMed</a></div><div class="core-xlink-isi"><a href="https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;DestApp=WOS_CPL&amp;UsrCustomerID=5e3815c904498985e796fc91436abd9a&amp;SrcAuth=atyponcel&amp;SrcApp=literatum&amp;DestLinkType=FullRecord&amp;KeyUT=000531472400010" target="_blank">Web of Science</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=Type+I+IFN+response+associated+with+mTOR+activation+in+the+TAFRO+subtype+of+idiopathic+multicentric+Castleman+disease.&amp;publication_year=2020&amp;journal=JCI+Insight&amp;pages=e135031-e135031&amp;doi=10.1172%2Fjci.insight.135031&amp;pmid=32376796" target="_blank">Google Scholar</a></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">84.</div><div id="core-r84" class="citations"><div class="citation"><div class="citation-content">Arenas DJ, Floess K, Kobrin D, et al. Increased mTOR activation in idiopathic multicentric Castleman disease. <em>Blood</em> 2020;135:1673-1684.</div><div class="external-links"><div class="to-citation__wrapper"><a class="to-citation" href="#body-ref-r84"><i aria-hidden="true" class="icon-return"></i><span>Go to Citation</span></a></div><div class="core-xlink-crossref"><a href="https://doi.org/10.1182/blood.2019002792" target="_blank">Crossref</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/32206779/" target="_blank">PubMed</a></div><div class="core-xlink-isi"><a href="https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;DestApp=WOS_CPL&amp;UsrCustomerID=5e3815c904498985e796fc91436abd9a&amp;SrcAuth=atyponcel&amp;SrcApp=literatum&amp;DestLinkType=FullRecord&amp;KeyUT=000534369200012" target="_blank">Web of Science</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=Increased+mTOR+activation+in+idiopathic+multicentric+Castleman+disease.&amp;publication_year=2020&amp;journal=Blood&amp;pages=1673-1684&amp;doi=10.1182%2Fblood.2019002792&amp;pmid=32206779" target="_blank">Google Scholar</a></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">85.</div><div id="core-r85" class="citations"><div class="citation"><div class="citation-content">Fajgenbaum DC, Langan R-A, Sada Japp A, et al. Identifying and targeting pathogenic PI3K/AKT/mTOR signaling in IL-6-blockade-refractory idiopathic multicentric Castleman disease. <em>J Clin Invest</em> 2019;129:4451-4463.</div><div class="external-links"><div class="to-citation__wrapper"><a class="to-citation" href="#body-ref-r85"><i aria-hidden="true" class="icon-return"></i><span>Go to Citation</span></a></div><div class="core-xlink-crossref"><a href="https://doi.org/10.1172/JCI126091" target="_blank">Crossref</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/31408438/" target="_blank">PubMed</a></div><div class="core-xlink-isi"><a href="https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;DestApp=WOS_CPL&amp;UsrCustomerID=5e3815c904498985e796fc91436abd9a&amp;SrcAuth=atyponcel&amp;SrcApp=literatum&amp;DestLinkType=FullRecord&amp;KeyUT=000488537800047" target="_blank">Web of Science</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=Identifying+and+targeting+pathogenic+PI3K%2FAKT%2FmTOR+signaling+in+IL-6-blockade-refractory+idiopathic+multicentric+Castleman+disease.&amp;publication_year=2019&amp;journal=J+Clin+Invest&amp;pages=4451-4463&amp;doi=10.1172%2FJCI126091&amp;pmid=31408438" target="_blank">Google Scholar</a></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">86.</div><div id="core-r86" class="citations"><div class="citation"><div class="citation-content">Huang K-J, Su I-J, Theron M, et al. An interferon-gamma-related cytokine storm in SARS patients. <em>J Med Virol</em> 2005;75:185-194.</div><div class="external-links"><div class="to-citation__wrapper"><a class="to-citation" href="#body-ref-r86"><i aria-hidden="true" class="icon-return"></i><span>Go to Citation</span></a></div><div class="core-xlink-crossref"><a href="https://doi.org/10.1002/jmv.20255" target="_blank">Crossref</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/15602737/" target="_blank">PubMed</a></div><div class="core-xlink-isi"><a href="https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;DestApp=WOS_CPL&amp;UsrCustomerID=5e3815c904498985e796fc91436abd9a&amp;SrcAuth=atyponcel&amp;SrcApp=literatum&amp;DestLinkType=FullRecord&amp;KeyUT=000226009400002" target="_blank">Web of Science</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=An+interferon-gamma-related+cytokine+storm+in+SARS+patients.&amp;publication_year=2005&amp;journal=J+Med+Virol&amp;pages=185-194&amp;doi=10.1002%2Fjmv.20255&amp;pmid=15602737" target="_blank">Google Scholar</a></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">87.</div><div id="core-r87" class="citations"><div class="citation"><div class="citation-content">Moore JB, June CH. Cytokine release syndrome in severe COVID-19. <em>Science</em> 2020;368:473-474.</div><div class="external-links"><div class="to-citation__wrapper"><a class="to-citation" href="#body-ref-r88-1"><i aria-hidden="true" class="icon-return"></i><span>Go to Citation</span></a></div><div class="core-xlink-crossref"><a href="https://doi.org/10.1126/science.abb8925" target="_blank">Crossref</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/32303591/" target="_blank">PubMed</a></div><div class="core-xlink-isi"><a href="https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;DestApp=WOS_CPL&amp;UsrCustomerID=5e3815c904498985e796fc91436abd9a&amp;SrcAuth=atyponcel&amp;SrcApp=literatum&amp;DestLinkType=FullRecord&amp;KeyUT=000531178400028" target="_blank">Web of Science</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=Cytokine+release+syndrome+in+severe+COVID-19.&amp;publication_year=2020&amp;journal=Science&amp;pages=473-474&amp;doi=10.1126%2Fscience.abb8925&amp;pmid=32303591" target="_blank">Google Scholar</a></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">88.</div><div id="core-r88" class="citations"><div class="citation"><div class="citation-content">The RECOVERY Collaborative Group. Dexamethasone in hospitalized patients with Covid-19 — preliminary report. <em>N Engl J Med</em>.</div><div class="external-links"><div class="to-citation__wrapper"><button aria-controls="to-citation__accordion-r88-core" aria-expanded="false" aria-label="Toggle citations menu" class="to-citation__toggle"><i aria-hidden="true" class="icon-plus"></i><span data-expand-title="Hide Citations" data-collapsed-title="Show Citations" class="accordion__toggle__title"></span></button></div><div class="core-xlink-crossref"><a href="/servlet/linkout?suffix=e_1_3_4_89_2&amp;dbid=4&amp;doi=10.1056%2FNEJMra2026131&amp;key=10.1056%2FNEJMoa2021436&amp;site=mms-site" target="_blank">Crossref</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/32678530/" target="_blank">PubMed</a></div><div class="core-xlink-isi"><a href="https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;DestApp=WOS_CPL&amp;UsrCustomerID=5e3815c904498985e796fc91436abd9a&amp;SrcAuth=atyponcel&amp;SrcApp=literatum&amp;DestLinkType=FullRecord&amp;KeyUT=000584372000001" target="_blank">Web of Science</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=Dexamethasone+in+hospitalized+patients+with+Covid-19+%E2%80%94+preliminary+report.&amp;journal=N+Engl+J+Med&amp;doi=10.1056%2FNEJMoa2021436&amp;pmid=32678530" target="_blank">Google Scholar</a></div><div role="menu" aria-label="links" class="to-citation__accordion no-separator" id="to-citation__accordion-r88-core" style="display: none;"><ul role="none"><li role="none"><a class="to-citation" href="#body-ref-r88-1" role="menuitem"><i aria-hidden="true" class="icon-return"></i><span>a [...] contribute to the pathogenesis of Covid-19. </span></a></li><li role="none"><a class="to-citation" href="#body-ref-r88-2" role="menuitem"><i aria-hidden="true" class="icon-return"></i><span>b [...] inflammation contributes to mortality. </span></a></li></ul></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">89.</div><div id="core-r89" class="citations"><div class="citation"><div class="citation-content">Huang C, Wang Y, Li X, et al. Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China. <em>Lancet</em> 2020;395:497-506.</div><div class="external-links"><div class="to-citation__wrapper"><a class="to-citation" href="#body-ref-r90"><i aria-hidden="true" class="icon-return"></i><span>Go to Citation</span></a></div><div class="core-xlink-crossref"><a href="https://doi.org/10.1016/S0140-6736(20)30183-5" target="_blank">Crossref</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/31986264/" target="_blank">PubMed</a></div><div class="core-xlink-isi"><a href="https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;DestApp=WOS_CPL&amp;UsrCustomerID=5e3815c904498985e796fc91436abd9a&amp;SrcAuth=atyponcel&amp;SrcApp=literatum&amp;DestLinkType=FullRecord&amp;KeyUT=000514576900032" target="_blank">Web of Science</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=Clinical+features+of+patients+infected+with+2019+novel+coronavirus+in+Wuhan%2C+China.&amp;publication_year=2020&amp;journal=Lancet&amp;pages=497-506&amp;doi=10.1016%2FS0140-6736%2820%2930183-5&amp;pmid=31986264" target="_blank">Google Scholar</a></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">90.</div><div id="core-r90" class="citations"><div class="citation"><div class="citation-content">Zhu Z, Cai T, Fan L, et al. Clinical value of immune-inflammatory parameters to assess the severity of coronavirus disease 2019. <em>Int J Infect Dis</em> 2020;95:332-339.</div><div class="external-links"><div class="to-citation__wrapper"><a class="to-citation" href="#body-ref-r90"><i aria-hidden="true" class="icon-return"></i><span>Go to Citation</span></a></div><div class="core-xlink-crossref"><a href="https://doi.org/10.1016/j.ijid.2020.04.041" target="_blank">Crossref</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/32334118/" target="_blank">PubMed</a></div><div class="core-xlink-isi"><a href="https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;DestApp=WOS_CPL&amp;UsrCustomerID=5e3815c904498985e796fc91436abd9a&amp;SrcAuth=atyponcel&amp;SrcApp=literatum&amp;DestLinkType=FullRecord&amp;KeyUT=000540737100060" target="_blank">Web of Science</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=Clinical+value+of+immune-inflammatory+parameters+to+assess+the+severity+of+coronavirus+disease+2019.&amp;publication_year=2020&amp;journal=Int+J+Infect+Dis&amp;pages=332-339&amp;doi=10.1016%2Fj.ijid.2020.04.041&amp;pmid=32334118" target="_blank">Google Scholar</a></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">91.</div><div id="core-r91" class="citations"><div class="citation"><div class="citation-content">Del Valle DM, Kim-Schulze S, Huang H-H, et al. An inflammatory cytokine signature predicts COVID-19 severity and survival. <em>Nat Med</em> 2020;26:1636-1643.</div><div class="external-links"><div class="to-citation__wrapper"><a class="to-citation" href="#body-ref-r91"><i aria-hidden="true" class="icon-return"></i><span>Go to Citation</span></a></div><div class="core-xlink-crossref"><a href="https://doi.org/10.1038/s41591-020-1051-9" target="_blank">Crossref</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/32839624/" target="_blank">PubMed</a></div><div class="core-xlink-isi"><a href="https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;DestApp=WOS_CPL&amp;UsrCustomerID=5e3815c904498985e796fc91436abd9a&amp;SrcAuth=atyponcel&amp;SrcApp=literatum&amp;DestLinkType=FullRecord&amp;KeyUT=000562338700004" target="_blank">Web of Science</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=An+inflammatory+cytokine+signature+predicts+COVID-19+severity+and+survival.&amp;publication_year=2020&amp;journal=Nat+Med&amp;pages=1636-1643&amp;doi=10.1038%2Fs41591-020-1051-9&amp;pmid=32839624" target="_blank">Google Scholar</a></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">92.</div><div id="core-r92" class="citations"><div class="citation"><div class="citation-content">Mathew D, Giles JR, Baxter AE, et al. Deep immune profiling of COVID-19 patients reveals distinct immunotypes with therapeutic implications. <em>Science</em> 2020;369(6508):eabc8511-eabc8511.</div><div class="external-links"><div class="to-citation__wrapper"><a class="to-citation" href="#body-ref-r92"><i aria-hidden="true" class="icon-return"></i><span>Go to Citation</span></a></div><div class="core-xlink-crossref"><a href="https://doi.org/10.1126/science.abc8511" target="_blank">Crossref</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/32669297/" target="_blank">PubMed</a></div><div class="core-xlink-isi"><a href="https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;DestApp=WOS_CPL&amp;UsrCustomerID=5e3815c904498985e796fc91436abd9a&amp;SrcAuth=atyponcel&amp;SrcApp=literatum&amp;DestLinkType=FullRecord&amp;KeyUT=000567525400046" target="_blank">Web of Science</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=Deep+immune+profiling+of+COVID-19+patients+reveals+distinct+immunotypes+with+therapeutic+implications.&amp;publication_year=2020&amp;journal=Science&amp;pages=eabc8511-eabc8511&amp;doi=10.1126%2Fscience.abc8511&amp;pmid=32669297" target="_blank">Google Scholar</a></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">93.</div><div id="core-r93" class="citations"><div class="citation"><div class="citation-content">Caricchio R, Gallucci M, Dass C, et al. Preliminary predictive criteria for COVID-19 cytokine storm. <em>Ann Rheum Dis</em> 2020 September 25 (Epub ahead of print).</div><div class="external-links"><div class="to-citation__wrapper"><a class="to-citation" href="#body-ref-r93"><i aria-hidden="true" class="icon-return"></i><span>Go to Citation</span></a></div><div class="core-xlink-crossref"><a href="https://doi.org/10.1136/annrheumdis-2020-218323" target="_blank">Crossref</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/32978237/" target="_blank">PubMed</a></div><div class="core-xlink-isi"><a href="https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;DestApp=WOS_CPL&amp;UsrCustomerID=5e3815c904498985e796fc91436abd9a&amp;SrcAuth=atyponcel&amp;SrcApp=literatum&amp;DestLinkType=FullRecord&amp;KeyUT=000607296800025" target="_blank">Web of Science</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=Preliminary+predictive+criteria+for+COVID-19+cytokine+storm.&amp;publication_year=2020&amp;journal=Ann+Rheum+Dis&amp;doi=10.1136%2Fannrheumdis-2020-218323&amp;pmid=32978237" target="_blank">Google Scholar</a></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">94.</div><div id="core-r94" class="citations"><div class="citation"><div class="citation-content">Zhang Q, Bastard P, Liu Z, et al. Inborn errors of type I IFN immunity in patients with life-threatening COVID-19. <em>Science</em> 2020 September 24 (Epub ahead of print).</div><div class="external-links"><div class="to-citation__wrapper"><a class="to-citation" href="#body-ref-r95"><i aria-hidden="true" class="icon-return"></i><span>Go to Citation</span></a></div><div class="core-xlink-crossref"><a href="https://doi.org/10.1126/science.abd4570" target="_blank">Crossref</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/32972995/" target="_blank">PubMed</a></div><div class="core-xlink-isi"><a href="https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;DestApp=WOS_CPL&amp;UsrCustomerID=5e3815c904498985e796fc91436abd9a&amp;SrcAuth=atyponcel&amp;SrcApp=literatum&amp;DestLinkType=FullRecord&amp;KeyUT=000581077200034" target="_blank">Web of Science</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=Inborn+errors+of+type+I+IFN+immunity+in+patients+with+life-threatening+COVID-19.&amp;publication_year=2020&amp;journal=Science&amp;doi=10.1126%2Fscience.abd4570&amp;pmid=32972995" target="_blank">Google Scholar</a></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">95.</div><div id="core-r95" class="citations"><div class="citation"><div class="citation-content">Bastard P, Rosen LB, Zhang Q, et al. Auto-antibodies against type I IFNs in patients with life-threatening COVID-19. <em>Science</em> 2020 September 24 (Epub ahead of print).</div><div class="external-links"><div class="to-citation__wrapper"><a class="to-citation" href="#body-ref-r95"><i aria-hidden="true" class="icon-return"></i><span>Go to Citation</span></a></div><div class="core-xlink-crossref"><a href="https://doi.org/10.1126/science.abd4585" target="_blank">Crossref</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/32972996/" target="_blank">PubMed</a></div><div class="core-xlink-isi"><a href="https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;DestApp=WOS_CPL&amp;UsrCustomerID=5e3815c904498985e796fc91436abd9a&amp;SrcAuth=atyponcel&amp;SrcApp=literatum&amp;DestLinkType=FullRecord&amp;KeyUT=000581077200035" target="_blank">Web of Science</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=Auto-antibodies+against+type+I+IFNs+in+patients+with+life-threatening+COVID-19.&amp;publication_year=2020&amp;journal=Science&amp;doi=10.1126%2Fscience.abd4585&amp;pmid=32972996" target="_blank">Google Scholar</a></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">96.</div><div id="core-r96" class="citations"><div class="citation"><div class="citation-content">Lauder SN, Jones E, Smart K, et al. Interleukin-6 limits influenza-induced inflammation and protects against fatal lung pathology. <em>Eur J Immunol</em> 2013;43:2613-2625.</div><div class="external-links"><div class="to-citation__wrapper"><a class="to-citation" href="#body-ref-r96"><i aria-hidden="true" class="icon-return"></i><span>Go to Citation</span></a></div><div class="core-xlink-crossref"><a href="https://doi.org/10.1002/eji.201243018" target="_blank">Crossref</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/23857287/" target="_blank">PubMed</a></div><div class="core-xlink-isi"><a href="https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;DestApp=WOS_CPL&amp;UsrCustomerID=5e3815c904498985e796fc91436abd9a&amp;SrcAuth=atyponcel&amp;SrcApp=literatum&amp;DestLinkType=FullRecord&amp;KeyUT=000329155200012" target="_blank">Web of Science</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=Interleukin-6+limits+influenza-induced+inflammation+and+protects+against+fatal+lung+pathology.&amp;publication_year=2013&amp;journal=Eur+J+Immunol&amp;pages=2613-2625&amp;doi=10.1002%2Feji.201243018&amp;pmid=23857287" target="_blank">Google Scholar</a></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">97.</div><div id="core-r97" class="citations"><div class="citation"><div class="citation-content">Hermine O, Mariette X, Tharaux PL, et al. Effect of tocilizumab vs usual care in adults hospitalized with COVID-19 and moderate or severe pneumonia: a randomized clinical trial. <em>JAMA Intern Med</em> 2020 October 20 (Epub ahead of print).</div><div class="external-links"><div class="to-citation__wrapper"><a class="to-citation" href="#body-ref-r98"><i aria-hidden="true" class="icon-return"></i><span>Go to Citation</span></a></div><div class="core-xlink-crossref"><a href="https://doi.org/10.1001/jamainternmed.2020.6820" target="_blank">Crossref</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/33080017/" target="_blank">PubMed</a></div><div class="core-xlink-isi"><a href="https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;DestApp=WOS_CPL&amp;UsrCustomerID=5e3815c904498985e796fc91436abd9a&amp;SrcAuth=atyponcel&amp;SrcApp=literatum&amp;DestLinkType=FullRecord&amp;KeyUT=000587482200001" target="_blank">Web of Science</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=Effect+of+tocilizumab+vs+usual+care+in+adults+hospitalized+with+COVID-19+and+moderate+or+severe+pneumonia%3A+a+randomized+clinical+trial.&amp;publication_year=2020&amp;journal=JAMA+Intern+Med&amp;doi=10.1001%2Fjamainternmed.2020.6820&amp;pmid=33080017" target="_blank">Google Scholar</a></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">98.</div><div id="core-r98" class="citations"><div class="citation"><div class="citation-content">Stone JH, Frigault MJ, Serling-Boyd NJ, et al. Efficacy of tocilizumab in patients hospitalized with Covid-19. <em>N Engl J Med</em> 2020 October 21 DOI: 10.1056/NEJMoa2028836.</div><div class="external-links"><div class="to-citation__wrapper"><a class="to-citation" href="#body-ref-r98"><i aria-hidden="true" class="icon-return"></i><span>Go to Citation</span></a></div><div class="core-xlink-crossref"><a href="/servlet/linkout?suffix=e_1_3_4_99_2&amp;dbid=4&amp;doi=10.1056%2FNEJMra2026131&amp;key=10.1056%2FNEJMoa2028836&amp;site=mms-site" target="_blank">Crossref</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/33085857/" target="_blank">PubMed</a></div><div class="core-xlink-isi"><a href="https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;DestApp=WOS_CPL&amp;UsrCustomerID=5e3815c904498985e796fc91436abd9a&amp;SrcAuth=atyponcel&amp;SrcApp=literatum&amp;DestLinkType=FullRecord&amp;KeyUT=000627165900012" target="_blank">Web of Science</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=Efficacy+of+tocilizumab+in+patients+hospitalized+with+Covid-19.&amp;publication_year=2020&amp;journal=N+Engl+J+Med&amp;doi=10.1056%2FNEJMoa2028836&amp;pmid=33085857" target="_blank">Google Scholar</a></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">99.</div><div id="core-r99" class="citations"><div class="citation"><div class="citation-content">Klok FA, Kruip MJHA, van der Meer NJM, et al. Confirmation of the high cumulative incidence of thrombotic complications in critically ill ICU patients with COVID-19: an updated analysis. <em>Thromb Res</em> 2020;191:148-150.</div><div class="external-links"><div class="to-citation__wrapper"><a class="to-citation" href="#body-ref-r99"><i aria-hidden="true" class="icon-return"></i><span>Go to Citation</span></a></div><div class="core-xlink-crossref"><a href="https://doi.org/10.1016/j.thromres.2020.04.041" target="_blank">Crossref</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/32381264/" target="_blank">PubMed</a></div><div class="core-xlink-isi"><a href="https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;DestApp=WOS_CPL&amp;UsrCustomerID=5e3815c904498985e796fc91436abd9a&amp;SrcAuth=atyponcel&amp;SrcApp=literatum&amp;DestLinkType=FullRecord&amp;KeyUT=000582054800029" target="_blank">Web of Science</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=Confirmation+of+the+high+cumulative+incidence+of+thrombotic+complications+in+critically+ill+ICU+patients+with+COVID-19%3A+an+updated+analysis.&amp;publication_year=2020&amp;journal=Thromb+Res&amp;pages=148-150&amp;doi=10.1016%2Fj.thromres.2020.04.041&amp;pmid=32381264" target="_blank">Google Scholar</a></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">100.</div><div id="core-r100" class="citations"><div class="citation"><div class="citation-content">Sterne JAC, Murthy S, Diaz JV, et al. Association between administration of systemic corticosteroids and mortality among critically ill patients with COVID-19: a meta-analysis. <em>JAMA</em> 2020;324:1330-1341.</div><div class="external-links"><div class="to-citation__wrapper"><a class="to-citation" href="#body-ref-r100"><i aria-hidden="true" class="icon-return"></i><span>Go to Citation</span></a></div><div class="core-xlink-crossref"><a href="https://doi.org/10.1001/jama.2020.17023" target="_blank">Crossref</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/32876694/" target="_blank">PubMed</a></div><div class="core-xlink-isi"><a href="https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;DestApp=WOS_CPL&amp;UsrCustomerID=5e3815c904498985e796fc91436abd9a&amp;SrcAuth=atyponcel&amp;SrcApp=literatum&amp;DestLinkType=FullRecord&amp;KeyUT=000590156000017" target="_blank">Web of Science</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=Association+between+administration+of+systemic+corticosteroids+and+mortality+among+critically+ill+patients+with+COVID-19%3A+a+meta-analysis.&amp;publication_year=2020&amp;journal=JAMA&amp;pages=1330-1341&amp;doi=10.1001%2Fjama.2020.17023&amp;pmid=32876694" target="_blank">Google Scholar</a></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">101.</div><div id="core-r101" class="citations"><div class="citation"><div class="citation-content">Keller MJ, Kitsis EA, Arora S, et al. Effect of systemic glucocorticoids on mortality or mechanical ventilation in patients with COVID-19. <em>J Hosp Med</em> 2020;15:489-493.</div><div class="external-links"><div class="to-citation__wrapper"><a class="to-citation" href="#body-ref-r101"><i aria-hidden="true" class="icon-return"></i><span>Go to Citation</span></a></div><div class="core-xlink-crossref"><a href="https://doi.org/10.12788/jhm.3497" target="_blank">Crossref</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/32804611/" target="_blank">PubMed</a></div><div class="core-xlink-isi"><a href="https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;DestApp=WOS_CPL&amp;UsrCustomerID=5e3815c904498985e796fc91436abd9a&amp;SrcAuth=atyponcel&amp;SrcApp=literatum&amp;DestLinkType=FullRecord&amp;KeyUT=000553411500007" target="_blank">Web of Science</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=Effect+of+systemic+glucocorticoids+on+mortality+or+mechanical+ventilation+in+patients+with+COVID-19.&amp;publication_year=2020&amp;journal=J+Hosp+Med&amp;pages=489-493&amp;doi=10.12788%2Fjhm.3497&amp;pmid=32804611" target="_blank">Google Scholar</a></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">102.</div><div id="core-r102" class="citations"><div class="citation"><div class="citation-content">Fajgenbaum DC, Khor JS, Gorzewski A, et al. Treatments administered to the first 9152 reported cases of COVID-19: a systematic review. <em>Infect Dis Ther</em> 2020;9:435-449.</div><div class="external-links"><div class="to-citation__wrapper"><button aria-controls="to-citation__accordion-r102-core" aria-expanded="false" aria-label="Toggle citations menu" class="to-citation__toggle"><i aria-hidden="true" class="icon-plus"></i><span data-expand-title="Hide Citations" data-collapsed-title="Show Citations" class="accordion__toggle__title"></span></button></div><div class="core-xlink-crossref"><a href="https://doi.org/10.1007/s40121-020-00303-8" target="_blank">Crossref</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/32462545/" target="_blank">PubMed</a></div><div class="core-xlink-isi"><a href="https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;DestApp=WOS_CPL&amp;UsrCustomerID=5e3815c904498985e796fc91436abd9a&amp;SrcAuth=atyponcel&amp;SrcApp=literatum&amp;DestLinkType=FullRecord&amp;KeyUT=000553933300001" target="_blank">Web of Science</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=Treatments+administered+to+the+first+9152+reported+cases+of+COVID-19%3A+a+systematic+review.&amp;publication_year=2020&amp;journal=Infect+Dis+Ther&amp;pages=435-449&amp;doi=10.1007%2Fs40121-020-00303-8&amp;pmid=32462545" target="_blank">Google Scholar</a></div><div role="menu" aria-label="links" class="to-citation__accordion no-separator" id="to-citation__accordion-r102-core" style="display: none;"><ul role="none"><li role="none"><a class="to-citation" href="#body-ref-r105" role="menuitem"><i aria-hidden="true" class="icon-return"></i><span>a [...] JAK1 and JAK2 in patients with Covid-19. </span></a></li><li role="none"><a class="to-citation" href="#body-ref-r102-2" role="menuitem"><i aria-hidden="true" class="icon-return"></i><span>b [...] drugs are currently under investigation. </span></a></li></ul></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">103.</div><div id="core-r103" class="citations"><div class="citation"><div class="citation-content">De Luca G, Cavalli G, Campochiaro C, et al. GM-CSF blockade with mavrilimumab in severe COVID-19 pneumonia and systemic hyperinflammation: a single-centre, prospective cohort study. <em>Lancet Rheumatol</em> 2020;2(8):e465-e473.</div><div class="external-links"><div class="to-citation__wrapper"><a class="to-citation" href="#body-ref-r105"><i aria-hidden="true" class="icon-return"></i><span>Go to Citation</span></a></div><div class="core-xlink-crossref"><a href="https://doi.org/10.1016/S2665-9913(20)30170-3" target="_blank">Crossref</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/32835256/" target="_blank">PubMed</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=GM-CSF+blockade+with+mavrilimumab+in+severe+COVID-19+pneumonia+and+systemic+hyperinflammation%3A+a+single-centre%2C+prospective+cohort+study.&amp;publication_year=2020&amp;journal=Lancet+Rheumatol&amp;pages=e465-e473&amp;doi=10.1016%2FS2665-9913%2820%2930170-3&amp;pmid=32835256" target="_blank">Google Scholar</a></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">104.</div><div id="core-r104" class="citations"><div class="citation"><div class="citation-content">Bronte V, Ugel S, Tinazzi E, et al. Baricitinib restrains the immune dysregulation in patients with severe COVID-19. <em>J Clin Invest</em> 2020 November 03 (Epub ahead of print).</div><div class="external-links"><div class="to-citation__wrapper"><a class="to-citation" href="#body-ref-r105"><i aria-hidden="true" class="icon-return"></i><span>Go to Citation</span></a></div><div class="core-xlink-crossref"><a href="https://doi.org/10.1172/JCI141772" target="_blank">Crossref</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/32809969/" target="_blank">PubMed</a></div><div class="core-xlink-isi"><a href="https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;DestApp=WOS_CPL&amp;UsrCustomerID=5e3815c904498985e796fc91436abd9a&amp;SrcAuth=atyponcel&amp;SrcApp=literatum&amp;DestLinkType=FullRecord&amp;KeyUT=000600281700001" target="_blank">Web of Science</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=Baricitinib+restrains+the+immune+dysregulation+in+patients+with+severe+COVID-19.&amp;publication_year=2020&amp;journal=J+Clin+Invest&amp;doi=10.1172%2FJCI141772&amp;pmid=32809969" target="_blank">Google Scholar</a></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">105.</div><div id="core-r105" class="citations"><div class="citation"><div class="citation-content">Rodriguez-Garcia JL, Sanchez-Nievas G, Arevalo-Serrano J, Garcia-Gomez C, Jimenez-Vizuete JM, Martinez-Alfaro E. Baricitinib improves respiratory function in patients treated with corticosteroids for SARS-CoV-2 pneumonia: an observational cohort study. <em>Rheumatology (Oxford)</em> 2020 October 06 (Epub ahead of print).</div><div class="external-links"><div class="to-citation__wrapper"><a class="to-citation" href="#body-ref-r105"><i aria-hidden="true" class="icon-return"></i><span>Go to Citation</span></a></div><div class="core-xlink-crossref"><a href="https://doi.org/10.1093/rheumatology/keaa587" target="_blank">Crossref</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/33020836/" target="_blank">PubMed</a></div><div class="core-xlink-isi"><a href="https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;DestApp=WOS_CPL&amp;UsrCustomerID=5e3815c904498985e796fc91436abd9a&amp;SrcAuth=atyponcel&amp;SrcApp=literatum&amp;DestLinkType=FullRecord&amp;KeyUT=000610050100068" target="_blank">Web of Science</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=Baricitinib+improves+respiratory+function+in+patients+treated+with+corticosteroids+for+SARS-CoV-2+pneumonia%3A+an+observational+cohort+study.&amp;publication_year=2020&amp;journal=Rheumatology+%28Oxford%29&amp;doi=10.1093%2Frheumatology%2Fkeaa587&amp;pmid=33020836" target="_blank">Google Scholar</a></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">106.</div><div id="core-r106" class="citations"><div class="citation"><div class="citation-content">Roschewski M, Lionakis MS, Sharman JP, et al. Inhibition of Bruton tyrosine kinase in patients with severe COVID-19. <em>Sci Immunol</em> 2020;5(48):eabd0110-eabd0110.</div><div class="external-links"><div class="to-citation__wrapper"><a class="to-citation" href="#body-ref-r106"><i aria-hidden="true" class="icon-return"></i><span>Go to Citation</span></a></div><div class="core-xlink-crossref"><a href="https://doi.org/10.1126/sciimmunol.abd0110" target="_blank">Crossref</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/32503877/" target="_blank">PubMed</a></div><div class="core-xlink-isi"><a href="https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;DestApp=WOS_CPL&amp;UsrCustomerID=5e3815c904498985e796fc91436abd9a&amp;SrcAuth=atyponcel&amp;SrcApp=literatum&amp;DestLinkType=FullRecord&amp;KeyUT=000546993600010" target="_blank">Web of Science</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=Inhibition+of+Bruton+tyrosine+kinase+in+patients+with+severe+COVID-19.&amp;publication_year=2020&amp;journal=Sci+Immunol&amp;pages=eabd0110-eabd0110&amp;doi=10.1126%2Fsciimmunol.abd0110&amp;pmid=32503877" target="_blank">Google Scholar</a></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">107.</div><div id="core-r107" class="citations"><div class="citation"><div class="citation-content">Zhang W, Zhao Y, Zhang F, et al. The use of anti-inflammatory drugs in the treatment of people with severe coronavirus disease 2019 (COVID-19): the perspectives of clinical immunologists from China. <em>Clin Immunol</em> 2020;214:108393-108393.</div><div class="external-links"><div class="to-citation__wrapper"><a class="to-citation" href="#body-ref-r107"><i aria-hidden="true" class="icon-return"></i><span>Go to Citation</span></a></div><div class="core-xlink-crossref"><a href="https://doi.org/10.1016/j.clim.2020.108393" target="_blank">Crossref</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/32222466/" target="_blank">PubMed</a></div><div class="core-xlink-isi"><a href="https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;DestApp=WOS_CPL&amp;UsrCustomerID=5e3815c904498985e796fc91436abd9a&amp;SrcAuth=atyponcel&amp;SrcApp=literatum&amp;DestLinkType=FullRecord&amp;KeyUT=000530692800022" target="_blank">Web of Science</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=The+use+of+anti-inflammatory+drugs+in+the+treatment+of+people+with+severe+coronavirus+disease+2019+%28COVID-19%29%3A+the+perspectives+of+clinical+immunologists+from+China.&amp;publication_year=2020&amp;journal=Clin+Immunol&amp;pages=108393-108393&amp;doi=10.1016%2Fj.clim.2020.108393&amp;pmid=32222466" target="_blank">Google Scholar</a></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">108.</div><div id="core-r108" class="citations"><div class="citation"><div class="citation-content">Behrens EM, Koretzky GA. Review: cytokine storm syndrome: looking toward the precision medicine era. <em>Arthritis Rheumatol</em> 2017;69:1135-1143.</div><div class="external-links"><div class="to-citation__wrapper"><a class="to-citation" href="#body-ref-r109"><i aria-hidden="true" class="icon-return"></i><span>Go to Citation</span></a></div><div class="core-xlink-crossref"><a href="https://doi.org/10.1002/art.40071" target="_blank">Crossref</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/28217930/" target="_blank">PubMed</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=Review%3A+cytokine+storm+syndrome%3A+looking+toward+the+precision+medicine+era.&amp;publication_year=2017&amp;journal=Arthritis+Rheumatol&amp;pages=1135-1143&amp;doi=10.1002%2Fart.40071&amp;pmid=28217930" target="_blank">Google Scholar</a></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">109.</div><div id="core-r109" class="citations"><div class="citation"><div class="citation-content">de Jesus AA, Hou Y, Brooks S, et al. Distinct interferon signatures and cytokine patterns define additional systemic autoinflammatory diseases. <em>J Clin Invest</em> 2020;130:1669-1682.</div><div class="external-links"><div class="to-citation__wrapper"><a class="to-citation" href="#body-ref-r109"><i aria-hidden="true" class="icon-return"></i><span>Go to Citation</span></a></div><div class="core-xlink-crossref"><a href="https://doi.org/10.1172/JCI129301" target="_blank">Crossref</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/31874111/" target="_blank">PubMed</a></div><div class="core-xlink-isi"><a href="https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;DestApp=WOS_CPL&amp;UsrCustomerID=5e3815c904498985e796fc91436abd9a&amp;SrcAuth=atyponcel&amp;SrcApp=literatum&amp;DestLinkType=FullRecord&amp;KeyUT=000530101000019" target="_blank">Web of Science</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=Distinct+interferon+signatures+and+cytokine+patterns+define+additional+systemic+autoinflammatory+diseases.&amp;publication_year=2020&amp;journal=J+Clin+Invest&amp;pages=1669-1682&amp;doi=10.1172%2FJCI129301&amp;pmid=31874111" target="_blank">Google Scholar</a></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">110.</div><div id="core-r110" class="citations"><div class="citation"><div class="citation-content">Shimizu M, Nakagishi Y, Yachie A. Distinct subsets of patients with systemic juvenile idiopathic arthritis based on their cytokine profiles. <em>Cytokine</em> 2013;61:345-348.</div><div class="external-links"><div class="to-citation__wrapper"><a class="to-citation" href="#body-ref-r110"><i aria-hidden="true" class="icon-return"></i><span>Go to Citation</span></a></div><div class="core-xlink-crossref"><a href="https://doi.org/10.1016/j.cyto.2012.11.025" target="_blank">Crossref</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/23276493/" target="_blank">PubMed</a></div><div class="core-xlink-isi"><a href="https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;DestApp=WOS_CPL&amp;UsrCustomerID=5e3815c904498985e796fc91436abd9a&amp;SrcAuth=atyponcel&amp;SrcApp=literatum&amp;DestLinkType=FullRecord&amp;KeyUT=000314742800003" target="_blank">Web of Science</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=Distinct+subsets+of+patients+with+systemic+juvenile+idiopathic+arthritis+based+on+their+cytokine+profiles.&amp;publication_year=2013&amp;journal=Cytokine&amp;pages=345-348&amp;doi=10.1016%2Fj.cyto.2012.11.025&amp;pmid=23276493" target="_blank">Google Scholar</a></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">111.</div><div id="core-r111" class="citations"><div class="citation"><div class="citation-content">Vercruysse F, Barnetche T, Lazaro E, et al. Adult-onset Still’s disease biological treatment strategy may depend on the phenotypic dichotomy. <em>Arthritis Res Ther</em> 2019;21:53-53.</div><div class="external-links"><div class="to-citation__wrapper"><a class="to-citation" href="#body-ref-r111"><i aria-hidden="true" class="icon-return"></i><span>Go to Citation</span></a></div><div class="core-xlink-crossref"><a href="https://doi.org/10.1186/s13075-019-1838-6" target="_blank">Crossref</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/30755262/" target="_blank">PubMed</a></div><div class="core-xlink-isi"><a href="https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;DestApp=WOS_CPL&amp;UsrCustomerID=5e3815c904498985e796fc91436abd9a&amp;SrcAuth=atyponcel&amp;SrcApp=literatum&amp;DestLinkType=FullRecord&amp;KeyUT=000458723300003" target="_blank">Web of Science</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=Adult-onset+Still%E2%80%99s+disease+biological+treatment+strategy+may+depend+on+the+phenotypic+dichotomy.&amp;publication_year=2019&amp;journal=Arthritis+Res+Ther&amp;pages=53-53&amp;doi=10.1186%2Fs13075-019-1838-6&amp;pmid=30755262" target="_blank">Google Scholar</a></div></div></div></div></div></div></div></div><aside data-core-aside="right-rail">



        
        <div id="DTM_Position_MedRectangle" class="ad">
 <!--emptycomment-->
</div>




        
        <div class="ng-page_layout-sidebarSpacing"></div>










    
    
        <div data-widget-def="relatedArticlesWidget" data-widget-id="8206d5cd-cb8c-4ff9-8c46-3d22e0dee215" data-location="recirc_curatedRelated_article">
        



        
        <div class="ng-related-articles"><h3 class="ng-subsection-title"><span class="ng-subsection-title_text">Related articles</span></h3><ul class="ng-related-articles_list"><li class="ng-related-articles_item"><div class="issue-item issue-item_sm"><div class="issue-item_meta"><ul class="issue-item_meta-list clearfix"><li class="issue-item_meta-item"><a href="/browse/nejm-article-type/correspondence" class="issue-item_type">Correspondence</a></li><li class="issue-item_meta-item"><span class="issue-item_date">Apr 21, 2021</span></li></ul></div><div class="issue-item_row"><div class="issue-item_left"><div class="issue-item_content clearfix"><h4 class="issue-item_title"><a href="/doi/full/10.1056/NEJMc2036236" data-interactiontype="article_recirculation_click" class="issue-item_title-link animation-underline">Cytokine Storm</a></h4><div class="issue-item_authors-and-text"></div></div></div></div></div></li></ul></div>

        </div>
    





        
        <div class="ng-page_layout-sidebarSpacing"></div>




        
        <div id="nejm_jobs" class="nejm_jobs"> <!-- top red rectangle --><div id="nejm-widget" class="nejm-widget" style="display: block;"><div class="nejm-widget_logo">	<a target="nejm-win" href="https://www.nejmcareercenter.org/?query=fjw">		<img alt="CareerCenter" src="https://apps1.nejmcareercenter.org/images/nejmCCID-JobsWidget.gif" width="140" height="36">	</a></div><div class="nejm-widget_cont"> <!-- content --><div class="nejm-widget_title">PHYSICIAN JOBS</div><div class="nejm-widget_date">June 9, 2025</div><div class="nejm-widget_item"><div><span> Salem, New Hampshire</span></div><div><span>Cardiology</span></div><div><a target="nejm-job-win" onmouseover="jlho(this);" onmouseout="jlou(this);" href="https://www.nejmcareercenter.org/job/881815/non-invasive-cardiologist-merrimack-valley-and-southern-nh/?query=fjwp&amp;rid=428606">Non-Invasive Cardiologist, Merrimack Valley and Southern NH</a></div></div><div class="nejm-widget_item"><div><span> New Hyde Park, New York</span></div><div><span>Hospitalist</span></div><div><a target="nejm-job-win" onmouseover="jlho(this);" onmouseout="jlou(this);" href="https://www.nejmcareercenter.org/job/715653/pediatric-hospitalists-cohen-children-s-medical-center/?query=fjwp&amp;rid=3059">Pediatric Hospitalists - Cohen Children's Medical Center</a></div></div><div class="nejm-widget_item"><div><span> San Francisco, California</span></div><div><span>Neonatal / Perinatal Medicine</span></div><div><a target="nejm-job-win" onmouseover="jlho(this);" onmouseout="jlou(this);" href="https://www.nejmcareercenter.org/job/881703/swbmg-neonatal-hospitalist/?query=fjwf&amp;rid=845672">SWBMG - Neonatal Hospitalist</a></div></div><div class="nejm-widget_item"><div><span> Staten Island, New York</span></div><div><span>Pulmonary Disease</span></div><div><a target="nejm-job-win" onmouseover="jlho(this);" onmouseout="jlou(this);" href="https://www.nejmcareercenter.org/job/746127/interventional-pulmonary-physician-major-new-york-teaching-hospital-siuh/?query=fjwp&amp;rid=3059">Interventional Pulmonary Physician, Major New York Teaching Hospital, SIUH</a></div></div><div class="nejm-widget_item"><div><span> Lutz, Florida</span></div><div><span>Neonatal / Perinatal Medicine</span></div><div><a target="nejm-job-win" onmouseover="jlho(this);" onmouseout="jlou(this);" href="https://www.nejmcareercenter.org/job/887370/neonatologist/?query=fjwf&amp;rid=49812">Neonatologist</a></div></div><div class="nejm-widget_item"><div><span> Bountiful, Utah</span></div><div><span>Psychiatry</span></div><div><a target="nejm-job-win" onmouseover="jlho(this);" onmouseout="jlou(this);" href="https://www.nejmcareercenter.org/job/891177/resident-and-fellowship-trained-psychiatrists-outpatient/?query=fjwf&amp;rid=377088">Resident and Fellowship trained Psychiatrists Outpatient</a></div></div></div> <!-- content --> <!-- footer --></div> <!-- nejm-widget --></div><script src="https://apps1.nejmcareercenter.org/?width=300&amp;sp=all"></script>




        
        <div class="ng-page_layout-sidebarSpacing"></div>










    
    
        <div data-widget-def="literatumAd" data-widget-id="001e4aa7-b6fe-4b21-9d5b-5bde81227c67" id="ad-article-right-rail-300x250-1">
        



        
        



    
        <div class="pb-house-message adplaceholder exists">
            <a href="/action/clickThrough?id=128720&amp;url=https%3A%2F%2Fstore.nejm.org%2Fsignup%2Fnejmai%2Fregister%2Faifallpdf24%3Fpromo%3DOAFQF4NA%26query%3Dcm-rr%26utm_source%3Dnejm%26utm_medium%3Dcm%26utm_campaign%3Daifallpdf24&amp;loc=%2Fdoi%2Ffull%2F10.1056%2FNEJMra2026131&amp;pubId=41289057&amp;placeholderId=101337&amp;productId=1007" target="_blank"><img src="/sda/128720/NEJ-AI-Fall24-300x250---002.jpg" width="300" height="250"></a>
            
        </div>
    

    

    



        </div>
    





        
        <div class="ng-page_layout-sidebarSpacing"></div>




        
        <script src="https://widgets.nejm.org/onepub-widgets/loader/webcomponents-loader.js" async="" nonce="94d65ade13caf211-SJC">
<script src="https://widgets.nejm.org/onepub-widgets/loader/polyfill-support.js"  nonce="94d65ade13caf211-SJC"></script>
<script src="https://widgets.nejm.org/onepub-widgets/more-like-this.js" type="module" nonce="94d65ade13caf211-SJC"></script>

<more-like-this class="onepub-widget" dataid="onepub-more-like-this" collections="catalyst-article, clinician-article, evidence-article, nejm-ai-article, nejm-article" headertitle="More Like This" maxitems="5"><!----><div class="more-like-this onepub-more-like-this_"><!--?lit$249620204$--><onepub-fonts><wc-fetch></wc-fetch><!--?lit$249620204$--><div class="mlt-wrapper"><div class="mlt-header-container"><div class="mlt-header-content-left"><div class="mlt-header-title-container"><span class="mlt-header-title">More Like This</span></div><!--?lit$249620204$--></div></div><div class="mlt-body"><!--?lit$249620204$--><!----><div class="mlt-article-container"><div class="mlt-article-container-header"><a data-location="recirc_Semantic" class="mlt-article-type nejm" href="https://www.nejm.org/browse/nejm-article-type/original-article" target="_self"><!--?lit$249620204$-->Original Article</a> <span class="mlt-article-site-label"><!--?lit$249620204$-->NEJM</span> <span class="mlt-article-pubdate"><!--?lit$249620204$-->May 08, 2025</span></div><div class="mlt-article-title"><a data-location="recirc_Semantic" href="https://www.nejm.org/doi/full/10.1056/NEJMoa2408771?query=recirc_Semantic" target="_self">Enhanced CAR T-Cell Therapy for Lymphoma after Previous Failure</a></div><div class="mlt-article-authors"><!--?lit$249620204$-->J. Svoboda and Others</div></div><!----><!----><div class="mlt-article-container"><div class="mlt-article-container-header"><a data-location="recirc_Semantic" class="mlt-article-type nejm" href="https://www.nejm.org/browse/nejm-article-type/original-article" target="_self"><!--?lit$249620204$-->Original Article</a> <span class="mlt-article-site-label"><!--?lit$249620204$-->NEJM</span> <span class="mlt-article-pubdate"><!--?lit$249620204$-->Jan 09, 2025</span></div><div class="mlt-article-title"><a data-location="recirc_Semantic" href="https://www.nejm.org/doi/full/10.1056/NEJMoa2406536?query=recirc_Semantic" target="_self">Talquetamab plus Teclistamab in Relapsed or Refractory Multiple Myeloma</a></div><div class="mlt-article-authors"><!--?lit$249620204$-->Y.C. Cohen and Others</div></div><!----><!----><div class="mlt-article-container"><div class="mlt-article-container-header"><a data-location="recirc_Semantic" class="mlt-article-type nejm" href="https://www.nejm.org/browse/nejm-article-type/original-article" target="_self"><!--?lit$249620204$-->Original Article</a> <span class="mlt-article-site-label"><!--?lit$249620204$-->NEJM</span> <span class="mlt-article-pubdate"><!--?lit$249620204$-->Jun 02, 2025</span></div><div class="mlt-article-title"><a data-location="recirc_Semantic" href="https://www.nejm.org/doi/full/10.1056/NEJMoa2502099?query=recirc_Semantic" target="_self">Tarlatamab in Small-Cell Lung Cancer after Platinum-Based Chemotherapy</a></div><div class="mlt-article-authors"><!--?lit$249620204$-->G. Mountzios and Others</div></div><!----><!----><div class="mlt-article-container"><div class="mlt-article-container-header"><a data-location="recirc_Semantic" class="mlt-article-type nejm" href="https://www.nejm.org/browse/nejm-article-type/original-article" target="_self"><!--?lit$249620204$-->Original Article</a> <span class="mlt-article-site-label"><!--?lit$249620204$-->NEJM</span> <span class="mlt-article-pubdate"><!--?lit$249620204$-->Dec 12, 2024</span></div><div class="mlt-article-title"><a data-location="recirc_Semantic" href="https://www.nejm.org/doi/full/10.1056/NEJMoa2406526?query=recirc_Semantic" target="_self">Obecabtagene Autoleucel in Adults with B-Cell Acute Lymphoblastic Leukemia</a></div><div class="mlt-article-authors"><!--?lit$249620204$-->C. Roddie and Others</div></div><!----><!----><div class="mlt-article-container"><div class="mlt-article-container-header"><a data-location="recirc_Semantic" class="mlt-article-type nejm" href="https://www.nejm.org/browse/nejm-article-type/editorial" target="_self"><!--?lit$249620204$-->Editorial</a> <span class="mlt-article-site-label"><!--?lit$249620204$-->NEJM</span> <span class="mlt-article-pubdate"><!--?lit$249620204$-->Dec 10, 2020</span></div><div class="mlt-article-title"><a data-location="recirc_Semantic" href="https://www.nejm.org/doi/full/10.1056/NEJMe2032071?query=recirc_Semantic" target="_self">Tocilizumab for Covid-19 — The Ongoing Search for Effective Therapies</a></div><div class="mlt-article-authors"><!--?lit$249620204$-->E. Huang and S.C. Jordan</div></div><!----></div><div class="mlt-footer"></div></div></onepub-fonts><style>:host{display:block}@keyframes fadeIn{0%{opacity:0}100%{opacity:1}}.more-like-this{max-width:25rem}.more-like-this *{font-variant-numeric:lining-nums}.mlt-wrapper{animation:fadeIn 1s}.mlt-header-container{border-bottom:#4d4d4d solid .0625rem;border-top:#4d4d4d solid .125rem}.mlt-header-title{color:#1a1a1a;display:block;font-family:var(--sans-serif);font-size:1rem;font-weight:700;letter-spacing:.02rem;line-height:1.5rem;padding-bottom:.94rem;padding-top:.94rem;text-transform:uppercase}.mlt-header-description{color:#333;display:block;font-family:ff-scala-sans-pro;font-size:.75rem;letter-spacing:.05rem;margin-top:-.5rem;padding-bottom:1rem;text-transform:uppercase}.mlt-article-container{border-bottom:#e5e5e5 solid .0625rem;margin-top:1.38rem}.mlt-article-container-header{font-family:var(--sans-serif);font-size:.6875rem;letter-spacing:.04em;line-height:1.125rem;margin:0 0 1rem;text-transform:uppercase}.mlt-article-type{font-weight:700;line-height:1.25rem;letter-spacing:.04rem;text-decoration:none}.mlt-article-type:hover{text-decoration:underline}.nejm{color:#f30}.nejm-ai{color:#006197}.nejm-catalyst{color:#5708a6}.nejm-evidence{color:#69a323}.mlt-article-site-label::after,.mlt-article-type::after{border-right:1px solid #e5e5e5;content:'';display:inline;padding:.1875rem .375rem .125rem 0;margin:0 .375rem 0 0}.mlt-article-pubdate{color:#666;font-style:normal;font-weight:700;line-height:1.25rem;letter-spacing:.04em}.mlt-article-authors{color:#666;font-family:var(--sans-serif);font-size:1rem;font-style:normal;font-weight:400;letter-spacing:normal;line-height:1.5rem;margin-bottom:1.38rem}.mlt-article-site-label{color:#666;font-style:normal;font-weight:700;letter-spacing:.04em}.mlt-article-title{margin-bottom:.5rem}.mlt-article-title>a{background-image:linear-gradient(#f30,#f30);background-position:0 90%;background-repeat:no-repeat;background-size:0 0;color:#1a1a1a;font-family:var(--quadraat-web);font-size:1.25rem;font-style:normal;font-weight:700;letter-spacing:normal;line-height:1.8rem;margin:1.5rem 0 .35rem 0;text-decoration:none;transition:background .25s ease-in-out}.mlt-article-title>a:hover{background-position:0 98%;background-size:100% .125rem;text-decoration:none}.skeleton-card{box-shadow:0 0 4px 1px rgba(0,0,0,.1);margin:1rem 0;padding:1rem}</style></div></more-like-this>




        
        <div><div class="pb-dropzone" data-pb-dropzone="col-0" title="col-0"></div></div>










    
    
        <div data-widget-def="UX3HTMLWidget" data-widget-id="ad06db99-f228-4c92-9ad7-c4ae0fdbdbf1" id="bc-web-rec">
        



        
        <!-- BlueConic TEST empty HTML widget with DIV wrapper with id=bc-web-rec -->

        </div>
    

</aside></article><div data-extent="article-wrapper"><div class="core-container"></div><div class="after-credits"><div class="core-container"><a href="/doi/pdf/10.1056/NEJMra2026131?download=true" id="downloadPdfUrl" data-doi="10.1056/NEJMra2026131" data-behavior="trackDownloadEvent" data-interactiontype="article_tools_download_pdf" data-multimedia-type="Article PDF" data-multimedia-filename="nejmra2026131.pdf"><span>Download PDF</span></a></div></div></div><script id="axel-publication-metadata" type="application/json">{"doi":"10.1056/NEJMra2026131"}
</script><script type="text/javascript" data-ot-ignore="data-ot-ignore" defer="defer" src="https://static.addtoany.com/menu/page.js" class="optanon-category-C0004 ot-vscat-C0004"></script><div class="articles-nav"></div><template id="figure_nav_template"><nav><a href="#" title="Open in viewer" class="open-in-viewer"><i aria-hidden="true" class="icon-expand"></i></a></nav></template><template id="fv_panel_template" data-sharesocial="Share"><div class="fv__panel js--hidden"><div class="fv__panel__text"><div class="fv__panel__contentTitle"></div><div class="fv__panel__contentText"></div></div></div></template>
<template id="fv_directory_template" data-overlay="View figure"><div class="fv__directory"><div class="fv__header"><nav class="tab__nav"></nav><a href="#" title="Close figure viewer" class="fv__close"><i aria-hidden="true" class="icon-close"></i></a></div><div class="fv__content tab__content"></div></div></template><template id="fv_directory_tabItem_template" data-figures="Figures" data-others="Others" data-tables="Tables"><button role="tab" data-toggle="tab" class="tab__nav__item"></button></template>
<template id="fv_lightbox_template" data-sr-back="Go to figure location within the article" data-sr-closealt="Close" data-sr-download="Toggle download panel" data-sr-download-pptx="Download PPT" data-sr-info="Toggle information panel" data-sr-panel="Close panel" data-sr-share="Toggle share panel" data-sr-zoom="Zoom" data-text-close="Back to article" data-text-nav-figures="All figures" data-text-nav-others="All others" data-text-nav-tables="All tables" data-text-viewall="View all material" data-title-back="Back to article" data-title-closealt="Close" data-title-download="Download" data-title-download-pptx="Download PPT" data-title-info="Info" data-title-share="Share" data-title-zoom="Zoom"></template>
<template id="fv_toolbar_template"><div class="fv__toolbar__info"><strong class="fv__toolbar__contentTitle uppercase"></strong><p class="fv__toolbar__contentText"></p></div></template><template id="toCitationLink" data-citation="Citation" data-footnote="Footnote"><div class="to-citation__wrapper"><a class="to-citation"><i aria-hidden="true" class="icon-return"></i><span>Go to</span></a></div></template><template id="toCitationButton" data-citation="Citation" data-footnote="Footnote"><div class="to-citation__wrapper"><button class="to-citation"><i aria-hidden="true" class="icon-return"></i><span>Go to</span></button></div></template><template id="toCitationAccordion" data-collapse-citation="Hide Citations" data-expand-citation="Show Citations" data-collapse-footnote="Hide Footnotes" data-expand-footnote="Show Footnotes"><div class="to-citation__wrapper"><button aria-controls="aria-controls" aria-expanded="false" aria-label="Toggle citations menu" class="to-citation__toggle"><i aria-hidden="true" class="icon-plus"></i><span data-expand-title="data-expand-title" data-collapsed-title="data-collapsed-title" class="accordion__toggle__title"></span></button><div role="menu" aria-label="links" class="to-citation__accordion no-separator"><ul></ul></div></div></template><template id="toCitationAccordionItem"><li><a class="to-citation"><i aria-hidden="true" class="icon-return"></i><span></span></a></li></template><template id="citations_truncate_template"><div class="citations-truncation"><button data-label-expand="Show all references" data-label-collapse="Show fewer" data-label-remaining="references remaining" class="btn btn--secondary"><span>Show all references</span></button></div></template><template id="collateral_texts_template" data-references="References" data-figure="Go to Figure" data-media="Go to Media" data-more="More" data-original="Go to original" data-table="Go to Table" data-inviewer="Open in Viewer" data-allinviewer="Open all in viewer"><svg data-tags="copyright" viewBox="0 0 24 24"><path d="M12 20.016q3.281 0 5.648-2.368T20.016 12t-2.368-5.648T12 3.984 6.352 6.352 3.984 12t2.368 5.648T12 20.016zm0-18q4.125 0 7.055 2.93T21.985 12t-2.93 7.055T12 21.985t-7.055-2.93T2.015 12t2.93-7.055T12 2.015zm-.14 7.125q-1.876 0-1.876 2.718v.282q0 2.718 1.875 2.718.704 0 1.172-.398t.469-1.008h1.781q0 1.172-1.031 2.063-.984.843-2.39.843-1.876 0-2.86-1.125t-.984-3.093v-.282q0-1.921.937-3 1.125-1.265 2.906-1.265 1.547 0 2.438.89.984.985.984 2.297H13.5q0-.328-.14-.61-.235-.468-.329-.562-.469-.468-1.172-.468z"></path></svg><span>Request permissions</span><i aria-hidden="true" class="icon-open_in_new"></i></template><template id="collapsible_authors_template"><button aria-expanded="false" data-expandable="all" data-label-expand="Expand All" data-label-collapse="Collapse All" class="collateral-contributors-control"><span>Expand All</span></button></template>
<template id="collapsible_tables_collapse_template"><div class="collapsible-figure-btn__wrapper expanded"><button aria-expanded="true" class="btn collapsible-figure-btn btn--inverse"><i aria-hidden="true" class="icon-arrow-up"></i><span class="text-uppercase">Collapse</span></button></div></template>
<template id="collapsible_tables_expand_template"><div class="collapsible-figure-btn__wrapper collapsed"><button aria-expanded="false" class="btn collapsible-figure-btn btn--inverse"><i aria-hidden="true" class="icon-arrow-down"></i><span class="text-uppercase">Expand Table</span></button></div></template><template id="authorsAffiliationsLink"><a href="#tab-contributors" class="to-authors-affiliations">Authors Info &amp; Affiliations</a></template>

        <div role="navigation" aria-label="Sticky Navigation" class="st-header"><div class="st-header__content"><div class="st-header__item st-header__menu"></div><div class="st-header__current st-header__item"><div class="st-header__label">Now Reading:</div><div class="st-header__title">Cytokine Storm</div></div><div class="st-header__share st-header__item"><div class="share-dropblock dropdown"><a id="sticky-header-dropBlock" href="#" role="button" data-toggle="dropdown" aria-haspopup="true" aria-expanded="false" class="dropdown-toggle"><span title="" data-toggle="tooltip" data-trigger="hover" data-original-title="Share options"><span class="sr-only">Share</span><i aria-hidden="true" class="icon-share"></i></span></a><div aria-labelledby="sticky-header-dropBlock" data-location="share_tools_article" class="dropdown-menu"><ul class="rlist--inline a2a a2a_kit" style="line-height: 16px;"><li><a href="/#facebook" aria-label="Share on Facebook" data-id="article-share-facebook" rel="nofollow noopener" role="link" target="_blank" title="Share on Facebook" class="btn btn--facebook a2a_button_facebook" data-interactiontype="social"><i aria-hidden="true" class="icon-facebook"></i></a></li><li><a href="/#twitter" aria-label="Share on X (formerly Twitter)" data-id="article-share-twitter" rel="nofollow noopener" role="link" target="_blank" title="Share on X (formerly Twitter)" class="btn btn--twitter a2a_button_twitter" data-interactiontype="social"><i aria-hidden="true" class="icon-twitter"></i></a></li><li><a href="/#linkedin" aria-label="Share on LinkedIn" data-id="article-share-linkedin" rel="nofollow noopener" role="link" target="_blank" title="Share on LinkedIn" class="btn btn--linkedin a2a_button_linkedin" data-interactiontype="social"><i aria-hidden="true" class="icon-linkedin"></i></a></li><li><a href="/#email" aria-label="Share on email" data-id="article-share-email" rel="nofollow noopener" role="link" target="_blank" title="Share on email" class="btn btn--email a2a_button_email" data-interactiontype="content_email_click"><i aria-hidden="true" class="icon-mail"></i></a></li><li><a href="/#bluesky" aria-label="Share on Bluesky" data-id="article-share-bluesky" rel="nofollow noopener" role="link" target="_blank" title="Share on Bluesky" class="btn btn--bluesky a2a_button_bluesky" data-interactiontype="social"><i aria-hidden="true" class="icon-bluesky"></i></a></li></ul></div></div></div><div class="st-header__nav st-header__item"><div class="content-navigation"><a href="/doi/full/10.1056/NEJMoa2002820" aria-label="Previous article" aria-disabled="false" class="content-navigation__prev"><div aria-hidden="true" class="content-navigation__hint"><div class="content-navigation__hint__content"><h6>PREVIOUS ARTICLE</h6><div>Malaria Chemoprevention in the Postdischarge Management of Severe Anemia</div></div></div><i aria-hidden="true" class="icon-arrow-left"></i><span>Previous</span></a><a href="/doi/full/10.1056/NEJMicm2024132" aria-label="Next article" aria-disabled="false" class="content-navigation__next"><div aria-hidden="true" class="content-navigation__hint"><div class="content-navigation__hint__content"><h6>NEXT ARTICLE</h6><div>Corneal Bee Sting</div></div></div><span>Next</span><i aria-hidden="true" class="icon-arrow-right"></i></a></div></div></div><div class="st-header__track"><div id="progress-tracker" class="st-header__tracker" style="width: 0px;"></div></div></div><div class="fv figureViewer js--has-focus-mode"><div class="fv__directory" data-core-tabs="default" style="display: flex;"><div class="fv__header"><nav class="tab__nav" role="tablist"><button role="tab" data-toggle="tab" class="tab__nav__item active" aria-controls="#tab-pane-figures" aria-selected="true">Figures</button><button role="tab" data-toggle="tab" class="tab__nav__item" aria-controls="#tab-pane-tables" tabindex="-1" aria-selected="false">Tables</button></nav><a href="#" title="Close figure viewer" class="fv__close"><i aria-hidden="true" class="icon-close"></i></a></div><div class="fv__content tab__content"><div class="tab__pane fv__list fv__list--figures" id="tab-pane-figures" aria-label="All figures" tabindex="0" role="tabpanel"><div class="fv__item"><a class="fv__open-item fv__item__view fv__fit" href="#fv-f1" data-type="figures" data-interactiontype="multimedia_click" data-multimedia-type="Figure" data-multimedia-filename="nejmra2026131_f1.jpg"><img src="/cms/10.1056/NEJMra2026131/asset/909f0648-4b51-4338-9760-cefa7aab4ca6/assets/images/large/nejmra2026131_f1.jpg" height="2206" width="2640" aria-labelledby="f1" loading="lazy"><span class="fv__fit--overlay"><span>View figure</span></span></a><div class="fv__item__title">Figure 1</div><div class="fv__item__description"><figcaption><div class="caption">Clinical Presentation of Cytokine Storm.</div><div class="notes"><div role="doc-footnote">A wide range of clinical and laboratory abnormalities can be observed in cytokine storm. However, all cases involve elevated circulating cytokine levels, acute systemic inflammatory symptoms, and secondary organ dysfunction (often renal, hepatic, or pulmonary). ARDS denotes acute respiratory distress syndrome, CRP C-reactive protein, and VEGF vascular endothelial growth factor.</div></div></figcaption></div></div><div class="fv__item"><a class="fv__open-item fv__item__view fv__fit" href="#fv-f2" data-type="figures" data-interactiontype="multimedia_click" data-multimedia-type="Figure" data-multimedia-filename="nejmra2026131_f2.jpg"><img src="/cms/10.1056/NEJMra2026131/asset/90086a76-be54-4325-874f-c36584350de8/assets/images/large/nejmra2026131_f2.jpg" height="3341" width="2640" aria-labelledby="f2" loading="lazy"><span class="fv__fit--overlay"><span>View figure</span></span></a><div class="fv__item__title">Figure 2</div><div class="fv__item__description"><figcaption><div class="caption">Pathophysiological Features of Cytokine Storm.</div><div class="notes"><div role="doc-footnote">Cytokine storm can occur as a result of inappropriate recognition (e.g., in hypersensitivity) or ineffective recognition with immune evasion (e.g., in Epstein–Barr virus [EBV]–associated hemophagocytic lymphohistiocytosis [HLH]), an inappropriate response with an exaggerated effector response and cytokine production (e.g., in chimeric antigen receptor [CAR] T-cell therapy) or an ineffective response due to immune evasion (e.g., in sepsis), or failure to terminate homeostasis or return to homeostasis (e.g., in HLH). Examples of drugs that can inhibit signaling pathways are shown in boxes. Covid-19 denotes coronavirus disease 2019, CS cytokine storm, IL1RA interleukin-1–receptor antagonist, IP-10 interferon-inducible protein 10, JAK-STAT3 Janus kinase–signal transducer and activator of transcription 3, MAPK mitogen-activated protein kinase, MCP-1 monocyte chemotactic protein 1, MIP-1α macrophage inflammatory protein 1α, mTOR mammalian target of rapamycin, NF-κB nuclear factor κB, TNF tumor necrosis factor, and Tregs regulatory T cells.</div></div></figcaption></div></div><div class="fv__item"><a class="fv__open-item fv__item__view fv__fit" href="#fv-f3" data-type="figures" data-interactiontype="multimedia_click" data-multimedia-type="Figure" data-multimedia-filename="nejmra2026131_f3.jpg"><img src="/cms/10.1056/NEJMra2026131/asset/7aaf6482-acae-4bdc-8a34-aeafb104077d/assets/images/large/nejmra2026131_f3.jpg" height="1605" width="2640" aria-labelledby="f3" loading="lazy"><span class="fv__fit--overlay"><span>View figure</span></span></a><div class="fv__item__title">Figure 3</div><div class="fv__item__description"><figcaption><div class="caption">T-Cell Effector Subgroups Involved in Cytokine Storm.</div><div class="notes"><div role="doc-footnote">The master transcription factors (T-bet, GATA-3, PU.1, RORγT, and eomesodermin [eomes]), effector molecules, and cell targets are shown for the following T-cell subgroups: types 1, 2, 9, and 17 helper T (Th1, Th2, Th9, and Th17, respectively) cells and cytotoxic T lymphocytes.</div></div></figcaption></div></div></div><div class="tab__pane fv__list fv__list--tables" id="tab-pane-tables" aria-label="All tables" tabindex="-1" role="tabpanel"><div class="fv__item"><a class="fv__open-item fv__item__view" href="#fv-t1" data-type="tables" data-interactiontype="multimedia_click" data-multimedia-type="Table"><i class="icon-tables"></i></a><div class="fv__item__title">Table 1</div><div class="fv__item__description"><figcaption><div class="caption">Soluble Mediators in Cytokine Storm.<a href="#fv-t1fn1" role="doc-noteref">*</a></div></figcaption></div></div><div class="fv__item"><a class="fv__open-item fv__item__view" href="#fv-t2" data-type="tables" data-interactiontype="multimedia_click" data-multimedia-type="Table"><i class="icon-tables"></i></a><div class="fv__item__title">Table 2</div><div class="fv__item__description"><figcaption><div class="caption">Clinical Causes of Cytokine Storm, Pathologic Drivers, and Therapeutic Approaches.<a href="#fv-t2fn1" role="doc-noteref">*</a></div></figcaption></div></div></div></div></div></div><div class="references-pop-up fade" aria-hidden="true"><div class="references-pop-up__heading text-dark d-flex align-items-center"><div class="references-pop-up__title flex-grow-1">Reference <span class="references-pop-up__heading-number">1</span></div><a class="references-pop-up__close text-dark" href="#" title="close pop-up" tabindex="-1" aria-hidden="true"><i class="icon-close" aria-hidden="true"></i></a></div><div class="references-pop-up__items citations to-citation__accordion external-links"></div></div></main>
    

</div>

                    
                        



        
        <div class="ng-page_layout ng-page_layout-fullWidth"><div class="container-fluid"><div class="row"><div class="col-12">



        
        




        
        <div class="ng-page_layout-contentSpacing"></div>










    
    
        <div data-widget-def="oneSearchMultiSearch" data-widget-id="778b3ad8-1a8d-43d8-8196-63b03df4a138" data-location="recirc_inIssue_bottom_article">
        



        
        <div class="os-ms os-ms-more-from-issue"><h3 class="ng-subsection-title"><a href="/toc/nejm/383/23" class="ng-subsection-title_link animation-icon-shift"><span class="ng-subsection-title_text">More from Vol. 383 No. 23</span><span class="ng-subsection-title_icon"><span class="icon-component "><svg aria-hidden="true" style=""><use xlink:href="/specs/products/mms-nextgen/mms/releasedAssets/icons/icons-3acb348e68a3edd0c676698e8d598c68.spritemap.svg#arrows-longArrowRight"></use></svg></span></span></a></h3><ul class="os-ms-more-from-issue_list"><li class="os-ms-more-from-issue_item"><div class="issue-item issue-item_sm"><div class="issue-item_meta"><ul class="issue-item_meta-list clearfix"><li class="issue-item_meta-item"><a href="/browse/nejm-article-type/original-article" class="issue-item_type">Original Article</a></li><li class="issue-item_meta-item"><span class="issue-item_date">Dec 03, 2020</span></li><li class="issue-item_meta-item"><span class="issue-item_free">FREE</span></li></ul></div><div class="issue-item_row"><div class="issue-item_left"><div class="issue-item_content clearfix"><h4 class="issue-item_title"><a href="/doi/full/10.1056/NEJMoa2017699" data-interactiontype="article_recirculation_click" class="issue-item_title-link animation-underline">Pembrolizumab in Microsatellite-Instability–High Advanced Colorectal Cancer</a></h4><div class="issue-item_authors-and-text"><span class="issue-item_authors">T. André and Others</span></div></div></div></div></div></li><li class="os-ms-more-from-issue_item"><div class="issue-item issue-item_sm"><div class="issue-item_meta"><ul class="issue-item_meta-list clearfix"><li class="issue-item_meta-item"><a href="/browse/nejm-article-type/original-article" class="issue-item_type">Original Article</a></li><li class="issue-item_meta-item"><span class="issue-item_date">Dec 03, 2020</span></li><li data-toggle="tooltip" data-original-title="Visual Abstract" class="issue-item_meta-item"><span role="img" aria-label="Visual Abstract" tabindex="0" class="issue-item_visualAbstract"><span class="icon-component "><svg aria-hidden="true" style=""><use xlink:href="/specs/products/mms-nextgen/mms/releasedAssets/icons/icons-3acb348e68a3edd0c676698e8d598c68.spritemap.svg#tooltip-visual"></use></svg></span></span></li><li class="issue-item_meta-item"><span class="issue-item_free">FREE</span></li></ul></div><div class="issue-item_row"><div class="issue-item_left"><div class="issue-item_content clearfix"><h4 class="issue-item_title"><a href="/doi/full/10.1056/NEJMoa2002820" data-interactiontype="article_recirculation_click" class="issue-item_title-link animation-underline">Malaria Chemoprevention in the Postdischarge Management of Severe Anemia</a></h4><div class="issue-item_authors-and-text"><span class="issue-item_authors">T.K. Kwambai and Others</span></div></div></div></div></div></li><li class="os-ms-more-from-issue_item"><div class="issue-item issue-item_sm"><div class="issue-item_meta"><ul class="issue-item_meta-list clearfix"><li class="issue-item_meta-item"><a href="/browse/nejm-article-type/original-article" class="issue-item_type">Original Article</a></li><li class="issue-item_meta-item"><span class="issue-item_date">Dec 03, 2020</span></li><li data-toggle="tooltip" data-original-title="Video" class="issue-item_meta-item"><span role="img" aria-label="Video" tabindex="0" class="issue-item_video"><span class="icon-component "><svg aria-hidden="true" style=""><use xlink:href="/specs/products/mms-nextgen/mms/releasedAssets/icons/icons-3acb348e68a3edd0c676698e8d598c68.spritemap.svg#tooltip-video"></use></svg></span></span></li><li class="issue-item_meta-item"><span class="issue-item_free">FREE</span></li></ul></div><div class="issue-item_row"><div class="issue-item_left"><div class="issue-item_content clearfix"><h4 class="issue-item_title"><a href="/doi/full/10.1056/NEJMoa2025845" data-interactiontype="article_recirculation_click" class="issue-item_title-link animation-underline">Effect of Finerenone on Chronic Kidney Disease Outcomes in Type 2 Diabetes</a></h4><div class="issue-item_authors-and-text"><span class="issue-item_authors">G.L. Bakris and Others</span></div></div></div></div></div></li></ul></div>

        </div>
    

</div></div></div></div>

                    
                        



        
        <div class="ng-page_layout-bottomAd"><div class="container-fluid"><div class="row"><div class="col-12">









    
    
        <div data-widget-def="literatumAd" data-widget-id="7e022d0d-4a48-44a7-af66-033cf5c13eb8" id="ad-article-bottom-FULLx320-1">
        



        
        



    
        <div class="pb-house-message adplaceholder exists">
            <!-- START: Circulation Footer 3 -->
<aside class="g-cta-subscribe">
	<style>
.bads_footer-banner24-ONJQNRF1{background:url(/pb-assets/contextual_messaging/footer-yel-background-2x-1513629627453.jpg) center center no-repeat;padding:20px;display:block;margin:0;min-height:inherit;background-size:cover;text-decoration:none!important;color:#1a1a1a;text-align:left}.bads_footer-banner24-ONJQNRF1 .g-cta-subscribe__title{font-size:42px;line-height:44px;letter-spacing:.2px;margin:0 0 20px;font-family:ff-quadraat-web-pro,sans-serif;font-weight:600}.bads_footer-banner24-ONJQNRF1-inner{max-width:1300px;margin:0 auto}.bads_footer-banner24-ONJQNRF1-inner .g-cta-subscribe__actions .a-btn{width:130px;padding-left:12px}.bads_footer-banner24-ONJQNRF1-inner .g-cta-subscribe__login{position:static;color:#000;font-size:18px;line-height:27px;border:0}.bads_footer-banner24-ONJQNRF1-inner .g-cta-subscribe__actions{margin:20px 0 20px 0;list-style-type:none;padding:0}.bads_footer-banner24-ONJQNRF1-inner .g-cta-subscribe__login a{color:#0a68ad}.bads_clearfix:after{visibility:hidden;display:block;font-size:0;content:" ";clear:both;height:0}.bads_clearfix{display:block}.bads_footer-banner24-ONJQNRF1-inner .bads_subs-btn{float:left;width:50%;padding:30px 0}.bads_footer-banner24-ONJQNRF1-inner .bads_device-img{float:left;padding-left:30px;width:50%}.bads_footer-banner24-ONJQNRF1 .bads_device-img>img{display:block;max-width:100%;height:auto}.bads_footer-banner24-ONJQNRF1 .bads_h5{font-size:18px;text-transform:uppercase;line-height:24px;font-weight:600;margin:-15px 0 0;letter-spacing:.2px}@media only screen and (max-width:480px){.bads_footer-banner24-ONJQNRF1-inner .bads_device-img,.bads_footer-banner24-ONJQNRF1-inner .bads_subs-btn{width:100%;float:none}.bads_footer-banner24-ONJQNRF1-inner .bads_device-img{padding-left:0}.bads_footer-banner24-ONJQNRF1 .g-cta-subscribe__title{font-size:20px;line-height:27px;margin-bottom:10px}.bads_footer-banner24-ONJQNRF1-inner .bads_subs-btn{padding-top:0;padding-bottom:0}.bads_footer-banner24-ONJQNRF1{height:auto}.bads_footer-banner24-ONJQNRF1-inner .g-cta-subscribe__actions{margin:0 0 12px;list-style-type:none}.bads_footer-banner24-ONJQNRF1-inner .g-cta-subscribe__login{line-height:25px;font-size:15px;margin-bottom:10px}.bads_footer-banner24-ONJQNRF1 .bads_device-img{width:280px!important;margin:0 auto}.bads_footer-banner24-ONJQNRF1 .bads_h5{margin:0 0 3px;font-size:14px}}@media only screen and (min-width:480px) and (max-width:1024px){.bads_footer-banner24-ONJQNRF1 .g-cta-subscribe__title{font-size:20px;line-height:30px;margin-bottom:15px}.bads_footer-banner24-ONJQNRF1-inner .bads_subs-btn{padding:0}.bads_footer-banner24-ONJQNRF1-inner .g-cta-subscribe__login{font-size:14px}.bads_footer-banner24-ONJQNRF1 .bads_h5{font-size:13px;margin-top:0}}@media only screen and (min-width:1025px) and (max-width:1200px){.bads_footer-banner24-ONJQNRF1-inner .bads_subs-btn{padding:10px 0}.bads_footer-banner24-ONJQNRF1 .bads_h5{margin:0 0 5px}}@media only screen and (min-width:1401px){.bads_footer-banner24-ONJQNRF1 .bads_device-img>img{float:right}}
	</style>
	<div class="bads_footer-banner24-ONJQNRF1">
	  <div class="bads_footer-banner24-ONJQNRF1-inner bads_clearfix">
		 <div class="bads_subs-btn">
			<p class="g-cta-subscribe__title">Tap into groundbreaking research and clinically relevant insights</p>
			<ul class="g-cta-subscribe__actions">
				<li class="g-cta-subscribe__actions-primary">
				  <a href="/action/clickThrough?id=127716&amp;url=%2Faction%2FstoreProxy%3Faction%3Dsubscribe%26url%3Dhttps%253A%252F%252Fwww.nejm.org%252Fdoi%252Ffull%252F10.1056%252FNEJMra2026131%26promo%3DONFQNRF1&amp;loc=%2Fdoi%2Ffull%2F10.1056%2FNEJMra2026131&amp;pubId=41289057&amp;placeholderId=101336&amp;productId=1035" class="ng-btn_primary ng-btn_iconRight"><span class="ng-btn_text">Subscribe </span><span class="icon-component"><svg aria-hidden="true"><use xlink:href="/specs/products/mms-nextgen/mms/releasedAssets/icons/icons.spritemap.svg#arrows-longArrowRight"></use></svg></span></a>
				</li>
			</ul>
			<p class="g-cta-subscribe__login">Already a subscriber? <a href="/action/clickThrough?id=127716&amp;url=%2Faction%2FstoreProxy%3Faction%3Dactivate%26url%3Dhttps%253A%252F%252Fwww.nejm.org%252Fdoi%252Ffull%252F10.1056%252FNEJMra2026131%26promo%3DONFQANR4&amp;loc=%2Fdoi%2Ffull%2F10.1056%2FNEJMra2026131&amp;pubId=41289057&amp;placeholderId=101336&amp;productId=1035">Activate</a> your online access.</p>
		 </div>

		<div class="bads_device-img">
		   <img src="/sda/127716/footer-devices-2x.png" alt="Devices">
		</div>
	   </div>
	</div>
</aside>
<!--/END: Circulation Footer 3 -->
            
        </div>
    

    

    



        </div>
    

</div></div></div></div>

                    
                        



        
        <footer class="ng-footer footer__top" style="position: relative;"><div data-location="footer" class="ng-footer_columns"><div class="container-fluid"><div class="row"><div class="col-lg-4 col-md-6 col-sm-12 ng-footer_column"><div class="row"><div class="col-6 ng-footer_column-nested">



        
        <h4 class="ng-footer_column-title">ARTICLE CATEGORIES</h4>
<ul class="ng-footer_column-list">
    <li class="ng-footer_column-list-item">
        <a href="/browse/nejm-article-category/research" class="ng-footer_column-link animation-underline"><span class="ng-footer_column-link-text">Research</span></a></li>
    <li class="ng-footer_column-list-item"><a href="/browse/nejm-article-category/review" class="ng-footer_column-link animation-underline"><span class="ng-footer_column-link-text">Reviews</span></a></li>
    <li class="ng-footer_column-list-item"><a href="/browse/nejm-article-category/clinical-cases" class="ng-footer_column-link animation-underline"><span class="ng-footer_column-link-text">Clinical Cases</span></a></li>
    <li class="ng-footer_column-list-item"><a href="/browse/nejm-article-category/perspective" class="ng-footer_column-link animation-underline"><span class="ng-footer_column-link-text">Perspective</span></a></li>
    <li class="ng-footer_column-list-item"><a href="/browse/nejm-article-category/commentary" class="ng-footer_column-link animation-underline"><span class="ng-footer_column-link-text">Commentary</span></a></li>
    <li class="ng-footer_column-list-item"><a href="/browse/nejm-article-category/other" class="ng-footer_column-link animation-underline"><span class="ng-footer_column-link-text">Other</span></a></li>
    <li class="ng-footer_column-list-item"><a href="/medical-article-index" class="ng-footer_column-link animation-underline"><span class="ng-footer_column-link-text">Browse all Articles</span></a></li>
    <li class="ng-footer_column-list-item"><a href="/toc/nejm/current" class="ng-footer_column-link animation-underline"><span class="ng-footer_column-link-text">Current Issue</span></a></li>
    <li class="ng-footer_column-list-item"><a href="/loi/nejm" class="ng-footer_column-link animation-underline"><span class="ng-footer_column-link-text">Issue Index</span></a></li>
</ul>
</div><div class="col-6 ng-footer_column-nested">



        
        <h4 class="ng-footer_column-title">RESOURCES</h4>
<ul class="ng-footer_column-list">
    <li class="ng-footer_column-list-item"><a href="/author-center/home" class="ng-footer_column-link animation-underline"><span class="ng-footer_column-link-text">Authors &amp; Reviewers</span></a></li>
    <li class="ng-footer_column-list-item"><a href="/author-center/home" class="ng-footer_column-link animation-underline"><span class="ng-footer_column-link-text">Submit a Manuscript</span></a></li>
    <li class="ng-footer_column-list-item"><a href="/about-nejm/products-and-services" class="ng-footer_column-link animation-underline"><span class="ng-footer_column-link-text">Subscribers</span></a></li>
    <li class="ng-footer_column-list-item"><a href="https://tools.ovid.com/ovidtools/nejm.html" target="_blank" rel="noopener" class="ng-footer_column-link animation-underline"><span class="ng-footer_column-link-text">Institutional Administrators</span></a></li>
    <li class="ng-footer_column-list-item"><a href="/media" class="ng-footer_column-link animation-underline"><span class="ng-footer_column-link-text">Media</span></a></li>
    <li class="ng-footer_column-list-item"><a href="/about-nejm/how-to-advertise" class="ng-footer_column-link animation-underline"><span class="ng-footer_column-link-text">Advertisers</span></a></li>
    <li class="ng-footer_column-list-item"><a href="/information-for-subscription-agents" class="ng-footer_column-link animation-underline"><span class="ng-footer_column-link-text">Agents</span></a></li>
    <li class="ng-footer_column-list-item"><a href="/about-nejm/permissions" class="ng-footer_column-link animation-underline"><span class="ng-footer_column-link-text">Permissions &amp; Licensing</span></a></li>
    <li class="ng-footer_column-list-item"><a href="/about-nejm/reprints" class="ng-footer_column-link animation-underline"><span class="ng-footer_column-link-text">Reprints</span></a></li>
    <li class="ng-footer_column-list-item"><a href="https://www.nejmcareercenter.org" target="_blank" rel="noopener" class="ng-footer_column-link animation-underline"><span class="ng-footer_column-link-text">NEJM CareerCenter</span></a>
    </li>
</ul>
</div></div></div><div class="col-lg-4 col-md-6 col-sm-12 ng-footer_column"><div class="row"><div class="col-6 ng-footer_column-nested">



        
        <h4 class="ng-footer_column-title" aria-label="About us">ABOUT US</h4>
<ul class="ng-footer_column-list">
    <li class="ng-footer_column-list-item"><a href="/about-nejm/about-nejm" class="ng-footer_column-link animation-underline"><span class="ng-footer_column-link-text">About NEJM</span></a></li>
    <li class="ng-footer_column-list-item"><a href="https://www.nejmgroup.org/" target="_blank" rel="noopener" class="ng-footer_column-link animation-underline"><span class="ng-footer_column-link-text">NEJM Group</span></a></li>
    <li class="ng-footer_column-list-item"><a href="/about-nejm/products-and-services" class="ng-footer_column-link animation-underline"><span class="ng-footer_column-link-text">Products &amp; Services</span></a></li>
    <li class="ng-footer_column-list-item"><a href="/about-nejm/editors-and-publishers" class="ng-footer_column-link animation-underline"><span class="ng-footer_column-link-text">Editors &amp; Publishers</span></a></li>
    <li class="ng-footer_column-list-item"><a href="/about-nejm/advertising-policies" class="ng-footer_column-link animation-underline"><span class="ng-footer_column-link-text">Advertising Policies</span></a></li>
    <li class="ng-footer_column-list-item"><a href="/contact-nejm" class="ng-footer_column-link animation-underline"><span class="ng-footer_column-link-text" aria-label="Contact us">Contact Us</span></a></li>
    <li class="ng-footer_column-list-item"><a href="/about-nejm/frequently-asked-questions?#Accessibility" class="ng-footer_column-link animation-underline"><span class="ng-footer_column-link-text">Accessibility</span></a></li>
    <li class="ng-footer_column-list-item"><a href="/about-nejm/frequently-asked-questions" class="ng-footer_column-link animation-underline"><span class="ng-footer_column-link-text">FAQs</span></a></li>
    <li class="ng-footer_column-list-item"><a href="/about-nejm/help" class="ng-footer_column-link animation-underline"><span class="ng-footer_column-link-text">Help</span></a></li>
    <li class="ng-footer_column-list-item"><a href="mailto:sitefeedback@nejm.org" class="ng-footer_column-link animation-underline"><span class="ng-footer_column-link-text">Site Feedback</span></a></li>
</ul>
</div><div class="col-6 ng-footer_column-nested">



        
        <h4 class="ng-footer_column-title">SUBSCRIPTIONS</h4>
<ul class="ng-footer_column-list">
    <li class="ng-footer_column-list-item"><a href="/action/storeProxy?action=subscribe&amp;promo=ONF4NRS3" class="ng-footer_column-link animation-underline ro-mode_disabled"><span class="ng-footer_column-link-text">Subscribe</span></a></li>
    <li class="ng-footer_column-list-item"><a href="/action/storeProxy?action=renew&amp;product=nejm&amp;promo=ONFLNRR3&amp;prc=ONFARN52" class="ng-footer_column-link animation-underline ro-mode_disabled"><span class="ng-footer_column-link-text">Renew</span></a></li>
    <li class="ng-footer_column-list-item"><a href="/action/storeProxy?action=activate&amp;promo=ONFLNAA1" class="ng-footer_column-link animation-underline ro-mode_disabled"><span class="ng-footer_column-link-text">Activate Subscription</span></a></li>
    <li class="ng-footer_column-list-item"><a href="/action/storeProxy?action=register&amp;promo=ONFLNRC4" class="ng-footer_column-link animation-underline ro-mode_disabled"><span class="ng-footer_column-link-text">Create Account</span></a></li>
    <li class="ng-footer_column-list-item"><a href="https://myaccount.nejm.org" class="ng-footer_column-link animation-underline"><span class="ng-footer_column-link-text">Manage Account</span></a></li>
    <li class="ng-footer_column-list-item"><a href="/action/storeProxy?action=paybill&amp;product=nejm&amp;promo=BNFLPBA1" class="ng-footer_column-link animation-underline ro-mode_disabled"><span class="ng-footer_column-link-text">Pay Bill</span></a></li>
    <li class="ng-footer_column-list-item"><a href="https://www.wolterskluwer.com/en/solutions/ovid/nejm-complete-collection" target="_blank" rel="noopener" class="ng-footer_column-link animation-underline"><span class="ng-footer_column-link-text">Institutional Sales</span></a></li>    
    <li class="ng-footer_column-list-item"><a href="https://myaccount.nejm.org/special-content" class="ng-footer_column-link animation-underline"><span class="ng-footer_column-link-text">Special Content</span></a></li>
</ul>
</div></div></div><div class="col-lg-4 col-md-12 ng-footer_column"><div class="row"><div class="col-6 ng-footer_column-nested">



        
        <h4 class="ng-footer_column-title">STAY CONNECTED</h4>
<ul class="ng-footer_column-list">
    <li class="ng-footer_column-list-item"><a href="https://myaccount.nejm.org/emails?section=NEJM" class="ng-footer_column-link animation-underline"><span class="ng-footer_column-link-text">Email Alerts</span></a></li>
    <li class="ng-footer_column-list-item"><a href="/action/storeProxy?action=register&amp;promo=ONFLNRC3" class="ng-footer_column-link animation-underline ro-mode_disabled"><span class="ng-footer_column-link-text">Create Account</span></a></li>
    <li class="ng-footer_column-list-item"><a href="/about-nejm/products-and-services" class="ng-footer_column-link animation-underline"><span class="ng-footer_column-link-text">Apps</span></a></li>
    <li class="ng-footer_column-list-item"><a href="https://www.nejmcareercenter.org" target="_blank" rel="noopener" class="ng-footer_column-link animation-underline"><span class="ng-footer_column-link-text">NEJM CareerCenter</span></a></li>
    <li class="ng-footer_column-list-item"><a href="/rss-feed/" class="ng-footer_column-link animation-underline"><span class="ng-footer_column-link-text">Podcasts</span></a></li>
    <li class="ng-footer_column-list-item"><a href="/rss-feed/" class="ng-footer_column-link animation-underline"><span class="ng-footer_column-link-text">RSS Feed</span></a></li>
    <li class="ng-footer_column-list-item"><a href="/about-nejm/institutional-access" class="ng-footer_column-link animation-underline"><span class="ng-footer_column-link-text">Remote Access</span></a></li>
</ul>
</div><div class="col-6 ng-footer_column-nested">



        
        <h4 class="ng-footer_column-title" aria-label="Follow us">FOLLOW US</h4>
<ul class="ng-footer_column-list">
<li class="ng-footer_column-list-item"><a href="https://www.facebook.com/TheNewEnglandJournalofMedicine" target="_blank" rel="noopener" class="ng-footer_column-link animation-underline"><span class="ng-footer_column-link-icon"><span class="icon-component"><svg aria-hidden="true"><use xlink:href="/specs/products/mms-nextgen/mms/releasedAssets/icons/icons.spritemap.svg#social-facebook"></use></svg></span></span><span class="ng-footer_column-link-text">Facebook</span></a></li>
<li class="ng-footer_column-list-item"><a href="https://twitter.com/nejm" target="_blank" rel="noopener" class="ng-footer_column-link animation-underline"><span class="ng-footer_column-link-icon"><span class="icon-component"><svg aria-hidden="true"><use xlink:href="/specs/products/mms-nextgen/mms/releasedAssets/icons/icons.spritemap.svg#social-twitter"></use></svg></span></span><span class="ng-footer_column-link-text">X (formerly Twitter)</span></a></li>
<li class="ng-footer_column-list-item"><a href="https://www.instagram.com/nejm/" target="_blank" rel="noopener" class="ng-footer_column-link animation-underline"><span class="ng-footer_column-link-icon"><span class="icon-component"><svg aria-hidden="true"><use xlink:href="/specs/products/mms-nextgen/mms/releasedAssets/icons/icons.spritemap.svg#social-instagram"></use></svg></span></span><span class="ng-footer_column-link-text">Instagram</span></a></li>
<li class="ng-footer_column-list-item"><a href="https://www.youtube.com/user/NEJMvideo" target="_blank" rel="noopener" class="ng-footer_column-link animation-underline"><span class="ng-footer_column-link-icon"><span class="icon-component"><svg aria-hidden="true"><use xlink:href="/specs/products/mms-nextgen/mms/releasedAssets/icons/icons.spritemap.svg#social-youtube"></use></svg></span></span><span class="ng-footer_column-link-text">Youtube</span></a></li>
<li class="ng-footer_column-list-item"><a href="https://www.linkedin.com/company/nejm-group" target="_blank" rel="noopener" class="ng-footer_column-link animation-underline"><span class="ng-footer_column-link-icon"><span class="icon-component"><svg aria-hidden="true"><use xlink:href="/specs/products/mms-nextgen/mms/releasedAssets/icons/icons.spritemap.svg#social-linkedin"></use></svg></span></span><span class="ng-footer_column-link-text">LinkedIn</span></a></li>
<li class="ng-footer_column-list-item"><a href="https://bsky.app/profile/nejm.org" target="_blank" rel="noopener" class="ng-footer_column-link animation-underline"><span class="ng-footer_column-link-icon"><span class="icon-component"><svg aria-hidden="true"><use xlink:href="/specs/products/mms-nextgen/mms/releasedAssets/icons/icons.spritemap.svg#social-bluesky"></use></svg></span></span><span class="ng-footer_column-link-text">Bluesky</span></a></li>
<li class="ng-footer_column-list-item"><a href="https://www.tiktok.com/@nejm.org" target="_blank" rel="noopener" class="ng-footer_column-link animation-underline"><span class="ng-footer_column-link-icon"><span class="icon-component"><svg aria-hidden="true"><use xlink:href="/specs/products/mms-nextgen/mms/releasedAssets/icons/icons.spritemap.svg#social-tiktok"></use></svg></span></span><span class="ng-footer_column-link-text">TikTok</span></a></li>
</ul>
</div></div></div></div></div></div><div data-location="footer" class="ng-footer_journals"><div class="container-fluid"><div class="row"><div class="col-12">



        
        <h4 class="ng-footer_journals-label">JOURNALS</h4>
<ul class="ng-footer_journals-list">
<li class="ng-footer_journals-item"><a href="https://www.nejm.org/" target="_blank" rel="noopener" class="ng-footer_journals-link">The New England Journal of Medicine</a></li>
<li class="ng-footer_journals-item"><a href="https://catalyst.nejm.org/" target="_blank" rel="noopener" class="ng-footer_journals-link">NEJM Catalyst Innovations in Care Delivery</a></li>
<li class="ng-footer_journals-item"><a href="https://evidence.nejm.org/" target="_blank" rel="noopener" class="ng-footer_journals-link">NEJM Evidence</a></li>
<li class="ng-footer_journals-item"><a href="https://ai.nejm.org/" target="_blank" rel="noopener" class="ng-footer_journals-link">NEJM AI</a></li>
</ul>
</div></div></div></div><div data-location="legal" class="ng-footer_bottom"><div class="container-fluid"><div class="row"><div class="col-lg-7 col-md-6 ng-footer_bottom-left">



        
        <p>Copyright © 2025 <a href="https://www.massmed.org/" target="_blank" rel="noopener" class="ng-footer_bottom-link"><b>Massachusetts Medical Society</b></a>. All rights reserved, including those for text and data mining, AI training, and similar technologies. Electronic ISSN 1533-4406. Print ISSN 0028-4793.The content of this site is intended for health care professionals.</p>
</div><div class="col-lg-5 col-md-6 ng-footer_bottom-right">



        
        <style>
  #teconsent a {
    color: #666;
    text-decoration: none;
  }
  #teconsent a:hover {
    color: #666;
    text-decoration: underline;
  }
</style>
<ul class="ng-footer_bottom-list">
<li class="ng-footer_bottom-list-item"><a href="https://www.nejmgroup.org/legal/copyright-information.htm" target="_blank" rel="noopener" class="ng-footer_bottom-link">Copyright</a></li>
<li class="ng-footer_bottom-list-item"><a href="https://www.nejmgroup.org/legal/terms-of-use.htm" target="_blank" rel="noopener" class="ng-footer_bottom-link">Terms</a></li>
<li class="ng-footer_bottom-list-item"><a href="https://www.nejmgroup.org/legal/privacy-policy.htm" target="_blank" rel="noopener" class="ng-footer_bottom-link">Privacy Policy</a></li>
<li class="ng-footer_bottom-list-item"><span id="teconsent" consent="undefined" aria-label="Open Cookie Preferences Modal" role="complementary"><a role="link" id="icon-id09176116689735269" tabindex="0" lang="en" aria-haspopup="dialog" aria-label="Cookie Preferences, opens a dedicated popup modal window" class="truste_cursor_pointer">Cookie Preferences</a></span></li>
</ul>
<a href="https://www.nejmgroup.org/" title="NEJM Group" target="_blank" rel="noopener" class="ng-footer_logo-link"><img src="/specs/products/mms-nextgen/mms/releasedAssets/images/other-images/logo_group.svg" alt="NEJM Group logo" class="ng-footer_logo" loading="lazy" width="103" height="40"></a>
</div></div></div></div><div data-show-after="400" class="back-to-top back-to-top--align-right  "><button data-snap="footer__top" class="back-to-top__action position-relative p-0 m-0 border-0 d-flex flex-column align-items-center justify-content-center"><svg viewBox="0 0 36 36" class="position-relative"><path d="M18 2.0845 a 15.9155 15.9155 0 0 1 0 31.831 a 15.9155 15.9155 0 0 1 0 -31.831" class="back-to-top__action__ring-bg"></path><path d="M18 2.0845 a 15.9155 15.9155 0 0 1 0 31.831 a 15.9155 15.9155 0 0 1 0 -31.831" stroke-dasharray="0, 100" class="back-to-top__action__ring"></path></svg><span class="back-to-top__action-icon position-absolute d-flex"><span class="icon-component "><svg aria-hidden="true" style=""><use xlink:href="/specs/products/mms-nextgen/mms/releasedAssets/icons/icons-3acb348e68a3edd0c676698e8d598c68.spritemap.svg#arrows-up"></use></svg></span></span><span class="sr-only">Back to top</span></button></div></footer>

                    
                        



        
        <!-- TrustArc: Banner -->
<div id="consent_blackbar"><style>  #consent_blackbar{    position:relative;    width:100%;    z-index: 999999;  }    #trustarc-banner-overlay {  background-color: rgb(0, 0, 0);   opacity: 0.3;   position: fixed;   z-index: 1000000;   width: 100%;  height: 100%;   top: 0px;   left: 0px;   overflow: hidden;}.truste-title {  /*font-family: "Source Sans Pro", sans-serif;  font-size: 23px;  font-style: normal;  font-stretch: normal;*/  color: #222;  margin-bottom: 20px;  text-align: center;/*  font-weight:bold;*/}.truste-footer {  margin: 0 auto;      }.truste-left {  margin: 0px 0px 15px 15px;/*font-family: "Source Sans Pro", sans-serif;  font-size: 14px;    */}.truste-banner { margin: 0 auto; }.truste-messageColumn {/*font-family: "Source Sans Pro", sans-serif;  font-size: 14px;*/  color: #666666;  margin: 0px;}#truste-consent-button, #truste-consent-required {    background-color: #FF1E00;    color: #F2F1F1;    padding: 5px 10px;    border: 1px solid #FF1E00;    border-radius: 0px;    cursor: pointer;    text-transform:uppercase;/*    font-family: "Source Sans Pro",sans-serif;    font-size: 15px;*/  }      #truste-show-consent {    background-color: #FF1E00;    color: #F2F1F1;    border: 1px solid #FF1E00;    padding: 5px 10px;    border-radius: 0px;    cursor: pointer;    text-transform:uppercase;/*    font-family: "Source Sans Pro",sans-serif;    font-size: 15px;*/  }div.truste-consent-track-class {  position: fixed;  z-index:9999999;   background: #666;   border: 1px solid #333;    /*padding: 10px 60px;*/    bottom:0px;    right:0px;    left:0px;    margin: 10px;}.truste-left {  margin: 0;}div.text-content {  display: flex;  flex-direction: column;  align-self: baseline;}#truste-consent-text {    /*font-family: "Source Sans Pro", sans-serif;    font-size: 16px;*/    color: #fff;    margin: 15px 0px;}.truste-footer {  padding-top: 15px;}#truste-consent-content {  margin: 0 auto;    padding: 0 10px;    max-width: 1366px;}.truste-consent-footer {  display: none;}.flex-container {  display: block;  align-items: center;  justify-content: space-between;}#truste-consent-buttons {  float: right;  margin: 10px 5px 10px 0px;}#truste-show-consent { background: #F30 !important;}#truste-consent-button, #truste-consent-required { background: #F30 !important; } /* MEDIA QUERIES */  @media screen and (max-width: 500px) {  #truste-consent-track {    padding: 5px 20px;  }  }@media screen and (max-width: 375px) {  .truste-buttonsColumn {    float: none;    margin: 0;  }  #truste-consent-button, #truste-consent-required, #truste-show-consent {    width: 100%;    margin-bottom: 5px;  }          #truste-consent-buttons {  float: none;  margin: 10px 0px 10px 0px;	}}</style><div id="truste-consent-track" style="display: block; opacity: 1;">  <div id="trustarc-banner-overlay"></div>  <div class="truste-consent-track-class">    <div id="truste-consent-content" class="truste-banner">        <div class="flex-container">          <div class="text-content">            <div id="truste-consent-text" class="truste-messageColumn">This site uses cookies and related technologies, as described in our privacy policy, for purposes that may include site operation, analytics, enhanced user experience, or advertising. You may choose to consent to our use of these technologies, or manage your own preferences.                       </div>          </div>          <div id="truste-consent-buttons" class="truste-buttonsColumn">            <button id="truste-show-consent" aria-haspopup="dialog">Manage Settings</button>      <button id="truste-consent-button">Accept</button>      <!-- <button id="truste-consent-required">Decline All</button> -->          </div>        </div>                <div style="clear:both;"></div>    </div>  </div></div><!--emptycomment--></div>
<!-- /TrustArc: Banner -->

                    
                        



        
        <link rel="stylesheet" href="https://cssjs.nejm.org/mmsWidgets.css"><script nonce="94d65ade13caf211-SJC" type="text/javascript" src="https://cssjs.nejm.org/mmsWidgets.js"></script><script nonce="94d65ade13caf211-SJC" type="text/javascript">var litSSO = {
    "ucid": null,
    "accessToken": null,
    "authState": null
};

var loginUri = '/action/doSsoLogin';
var logoutUri = '/action/doLogout';

displayAuthenticatedMessage();

mmsWidgets.init({
    clientId: 'qsra7g4d6jwdsgn3zbe6udp6r6278mr9',
    origin: 'NEJM',
    xdReceiver: 'http://www.nejm.org/pb-assets/sso/xd.html',
    isFullPageSignIn: isSignInPage(),
    debug: true,

    onReady: function (e) {
        console.log('<<<<<<<<<< client: received onReady event.');
        $("A.litSsoLogin").click(function (e) {
            if (!$(e.currentTarget).hasClass("noMd") || $(e.currentTarget).parents(".header_sm-login").length === 0) {
                mmsWidgets.signIn(e);
                return false;
            }
        });
        $("A.litSsoLogout").click(function (e) {
            mmsWidgets.signOut(e);
            return false;
        });
        $("A.litSsoCreate").click(function (e) {
            mmsWidgets.showRegModal(e);
            return false;
        });
        $("A.litSsoSubscribe").click(function (e) {
            if (!$(e.currentTarget).hasClass("noMd") || $(e.currentTarget).parents(".header_sm-login").length === 0)
                location.assign(e.currentTarget.href);
            return false;
        });
        if (window.doSSOLogin) {
            window.setTimeout(function () {
                mmsWidgets.signIn();
            }, 500);
        }
        ;
    },
    onLoginSuccess: function (e) {
        console.log('<<<<<<<<<< client: received onLoginSuccess event.' + JSON.stringify(e));

        const redirectUrl = getRedirectUri(window.location.search, location.href.replace(window.location.origin, ""));
        document.cookie = "skipSso=; expires=; path=/";
        if (!litSSO.ucid || e.ucid != litSSO.ucid || !litSSO.accessToken || e.accessToken != litSSO.accessToken) {
            location.assign(loginUri + "?ucid=" + e.profile.ucid
                + "&accessToken=" + e.accessToken
                + "&authState=" + e.authState
                + "&email=" + encodeURIComponent(e.profile.email)
                + "&givenNames=" + e.profile.givenName
                + "&surname=" + e.profile.familyName
                + "&redirectUri=" + redirectUrl
                + "&uccLastUpdatedDate=" + encodeURIComponent(e.profile.uccLastUpdatedDate)
                + "&rememberMe=" + e.rememberMe);
        }
    },
    onAuthStateReady: function (e) {
        console.log('<<<<<<<<<< client: received onAuthStateReady event.' + JSON.stringify(e))

        var isMmsSsoAuthenticated = (e.authState && e.authState !== "anonymous" && e.authState !== "lead" && e.ucid && e.accessToken) ? true : false;
        var isLitSsoAuthenticated = (litSSO.ucid && litSSO.accessToken && litSSO.authState) ? true : false;
        console.log('           isMmsSsoAuthenticated=' + isMmsSsoAuthenticated + ', isLitSsoAuthenticated=' + isLitSsoAuthenticated);

        if (isMmsSsoAuthenticated) {
            if (!isLitSsoAuthenticated || litSSO.ucid != e.ucid) {
                if (window.skipSso)
                    document.cookie = "skipSso=" + encodeURIComponent(e.ucid) + "; expires=; path=/";

                if (!window.skipSso && document.cookie.indexOf("skipSso=" + encodeURIComponent(e.ucid)) == -1) {
                    location.assign(loginUri + "?ucid=" + e.profile.ucid
                        + "&accessToken=" + e.accessToken
                        + "&authState=" + e.authState
                        + "&email=" + encodeURIComponent(e.profile.email)
                        + "&givenNames=" + e.profile.givenName
                        + "&surname=" + e.profile.familyName
                        + "&redirectUri=" + location.href.replace(window.location.origin, "")
                        + "&uccLastUpdatedDate=" + encodeURIComponent(e.profile.uccLastUpdatedDate)
                        + "&rememberMe=" + e.rememberMe);
                } else
                    console.log('**** client: Skip SSO ****');
            } else if (e.accessToken !== litSSO.accessToken)
                updateLitSession(e.ucid, e.accessToken);
        } else if (isLitSsoAuthenticated)
            location.assign(logoutUri + "?redirectUri=" + encodeURIComponent(location.href.replace(window.location.origin, "")));

        if (document.getElementById("ssoerr-ucid"))
            document.getElementById("ssoerr-ucid").innerHTML = e.ucid;

    },
    onRegistrationSuccess: function (e) {
        console.log('<<<<<<<<<< client: received onRegistrationSuccess event.' + JSON.stringify(e))
        document.cookie = "skipSso=; expires=; path=/";
        var uccLastUpdatedDate = '1812-01-01 00:00:00.1 +0000';
        location.assign(loginUri + "?ucid=" + e.profile.ucid
            + "&accessToken=" + e.accessToken
            + "&authState=" + e.authState
            + "&email=" + encodeURIComponent(e.profile.email)
            + "&givenNames=" + e.profile.givenName
            + "&surname=" + e.profile.familyName
            + "&redirectUri=" + location.href.replace(window.location.origin, "")
            + "&uccLastUpdatedDate=" + encodeURIComponent(uccLastUpdatedDate)
            + "&rememberMe=" + e.rememberMe);
    },
    onLogoutSuccess: function (e) {
        console.log('<<<<<<<<<< client: received onLogoutSuccess event.' + JSON.stringify(e))

        document.cookie = "skipSso=; expires=; path=/";
        location.assign(logoutUri);
    },
});

function updateLitSession(ucid, accessToken) {
    $.ajax({
        method: "GET",
        url: "/action/doSsoSessionUpdate",
        data: {ucid: ucid, accessToken: accessToken},
        success: function (callData, textStatus) {
            console.log("Session accessToken updated")
            litSSO.accessToken = accessToken
        },
        error: function (jqXHR, textStatus, errorThrown) {
            alert("Your website session has expired and will now be reset.")
            console.log("Session update failed: " + jqXHR.responseText)
            location.assign(logoutUri + "?redirectUri=" + encodeURIComponent(location.href.replace(window.location.origin, "")));
        }
    });
}

function getRedirectUri(location, fallback) {
    const urlParams = new URLSearchParams(location);
    const uriUrlParam = urlParams.get('uri');
    if (uriUrlParam)
        return encodeURIComponent(uriUrlParam);
    else
        return encodeURIComponent(fallback);
}

function isSignInPage() {
    return document.querySelector('meta[name="pbContext"]').content.indexOf("customPage:string:/sign-in") > -1;
}

function displayAuthenticatedMessage() {
    if (isSignInPage()) {
        var div = document.getElementById('authMsg');
        if ("" === "PersonUser") {
            div.innerHTML += "You are already signed in to " + window.location.origin.replace("https://", "").replace("www.", "") + ". If you would like to sign in with a different email address, please use the form below.";
        } else {
            div.innerHTML = '';
        }
    }
}</script>

                    
                
            </div>
        </div><iframe name="trustarc_notice" id="trustarcNoticeFrame" title="Trustarc Cross-Domain Consent Frame" src="https://consent.trustarc.com/get?name=crossdomain.html&amp;domain=nejm.com" style="display: none;"></iframe><script src="https://consent.trustarc.com/asset/notice.js/v/v1.7-1576" async="async" crossorigin="" importance="high" nonce="94d65ade13caf211-SJC"></script>
        


        
        

            <script src="/products/mms-nextgen/mms/releasedAssets/js/build.lazyload.bundle-c8c4e7d20884f81951fb.js" nonce="94d65ade13caf211-SJC"></script>

        <script src="/products/mms-nextgen/mms/releasedAssets/js/main.bundle-3819a02ec7bc2aca01ec.js" nonce="94d65ade13caf211-SJC"></script>
        


<div id="adModal" tabindex="-1" aria-labelledby="exampleModalCenterTitle" class="ng-modal modal" style="display: none;" aria-hidden="true">
    <div role="document" class="ng-modal_dialog modal-dialog modal-dialog-centered ad-promoLayer">
        <div class="ng-modal_content modal-content p-0">
            <div class="ng-modal_body modal-body m-0">
                <div class="ng-modal_header modal-header">
                    <button type="button" data-dismiss="modal" aria-label="Close" class="ng-modal_close close"><span aria-hidden="true"><span class="icon-component "><svg aria-hidden="true"><use xlink:href="/specs/products/mms-nextgen/mms/releasedAssets/icons/icons.spritemap.svg#close"></use></svg></span></span>
                    </button>
                </div>

            </div>
        </div>
    </div>
</div>
<script type="text/javascript" src="/wro/1125813~product.js" nonce="94d65ade13caf211-SJC"></script>








<input id="showLayers" type="hidden" value="true">

    <!-- placeholder id=null, description=ad-layer-config -->
    <!-- placeholder id=null, description=ad-lauchLayer-1 -->
    <!-- placeholder id=null, description=ad-layer-promo-1 -->

    <input id="firstAd" type="hidden" value="">
    <input id="secondAd" type="hidden" value="">

    
    
    

    
    
    <input id="IsInstitution" type="hidden" value="false">
    <input id="IsSubscriber" type="hidden" value="true">
    <input id="CustomerId" type="hidden" value="">


<script type="text/javascript" nonce="94d65ade13caf211-SJC">
  jQuery.extend(jQuery.mmsLayers.config, {
    rules: [{
      "name": "Launch Layer Ad",
      "frequency": 30,
      "showOnPage": 5,
      "enabled": false,
      "cookieName": "MarketingLaunchLayer",
      "styleClass": "launchLayer"
    },
    {
      "name": "Promo Layer Ad",
      "frequency": 14,
      "enabled": true,
      "cookieName": "PromoLayer",
      "styleClass": "promoLayer"
    },
    {
      "name": "Interstitial Ad",
      "frequency": 7,
      "enabled": false,
      "cookieName": "InterstitialAd"
    },
    {
      "name": "Iperceptions - Ion Layer Ad",
      "showOnPage": 1,
      "enabled": false,
      "test": false,
      "cookieName":"Iperceptions"
    }]
 });
</script>

















    <script type="text/javascript" nonce="94d65ade13caf211-SJC">
        $(document).ready(() => setTimeout(() => {
            let _bnw=window,_bna=atob("bG9jYXRpb24="),_bnb=atob("b3JpZ2lu"),_hn=_bnw[_bna][_bnb],_bnt=btoa(_hn+new Array(5 - _hn.length % 4).join(" "));
            $.get("/resource/lodash?t="+_bnt);
        },4000));
    </script>












    

    
    

    
    
    
    
        
            
                <script type="text/javascript" src="/wro/1125813~article-metrics.js" nonce="94d65ade13caf211-SJC"></script>
            
            
            
        
    




<script type="text/javascript" src="/wro/1125813~full-text-analytics.js" nonce="94d65ade13caf211-SJC"></script>


    


            <script>(function(){function c(){var b=a.contentDocument||a.contentWindow.document;if(b){var d=b.createElement('script');d.innerHTML="window.__CF$cv$params={r:'94d65ade08d7f211',t:'MTc0OTUzMjE0OS4wMDAwMDA='};var a=document.createElement('script');a.nonce='';a.src='/cdn-cgi/challenge-platform/scripts/jsd/main.js';document.getElementsByTagName('head')[0].appendChild(a);";b.getElementsByTagName('head')[0].appendChild(d)}}if(document.body){var a=document.createElement('iframe');a.height=1;a.width=1;a.style.position='absolute';a.style.top=0;a.style.left=0;a.style.border='none';a.style.visibility='hidden';document.body.appendChild(a);if('loading'!==document.readyState)c();else if(window.addEventListener)document.addEventListener('DOMContentLoaded',c);else{var e=document.onreadystatechange||function(){};document.onreadystatechange=function(b){e(b);'loading'!==document.readyState&&(document.onreadystatechange=e,c())}}}})();</script><iframe height="1" width="1" style="position: absolute; top: 0px; left: 0px; border: none; visibility: hidden;"></iframe><script defer="" src="https://static.cloudflareinsights.com/beacon.min.js/vcd15cbe7772f49c399c6a5babf22c1241717689176015" integrity="sha512-ZpsOmlRQV6y907TI0dKBHq9Md29nnaEIPlkf84rnaERnq6zvWvPUqr2ft8M1aS28oN72PdrCzSjY4U6VaAw1EQ==" data-cf-beacon="{&quot;rayId&quot;:&quot;94d65ade08d7f211&quot;,&quot;serverTiming&quot;:{&quot;name&quot;:{&quot;cfExtPri&quot;:true,&quot;cfEdge&quot;:true,&quot;cfOrigin&quot;:true,&quot;cfL4&quot;:true,&quot;cfSpeedBrain&quot;:true,&quot;cfCacheStatus&quot;:true}},&quot;version&quot;:&quot;2025.5.0&quot;,&quot;token&quot;:&quot;f55e150c7a5f4a4ab9ef82f4a1c9c43c&quot;}" crossorigin="anonymous"></script>

        
        
    

<div style="display:none;" id="signInEmbedded" class="ucc-fullpage-signin ucc-widgets-nejm-next">
  <div class="capture_header">
    <h1>Sign In</h1>
  </div>    
  <div class="capture_signin">
    {* #signInForm *}
    <div class="ucc-form-inner-wrapper">
      {* signInEmailAddress *}
      {* currentPassword *}
      <div style="padding-top:10px;">
          <div class="capture_form_item capture_form_rememberme">
          <label class="ucc-form-checkbox">                
            <input checked="checked" id="ucc-remember-me-cb-embedded" name="ucc-remember-me-cb-embedded" type="checkbox" value="true">
            <span>Remember Me</span>
          </label>                           
          </div>
          <div class="capture_form_item capture_form_forgotpwd">
            <a role="button" class="ucc-anchor-button" data-capturescreen="forgotPassword">Forgot your password?</a>
          </div>
      </div>
      <div class="capture_form_item">      
        <button id="ucc-sign-in-submit-embedded" class="capture_primary capture-full-width-btn" type="submit">Sign In</button>
      </div>
      <div class="capture_form_item capture_form_footer">
        <div class="ucc-no-acct-msg">Don't have an account?</div>
        <div class="ucc-no-acct-msg-2">
          <a role="button" class="ucc-anchor-button" onclick="mmsWidgets.closeSignIn(event); mmsWidgets.showRegAuto(event);">Create Account</a>
          <span></span><a href="https://store.nejm.org/nejm?promo=ONF4NRS1">Subscribe</a>
        </div>
      </div>
      <div class="capture_form_item capture_form_submit">
        
      </div>      
    </div>
    {* /signInForm *}
  </div>
</div><div style="display:none;" id="forgotPassword" class="ucc-widgets-nejm-next">
  <div class="capture_header">
    <h1>Forgot Password</h1>
  </div>   
  <div class="ucc-form-inner-wrapper">
  <p style="color:black">Enter the email address associated with your account then click Continue. We will email you a link to a page where you can easily create a new password.</p>
  </div> 
  <div class="capture_forgotpassword">
    {* #forgotPasswordForm *}      
      <div class="ucc-form-inner-wrapper">
        {* forgotPasswordEmailAddress *}
        {* captcha *}
        <div class="capture_form_item" style="padding-top: 20px;">        
          <input id="ucc-widget-forgotpwd-submit" value="Continue" type="submit" class="capture_btn capture_primary capture-full-width-btn">
        </div>
      </div>
    {* /forgotPasswordForm *}
  </div>
  </div><div style="display:none;" id="forgotPasswordSuccess" class="ucc-widgets-nejm-next">
  <div class="capture_header">
    <h1>Create New Password</h1>
  </div>    
  <div class="capture_forgotpassword">
      <div class="ucc-form-inner-wrapper">
        <p style="padding-top: 30px; padding-bottom: 30px;">We've sent an email with instructions to create a new password. Your existing password has not been changed.</p>        
        <div class="capture_form_item">      
          <button class="capture_btn capture_primary capture-full-width-btn" onclick="janrain.capture.ui.modal.close()">CLOSE</button>
        </div>
      </div>
  </div>
  </div><div style="display:none;" id="resetPassword" class="ucc-widgets-nejm-next">
      <div class="row">      
        <div class="col-md-8 col-md-offset-2 reset-pwd-info"><p>To reset your password, enter a new password twice and click the 'Reset Password' button.</p></div>
      </div>
      <div class="col-md-4 col-md-offset-4">
        {* #changePasswordFormNoAuth *}
          {* newPassword *}
          {* newPasswordConfirm *}     
          <div class="capture_form_item">
            <input value="RESET PASSWORD" type="submit" class="capture_btn capture_primary capture-full-width-btn">
          </div>
          {* /changePasswordFormNoAuth *}
      </div>
    </div><div style="display:none;" id="resetPasswordSuccess">
        <div class="reset-pwd-info">
          <div class="reset-pwd-success-welcome"></div>
          <p class="reset-pwd-success-msg">Your password has been reset. You will need to <a href="/signin" onclick="mmsWidgets.signIn(event)">sign in</a> again using your new password to access site content and features.</p>
          <p class="reset-pwd-success-nav"></p>
        </div>      
    </div><div style="display:none;" id="resetPasswordRequestCode" class="ucc-widgets-nejm-next">
        {* #resetPasswordForm *}
        <div class="capture_form_error">The link that you followed to reset your password has expired.</div>
          <div class="col-md-8 col-md-offset-2">
            <p class="reset-pwd-info">Enter the email address associated with your account then click Continue. We will email you a link to a page where you can easily create a new password.</p>
          </div>
          <div class="col-md-4 col-md-offset-4">
            {* signInEmailAddress *}
            <div class="capture_form_item">
              <input value="continue" type="submit" class="capture_btn capture_primary capture-full-width-btn">
            </div>
          </div>
        {* /resetPasswordForm *}
    </div><div style="display:none;" id="resetPasswordRequestCodeSuccess">
      <div class="reset-pwd-info">
        <p>If the address matches an existing account, you will receive an email with instructions to reset your password.</p>
        <p class="reset-pwd-success-nav"></p>
      </div>
  </div><script type="text/javascript" src="https://api.altmetric.com/v1/internal-556fdf0f/doi/10.1056/nejmra2026131?callback=_altmetric.embed_callback&amp;domain=www.nejm.org&amp;cache_until=2-10"></script><div id="janrainEngageEmbed" style="display: none;"><div class="janrainContent" style="width: 380px !important; height: 156px !important; padding-left: 5px !important; padding-right: 5px !important; box-sizing: content-box !important; background-color: rgb(255, 255, 255) !important; border: 1px solid rgb(192, 192, 192) !important; border-radius: 10px !important; overflow: hidden !important; position: relative !important;"><div id="janrainView"><div class="janrainHeader" style="background-color: rgb(255, 255, 255) !important; font-size: 14px !important; color: rgb(102, 102, 102) !important; position: relative !important; height: 20px !important; left: -5px !important; padding: 5px 5px 0px !important; white-space: nowrap !important; width: 380px !important; z-index: 100 !important; border-radius: 10px 10px 0px 0px !important; text-align: left !important;"><div style="padding-left: 1px !important; font-family: Helvetica, &quot;lucida grande&quot;, Verdana, sans-serif !important;">Sign in using your account with</div></div><div id="janrainProviderPages" style="padding-top: 5px; left: 5px; position: absolute;"><div class="janrainPage" pageindex="0"><ul class="providers" id="janrainProviders_0" style="float: left !important; list-style-type: none !important; margin: 0px !important; padding: 0px !important;"><li id="janrain-aol" role="button" style="list-style: none !important; height: 30px !important; width: 185px !important; margin-top: 0px !important; margin-right: 5px !important; margin-bottom: 5px !important; position: relative !important; border: 1px solid rgb(204, 204, 204) !important; border-radius: 5px !important; cursor: pointer !important; white-space: nowrap !important; overflow: hidden !important; background-image: -webkit-linear-gradient(bottom, rgb(238, 238, 238), rgb(255, 255, 255)) !important;"><a tabindex="1" href="javascript:void(0);" style="font-family: Helvetica, &quot;lucida grande&quot;, Verdana, sans-serif !important; font-size: 12px !important; line-height: 14px !important; margin-left: auto !important; margin-right: auto !important; text-decoration: none !important; display: block !important; padding-left: 5px !important; padding-right: 5px !important; text-align: left !important; width: auto !important;"><span class="janrain-provider-icon-24 janrain-provider-icon-aol" style="margin-top: 3px !important; background-color: transparent !important;"></span><span class="janrain-provider-text-color-aol" style="font-family: Helvetica, &quot;lucida grande&quot;, Verdana, sans-serif !important; cursor: pointer !important; margin-left: 7px !important; text-align: left !important; margin-top: 9px !important; vertical-align: top !important; display: inline-block !important;">AOL</span></a></li><li id="janrain-openid" role="button" style="list-style: none !important; height: 30px !important; width: 185px !important; margin-top: 0px !important; margin-right: 5px !important; margin-bottom: 5px !important; position: relative !important; border: 1px solid rgb(204, 204, 204) !important; border-radius: 5px !important; cursor: pointer !important; white-space: nowrap !important; overflow: hidden !important; background-image: -webkit-linear-gradient(bottom, rgb(238, 238, 238), rgb(255, 255, 255)) !important;"><a tabindex="3" href="javascript:void(0);" style="font-family: Helvetica, &quot;lucida grande&quot;, Verdana, sans-serif !important; font-size: 12px !important; line-height: 14px !important; margin-left: auto !important; margin-right: auto !important; text-decoration: none !important; display: block !important; padding-left: 5px !important; padding-right: 5px !important; text-align: left !important; width: auto !important;"><span class="janrain-provider-icon-24 janrain-provider-icon-openid" style="margin-top: 3px !important; background-color: transparent !important;"></span><span class="janrain-provider-text-color-openid" style="font-family: Helvetica, &quot;lucida grande&quot;, Verdana, sans-serif !important; cursor: pointer !important; margin-left: 7px !important; text-align: left !important; margin-top: 9px !important; vertical-align: top !important; display: inline-block !important;">OpenID</span></a></li></ul><ul class="providers" id="janrainProviders_1" style="float: left !important; list-style-type: none !important; margin: 0px !important; padding: 0px !important;"><li id="janrain-yahoo" role="button" style="list-style: none !important; height: 30px !important; width: 185px !important; margin-top: 0px !important; margin-right: 5px !important; margin-bottom: 5px !important; position: relative !important; border: 1px solid rgb(204, 204, 204) !important; border-radius: 5px !important; cursor: pointer !important; white-space: nowrap !important; overflow: hidden !important; background-image: -webkit-linear-gradient(bottom, rgb(238, 238, 238), rgb(255, 255, 255)) !important;"><a tabindex="2" href="javascript:void(0);" style="font-family: Helvetica, &quot;lucida grande&quot;, Verdana, sans-serif !important; font-size: 12px !important; line-height: 14px !important; margin-left: auto !important; margin-right: auto !important; text-decoration: none !important; display: block !important; padding-left: 5px !important; padding-right: 5px !important; text-align: left !important; width: auto !important;"><span class="janrain-provider-icon-24 janrain-provider-icon-yahoo" style="margin-top: 3px !important; background-color: transparent !important;"></span><span class="janrain-provider-text-color-yahoo" style="font-family: Helvetica, &quot;lucida grande&quot;, Verdana, sans-serif !important; cursor: pointer !important; margin-left: 7px !important; text-align: left !important; margin-top: 9px !important; vertical-align: top !important; display: inline-block !important;">Yahoo!</span></a></li></ul></div></div><div style="background-color: rgb(255, 255, 255) !important; width: 380px !important; height: 10px !important; position: absolute !important; left: 0px !important; padding-left: 5px !important; padding-right: 5px !important; padding-bottom: 5px !important; bottom: 0px !important; font-size: 10px !important; text-align: left !important; color: rgb(102, 102, 102) !important; font-family: Helvetica, &quot;lucida grande&quot;, Verdana, sans-serif !important; border-radius: 0px 0px 10px 10px !important;"><div style="padding-left: 1px !important;"><a href="http://janrain.com/products/engage/social-login?utm_source=mms.rpxnow.com&amp;utm_medium=Partner&amp;utm_campaign=attribution" target="_blank">Social Login by Janrain</a></div></div></div></div></div><iframe name="captureIFrame_f62iuajzes785yt26n7g69feam73myeix9v8l8xu" data-transactionid="f62iuajzes785yt26n7g69feam73myeix9v8l8xu" id="captureIFrame_f62iuajzes785yt26n7g69feam73myeix9v8l8xu" src="about:blank" class="" data-captureiframeloadeventbound="yes" style="display: none;"></iframe><div id="janrainModalOverlay" style="inset: 0px; position: fixed; background-color: rgb(0, 0, 0); opacity: 0.4; display: none; z-index: 1000;"></div><div id="janrainModal" style="width: 380px; height: 131px; position: absolute; z-index: 1000; display: none;"><a href="#" class="janrain_modal_closebutton" style="position: absolute; cursor: pointer; z-index: 1000;">X</a><div style="display: block;" id="signIn" class="ucc-widgets-nejm-next janrain-capture-ui capture-ui-content capture_screen_container" data-capturescreenname="signIn" data-captureventadded="true">
    <div class="capture_header">
      <h1>Sign In</h1>
    </div>    
    <div class="capture_signin">
      <form id="capture_signIn_signInForm" name="signInForm" data-capturefield="signInForm" action="https://mms.us.janraincapture.com/widget/traditional_signin.jsonp" class="capture_form capture_signInForm" method="POST" novalidate="novalidate" data-transactionid="f62iuajzes785yt26n7g69feam73myeix9v8l8xu" target="captureIFrame_f62iuajzes785yt26n7g69feam73myeix9v8l8xu" accept-charset="UTF-8" next="{&quot;noop&quot;:&quot;&quot;}"><div id="capture_signIn_signInForm_defaultSavedProfileMessage"></div><div id="capture_signIn_signInForm_errorMessages"></div><input id="capture_signIn_utf8" data-capturefield="undefined" value="✓" type="hidden" class="capture_utf8" name="utf8"><input id="capture_signIn_screen_f62iuajzes785yt26n7g69feam73myeix9v8l8xu" data-capturefield="undefined" value="signIn" type="hidden" class="capture_screen_f62iuajzes785yt26n7g69feam73myeix9v8l8xu" name="capture_screen"><input id="capture_signIn_js_version_f62iuajzes785yt26n7g69feam73myeix9v8l8xu" data-capturefield="undefined" value="d445bf4" type="hidden" class="capture_js_version_f62iuajzes785yt26n7g69feam73myeix9v8l8xu" name="js_version"><input id="capture_signIn_transactionId_f62iuajzes785yt26n7g69feam73myeix9v8l8xu" data-capturefield="undefined" value="f62iuajzes785yt26n7g69feam73myeix9v8l8xu" type="hidden" class="capture_transactionId_f62iuajzes785yt26n7g69feam73myeix9v8l8xu" name="capture_transactionId"><input id="capture_signIn_form_f62iuajzes785yt26n7g69feam73myeix9v8l8xu" data-capturefield="undefined" value="signInForm" type="hidden" class="capture_form_f62iuajzes785yt26n7g69feam73myeix9v8l8xu" name="form"><input id="capture_signIn_flow_f62iuajzes785yt26n7g69feam73myeix9v8l8xu" data-capturefield="undefined" value="standard" type="hidden" class="capture_flow_f62iuajzes785yt26n7g69feam73myeix9v8l8xu" name="flow"><input id="capture_signIn_client_id_f62iuajzes785yt26n7g69feam73myeix9v8l8xu" data-capturefield="undefined" value="qsra7g4d6jwdsgn3zbe6udp6r6278mr9" type="hidden" class="capture_client_id_f62iuajzes785yt26n7g69feam73myeix9v8l8xu" name="client_id"><input id="capture_signIn_redirect_uri_f62iuajzes785yt26n7g69feam73myeix9v8l8xu" data-capturefield="undefined" value="https://www.nejm.org" type="hidden" class="capture_redirect_uri_f62iuajzes785yt26n7g69feam73myeix9v8l8xu" name="redirect_uri"><input id="capture_signIn_response_type_f62iuajzes785yt26n7g69feam73myeix9v8l8xu" data-capturefield="undefined" value="code" type="hidden" class="capture_response_type_f62iuajzes785yt26n7g69feam73myeix9v8l8xu" name="response_type"><input id="capture_signIn_flow_version_f62iuajzes785yt26n7g69feam73myeix9v8l8xu" data-capturefield="undefined" value="20240514181256512029" type="hidden" class="capture_flow_version_f62iuajzes785yt26n7g69feam73myeix9v8l8xu" name="flow_version"><input id="capture_signIn_settings_version_f62iuajzes785yt26n7g69feam73myeix9v8l8xu" data-capturefield="undefined" value="" type="hidden" class="capture_settings_version_f62iuajzes785yt26n7g69feam73myeix9v8l8xu" name="settings_version"><input id="capture_signIn_locale_f62iuajzes785yt26n7g69feam73myeix9v8l8xu" data-capturefield="undefined" value="en-US" type="hidden" class="capture_locale_f62iuajzes785yt26n7g69feam73myeix9v8l8xu" name="locale"><input id="capture_signIn_recaptcha_version_f62iuajzes785yt26n7g69feam73myeix9v8l8xu" data-capturefield="undefined" value="2" type="hidden" class="capture_recaptcha_version_f62iuajzes785yt26n7g69feam73myeix9v8l8xu" name="recaptchaVersion">
      <div class="ucc-form-inner-wrapper">
        <div id="capture_signIn_form_item_signInEmailAddress" class="capture_form_item capture_email capture_form_item_signInEmailAddress" data-capturefield="undefined"><label for="capture_signIn_signInEmailAddress">Email Address</label><input id="capture_signIn_signInEmailAddress" data-capturefield="signInEmailAddress" value="" type="email" class="capture_signInEmailAddress capture_required capture_text_input" placeholder="Email Address" name="signInEmailAddress"><div class="capture_tip" style="display:none;"></div><div class="capture_tip_validating" data-elementname="signInEmailAddress">Validating</div><div class="capture_tip_error" data-elementname="signInEmailAddress"></div></div>
        <div id="capture_signIn_form_item_currentPassword" class="capture_form_item capture_password capture_form_item_currentPassword" data-capturefield="undefined"><label for="capture_signIn_currentPassword">Password</label><input id="capture_signIn_currentPassword" data-capturefield="currentPassword" value="" type="password" class="capture_currentPassword capture_required capture_text_input" placeholder="Password" name="currentPassword"><div class="capture_tip" style="display:none;"></div><div class="capture_tip_validating" data-elementname="currentPassword">Validating</div><div class="capture_tip_error" data-elementname="currentPassword"></div></div>
        <div style="padding-top:10px;">
            <div class="capture_form_item capture_form_rememberme">
                <label class="ucc-form-checkbox">                
                    <input checked="checked" id="ucc-remember-me-cb" name="ucc-remember-me-cb" type="checkbox" value="true">
                    <span>Remember Me</span>
                </label>          
            </div>
            <div class="capture_form_item capture_form_forgotpwd">
              <a role="button" class="ucc-anchor-button" data-capturescreen="forgotPassword">Forgot your password?</a>
            </div>
        </div>
        <div class="capture_form_item">
          <button id="ucc-sign-in-submit" class="capture_primary capture-full-width-btn" type="submit">Sign In</button>
        </div>
       
        <div class="capture_form_item">
          <div class="ucc-no-acct-msg">Don't have an account?</div>
          <div class="ucc-no-acct-msg-2" id="signInModalCreateAccountLink">
          <a role="button" class="ucc-anchor-button" onclick="mmsWidgets.closeSignIn(event); mmsWidgets.showRegAuto(event);">Create Account</a>
            <span></span><a href="https://store.nejm.org/nejm?promo=ONF4NRS1">Subscribe</a>
          </div>

          <div class="ucc-no-acct-msg-2" id="signInModalCloseLink" style="display:none">
          <a role="button" class="ucc-anchor-button" onclick="mmsWidgets.closeSignIn(event);">Create Account</a>
            <span></span><a href="https://store.nejm.org/nejm?promo=ONF4NRS1">Subscribe</a>
          </div>

        </div>
     
        <div class="capture_form_item capture_form_submit">
          
        </div>      
      </div>
      </form>
    </div>
  </div></div><div id="addtoany" style="position: static;"><div class="a2a_overlay" id="a2a_overlay"></div><div id="a2a_modal" class="a2a_modal a2a_hide" role="dialog" tabindex="-1" aria-label=""><div class="a2a_modal_body a2a_menu a2a_hide" id="a2a_copy_link"><label for="a2a_copy_link_text" id="a2a_copy_link_icon" class="a2a_svg a2a_s_link a2a_logo_color"><svg focusable="false" xmlns="http://www.w3.org/2000/svg" viewBox="0 0 32 32"><title>Copy link</title><path fill="#FFF" d="M7.591 21.177c0-.36.126-.665.377-.917l2.804-2.804a1.235 1.235 0 0 1 .913-.378c.377 0 .7.144.97.43-.026.028-.11.11-.255.25-.144.14-.24.236-.29.29a2.82 2.82 0 0 0-.2.256 1.056 1.056 0 0 0-.177.344 1.43 1.43 0 0 0-.046.37c0 .36.126.666.377.918a1.25 1.25 0 0 0 .918.377c.126.001.251-.015.373-.047.125-.037.242-.096.345-.175.09-.06.176-.127.256-.2.1-.094.196-.19.29-.29.14-.142.223-.23.25-.254.297.28.445.607.445.984 0 .36-.126.664-.377.916l-2.778 2.79a1.242 1.242 0 0 1-.917.364c-.36 0-.665-.118-.917-.35l-1.982-1.97a1.223 1.223 0 0 1-.378-.9l-.001-.004Zm9.477-9.504c0-.36.126-.665.377-.917l2.777-2.79a1.235 1.235 0 0 1 .913-.378c.35 0 .656.12.917.364l1.984 1.968c.254.252.38.553.38.903 0 .36-.126.665-.38.917l-2.802 2.804a1.238 1.238 0 0 1-.916.364c-.377 0-.7-.14-.97-.418.026-.027.11-.11.255-.25a7.5 7.5 0 0 0 .29-.29c.072-.08.139-.166.2-.255.08-.103.14-.22.176-.344.032-.12.048-.245.047-.37 0-.36-.126-.662-.377-.914a1.247 1.247 0 0 0-.917-.377c-.136 0-.26.015-.37.046-.114.03-.23.09-.346.175a3.868 3.868 0 0 0-.256.2c-.054.05-.15.148-.29.29-.14.146-.222.23-.25.258-.294-.278-.442-.606-.442-.983v-.003ZM5.003 21.177c0 1.078.382 1.99 1.146 2.736l1.982 1.968c.745.75 1.658 1.12 2.736 1.12 1.087 0 2.004-.38 2.75-1.143l2.777-2.79c.75-.747 1.12-1.66 1.12-2.737 0-1.106-.392-2.046-1.183-2.818l1.186-1.185c.774.79 1.708 1.186 2.805 1.186 1.078 0 1.995-.376 2.75-1.13l2.803-2.81c.751-.754 1.128-1.671 1.128-2.748 0-1.08-.382-1.993-1.146-2.738L23.875 6.12C23.13 5.372 22.218 5 21.139 5c-1.087 0-2.004.382-2.75 1.146l-2.777 2.79c-.75.747-1.12 1.66-1.12 2.737 0 1.105.392 2.045 1.183 2.817l-1.186 1.186c-.774-.79-1.708-1.186-2.805-1.186-1.078 0-1.995.377-2.75 1.132L6.13 18.426c-.754.755-1.13 1.672-1.13 2.75l.003.001Z"></path></svg></label><input id="a2a_copy_link_text" type="text" title="Copy link" readonly=""><div id="a2a_copy_link_copied">✓</div></div><div class="a2a_modal_body a2a_menu a2a_thanks a2a_hide" id="a2a_thanks"><div class="a2a_localize" data-a2a-localize="inner,ThanksForSharing">Thanks for sharing!</div></div></div><div class="a2a_menu a2a_full a2a_localize" id="a2apage_full" role="dialog" tabindex="-1" aria-label="Share" data-a2a-localize="title,Share"><div class="a2a_full_header"><div id="a2apage_find_container" class="a2a_menu_find_container"><label for="a2apage_find" id="a2apage_find_icon" class="a2a_svg a2a_s_find"><svg focusable="false" xmlns="http://www.w3.org/2000/svg" viewBox="0 0 24 24" aria-hidden="true"><title>Find any service</title><path fill="#CCC" d="M19.7 18.2l-4.5-4.5c.7-1.1 1.2-2.3 1.2-3.6 0-3.5-2.8-6.3-6.3-6.3s-6.3 2.8-6.3 6.3 2.8 6.3 6.3 6.3c1.4 0 2.6-.4 3.6-1.2l4.5 4.5c.6.6 1.3.7 1.7.2.5-.4.4-1.1-.2-1.7zm-9.6-3.6c-2.5 0-4.5-2.1-4.5-4.5 0-2.5 2.1-4.5 4.5-4.5 2.5 0 4.5 2.1 4.5 4.5s-2 4.5-4.5 4.5z"></path></svg></label><input id="a2apage_find" class="a2a_menu_find a2a_localize" type="text" autocomplete="off" title="Find any service" data-a2a-localize="title,FindAnyServiceToAddTo"></div></div><div class="a2a_full_services" id="a2apage_full_services" role="presentation"></div><div class="a2a_full_footer"><a href="https://www.addtoany.com" title="Share Buttons" rel="noopener" target="_blank"><span class="a2a_svg a2a_s__default a2a_s_a2a a2a_logo_color"><svg focusable="false" xmlns="http://www.w3.org/2000/svg" viewBox="0 0 32 32"><g fill="#FFF"><path d="M14 7h4v18h-4z"></path><path d="M7 14h18v4H7z"></path></g></svg></span>AddToAny</a></div></div><div id="a2apage_dropdown" class="a2a_menu a2a_mini a2a_localize a2a_hide" tabindex="-1" aria-label="Share" data-a2a-localize="label,Share"><div class="a2a_mini_services" id="a2apage_mini_services"></div><div id="a2apage_cols_container" class="a2a_cols_container"><div class="a2a_col1" id="a2apage_col1"></div><div id="a2apage_2_col1" class="a2a_hide"></div><div class="a2a_clear"></div></div><div class="a2apage_wide a2a_wide"><a href="#addtoany" id="a2apage_show_more_less" class="a2a_more a2a_localize" title="Show all" data-a2a-localize="title,ShowAll"><span class="a2a_svg a2a_s__default a2a_s_a2a a2a_logo_color"><svg focusable="false" xmlns="http://www.w3.org/2000/svg" viewBox="0 0 32 32"><g fill="#FFF"><path d="M14 7h4v18h-4z"></path><path d="M7 14h18v4H7z"></path></g></svg></span><span class="a2a_localize" data-a2a-localize="inner,More">More…</span></a></div></div><div style="height: 1px; width: 1px; position: absolute; z-index: 100000; top: 0px; visibility: hidden;"><iframe id="a2a_sm_ifr" title="AddToAny Utility Frame" aria-hidden="true" src="https://static.addtoany.com/menu/sm.25.html#type=core&amp;event=load" style="height: 1px; width: 1px; border: 0px; left: 0px; top: 0px; position: absolute; z-index: 100000; display: none;"></iframe></div></div><qix-houmbgdphtsa></qix-houmbgdphtsa><div role="status" aria-live="assertive" aria-relevant="additions" class="ui-helper-hidden-accessible"></div></body></html>